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ABSTRACT 
Lay Perspectives of Medicines for Dementia: a qualitative study 
This was a two phase study exploring lay perspectives of medicines for dementia. 
In phase one, participants were recruited from 4 local branches of the Alzheimer’s 
Society in the southwest to take part in a single focus group or interview. In total 5 
people with dementia and 23 carers participated. The aim was to explore 
perceptions of medicines on day­to­day life. Findings fell into 3 superordinate 
themes: On Being a Carer; Interacting with Healthcare Professionals and Living 
with a Degenerative Illness. Participants described great variability in access to 
medicines and in outcomes of consultations with healthcare professionals. Ageism 
and therapeutic nihilism were commonly encountered. 
Phase Two was a longitudinal study exploring the impact of medicines for 
dementia in early stage disease using a case study approach. Seven case 
studies were recruited via memory clinics; with four receiving a medicine for 
dementia and three not. Case study participants were followed over a 13­month 
period. The superordinate themes were: Living with a Memory Problem or 
Dementia; Interacting with Healthcare Professionals and Medicines for Dementia. 
Even in the early stages of a dementia spousal relationships were negatively 
affected. Medicines for dementia enabled renegotiation of spousal relationships 
and adjustment and acceptance to take place. The Mini­Mental State 
Examination was perceived to tell only half the story and was insensitive to 
improvements in alertness, initiative, engagement with the individuals’ lifeworld 
and ability to maintain and engage in social relationships. 
Overall both phases found access to medicines for dementia a complicated and 
long procedure. The methods for assessing response were perceived as 
threatening and unrealistic. There was a perceived need for greater education 
about dementia and its treatment for healthcare professionals, people with 
dementia and their carers. It was identified that pharmacists could take a more 
proactive role in providing a pharmaceutical care service. 
Word Count: 298 
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LIST OF ABBREVIATIONS AND GLOSSARY 
•	 Acetylcholinesterase inhibitors = AChEIs 
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•	 Code = a narrative excerpt from the data which depict a particular meaning 
•	 Coding = this process is to organise or manage data for analysis281 
•	 Dementia with Lewy bodies = DLB 
•	 Descriptor Code = This term is used to describe the ethos or the underlying 
meaning of the code. That is, it is like a definition of the code and helps to 
aid robustness of the coding process 
•	 Focus Group = FG 
•	 Healthcare Professional = HCP 
•	 Interview = IV 
•	 Location = L 
•	 Mild Cognitive Impairment = MCI 
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•	 Sub­code delineator = A code may cover a number of minor codes and a 
‘sub­code delineator’ is a definition of this level of analysis. 
•	 Summary of product Characteristics = SPC 
13 
•	 Super­ordinate Theme (Delineator) = This is an over­arching term used to 
describe a clumping of themes and sub­themes which describe in their 
totality the phenomenology or understanding of the data. 
•	 Theme = A theme is an term used to describe a number of codes and/or 
sub­codes. For example ‘problems with diagnosis’ could cover codes and 
sub­codes such as time to diagnosis; access to specialists etc 
•	 Vascular dementia = VaD 
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CHAPTER ONE: INTRODUCTION 
This chapter will give a short introduction to the background behind the research 
area which will be expanded on in Chapter Two. Following this introduction will be 
a short guide to the thesis and then an explanation of how researcher reflexivity 
will be presented throughout the thesis. 
1.1 An Introduction to the Ethos of the Research 
Dementia is an insidious and progressive neurodegenerative disorder, which has a 
major impact on both the person with dementia and their carers’ health and quality 
of life. As the disease progresses and the person with dementia declines, the 
accompanying mood and personality changes can be profoundly upsetting to 
loved ones. Until 1997 there was no licensed pharmacological treatment available 
for treatment of dementia syndromes in the United Kingdom (UK). With the 
licensing of the acetylcholinesterase inhibitors (AChEIs), [Donepezil (Aricept®)1 in 
1997, Rivastigmine (Exelon®)2 in 1998, and Galantamine (Reminyl®)3 in 2000 and 
the NMDA Receptor Antagonist Memantine (Ebixa®)4 in 2002], the possibility of 
symptomatic treatment for dementia was realised. 
However, there seemed reluctance5­7 to use these treatments even though robust 
trial evidence8­14 demonstrated statistically significant improvements in validated 
assessment scales including the mini­mental state examination (MMSE).15­19 
Healthcare professionals (HCPs) and those involved in the acceptance of these 
agents onto local prescribing formularies had difficulty translating improved MMSE 
scores into actual clinical benefits for people with dementia (PWD).20,22 Although 
there have been attempts to explain why these treatment effects may not be seen 
as useful by clinicians’ rating them. 23 There was also unfamiliarity with prescribing 
pharmacologically effective treatments for dementia as the previous licensed 
agents had either been withdrawn due to liver toxicity24 or inefficacy.25,26 In 2001 
the then National Institute for Clinical Excellence (NICE) produced prescribing 
guidance for the AChEIs. 27 This guidance stated that the AChEIs were effective in 
the treatment of mild and moderate Alzheimer’s disease (AD) and should be 
prescribed once a diagnosis had been made by a specialist.27 
On being presented with a diagnosis of a particular medical condition, many 
people will hold a belief about how medication may ameliorate or totally cure their 
medical condition.28,29 This may or may not coincide with the viewpoint of the 
persons’ carer, the prescriber or other healthcare professionals (HCPs) involved in 
their care, who may hold different views of efficacy.30 
However, prior to treatment being started, NICE guidance stated that compliance 
needed to be ensured and an end date when the treatment would be withdrawn, 
discussed. 27 It is possible that the viewpoints of all those concerned with use of 
AChEIs may change over a period of time. Also if the person with dementia, their 
carer and the physician expectations were widely different, then it may be 
impossible to agree on, and get informed consent for, an endpoint for cessation of 
treatment prior to starting treatment. 
Controversy still continues with revised guidelines published by the now National 
Institute for Health and Clinical Excellence (NICE) in 200631 (since revised in 
15 
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2009) suggesting that although these agents are clinically effective in controlling 
the symptoms of AD they should not be prescribed in the mild stages of the 
disease due to questionable cost effectiveness. 31 
Medicines management is an umbrella term for the responsible provision of 
medication for the purpose of achieving definite outcomes, which improve a 
patient’s quality of life. 32 However, many medicines may actually have a 
deleterious effect on a patient’s self­assessed quality of life to the extent they may 
eventually stop taking the medicine. Indeed it is well documented that the adverse 
effects of AChEIs can cause frequent adverse events in the recipient. (See Table 
1.1 below for the most common). 
Table 1.1: Common Gastrointestinal Adverse Effects * 
Gastrointestinal 
Adverse Effects 
Placebo 
n 2296 
Donepezil 
n 1209 
Galantamine 
n 1040 
Rivastigmine 
n 1188 
Nausea 9% 14% 24% 47% 
Vomiting 4% 8% 13% 31% 
Diarrhoea 7% 12% 9% 19% 
*(Adapted from Wilkinson) 33 
Evidence suggests that up to 25% of all people started on an AChEI in a clinical 
trial withdraw because of adverse effects.34,35 This could suggest that perhaps 
withdrawal rates due to adverse effects may be higher in a community­based 
setting where support facilities may be less than those offered to clinical trial 
participants. 
Often the initial choice of an AChEI is dependent on clinician experience and 
individual tolerance of side effects. Donepezil is commonly prescribed first­line 
because of its once daily dosing profile and also its propensity to cause less 
gastro­intestinal side effects than the other two agents. 1 However, there is some 
evidence that donepezil may have a shorter duration of effect than the other two 
agents36,37 and that switching to another AChEI may be beneficial in some 
patients.38­41 A further complication is that each of these agents has linear dose 
pharmacokinetics, meaning the best therapeutic effect is seen at the maximum 
licensed dose.1­3 This is confirmed by the numbers needed to treat falling from 13 
with low dose therapy to between 3 and 7 with high dose therapy). 42 
A local audit in 2003 highlighted that nearly 33% of patients receiving an AChEI 
withdrew or changed agents due to intolerable side effects. 43 The frequency of 
this withdrawal was dependent on the agent initiated, occurring less frequently in 
those people started on donepezil. However, many people remain on the dose 
they can tolerate or may be withdrawn from treatment before a therapeutic dose 
is reached. Pre­emptive treatment of side effects in this population group seems 
to be uncommon due to the risk of further iatrogenic disease from another 
pharmacological agent being introduced. 
Historically, patients with end­stage Parkinson’s disease who qualify for the 
prescription of apomorphine, a highly emetogenic parenteral dopamine agonist, 
are pre­emptively treated with domperidone (an antiemetic which does not cross 
the blood brain barrier).44 It would seem sensible that prior to initiation and at 
dose titration with the highly emetogenic AChEIs, that domperidone could be 
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used pre­emptively to reduce nausea and vomiting. This would then allow a more 
rapid titration. 
It has been suggested that the longer that treatment with AChEIs was delayed 
the less effective it became.35 Therefore once a person is diagnosed with AD, it 
would seem logical to titrate as rapidly as possible to the maximum tolerated 
therapeutic dose of the agent selected. 
The results of a questionnaire aimed at assessing the depth of service provision 
for PWD was published in the Forget me Not 2002 report.45 The findings 
demonstrated an inequity of service provision throughout England and Wales, 
with some health authorities having well established service provision for older 
people with mental health problems and others having much less.45 There has 
since been almost a plethora of other reports documenting the same 
shortcomings in service provision46­50prior to the publication of the National 
Dementia Strategy (NDS) in 2009.51 
An audit in 2002 investigated the prescribing and funding of AChEIs in dementia 
and findings demonstrated that only 76% of the 91 prescribing advisers of health 
authorities in England and Wales had identified formal funding for their use.5 
Since this report, the responsibility for the prescribing budget of medicines for 
dementia has been transferred to Primary Care Trusts (PCTs). Indeed the 
volume of prescribing of AChEIs has now become a Performance Indicator for 
Mental Health Service provision in England and Wales.52 The performance 
indicators suggest that the prescribing rates of these agents should increase as 
the identification of patients with probable AD increased.52 However prescribing 
rates are still low with a recent study showing little change to that of 2002.53 The 
NDS highlighted that even in the best geographical areas of prescribing; the 
United Kingdom (UK) was still performing less effectively than most countries in 
Europe.51 The question of why these medicines are not being funded sufficiently 
or prescribed for appropriate people remains unclear. 
In the second survey report by the Alzheimer’s Society in 2004, carers of people 
taking medicines for dementia were asked to describe the positive effects of 
these medicines on the person that they cared for. Descriptions included: “seems 
brighter / happier/ more aware / more active” to “calmer / less aggressive” to 
improved concentration / speech.” 30 That is, the end points of successful 
treatment in the eyes of a carer seemed at odds from those endpoints proposed 
by NICE as improvement in terms of increases or stability in MMSE scores.27,31 
It is therefore important to explore the perspectives of PWD and their carer’s in 
the use of medicines for dementia and the lived experience of response. Perhaps 
only PWD and their carers can describe what is important for them. Frank states 
“some treatment effects are known only to the patient” and “patients provide a 
unique perspective on treatment effectiveness.54 Why is it then that NICE55 and 
HCPs can take such little account of patient reported outcomes? 
In summary evidence suggests there may be a case for improved prescribing of 
AChEIs by co­prescription of preparations for gastrointestinal side effects; trying a 
different AChEI if the first is ineffective and making greater efforts towards equity 
in dementia services. In addition the differing perceptions of efficacy need to be 
17 
investigated with an aim of understanding the benefits of these medicines from the 
experiences of people with dementia, their carers and their families. 
1.2 A Guide to the Thesis 
In this chapter I have introduced a brief background to the perceived need for the 
research and this will be expanded in the literature review (Chapter Two). Chapter 
Three describes the methods and methodology used in phase one; including 
interpretative phenomenological analysis as the underpinning method of analyses 
and the use of focus group and semi­structured interview methodology. The 
results and discussion of phase one are outlined in Chapter Four. In Chapter Five 
the philosophy of using case study methodology as an approach to research in 
phase two is discussed and the findings are presented and discussed in Chapter 
Six. This is followed by Chapter Seven with an overarching discussion and 
conclusions of the key findings. Following this short guide to the thesis is a brief 
section on how researcher reflexivity will be used and presented throughout the 
thesis; and overall reflexivity will be summed up in Chapter Eight. Throughout this 
thesis an appendix will be represented by A, followed by the number of the chapter 
and then the number of the appendix. For example A2­1 means the first appendix 
of Chapter Two. 
1.3 Reflexivity on Starting 
“Reflection can be defined as ‘thinking about’ something after the event. 
Reflexivity, in contrast, involves a more immediate, dynamic and continuing 
self­awareness.” Linda Finlay and Brendan Gough, page xi).56 
I don’t completely agree with the definition above of reflection, as one can reflect 
in action as one is in the process of decision­making and many HCPs would be 
familiar with this experience; as I myself am. Reflecting on an event is something 
we all do; some perhaps better than others and we each have our different 
styles. As a pharmacist I was experienced at using reflection within my 
professional role and as an educator I also incorporated a reflective approach 
within my teaching units. This is because I strongly believe that reflection can 
positively impact on personal and professional growth. Reflection or reflexivity as 
a researcher; or the appreciation “that research is co­constituted – a joint product 
of the participants, researcher and their relationship” 57 was something I was less 
familiar with. However, I had not been involved in qualitative research before or 
particularly shared meaningful life discussions with patients as part of my 
previous research. 
My career as a pharmacist started in New Zealand (NZ) where I qualified and first 
worked in community pharmacy for two and a half years before heading out for the 
big OE (Overseas Experience). My original plan was to travel around before 
returning to NZ; funding this travel by working as a locum pharmacist. It was the 
mid 1980’s and I discovered hospital pharmacy and the new concept of clinical 
pharmacy and attachments to clinical teams. I was appointed Priority Care 
Pharmacist at the Dulwich Hospital in 1986 with responsibility for clinical input to 
the mental health and elderly care wards. I then moved to pharmacy lead for 
elderly care services at Gloucestershire Royal Hospital where I had clinical 
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attachments to three consultant wards and responsibility for prescribing budgets 
and improving patient pharmaceutical care. I also completed a Masters by 
Research which was a randomised controlled trial on whether medication 
counselling by a pharmacist improved adherence in older people. (A8­1) As part of 
the consent process I had to use the Abbreviated Mini Mental State Examination 
(AMMT) (A1­1). I was trained in the use of the AMMT and the Folstein MMSE (A1­
2) as part of my ward duties by the teams’ clinical psychologist as I routinely 
helped to care for people with cognitive impairment and delirium. 
In 1999 I became lead for Pharmacy Clinical Services at the Royal United Hospital 
in Bath and found myself providing services to the intensive and coronary care 
units as well as the mental health wards before being recruited to my current 
position at the University of Bath in June 2000. 
I had written several educational pieces for pharmacists on the dementias and 
associated pharmacological treatments. (See A8­1) I had become increasingly 
interested in the use of medicines for dementia in practice and made contact with 
a local research memory clinic to see if we could undertake joint research and by 
June 2003 I had secured funding with a collaborant for a national survey of 
prescribing habits of AChEIs as part of my doctorate studies. However there were 
a few hiccups including a new supervisor; luckily for me with experience in 
qualitative research. Professor Marjorie Weiss (my new supervisor) was someone 
who understood my need to undertake a qualitative piece of research in pharmacy 
practice. After completing my Masters I was aware that although processes within 
the hospital changed in terms of improving information given to patients and their 
general practitioners after discharge; I was really unclear about the true affect it 
had on participants. Consequently I designed the research around an exploratory 
focus group study (Phase One) to gain an idea of people’s experiences of living 
with these medicines and then went on to design Phase Two to explore these 
effects in early dementia in greater depth over time. 
In my thesis I use reflexive points throughout as a means of conveying what was 
happening to me as a researcher and how this affected progression or my attitude. 
As mentioned earlier, reflexivity of the entire thesis will be discussed further in 
Chapter Eight. 
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CHAPTER TWO: LITERATURE REVIEW 
This chapter will introduce the background literature in dementia as it relates to 
this research in terms of access to treatment; assessment of response and the 
effects that dementia has on all those involved in the care of a person with 
dementia. 
Overview of Search Strategy 
PubMed, (the then Medline), PsycINFO, the Cochrane Data Base and Web of 
Science were accessed as databases throughout the period of this research; the 
ability to save search strategies and have regular update feeds emailed directly 
has been a great help. Other access to data was from the follow­up of references 
found in relevant articles; conference proceedings, involvement in responding to 
calls from the Nuffield Council on Bioethics ‘Dementia: Ethical issues’ 
consultation,58 and Transforming the Quality of Dementia Care. 50 Also general 
reading updates from RSS feeds and the updating of previously written 
educational tools kept my knowledge and reference bank current. 
2.1 An Introduction to Dementia 
This section will give an overview of the current definitions of dementia; its 
epidemiology, diagnosis and classification as well as the wider effects not only to 
the individual but their carer, wider family and society. A brief overview of how 
societal and institutionalised ageism may affect care services in this area will also 
be presented. 
2.1.1 Definition, Epidemiology and Symptomatology 
The dementias are arguably the most insidious and cruel of all diseases, with a 
seemingly relentless progression from mild memory impairment through to 
behavioural and personality changes, to a complete inability for the individual to 
complete any activities of daily living or to communicate effectively within their 
surrounding environment. 
Dementia has been described as a syndrome where there is progressive 
impairment in two or more areas of cognitive function (these include memory, 
language, visuospatial and perceptual ability, thinking and problem­solving or 
personality) with the result that work, social function and relationships are 
affected. This impairment occurs in the absence of delirium (acute confusional 
state) or other psychiatric disorders such as depression or schizophrenia.59 
Dementia is generally irreversible except for a small number of so­called 
‘pseudo­dementias’ (about 1% of all dementias.59­61 
The dementias are primarily a disease of the elderly, with prevalence of 2% 
between the ages of 65 and 69 years rising to 20% in the 85 to 89 year­old age 
group. 62 The incidence is estimated at 1 new case per 100 population per year, 
with the prevalence being higher in men until the age of 74 years, but higher in 
women thereafter. In 2009, the NDS stated the number of PWD in England and 
Wales was 700,000 and that in 30years this would double to 1.4million. 51 
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Due to the heterogeneity of the disease and the areas of the brain that are 
affected, presenting features of dementia in individuals are many and varied, 
with the clinical picture affected by the individual’s pre­morbid personality. 
Individuals with good social skills can maintain a social façade despite gross 
intellectual impairment, however individuals in social isolation or with visual or 
hearing impairment are less likely to compensate so well. 59­61 Clinical features 
change over the time­course of the disorder, and are often subdivided into 
early, mid and late symptomatology (see Table 2.1). 
2.1.2 The Diagnosis of Dementia 
Diagnosis is a complex process, generally requiring specialist knowledge and 
application; however the NDS highlighted that many more frontline healthcare 
professionals (HCPs) such as general practitioners (GPs); nurses and 
pharmacists could be able, with appropriate training and education, to 
recognise early symptoms and refer appropriately.51 It is estimated that there 
are approximately 700,000 people with a dementia but only 20­40% of these 
receive a formal diagnosis.51 The NDS highlights a 30­fold variation in practice 
between primary care trusts (PCTs) in the provision of services for dementia51 
which seems to highlight a backdrop of inequity and ignorance. The following 
section will discuss the possible reasons for this discrepancy and poor 
recognition. 
2.1.2.1 Ageism 
A difficulty in diagnosis seems to be a misunderstanding that dementia is not a 
normal part of ageing and that there are non­pharmacological and 
pharmacological options which can improve the ability of a person to live with 
dementia. Ageism seems to be an inherent part of our society and a study in 
2009 suggested that 47% of the sampled clinicians from the British Geriatrics 
Society believed that the National Health Service (NHS) is “institutionally 
ageist” with 55% concerned about how they themselves would be treated by 
the NHS in the future. 64 A spokesperson from the British Medical Association 
suggested that "Institutional and unconscious ageism is not just a problem for 
the health service but for society as a whole.” 64 The charity Help the Aged has 
been campaigning for age to be included as an equality in current 
discrimination legislation changes. 65 It is also a telling indictment that the abuse 
of older people has no underpinning legislation to support reforms in health and 
social care in this country. 
The National Service Framework for Older People (NSFOP) published in 2001 
was an attempt to overhaul the ageist attitude to patient access to health 
services and ensure equity.66 However evidence suggests that access to 
appropriate care is still denied many older people.67 Terence Blacker,68 a 
journalist, describes ageism as “our most popular prejudice” and goes on to use 
the results of an American study 69 as an example of inherent ageism within the 
NHS. 
Langa and colleagues studied 8,299 Americans and 5,276 Britons aged over 
65 and found higher rates of depression and lower rates of cognitive capacity in 
the Britons. 69 The authors suggest this may be due to more aggressive 
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treatment of cardiovascular risks in middle age Americans in comparison to 
Britons. 69 
In 2006 the Healthcare Commission reported on their evaluation of the NSFOP 
in terms of access to care and ageism.70 Their results highlighted a decline in 
explicit ageism in access to physical healthcare services, but not in access to 
mental health services.70 
Ageism in mental health services71 and in access to medicines for dementia72 
are well documented as is the stigma of a mental illness.73 There have been 
several key reports which described the poor progress made in the provision of 
integrated and holistic services for older people with mental health issues such 
as dementia.46­48 These culminated in the publication of joint guidelines on 
supporting PWD and their carers in 2006.49 Perhaps the most important 
document relating to improving dementia services has been the publication of 
Living Well With Dementia, the National Dementia Strategy (NDS) in February 
2009.51 (See 2.3.1 for further information). 
2.1.2.2 Ageing or dementia 
Ageing is thought to arise from to a complex interaction of molecular damage 
which eventually overwhelms the bodies defence, maintenance and repair 
systems74,75 It is important to understand that age in years is a chronological 
marker for what is occurring at a biological and social level and there is great 
heterogeneity in people of any age.76 
It is well known that in the normal ageing process there are cognitive changes 
which present over time77,78 and the difficulty for frontline HCPs is understanding 
how these are different from those individuals presenting with a possible 
dementia. It has been suggested there should be a low threshold for referral to 
specialist services if a dementia is suspected.61 
2.1.2.3 Screening 
It has been identified that GP’s felt they were under­skilled in recognition and 
management of dementia and a significant minority thought that this role was the 
responsibility of specialist services.79 It was also suggested that that older male 
GP’s and those with less knowledge about dementia and local services were 
more pessimistic about care.79 Furthermore when GPs perceived specialist 
services were absent or unresponsive, this limited the recognition of dementia 
and was perceived as therapeutic nihilism by those seeking services.80 The NDS 
suggests that front­line professionals such as GPs should receive better training 
to enable them to recognise symptoms of dementia and refer earlier.51 
The trend for primary care clinicians to recognise and screen for dementia has 
resulted in a series of new, validated measures which take less time than the 
MMSE81 (See A1­2 for a copy) or ADAS­cog82 scales used in research and 
specialist services. These include a 6­item cognitive impairment test (6CIT) 83 the 
Memory Impairment Screen (MIS)84 the Mini­cog,85 the General Practitioner 
Assessment of Cognition,86 and the seven minute screening test.87 
A review of the efficacy and quality of the MIS, Mini­Cog and GPCOG in 
comparison to the MMSE in 2008 found the briefer tests more appropriate and 
robust for routine use in general practice. 88 
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Table 2.1: The Changing Clinical Features of Dementia

Feature Early clinical features Mid stage clinical features Late stage clinical features 
Mood • Anxious 
• Irritable 
• Depressed 
• Emotions and responses to 
events blunted. Sudden mood 
changes occur, often with 
explosive angry outbursts with 
no cause. 
• Often stuporous 
Thinking • Slowed with impoverished 
content 
• Concrete thinking with 
decreased flexibility & 
perseveration. 
• Impaired judgement 
• False ideas, especially 
persecutory, gain ground easily 
• Speech – searching for 
words 
• Syntactical errors (getting 
words with a sentence in the 
wrong order) 
• Nominal dysphasia 
(impaired content, order and/or 
understanding of speech) 
• Grossly fragmented and 
incoherent 
• Speech often meaningless, 
unintelligible or the patient is 
mute 
Behaviour • Disorganised, distractible, 
restless & inappropriate. 
• Loss of interest & initiative 
• Personality changes – 
neurotic traits exaggerated 
• Hallucinations or delusions 
common 
• Antisocial behaviours 
including sexual disinhibition 
and shoplifting 
• Self neglect 
• Neglect of social 
conventions 
• Behaviour often aimless, 
with stereotypes and 
mannerisms occurring. 
• Wandering 
• Disorientated 
• Incoherent 
• Double incontinence 
Cognitive 
function 
• Impaired memory 
• Difficulty in new learning 
• Memory loss for recent 
events rather than remote. 
Excuses or confabulation. 
• Impaired attention 
• Impaired concentration 
• Disorientation in time 
• Disorientation in time, 
place and person 
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2.1.2.4 Diagnosis of dementia 
The most important part of the diagnostic procedure seems to be an accurate 
and detailed history, paying particular attention to cognitive functioning as well 
as physical and neurological symptoms.60,61,89 A key part of this diagnostic 
process is information gained from informants (i.e. the individuals’ carer or 
family) who may be able to give more explicit details of symptom onset. In 
essence it remains a process of exclusion so that potentially remediable 
conditions can be identified and treated if appropriate.61 
In general practice it has been estimated that it takes a person 18 months to 
present to their GP after first experiencing a related symptom and a further 18 
months for the requisite tests to be completed and a diagnosis of dementia 
made. 61 An educational software intervention aimed at improving ‘diagnostic 
and management thinking’ has been developed and distributed to every 
general practice in England and has been incorporated into the general 
practice clinical software tool EMIS.61 It is unclear whether there is ongoing 
support for this intervention and/or the effect it is having on diagnostic rates. 
An early diagnosis51,61,89,90 allows people to receive supporting information; 
and access to appropriate care services and pharmacological and non­
pharmacological treatments. Another important reason for early diagnosis is 
the ability for individuals to initiate Advanced Directives and Lasting Power of 
Attorneys to guide future care needs. The Royal College of Physicians has 
suggested that GPs discuss advance planning with their patients at each 
annual review to ensure preferences are known.91 
2.1.3 Classification of the dementias 
The aim of an early diagnosis is not only to identify possible remedial causes 
but also to classify the type of dementia and its severity. The actual diagnosis 
is dependent on key features of a particular dementia being present and the 
severity rated by the MMSE, which is scored out of a possible 30 points (A1­2). 
It has been suggested that a score >27 equates to normal cognition; between 
25 to 27 associated with mild cognitive impairment (MCI); between 20 and 25 
mild dementia, between 10 and 20 moderate dementia and less than 10 
severe dementia.27 
AD is the most common form of dementia with some sources stating it 
accounts for about two­thirds of all cases of dementia.59 However Burns and 
Iliffe61 propose it accounts for 50% of cases, with vascular dementia (VaD) 
accounting for a further 25%.61 The authors propose that included within these 
two categories 25% will have a mixed AD and VaD picture; dementia with 
Lewy bodies (DLB) accounts for 15% of all diagnoses and all other dementias 
account for the rest. 61 
2.1.3.1 Mild Cognitive Impairment 
Mild cognitive impairment (MCI) may or may not progress to a dementia; 
recent findings suggest that individual’s with predominantly memory problems 
(amnestic MCI) on presentation will.92 It has been proposed that the prodromal 
period of AD is typically a 9­year decline in cognitive function, and part of that 
decline may possibly include a diagnosis of amnestic MCI.92 It is unknown 
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whether taking active steps to reduce personal risk factors for dementia will 
affect this progression. 
None of the three AChEIs are licensed for the symptomatic treatment of MCI 
or now recommended for mild AD, which means there is currently no 
pharmacological treatment to offer until a person is in the moderate stages of 
AD. (See 2.1.4) 
2.1.3.2 Alzheimer’s Disease 
AD, which includes an early onset and a late onset variant, was first described 
by Dr Lois Alzheimer in 1917.93 Key features include an insidious onset of 
symptoms (predominantly memory loss in the early stages) and emergence of 
aphasia and agnosia (failure of recognition). 
Established risk factors include increasing age and family history,94,95 
depression,95,96 (although it has been proposed that depression may be part of 
the prodromal period)97 cardiovascular risk factors95,98 and low mental94 and 
physical activity95,98 as well as a specific apoliprotein E4 status and genetic risk 
factors. 94,95,99 
The pathophysiology of AD is associated with an excess of intracellular 
neurofibrillary tangles (NFTs) and extracellular β­amyloid plaques.99,100 NFTs 
occur as a normal process of ageing, but have greater formation and 
deposition in AD.99,100 These depositions are thought to be responsible for the 
dramatic loss in cholinergic neurones, which result in reductions in 
neurotransmitters; mainly acetylcholine and enzymes such as choline 
acetyltransferase (CAT).99,100 
The cholinergic system is critical to normal memory and other cognitive 
functions. In AD there is selective loss of cells in the basal forebrain. These 
cells produce acetylcholine (ACh) and project diffusely into the hippocampus, 
basal nucleus of Meynert and the entorhinal cortex.101 The depletion of 
neurons in this area correlates with memory and cognitive decline in AD. 
2.1.3.3 Vascular Dementia (VaD) 
Vascular dementia (VaD) generally presents with sudden onset and the 
dementia follows a step­wise progression. This means there are periods of 
stability followed by periods of rapid decline. Generally there is a history of 
hypertension, stroke or transient ischaemic attack (TIA).59,102 There are focal 
neurological signs (which describe the physical or psychological symptoms 
directly related to the area of brain damage) which are absent in AD, and often 
emotional lability and depression. Common associated clinical features are 
early memory problems, apraxia, agnosia, dysarthria and dizziness.59 
Generally insight is more preserved than in AD, but this often leads to 
increasing distress for the person, as they can be more aware of the prognosis 
of the disease. Risk factors for VaD include: family history; male gender; 
hypertension; history of stroke or TIA; diabetes mellitus; smoking or atrial 
fibrillation (AF).59,102 
A number of health policy documents propose public health education 
programmes aimed at improving the treatment and prevention of 
cardiovascular risk factors in primary care.103­106 An improvement in these 
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areas may result in a decrease in the proportion of vascular dementia 
observed in future years. If the hypothesis of Langa and colleagues is 
correct, they may also help to improve the general cognitive function of older 
people if tighter control of vascular disease becomes more widespread.69 
2.1.3.4 Dementia with Lewy bodies 
Dementia with Lewy bodies (DLB) is a progressive, fluctuating dementia 
associated with hallucinations, periods of confusion and other psychotic 
symptoms.107,108 It is also associated with early gait disturbances, 
extrapyramidal features such as rigidity, bradykinesia, tremor and fixed 
posture (signs of parkinsonism).107,108 Sufferers demonstrate an extreme 
sensitivity to the extrapyramidal side effects of antipsychotic 
medication.107,108 This may be explained by deficits in nigrostriatal dopamine 
neurones. 
DLB is characterised by the histological feature of the presence of Lewy 
bodies (an intracellular inclusion of a round hyaline mass) in the cerebral 
cortex and substantia nigra and a disorder of alpha­synuclein metabolism.107­
109 Senile plaques may also be present, but NFTs are absent. Lewy bodies 
are also found in the post­mortem brains of people with Parkinson’s disease 
(PD), Pick’s disease and Huntington’s chorea. However, in people with PD 
without dementia, Lewy bodies are predominantly found in the subcortical 
regions and the loss of choline acetyltransferase (CAT) in the cortex is 
modest.107­109 In PD with dementia (PDD), Lewy bodies are present in the 
cortex and there is pronounced loss of CAT.109 There has been some 
controversy about the diagnosis of LBD and the overlap it has with PDD, and 
this is now linked to the timing of the appearance of a dementia syndrome in 
relation to symptoms of PD.109 
2.1.4 Medicines for Dementia 
Medicines for dementia are enshrouded in controversy, mainly related to 
their perceived lack of cost­effectiveness by NICE31 even though clinical 
effectiveness has been well established.9­12,27,31,110,111 This section will briefly 
describe the medicines licensed for dementia in the United Kingdom and 
mentioned within the study findings. 
2.1.4.1 The Acetylcholinesterase Inhibitors 
These agents are licensed for the symptomatic treatment of mild to moderate 
AD and exert their pharmacological activity by inhibiting the enzyme 
acetylcholinesterase (AChE) to increase the concentration of acetylcholine 
(ACh) at sites of neurotransmission.1­3 Galantamine also enhances the action 
of ACh on nicotinic receptors.3 Although these agents belong to the same 
group they all produce their pharmacological effect in a slightly different way, 
so if a response to one agent is not seen, it is justifiable to try another.38­41 
Anecdotal clinical evidence suggests that approximately one­third of people 
treated respond well; another one­third respond to a degree and the remaining 
third seem to have no discernible response. However evidence shows that 
stopping AChEIs can result in decline in individual functioning and behaviour, 
even in areas where the medicine was not thought to be affecting.111,112 
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The associated common side effect profiles of AChEIs have been illustrated 
previously in Figure 1.1 and care needs to be taken when prescribing with 
concomitant illness such as bradycardia or atrial fibrillation. The individual 
Summary of Product Characteristics should always be consulted prior to 
prescribing. 1­3 
Donepezil 
Donepezil (Aricept®) is once daily dosing with only two licensed dose 
increments (5 and 10mg). 1 This makes it an ideal choice for someone who 
lives on their own or when a complex titration process may not be 
appropriate. It has a half life of 70 to 80 hours meaning that a therapeutic 
level can be reached in about 350hours (14days and 14hours).1 Clinical 
response can take longer than this and for some people improvement 
continues or is maintained over many years.1 Further improvements can also 
be seen by increasing the dose to 10mg if tolerated.1 
Galantamine 
Galantamine (Reminyl®) is available as twice daily or a long acting once daily 
preparation, both of which require titration to achieve maximal clinical benefit.3 
The half life of regular galantamine is 7 to 8 hours so theoretically effective 
serum levels can be reached at about 40hours.3 However increased clinical 
benefit is seen at higher doses of 8 to 12mg twice daily (although actual dosing 
may start at 4mg twice daily).3The long acting form of galantamine (available in 
8mg, 12mg and 24mg strengths) has a half life of 8 to 10hours which 
theoretically means that therapeutic levels are achieved at about 50hours.3 
However the Summary of Product Characteristics indicates that the plasma 
level is not linked to the level of clinical benefits or side effect profile so 
increased dose titration should occur until maximum benefit is reached at the 
maximum tolerated dose. 3,27 
Because donepezil and galantamine can be administered as once daily 
preparations, findings from the AHEAD study demonstrated that these agents 
reduced the overall management costs of AD.113 The authors went on to 
postulate that it seemed galantamine had a greater cognitive affect than 
donepezil which delayed admission to full­time care services.113 However there 
are no head­to­head trials which compare all three agents within the same study 
so these results need to be interpreted with caution.113,114 
Rivastigmine 
Rivastigmine (Exelon®) has a twice daily dosing regimen, with a dose range of 
1.5mg to 6mg twice daily; or a 24­hour transdermal patch (maximum 
9.5mg/24hours) again with the proviso that the maximum tolerated dose 
should be aimed for to achieve maximum clinical benefit.2,27 Its half life is 
between 1 and 2 hours (meaning steady state will be reached in about 
10hours) but with an enzyme inhibitory response duration of 9 hours.2,27 
Rivastigmine is also licensed for the treatment of mild to moderate symptoms 
of PDD.2,27 
Choice of Agent 
Key considerations are patient factors such as concomitant illness or 
gastrointestinal sensitivities which may preclude a certain agent. For example 
these agents can worsen respiratory problems such as chronic obstructive 
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airways disease or asthma, but if thought appropriate a trial with a short acting 
agent such as rivastigmine could be an option. Increasing evidence is accruing 
for the use of the AChEIs in the management of behavioural and psychological 
symptoms associated with dementia as a safer alternative to 
antipsychotics.110,115­117 
2.1.4.2 Memantine: a N­Methyl D­Aspartate (NMDA) Receptor 
Antagonist 
Memantine was the first NMDA­receptor antagonist to be licensed in the United 
Kingdom (September 2002) for treatment of moderately severe to severe AD.4 
NMDA is involved in the regulation of glutamergic transmission. An excess of 
glutamate causes overstimulation of NMDA receptors which allows free­flow of 
calcium into the cell.4,118 Sustained levels of excess glutamate lead to a chronic 
overexposure of calcium, which in turn leads to cell degeneration and ultimately 
cell death. Memantine binds to NMDA receptors to block the glutamate­gated 
receptor channels.4,118 It allows the physiological activation of the receptors 
(which are involved in memory formation) but it blocks the pathological 
activation (which is involved in cell degeneration).4,118 
Memantine may cause significant improvements in cognitive function, 
behavioural disturbance118­120 and global outcomes.110, 118 A Cochrane review118 
highlighted its possible usefulness in treating VaD, mixed dementias and AD 
with increased efficacy and safety demonstrated when used concomitantly with 
AChEIs.121 
Dosing starts at 5mg once daily increasing to a maximum of 10mg twice daily, 
but is reduced in moderate renal impairment. The main side effects are 
hallucinations (5% versus 2.1% in placebo); confusion (1.3% versus 0.3%); 
dizziness (5% versus 2.8%); headache (5% versus 3.1%) and tiredness (1% 
versus 0.3%).4 
2.1.5 Monitoring Response 
There are two types of scales used to monitor response to treatment, subjective 
and objective. Subjective responses are those outcomes that are reported as 
being important to the individual receiving or the clinician monitoring treatment; 
whereas objective responses are those which are measured using validated 
rating scales such as the MMSE.(A1­2) 
The Folstein MMSE was designed by Marshal Folstein in the early 1970’s as 
a ‘mini’ or quick tool to assess “cognitive mental status.” 81It was designed to 
concentrate only on cognition and not to take account of “mood, abnormal 
mental experiences and the form of thinking.” 81 The MMSE is a two part 
scale consisting of eleven questions which cover orientation, memory, 
attention, the ability to follow verbal and written commands, write a sentence 
and copy a drawing.81 (See A1­2) The original validation process was 
completed with a total of 206 people including 38 people with dementia; 63 
normal subjects and the remaining with some form of affective disorder, 
personality disorder or schizophrenia.81 The scores demonstrated 
segregation at <20/30 for those people with dementia, delirium, 
schizophrenia or affective disorder.81 The authors recognised that people 
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with impaired vision were disadvantaged and the tool was not diagnostic but 
one which rated changes in cognition over time. 81 These limitations in 
practical application of the MMSE were supported by a review of its use in 
practice in 1992.112 A statistically significant correlation between the MMSE 
and ADAS­cog in term of assessment of severity of dementia was 
demonstrated by Doraiswamy and colleagues in 1997. 113 
The limitations of the MMSE are well documented122,123 including: environment, 
people with high or low levels of education/intellect, income, race/ethnicity, age 
and gender.124­128 The incidence of false negative and positives when the 
MMSE has been used as either a screening or diagnostic tool in primary care 
has been reported as high by some researchers127,128 yet a meta­analysis on 
the accuracy of the MMSE suggested the MMSE achieved less than 3 false 
negatives in every 100 screened.129 
For people of previously low intellect it is an inadequate reflection of cognitive 
status as individuals may end up with a score that reflects mild or even 
moderate dementia because they had never known the information.126 
Interestingly the use of the MMSE in people of low intelligence was ruled as 
discriminatory in England and Wales and not to be used as a basis for the 
prescribing of medicines for dementia.126 It is unclear why its use in people of 
high intellect is still countenanced when it can give false negatives also.124­128 
When the relationship between the MMSE, a person’s quality of life (QoL) and 
their instrumental activities of daily living (IADL) were explored the authors 
found no significant relationship between cognitive or psychological function and 
social relationships.130 Perhaps these also support the MMSE’s inability to 
successfully monitor changes in softer outcomes such as improved behaviours, 
initiative and sociability. 
In spite of the above limitations the MMSE continues to be chosen by NICE as 
the validated tool to classify severity and monitor response to treatment.27,31 
2.2 The Effect of Dementia on Individuals 
This section will briefly discuss the known effects of living with dementia on 
people with the disease and those that care for them. 
2.2.1 Perception of Self 
Historically there has not been a great deal of research into the experience of 
dementia from the point of view of the individual with dementia. However this is 
changing with a research emphasis on how the individual perceives the effect of 
dementia on relationships,131­133 on awareness of dementia as an illness134,135 
acceptance of dementia136 and sense of self or personhood.134,137­141 Li and 
Orleans suggest that because of the current biomedical viewpoint of dementia 
as a disease “characterised by losses, inabilities and deterioration we lose sight 
of the concept that the individual is still a person.” 141The authors also suggest 
that “respect for persons is predicated upon seeing individual’ as rational, self­
motivated and self­aware.” 141 Perhaps this is the reason that patient reported 
outcomes (PROs) are not routinely sought in PWD as there is an inherent 
disrespect for the person with dementia. 
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Findings from qualitative carer research suggests that for carers their biggest 
distress is the person they care for is no longer themself; their self has changed 
in someway in which they no longer recognise.131,141,142 
What is ‘self’ and is it really different in PWD or are they just adjusting to 
being themselves but different?142 Basting143 describes this process of 
adjusting to living with the symptoms of dementia as “a self in transition” and 
this sense of continually adjusting and re­adjusting of self in reaction to 
dementia has been described by others.132,136,142 For people learning to live 
with chronic illness there needs to be acceptance at a physical level but also 
in terms of their own self identity.135 Western culture places a great deal of 
importance on intellect and memory; almost to the point that without 
complete memory you can no longer be a person.141 This seems to be a very 
inhumane stance. Memories are shared and interwoven and bind people 
together in someway but not remembering does not make an individual a 
non­person. Li and Orleans argue that by appreciating PWD for the things 
they still are rather than what they once were can enable and empower a 
more harmonious relationship.141 
2.2.2 Behavioural Changes 
Behavioural changes in dementia are very common with up to 90% of 
individuals displaying these in such a way as to cause distress and concern for 
their carer and family.119,144,145 Jost and Grossberg tabulated the evolution of 
these behaviours in1996 in terms of their appearance (in months) prior to a 
diagnosis of AD being made.146 First to appear at about 34months prior to 
diagnosis was social withdrawal, followed by suicidal ideation and depression 
at about 25months; then paranoia (about 16months), followed by disturbances 
in diurnal rhythm and anxiety (at 5 to 7 months) with accusatory behaviour 
and mood changes occurring about the time of diagnosis.146 
From this we could surmise that a person living with dementia makes both 
behavioural and psychological adaptations in response to lived changes within 
that disease. It has been postulated that perhaps behavioural and 
psychological symptoms of dementia (BPSD) are a direct response of the 
individual trying to reconstruct their own sense of self within a 
neurodegenerative process.147, 148 It has also been suggested that unresolved 
and unremembered traumatic events from the past contribute to expressed 
aggression and agitation in PWD.149,150 Evidence suggests that PWD rely more 
on non­verbal methods of communication as their verbal skills reduce and 
carers need to be aware of this to help PWD to express themselves more 
completely.151 
Behavioural changes are well known to increase carer stress and carer burden 
and are the prime factor for early institutionalisation.49­51,61,119,144,145 Historically 
BPSD have been treated routinely with antipsychotics even though these are 
not licensed; there is little evidence of efficacy97,119,152 and an associated 
increase in morbidity and mortality.153,154 In 1999 the Ombudsman 
Reconciliation Act (OBRA) legislation in America155 made it illegal to prescribe 
antipsychotics to older people without informed consent, but practice continued 
in this country. In March 2004, the then Committee of Safety of Medicines 
(CSM); issued advice on the use of atypical antipsychotics in PWD in 
30 
England.156 This was followed by professional guidance on the risks of 
cerebrovascular and cardiovascular complications with the prescribing of 
risperidone and olanzapine for the treatment of BPSD.157 Since then many 
studies have outlined the increased risk of morbidity and mortality of typical and 
atypical antipsychotics when used to treat BPSD.158­163 However the practice 
continues perhaps as a response to poorly trained and/or low staffing levels 
which contribute to a less than patient­centred approach to care.164 
2.2.3 Effect on Carers and Families of Dementia 
As previously mentioned dementia can have catastrophic effects on carers and 
family as each adjusts to their individual perception of what is happening.165 It 
has been suggested that perhaps carers’ biggest distress is when the person 
they care for is no longer themself; that is their self has changed in someway 
in which they no longer recognise.131,141,142 
In this section early theoretical models which outline the possible causes of 
carer stress and carer burden will be discussed briefly. Later research exploring 
how couples make sense of the illness and learn to cope and live with it wil also 
be considered. 
Caring becomes a full­time job which includes supervision and changes in 
autonomy and relationship with the person with dementia.143 Changing spousal 
relationships as a result of living with a person with dementia mean a 
renegotiation of the whole relationship including roles, authority and 
autonomy.166­169 The quality of the pre­care giving relationship seems important 
in how well adjustments are made in response to the changing roles.167,168 
These changing roles may cause difficulties in coping which can be 
exacerbated by poor knowledge or understanding of dementia.167 
Pearlin et al in 1990 outlined a theoretical model of caregiver stress resulting 
from a number of interconnected factors that the caregiver was exposed to.170 
These could be primary or secondary stressors; with primary stressors being 
those directly related to the care­giving process and hardship. Secondary 
stressors were described as those occurring outside the role of care­giver (e.g. 
from family or life circumstance) or psychological stress, which ultimately led to 
the diminishment of self­concepts. The authors described these primary 
stressors as: 
• The ability to complete activities of daily living; 
• The level of cognitive impairment, and 
• The frequency of behavioural problems.170 
The full model is illustrated in the table below as it shows the inter­
connectedness between primary and secondary stressors and how these 
influenced carer outcome. 170 The possible impact of ‘mediators’ or interventions 
for caregivers are linked to primary and secondary stressors as well as carer 
outcomes. 170 This simple model illustrates well the complexity of the caregiving 
process. 
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Figure 2.1: Pearlins’ Conceptual model of Alzheimer’s caregivers’ stress. (Adapted from Pearlin 170) 
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Others such as Dumarche et al reasoned that primary objective stressors then 
directly presented as or led to primary subjective stressors which were: 
•	 Role overload, 
•	 Role captivity, and 
•	 Relational deprivation between caregivers and care recipients as

perceived by the care givers.171

A dementia carer’s survey published in 2008 found that the most problematic 
symptoms associated with caring were the inability of PWD to complete 
activities of daily living (68%) and behavioural problems (50%).172 As 
mentioned earlier the contribution of behavioural problems to the premature 
institutionalisation of PWD is well known.49­51,61,119,144,145,173 Research into 
how stress affects the physical and mental health of care­givers 
demonstrates the chronicity of stress is a major determinant in the 
psychological morbidity of the caregiver.174­176 
Li and Orleans proposed that due to the negative biomedical image of dementia 
and dementia care which is projected to the public, carers and PWD see and 
experience mainly negative aspects to living with dementia and caring for a 
person with dementia.141Support and/or resources offered to carers have been 
proposed as key variables which decrease negative psychological stress 
perceived by individual carers.170 These resources and support mechanisms 
have been proposed by Pearlin’s model of carer stress as variables, which 
mediate the stress­health relationship.170 That is they help to lessen some of the 
care burden and associated psychosocial stresses of caring. 
This is an important aspect of supporting carers as several studies suggest that 
carers respond differently to the stress associated with care­giving.171­177 
Campbell’s findings supported a multifactorial role and interdependence of 
stressors and suggested that “caregiver overload, carer­patient relationship 
quality, the experience of adverse life events, caregiver gender, caregivers’ level 
of neuroticism, caregiver role captivity and the level of caregiver confidence 
accounted for over 80% of the variance in caregiver burden.” 178 
Etters et al proposed that individualised multicomponent care interventions are 
needed in order to ease caregiver burden of those caring for PWD.179 More 
importantly such interventions improved health and well­being of the carer179­181 
which positively affected the health and well­being of the person with dementia 
and reduced rates of institutionalisation.177,182­184 Aneshensel et al177 and 
McClendon et al’s183 findings suggest that unrelieved carer stress results in 
poorer outcomes for the care­receiver (physically and mentally) and frequently 
led to institutionalisation183,184 and decreased longevity of the care­
recipient.183,185,186 
More importantly is that sustained stress and lack of understanding of how to 
deal with behavioural problems in a caring role or an inability to accept an 
unwanted caring role can lead to abuse of PWD185,186 and perhaps reduced 
survival.183It then becomes an important part of a GPs role to actively support 
carers in terms of maintaining their own physical and mental health188,189 to not 
only prevent further distress but also prevent harm to the person being cared 
for.183 
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In 2002 Nolan et al brought together key principles needed for caregiving in 
dementia from Aneshensel, Pearlin and others’work187 to develop the Carers’ 
Assessment of Managing Index (CAMI). 187 The most important aspect of this 
work was that the ability of the caregiver to cope and how they coped by use of 
their own caregiving strategies was assessed from their own perspective.187 
Nolan et al’s findings suggested that coping tactics of caregivers included 
problem­solving; cognitive approaches to reconsider a particular scenario and 
strategies to minimise stress.187 Caregivers were proactive in terms of problem­
solving; seeking information and valuing their own expertise in a given situation. 
187 Non­recognition of caregiver expertise has important consequences for 
service providers because if the coping strategies of the caregiver are not 
appropriately recognised by social and healthcare services; then inappropriate 
service provision may occur.187 
A systematic review by Ablitt on the effect of dementia on spousal relationships 
showed there were 3 key factors involved in the ability to live with dementia.188 
These were the way in which dementia impacted on relationship; affected the 
quality of the previous and present relationship and how relationships changed. 
188 The authors proposed a model for well­being and relationships as illustrated 
below. They suggest that the quality of the previous relationship will influence 
the ability to learn to cope with the associated effects of living with dementia 
which can be perceived as both negative (increased carer burden) and positive 
(increased intimacy and mutual well­being). 188 The implications for practice are 
that those with previously good quality relationships will experience the caring 
role as less distressing and less onerous. Those with previously less positive 
relationships will experience high levels of distress, carer burden and 
resentment. 188 By understanding these concepts, healthcare professionals 
supporting caring relationships could perhaps increase carer support and 
education as appropriate but be aware that all caring relationships are 
associated with emotional and physical exhaustion. 188 
Figure 2.2 Theoretical framework for well­being and relationships (adapted 
from Ablitt) 188 
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It hen becomes an important part of a GP’s role to actively support carers in 
teems of maintaining their own physical and mental health189,190 to not only 
prevent further distress but also prevent harm to the person being cared for.183 
2.3 NHS Health and Social Care for Dementia 
2.3.1 Services for Dementia 
It is estimated that informal carers save the UK taxpayer some £6billion pounds 
per year in terms of delayed admissions to care homes; the cost of which is 
equivalent to about 40% of the overall £17billion pounds per year spent on 
dementia care services.192 However, it seems that dementia care services for 
many are not individualised or sufficiently proactive to prevent carer distress, 
breakdown of the caring relationship, and/or early institutionalisation. 49­
51,61,119,144,145,171­177 It has been proposed for the effective delivery of mental 
health services that there are four key principles which should drive the 
intervention: 
•	 Positivity and inclusiveness of the HCPs involved to enable shared 
decision­making with those receiving care; 
•	 Flexible and individualised person­centred care provision, 
•	 Accessible and responsive services which offered rapid response and 
an out of hours approach, and 
•	 Integrated and co­ordinated services which are embedded within the 
mainstream service provision.192 
This review went on to report that although service interventions such as: 
working directly with families; educational programmes and offering breaks from 
caring were common; it was less common to find evidence of carer assessment 
and support packages; information available by telephone or computer­based 
packages or care services which were multi­dimensional or changed according 
to progression of the illness.192 Qualitative evidence suggests that carers 
appreciate integrated care services and proactive access to supporting 
information.193 The early provision of respite and day care services has long 
been recognised as a means of relieving carer stress and/or burden and 
decreasing institutionalisation by as much as 29%.193 Multidimensional 
psychosocial interventions aimed at PWD194­196 and their carers196­198 all 
demonstrate improvements in cognitive functioning, coping, and quality of life 
with one showing a delayed rate of institutionalisation over 5 years.196 
There has been a growth in dementia care mapping services based on the 
philosophy of delivering person­centred care. 199­203 In AD person­centred care 
was first proposed by Tom Kitwood and involved seeing the person with 
dementia as an individual who was still able to experience life and relationships 
but whose personality was increasingly concealed by the disease as it 
progressed.199 He also proposed that person­centred care should take account 
of the individuals personal history and should focus on the individuals current 
ability to do things rather than what they could no longer do whilst supporting 
their individual values, beliefs and rights. 199 Dementia care mapping supports 
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shared decision­making, preserving relationships and recognising behaviour 
from the perspective of the person with dementia.201,202 A cluster­randomised 
trial demonstrated that person­centred care and dementia care mapping both 
reduced agitation in PWD in residential care compared to usual care.203 This 
suggests that greater importance should be placed on adequately training 
formal and informal carers in these approaches to caring for a person with 
dementia. 
The NDS maps out a series of proposed reforms to dementia care service 
provision over the next five years; with funding for the next two.51 These reforms 
have been seen as necessary204 and also as less than evidence­based.205 
However a key proponent of the NDS from inception argues that cost savings 
will only be generated by spending money to improve service provision and 
education of HCPs and service users.206 It is unclear how integrated services 
will arise to support the 17 objectives of the NDS51 but it is hoped that findings 
from the current pilot project aiming to integrate health and social care service 
provision in 16 sites across England may help.207 Just as important to consider 
is the possible impact on workforce priorities in the next 5 years as much of the 
NDS is based on improved educational input to those providing dementia care 
services.208 On a more strategic level is the need for units in dementia care to 
be included in all relevant undergraduate and postgraduate curricula.208 
2.3.2 Therapeutic Relationships 
Therapeutic relationships are built by on­going mutual involvement in 
addressing the needs of the person with an illness and using shared decision­
making to arrive at a mutually acceptable treatment plan. These interactions are 
built on trust and mutual respect of each other’s needs. The current biomedical 
consultation preserves the rights and confidentiality of the individual with the 
medical problem, with no information being shared with others unless the 
patient gives explicit consent. This seems to be the root of some of the 
problems within consultations for PWD and their carers.209 It has been 
suggested that although the therapeutic relationship needs to still focus on the 
needs of the person with dementia, the implications of the diagnosis and 
associated treatment and support package needs also to include the 
spouse/main carer and implications for the wider family.210 
In primary care medicine there has been a move towards patient centred 
therapeutic relationships with a shared decision­making process. The Calgary­
Cambridge approach typifies this process where the relationships are about 
building mutual trust and respect in order to achieve concordant outcomes in 
terms of therapeutic recommendations for treatment.211 As mentioned 
previously the more paternalistic biomedical approach may protect patient 
confidentiality but may actually fail both the person with dementia and their carer 
if a holistic and inclusive approach not fully adopted.79,80,209,210 
Evidence suggests that there is a perception of therapeutic nihilism amongst 
GPs and specialists involved in dementia care and that this negatively impacts 
on shared decision­making.79,80 A study found when psychiatrists actively 
ignored patient’s attempts to describe their psychotic symptoms it resulted in 
unsatisfactory consultation outcomes for the patient.212 This negative outcome 
was also proposed as the reason for lack of long­term engagement with mental 
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health services. 212 Interestingly two survey studies which explored doctors 
attitudes towards the meaning of good medical practice found that poor 
interpersonal skills were not viewed as seriously as failures in technical 
skills213,214 even though service user complaints were mainly based around 
deficiencies in poor manner and communication.214 As mentioned earlier, 
person­centred care which takes account of values and outcomes important for 
the person with dementia and their carer seems to be the best way forward. 
2.3.2.1 The Pharmacist’s Role in Dementia Care 
Pharmacists have been pronounced as the ‘medicines expert’ in a number of 
key health policy documents in the last 10 years,215­218 with many focussing on 
how pharmacists can support people with medicines. In secondary care the 
emphasis of pharmacist input has been one of improving the safer and more 
cost­effective and evidence­based use of medicines.217,218 In 2003 legislation 
changes allowed the advent of pharmacist supplementary prescribers219 and 
then pharmacist independent prescribers in 2006. 220 This has been viewed as a 
method of improving patient access to healthcare in a more timely and effective 
manner allowing medical colleagues to concentrate on more complex cases.220 
In 2004 the community pharmacy contract changed and proposed there were 
three levels of services for delivering medicines associated healthcare from 
community pharmacists.221 These have been described as essential services 
(e.g. dispensing and checking prescriptions, provision of health promotion 
leaflets etc); enhanced services (minor ailment schemes; smoking cessation 
services, physical health clinics) and advanced services (medication usage 
reviews or prescription interventions).221 Medication Usage Reviews (MURs) are 
a planned review of an individual’s medication regimen which assesses 
appropriateness, compliance issues, side effect management and other aspects 
such as provision of information.222 In 2008 the government pharmacy White 
Paper highlighted the success of pharmacist independent prescribers in 
community and primary care and also proposed that community pharmacies 
could become the hub of healthcare information and service provision.223 The 
report went on to suggest that pharmacists could provide vascular assessments 
to support the delivery of health policy aims of reducing cardiovascular disease 
in the UK; and perhaps incidence of VaD in the future. 223 
With respect to dementia services the current community pharmacy contract is 
well placed to support the provision of medicine management services for PWD 
and their carers. However there is little evidence of proactive provision of 
medication management services for people with any mental illness in 
community. It is hoped that the publication of the Mental Health Pharmacy 
Toolkit will support service development. 224 
2.3.3 NICE Guidance 
2.3.3.1 NICE Guidance and Acetylcholinesterase Inhibitors 
The original NICE guidance in 2001 supported the prescribing of AChEIs for 
mild to moderate stages of Alzheimer’s disease subject to limitations as 
follows.27 
• A specialist diagnosis of AD with a MMSE >12. 
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•	 The carers' views of the patient's condition are sought before and during 
treatment with 6­monthly follow­up. Compliance with medication is 
confirmed. 
•	 The medication is only continued when further assessment shows an 
increase or no decrease in MMSE scores, together with improvements in 
behaviour and/or functioning.27 
The revision of NICE 2001 guidance was originally due in December 2003, but 
in 2005 there were conflicting media releases about the original guidance27 
being changed.225 This was denied by NICE who then requested further 
evidence from pharmaceutical companies.226 However in 2006 NICE announced 
their decision to limit the prescribing of AChEIs for moderate AD only.227 The 
new economic model used quality adjusted life years (QALY) which NICE linked 
to improvements in MMSE and ADAC­cog scales at mild, moderate and 
moderately severe stages of the disease. The latter two groups demonstrated 
greater improvements in the rating scales and this was perceived by NICE to 
mean the agents were more effective in moderate and moderately severe 
stages.114 However there are well argued and evidenced hypotheses that 
current rating scales are not actually measuring what needs to be measured 
and that it is inappropriate to use the same scale across the continuum of 
dementia.228 
Further more NICE did not include any costs related to carer quality of life and 
perceived benefits of the medicines because “the effect of the drug would be to 
delay progression of the condition, in which case the carer would still be faced 
at some time in the future with the same difficulties caused by disease 
progression.” (Section 4.3.10.2 NICE HTA)31 This is not evidence­based 
decision­making this is a value­based judgment based on the values of the 
decision­makers not the people living with disease and their carers.114 Various 
groups responded,229 with a joint position statement from the Royal College of 
Psychiatry (RCPsych) Faculty of Old Age Psychiatry, RCPsych Faculty of the 
Psychiatry of Learning Disability and the British Geriatrics Society230 and 
concerned pharmaceutical companies applying for a judicial review.231 The joint 
position paper reminded doctors of their duties under the General Medical 
Council (GMC) as follows: 
“... Whilst doctors have to be mindful of issues of equity and cost­
effectiveness, they should also consider an individual patient's needs and 
the circumstances that might warrant a departure from the general policy of 
NICE guidance.” 230 
Each published guideline from NICE contains a written disclaimer, part of which 
follows next: 
“…The guidance does not, however, override the individual responsibility 
of healthcare professionals to make decisions appropriate to the 
circumstances of the individual patient, in consultation with the patient 
and/or guardian or carer.” 31 
This has been taken to mean that “NICE clearly therefore does not expect its 
guidance to override a clinician’s duty as a doctor.” 230 
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Ultimately NICE’s decision was backed by the High Court232 which resulted in a 
warning that the decision had created “new ethical dilemmas about allocation of 
scarce resources” for older people and that “prescribing drugs according to cost 
effectiveness may be the opposite of the rights based approach.”233 Due to 
increasing use of NICE guidance worldwide the 2006 revision has provoked 
widespread debate.234 It has been suggested that NICE was “failing to take 
patients’ opinions into consideration when rationing healthcare interventions” 
and that these should be considered as part of the appraisal mechanism.114 
Interestingly economic analyses of AChEIs by others have demonstrated 
economic benefit for PWD, their carers and wider society235 and reduced time to 
institutionalisation especially for galantamine.113,236 
Consequent to this controversy prescribing rates of medicines for dementia in 
the United Kingdom remain low, in fact in the lowest quartile of prescribing in 
Europe.51A survey in2003 demonstrated the main reason these agents were not 
prescribed was due to lack of funding from health authorities.6 An audit of 
prescribing rates in the north­west of England in 2006 demonstrated lower than 
expected rates of prescribing from known prevalence rates perhaps related to 
poor funding and poor access by ethnic minorities.7 
2.3.3.2 NICE and the Prescribing of Memantine 
The prescribing of memantine was not considered in NICE 200127 guidelines 
and in the 2006 guidelines it made a statement that memantine should only be 
prescribed in moderately severe to severe disease within the confines of a well 
designed clinical trial.31 This caused controversy230 as the clinical effectiveness 
of memantine had been well established110,118 Positive cost benefits have been 
demonstrated using a resource utilisation in dementia scale237 and adaptations 
of a Markov model.238,239 The potential use of memantine as an ‘add­on’ agent 
to AChEI prescribing to improve cognitive function and activities of daily living 
had also been demonstrated.121 This was seen as a missed opportunity for 
clinicians to help stabilise people in the moderately severe to severe stage of 
the disease and help reduce carer burden.114,230 
NICE however, did not make a ruling on prescribing in mild or moderate 
dementia, whilst giving audit criteria that 100% of people should be offered a 
treatment for moderate dementia if appropriate. The side effect profile of 
AChEIs can exclude many people from receiving these medicines and clinicians 
were advised that memantine could be an alternative choice for select 
patients.230 There is now increasing evidence that memantine is safer and more 
effective to use to treat aggression and agitation in people with AD than 
antipsychotics.118­120 
2.3.4 Perceptions Of Response To Treatment 
Results from randomised controlled trials suggest benefits of AChEIs over a 
wide range of reported outcomes such as mood, cognitive function, activities of 
daily living and behavioural symptoms8­12,23,30,114­117,241 Supporting this is 
increasing evidence that treatment effects seem small but are consistent over 
time.23,240­242 Other authors suggested that even though measured responses 
were statistically significant their translation into meaning in actual clinical 
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practice was difficult and therefore the place of these medicines in therapy 
should be reviewed.243 
The findings of the Alzheimer’s Society Report in 2004 suggested that carers 
used descriptors such as: “seems brighter / happier/ more aware / more active” 
to “calmer / less aggressive” to improved concentration / speech” rather than 
specific responses such as memory or cognitive improvement.30 It has been 
suggested that the outcomes used in randomised controlled trials were a 
requirement of statutory organisations for licensing of the medication rather than 
measurement of the effect of treatment on day­to­day functioning. 244Since 2000 
there have been suggestions that current measures are not addressing the 
outcomes important for PWD and their carers.245­250 More globally in terms of 
treatment for older people, it has been suggested that PWD and carers wanted 
more individualised goals but physicians wanted more distant, policy­oriented 
goals.250 A further suggestion has been that the assessment of treatment 
benefits in randomised controlled trials should include both clinical data and 
patient­based measures in terms of benefits and outcomes.251 
There has been little qualitative research with people with dementia and their 
carers specifically about the effects of medicines for dementia on day­today 
experiences within relationship. Some prescribers’ of these medicines had 
previously voiced concerns about the ethical issues associated with prescribing 
such as: whether they issued false hope to those that cared for PWD and 
whether the regained insight by PWD was detrimental to their well­being. 252 An 
interview study of 12 carers by Huizing et al found that all participants felt a 
delay in the decline of cognitive function was beneficial; however those who 
cared for a person who experienced side effects of the medication felt these 
problems enhanced the time needed for caring.252 
Another study by Traynor and Derring endeavoured through consensus 
agreement between people who took medicines for dementia and their carers 
and prescribers to develop a series of statements, which could be used to 
assess effectiveness of treatment.253 Problems arose when clinicians rated 
improvements differently from people who took the medicines and those that 
cared for them. 253 This discrepancy has been noted in other studies23,246 and it 
raises the need for greater research for outcome assessments for treatment in 
dementia which satisfy criterion from PWD, their carers and prescribers. 
In 2001 Rockwood245 called for prescribers monitoring the effects of medicines 
for dementia to use the Clinician Interview­Based Impression of Change ­ Plus 
Carer Input (CIBIC­Plus) and annotate rigorously the positive changes reported 
by PWD and their carer’s on the CIBIC­Plus. Rockwood reasoned that 
clinicians’ narrative could form the basis of “widespread, systematic qualitative 
studies” to provide greater insight into the treatment effects of medicines for 
dementia and perhaps also illuminate the ‘clinical meaningfulness’ of these 
effects for clinciians.245 Although Rockwood continues to explore treatment 
effects which are meaningful to PWD and their carers these studies are not 
qualitative in design or analyses.247­249 
40 
2.3.4.1 Predicting response 
There seems to be no consensus of predicting which individuals may respond 
better to AChEIs. An Italian study measured the short latency afferent inhibition 
(SAI) as a means of predicting response to AChEIs.254 Findings suggested that 
if individuals with an abnormal baseline measure were given a single dose of 
rivastigmine and their SAI level improved then these individuals did better on 
rivastigmine than those with a normal SAI on baseline. 254 A retrospective study 
over 4years demonstrated that people with LBD or PDD did better on AChEIs 
than other diagnoses including AD.255 Interestingly they also found that people 
with mild dementia had a ‘cognitive’ response (as measured by a 2 point 
improvement on the MMSE) but not a ‘clinical’ response (defined as “those 
patients in whom the prescribing clinician decided that their response at 
reassessment was sufficient to recommend the GP took over prescribing.)” 255 
Treatment with AChEIs and memantine remains a controversial issue, although 
much of this controversy is centred on cost and conflicting opinion on what is 
indeed a valid response.243,245­250 It has long been established that AChEIs 
delay disease progress by about six months, but there is increasing evidence 
that some individuals may benefit for periods up to four years.256­258 
Interestingly a post mortem necropsy study in 2007 has shown possible benefits 
at a pathophysiological level in terms of reducing the amount of beta­amyloid 
protein being deposited in the brains of people with a dementia.259In the brains 
of people who had been treated with AChEIs there was a 70% reduction in 
parenchymal deposition of cortical ß­amyloid.259 This implies that there is actual 
change at a neuronal level perhaps resulting in a neuroprotective effect of these 
agents in the brains of people with dementia. 
In summary it is clear that the treatment and support of PWD and their carers is 
very complex and possibly one requiring a quantum shift of thought as to what a 
useful response actually is from the perspective of the person taking it and 
those that care for them. This may mean an acknowledgement that successful 
outcome criteria for PWD and their carers may be different than those of HCPs. 
2.4 The Aims and Objectives 
The proposed research was a two­part study, where the overall aim was to 
explore lay perspectives of the efficacy of medicines for dementia and how they 
impacted on living with a dementia. 
The objectives of phase one were to explore: 
1.	 the lay perspective of the use of these medicines in practice. 
2.	 lay perceptions of the outcomes of medicines for dementia and their 
affect and effects on living with a dementia. 
3.	 if participants perceived they were involved in decision­making and 
prescribing processes. 
4.	 the experience of the provision of support and information from

healthcare professionals.
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The second phase was a longitudinal study designed to explore the effects of 
medicines on people with early dementia and their carers over time. The 
objectives of this part of the study were to: 
1.	 explore lay and healthcare professional perceptions of the outcomes of 
medicines for dementia. 
2.	 explore whether there was consensus on perceived efficacy over time. 
3.	 explore perceptions on how medicines for dementia should be used in 
early dementia. 
4.	 to highlight the potential role of the pharmacist in supporting medication 
use in people with early dementia and their carers. 
5.	 to identify possible areas of educational need for healthcare

professionals.
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CHAPTER THREE: METHODOLOGY & METHODS 
PHASE ONE 
3.1 Introduction 
The first phase of the study was designed to explore what the attitudes and 
concerns of people that were taking or had taken medicines for dementia and 
the carers of these people may hold about these medicines. 
3.2 Aims and Objectives 
This phase of the research study was designed to provide qualitative evidence 
of the perceived effectiveness of medicines for dementia in a community setting 
(as compared to a clinical trial setting) by the person with dementia and their 
carer. The study proposed to recruit a number of local branches of the 
Alzheimer’s Society from the Southwest to invite members to take part in either 
a focus group or face­to­face interview to share their views and beliefs on 
medicines for dementia. It was hoped results would provide valuable information 
to aid in the education and training of healthcare professionals involved in the 
provision of a medicine for dementia in primary care settings. 
The aim of this phase of the research was to explore lay attitudes and concerns 
about medicines used for dementia. 
The objectives of phase one was to explore: 
1.	 the lay perspective of the use of these medicines in practice. 
2.	 lay perceptions of the outcomes of medicines for dementia and their 
affect and effects on living with a dementia. 
3.	 if participants perceived they were involved in decision­making and 
prescribing processes. 
4.	 the experience of the provision of support and information from

healthcare professionals.

3.3 Ethical Considerations 
Both people with dementia and their carers can be described as vulnerable 
subjects in research260 therefore multi­centred research ethics approval was 
needed before the study started. Prior to this application the research protocol 
had to satisfy the local University of Bath research ethics procedures for 
research protocols.261 The study protocol was submitted to the Department of 
Pharmacy and Pharmacology’s peer review process and reviewed by Dr Jenny 
Scott and a photocopy of her comments can be found in Appendix A3­1.The 
outline of the study was presented at the Department of Pharmacy and 
Pharmacology’s Research Seminar on the 6th April 2005 and discussed at a 
Carer Meeting at a local memory clinic, on the 13th June 2005. At this meeting 
carers suggested that separate interviews and focus groups should be held for 
the person with dementia so that shared sensitive information would not cause 
upset. They also thought the person they cared for (in the early stages of 
dementia) would be able to make the decision on whether to participate or not in 
an interview or a focus group on their own. 
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An application was submitted to the Central Manchester Local Research Ethics 
Committee (LREC) for multi­centred approval in June 2005 and final approval 
was granted 15th August 2005. (A3­2) The participant information sheet, the 
topic guide and the consent form can be found in Appendix A3­3 to A3­5 
respectively. Ethical considerations are outlined in further detail below. 
3.3.1 Consent issues 
People with mild dementia that are taking medication are often able to give 
informed consent. In order to be able to give informed consent the capacity of 
the person to do so must be assessed. Basically there are 4 main stages in 
assessing the capacity of a person to give informed consent these are: 
1.	 The person must be given sufficient jargon­free information in a format 
which they prefer (this could mean verbal, written, or audiovisual). The 
information must be presented to the person in a way in which they can 
understand it. Often people require a verbal explanation as well as a 
written information leaflet. 
2.	 The time to weigh up and consider the meaning of the information and to 
ask questions if appropriate 
3.	 The ability to take any risks and/or benefits into account when making 
their decision, 
4.	 Be able to convey their decision to another. 262 
Once a potential participant contacted the lead researcher for further 
information, the reason for the study was explained in further detail and what 
their involvement would be if they decided to take part. That is, it was explained 
they could either be part of a small group of people who met once only to 
discuss various issues about these medicines; or they could have a one­to­one 
interview. It was explained that if they were to get upset during the session by 
one of the questions, then they would be able to leave the group or stop the 
interview. It was also explained that the group session and/or the interview 
would be tape­recorded to help the researcher to gather all the information 
accurately. 
At this stage the potential participant was asked if they could summarise the 
information they had received and make a decision as to whether they wished to 
continue or not. If the person seemed able to do this process; then this 
demonstrated capacity to give informed consent.262 Jan Dewing has called for a 
“person­centred approach” to gaining consent from PWD to ensure that each 
individual has the consent process tailored to their individual needs without 
losing the replicability of the process.263 This is emphasised by McKillop and 
Wilkinson who also argue that time, place of consent; the communication style 
and the comfort of the individual are al important factors to gaining truly 
informed consent at any stage of the dementia process.264 
3.3.2 Participant Emotional needs 
Focus groups were to be held at the local branch meeting area and face­to­face 
interviews could also take place here or at the individual’s home. This was to 
ensure that participants felt able to make a choice about where they would feel 
most comfortable to take part. 
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Although participants freely enter their thoughts and opinions within an interview 
or focus group it is recognised that perhaps issues may be discussed or be 
reflected upon in a different way after an interaction with a researcher. This has 
important issues for the continued well­being of the participant so it was agreed 
with each branch lead if there were any incidences of emotional distress during 
the course of an interview or a focus group, then the following would occur: 
•	 The interview or focus group would be suspended until the participant 
was able to recollect themselves 
•	 During this time the tape recording would be stopped 
•	 The researcher would ask about any input that was needed 
•	 The participant could then decide whether to withdraw or continue 
If a participant were to become distressed the local branch manager would be 
telephoned by the researcher and informed of the event. The local branch lead 
would then contact the participant to offer advice and support. 
3.3.3 Researcher Safety 
Participants who requested interviews took place in their own home were 
informed they could have a friend or relative present if they wished. This was so 
they would feel as relaxed as possible during the interview. As the researcher I 
also had to account for my safety and as such agreed to inform my supervisor of 
when such interviews would take place and agreed to telephone prior to 
entering the home and on leaving the home to ensure an audit trail was 
available. A designated research phone number was used on all information 
sent out for the study in response to a request from the MREC approval 
decision. 
3.3.4 Data Protection and Confidentiality 
The Data Protection Act265and the NHS Confidentiality Code of Practice266 
guided the development of the ethical approval application and the development 
and the design of the research in terms of patient confidentiality and the 
management and utilisation of all data collated. Underpinning this important 
legislation were the Data Protection guidelines of the University of Bath267 which 
were also followed to ensure the safety of potentially sensitive information. The 
written and recorded versions of the focus groups and interviews will be kept in 
a locked secure cupboard within the locked office of the lead researcher for a 
period of 10 years when they will be destroyed appropriately. 
During transcribing each recording was transcribed as Focus Group (or 
Interview) 1 or 2 for example, as appropriate and all potentially identifiable 
names and places were removed in order to protect the confidentiality of the 
participant. However when using quotations all participants were assigned a 
pseudonym to protect their identity and to facilitate the narrative to depict a lived 
experience by real people. 
All names and addresses and contact telephone numbers of participants 
requesting an interview at home were destroyed after each interview as were 
names and addresses of participants requesting a summary of key findings 
once these were sent. At all other times sensitive data were stored in a locked 
and secure environment according to data protection guidance.265,267 Data was 
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stored on and analysed on University computers and/or laptops which were 
password protected and kept in locked offices.267 
3.4 Methodology 
Qualitative methodology and methods were appropriate for this study as the aim 
was to explore in greater depth the way in which the medicines for dementia 
affected the day to day lives of people who took them and their carers, therefore 
quantitative methodology would be inappropriate as this would only result in 
numerical information.268­271 Linda Finlay271 describes the process of qualitative 
research as “rather like going on a journey” and it seems that this journey takes 
place outside of the constraints of figures and statistics and in the realm of 
experienced phenomena. Of course there is a multitude of methodologies under 
the umbrella term of ‘qualitative research’268­272 so it became important to 
understand very clearly the focus of the research question. 
The underlying supposition was that if we knew how these medicines could 
change or affect behaviours and lifestyles of both the person taking them and 
those caring for them then healthcare professionals may be better placed to 
support these people. So this was about the philosophy of phenomenology. 
How did taking these medicines affect day­to­day lives of each participant; how 
was this experienced in terms of their ability to take part in usual daily activities 
such as relationships or completion of tasks? These points of interest were not 
existential or descriptive but idiographic in that they were more about the 
individual participants’ physical, cognitive and affective responses. This can also 
be termed Interpretative Phenomenological Analysis.273­276 
Phenomenological approaches to qualitative research support the use of in­
depth semi­structured interviews and focus groups as they allow the 
participant(s) to talk about and describe their experience in their own words and 
relate importance to the experience or not as relevant to themselves.273­276 
These methods also allow greater insight into the phenomena being explored 
(medicines for dementia) and the resultant effects (phenomenon) within the 
relationship and their lives.273 In terms of a philosophical position; 
phenomenology is generally seen to be one of a “constructivist­interpretive 
paradigm.”271 This is because phenomenology recognises that there may be 
multiple meanings and that experiences and realities are all subjective (that is 
events are interpreted by the person experiencing them who then makes sense 
of them using their own experience, knowledge and life history in order to come 
to an understanding of what actually happened). 
Point of 
Reflexivity 
What was interesting was that as the researcher I would be 
going through the same process when interviewing or 
facilitating a focus group and listening to resultant narratives 
and so I needed to be aware of this double hermeneutic 
experience. 
46 
3.4.1 Methods 
As mentioned earlier it had been decided that carers and PWD would be 
interviewed on their own or attend a separate focus groups. This was an attempt 
to reduce possible participant distress if sharing potentially sensitive and 
personal information in front of others which may have led to discord. 
Point of 
Reflexivity 
With greater than 16 years experience of working with older 
people and completing a Masters by Research in this 
population group I felt able to handle possible incidents of 
participants becoming upset or fractious. However, the local 
branch contact member would also be on standby in case a 
participant needed to be taken somewhere private or needed 
to talk to someone after an interview had finished. 
3.4.1.1 Focus group methodology 
Focus groups for carer participants were chosen as the original methodological 
basis of the study as they promote discussion and interaction on the subject of 
importance and allow participants to almost converse with each other as they 
describe their experiences and/or beliefs.277 This process is ‘naturalistic’ in that it 
allows participants to communicate in a more natural manner and often includes 
a variety of processes such as teasing; explanation; story telling and often 
heated debate or the sharing of personal experience.277,278 
Although focus group methodology has been used for many years as a 
marketing tool to try and define public opinion on a specific item,277 they were 
originally used in the 1920’s to support the development of survey 
instruments.278 In the 1940’s Robert Merton’s research team implemented 
‘focussed group interviews’ to explore public response to radio programmes of 
the day.275 
Focus group methodology seemed an ideal way for participants to explore 
individual questions from the topic guide and share with others their own 
experiences and comment on and learn from those of others. This is almost like 
facilitating a group discussion in a semi­structured way; whilst encouraging each 
member of the group to express their own opinion and to steer conversation 
back on track if a side road is taken. 
Focus groups should ideally consist of 6 to 10 participants in order to promote 
conversation and productive interaction, without the risk of the session 
becoming unmanageable if too many people speak at the same time.277 I was 
the group facilitator and aimed to follow the topic guide for each session (A3­4). 
The aim of the facilitating style was to be non­directional and to encourage 
participation from all members. However the order of introducing the topics was 
flexible in response to the dynamic interaction of the group and dependent on 
the narrative that the participants were following. Flexibility was needed in order 
to ensure that participants were not interrupted in such a manner that could 
impair their interaction within the focus group members.277,278 
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It was anticipated that each session would last approximately 40 to 60minutes 
and would be recorded, with the written consent of all participants, using a 
cassette−type recording device with multi­directional microphone. 
On the day of the focus group session, participants were asked to sign a 
consent form (A3­5) agreeing to take part and for the session to be recorded. 
Participants were reminded about the confidentiality of any personal information 
that was shared during the session. They were also reminded that if they 
became upset, they would be asked if they wished to continue or to leave the 
group and that during this time the recording device would be stopped. 
Participants were also informed that if they wished to leave during the focus 
group session for any reason then they were welcome to do so. 
3.4.1.2 Semi­structured Interview Methodology 
It was envisaged that some people taking medicines for dementia, may have 
insight into their disease and therefore give valuable reflection on receiving 
medicines for dementia. Therefore if they wished to participate in the research 
and were able to give informed consent they were eligible to participate. Semi­
structured interview methodology was originally chosen for participants with 
dementia as my previous experience suggested that PWD may prefer an 
interview in preference to attending a focus group. This is because even in mild 
dementia people may have difficulty in concentrating on the conversations of 
greater than one person at a time. Although this approach was intuitive at the 
time of designing this part of the study, McKillop and Wilkinson support the 
reduction of background noise and the use of face­to­face interviews.264 
However, at location 4 the participants with dementia expressed a wish to be 
interviewed together in the same place at their support group meeting. On 
reflection this seemed a reasonable request and was supported by McKillop and 
Hutchinson who suggest that if several people wish to be interviewed together it 
should be considered and should take place in a setting where they all feel safe. 
264 
Pre­study communication with local branches of the Alzheimer’s Society also 
raised the issue that some carers were not able to drive and that they also 
wanted to express their viewpoints via a face­to­face interview. 
As well as the above reasons, people may have personal or confidential 
concerns as to why they do not wish to take part in a focus group. For this 
reason carers and people with mild dementia who wanted to participate and 
who were able to give informed consent, were offered a face­to­face interview 
with the researcher, either at the local branch or in their own home. 
The interviews were semi­structured276,279,280 in that although they were based 
on the same topic guide used for the focus group sessions (A3­4), questions 
would not be asked in any particular order but rather as a response to where the 
narrative had led from a previous question. Also depending on a participants 
response further questions could be asked to explore interesting responses. 
The interview itself was informal and the questions asked in a language that 
was comparate to the participant. It was intended that each interview would last 
20 to 30 minutes and would be tape­recorded (with informed written consent) to 
ensure accuracy of any findings. It was also reiterated to potential participants 
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they may wish to be interviewed away from the person they cared for or 
correspondingly the person that cared for them. 
On the day of the interview participants were assessed as for capacity to give 
consent. In the cases of people with dementia, this process was observed by 
the local branch representative or their carer. Participants able to give consent 
to take part in the research were asked to sign a consent form as detailed above 
(Appendix A3­5). 
3.4.1.3 Development of the Topic Guides 
The topic guide (also referred to as an interview guide)280 is a means of 
ensuring that all potential areas of interest to the aims of the research question 
are covered. 
The Topic Guide can be found in Appendix A3­4 but ultimately aimed to explore 
attitudes and beliefs about: 
•	 the efficacy of the medication 
•	 perception of the success of treatment 
•	 medicine management issues e.g. adverse effects, compliance, dosing or 
titration problems; positive and negative effects on their day­to­day life 
•	 whether the medication taken by the person they care for effects their 
own day­to­day life (and in what way) 
•	 when they feel these agents should be withdrawn 
•	 their role in the decision­making process with the prescribing team and 
their perceived rights to be involved in this process 
•	 to determine views on outcome measures to determine efficacy of

treatment

3.4.2 Sampling and Recruitment 
The sampling framework was determined by the desire to recruit participants 
who would reflect the general population living in the community of people 
taking medicines for dementia and those that cared for them. Rather than 
advertise through newspapers or via outpatient clinics it was decided to use the 
local branches of the Alzheimer’s Society as the sampling frame. The potential 
population sample were all people attending their local Alzheimer’s Society 
branch living in the South­West of England. The actual sample was those that 
agreed to take part in the study. Sample size therefore was to be determined by 
the recruitment procedure at participating branches. 
3.4.2.1 Branch selection 
Alzheimer’s Society local branches were chosen as recruitment sites as they 
offer support to PWD and those that care for them, and therefore would have a 
local membership which was likely to include carers and PWD who took 
medicines for dementia. As lay perspectives were the focus of the study, 
recruitment was not held via local memory clinics or Old Age Psychiatry 
organisations because there was a chance that people selected from these 
centres may be part of a research study where they might not know if they were 
taking an active medication. There was also a desire to gain a broader 
population than those attending a memory clinic, who may have a more severe 
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illness or other factors which might influence their experience of medicines used 
for dementia. 
The details of all Alzheimer’s Society local branches in the Southwest in 2005 
were obtained via the internet281 and at the time of recruitment there were ten 
branches with named local branch managers and a local branch office. 
All branches were approached by letter describing an outline of the proposed 
study (Appendix A3­6). They were asked whether they would be willing support 
the study if felt appropriate for their local branch. This resulted in recruitment 
being dependent on the local branch managers’ decision. If branch managers 
felt able to support the study they were asked to complete and return the 
enclosed expression of interest form to the lead researcher. 
3.4.2.2 Participant recruitment 
The local branches agreeing to host the study were asked to advertise the study 
via a short announcement at one of their carer support days and/or placing 
advertising flyers on their notice board. (Appendix A3­7) For those who agreed 
to support the study discussions were held about the best way of notifying 
potential participants of the event with two local branch leads expressing the 
wish to contact people directly who they thought would be willing to take part in 
the study. This would be especially useful in identifying people with mild 
dementia within the local region as it was the intention to interview at least one 
person with dementia at each of the recruitment sites. 
Local branch leads suggested they would only offer participant information to 
those people they thought would be suitable. (A3­3) It was decided that the 
participant’s General Practitioner need not be informed of their inclusion in the 
study as it was for a one off event and no medical information would be 
accessed. The information leaflet explained the study in further detail and also 
directed potential participants to contact the lead researcher directly if they 
wanted to take part and/or if they required further information. People had at 
least one month to decide whether or not they wanted to take part, as dates 
were determined in advance by the activities of the local branch. 
3.4.2.3 Inclusion and Exclusion Criteria 
All people who attended a participating branch of the Alzheimer’s society and 
were taking or who had taken a medicine for dementia and who were able to 
give informed consent were eligible to take part. The carers of people who were 
taking or who had previously taken medicines for dementia were also eligible to 
take part in the study. People who were unable to give informed consent were 
not eligible to take part in the study. 
3.4.3 Data Handling 
Data handling, storage and analysis was guided by the Data Protection Act262 
the NHS Code of Confidentiality266and the University of Bath’s Data Protection 
Policy.267 
3.4.3.1 Recording and Transcribing 
Focus groups and interviews were audiotaped, with participants’ written consent 
and then transcribed verbatim whilst protecting confidentiality of each 
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participant. The recording devices used were two cassette recorders with multi­
directional microphones to collect as much detail as possible. 
Recorded sessions were initially transcribed by Departmental secretaries with 
some experience in transcribing. However, all transcriptions were checked by 
the researcher at least once because of the secretaries’ unfamiliarity with the 
research area and some of the terminology and language being used. This 
meant that the researcher could clarify any ambiguities and edit areas where 
sound quality was poor. This enabled the researcher to relive the interview or 
focus group experience and gain greater depth of understanding from actually 
listening to the tonality and expressions of the participant/s and relate this to the 
narrative arising from the transcription. During the transcribing process all 
identifying names, places and organisations were removed to ensure participant 
confidentiality.266 After transcribing, each recorded piece was converted into rich 
text format in order for processing by NVivo® a qualitative computer data 
package software system designed to facilitate data handling and analysis.282 
3.4.3.2 Methods for Coding and Analysis 
The analysis of the transcriptions was explored using Interpretative 
Phenomenological Analysis (IPA).273­276 This methodological philosophy was 
chosen because of the nature of the relationship between the researcher and 
the research area. With many years of experience of working with older people 
and nearly 8 years in the field of dementia I needed to allow participants to tell 
their own story with their own words. IPA recognises that the interpretation of 
this could be influenced by personal and professional experience in this area.273­
275 By acknowledging this potential conflict and potential for researcher bias IPA 
demands constant reassessment of the analytical process in relation to the 
experience of the individuals’ experience and not that of the researcher.273­275 
The aim of IPA is for the researcher to explore the way in which participants 
make sense of a life experience (i.e. receiving a medicine for dementia).273­276 
An idiographic approach to analysis takes place where each interview is 
analysed for particular examples before moving on to categorisation. This is 
done several times to ensure new insights are not lost before then moving on to 
naming emerging theme titles. These titles should clearly illustrate the 
theoretical connection with the original experience. Emergent themes are then 
sorted into clusters and superordinate concepts.273­276 Recurrent themes, 
common links, patterns of experience, internal differences are then mapped and 
tested to create categories that transcend the individual experience and capture 
what it means to be engaged in taking medicines for dementia or caring for 
those that do.273­276 
Subsequent interview analyses builds on repeating patterns and allow emerging 
themes which may be divergent or convergent. This iterative and interpretative 
stance allows the recognition that participant accounts may be similar but 
different which in turn enhances the richness of the findings as the researcher 
returns to previously analysed transcripts and reviews these in light of new 
findings.273 
The aim of IPA has been described by the School of Psychology Birkbeck 
University of London as “trying to understand lived experience and with how 
participants themselves make sense of their own experience.” 283 This means 
51 
that the researcher is trying to understand the meanings that those experiences 
may hold for the individual. This process is phenomenological because it aims 
to explore this understanding without producing an objective record of the event 
itself. It is also interpretative because as stated above, the researcher has their 
own conception’s through which they make sense of the world and experiences 
and they therefore use these concepts in an interpretative manner to explore the 
experiences of the participants lived experiences.273 
IPA is a relatively new qualitative research philosophy which was developed 
specifically for the area of psychology.273,274 However with the emphasis of 
biomedical care shifting more towards patient­centred care this process lends 
itself to researchers in health and social care. Phenomenology originated from 
work by Husserl272 at the start of the twentieth century, who attempted to 
construct a philosophical science of consciousness. His work was taking place 
at the same time that psychology was being founded as “the study of 
consciousness.” 272 From this early start phenomenological research has 
developed into a means of exploring an individuals’ experience of a phenomena 
in the actual context in which it occurred. This is often termed the “life world” of 
the individual.273 
Phenomenology then became linked with the theory of interpretation or 
hermeneutics which allow greater exploration of an individual’s experience or 
life world. In the 1930’s symbolic interactionism emerged which allowed the 
exploration of an individual’s sense of meaning from a particular life experience 
to be interpreted via social engagement.272 
Each transcript was coded in NVivo® using an inductive process. This means 
that prior to the coding process the final transcription was reread at least twice 
to update the setting of the participant and the interaction between the 
participant and the researcher.273,274 This allowed the coding to occur with a 
background understanding of the session. Then each sentence was explored 
for coding as appropriate. The process of analysis and coding will be 
described in greater depth in section 4.1. 
3.5 Recruitment 
This section will discuss the recruitment process of local branches of the 
Alzheimer’s Society in the Southwest and the resultant participating branches. 
3.5.1 Recruitment of Local Alzheimer’s Society Branches 
A total of ten local branches of the Alzheimer Society in the Southwest were 
contacted by letter and/or telephone to ascertain their interest in supporting the 
study. Of these there was one outright refusal; two branches who expressed an 
interest but were unable to support the study because of local branch re­
organisation commitments; two branches who agreed to organise focus group 
meetings but had to cancel these due to unforeseen operational difficulties, one 
branch who advertised the study in their local newsletter but received no replies 
and four acceptances. 
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It became apparent throughout this phase of the study that each branch 
operated slightly differently in accordance with local health and service 
organisations in place. This also meant that there was also different service 
provision and information available to local branch members. Table 3.1 outlines 
service provision in greater detail. The effect of this on access to medicines or 
support services by both PWD and their carers is discussed in further detail in 
section 4.2. Also dependent on the local circumstances, branches were able 
either to assist with hosting a focus group or in contacting people thought 
appropriate for and/or who might be interested in participating. 
3.5.1.1 Location One 
This branch was very interested in supporting the study and rang as soon as 
they had received the letter and prior to ethics approval being obtained. This 
branch is set in a village in a rural part of the southwest with some 
interconnecting bus service; but a high reliance on personal transport. Because 
of this issue and in organising a focus group at the local branch, individuals 
wishing to participate indicated a request for a one­to­one interview to be held in 
their own home. Anecdotal comments from the manager of the local branch also 
indicated that they did not wish to talk about their views and beliefs in front of 
other people. Five people were identified who wished to participate in the study; 
four female carers and one male person with dementia. 
All wished to participate in one­to­one interviews. Except for the first interview 
where the male participant with dementia and his carer were interviewed at the 
same address, in separate interviews; all other interviews occurred when the 
person they cared for was at a day centre. 
3.5.1.2 Location Two 
This branch also covered a large rural area and provided services from the 
nearest largest town. In the time leading up to this study the local Mental Health 
Trust had closed the one specialist ward at the local hospital for PWD. This 
included some day services. This had resulted in carers not having access to 
support as usual and it was not possible to organise a carer focus group 
meeting because there was an inability to buy in sitting services for the people 
that they cared for whilst they took part in a focus group. Hence this locations 
participant’s all opted for one­to­one interviews in their own homes, with two of 
the 4 participants having the person that they cared for present during the 
interview. These people had moderate to moderately severe dementia and sat 
relatively quietly during the interview process with no contribution to the 
interview itself. One participant had her cousin in attendance as a means of 
moral support. There were no people with mild dementia identified as being 
suitable to take part in the study at this location. 
3.5.1.3 Location Three 
This branch covered a large area and were keen to be involved. The branch 
lead supported the organisation of a carer focus group, which originally had 7 
participants taking part. Unfortunately due to a number of unforeseen 
circumstances on the day, (illness; a fall resulting in a fracture neck of femur; a 
social service review and a consultant appointment) only 3 people took part on 
the day. The branch lead was in attendance for about 10minutes at the start of 
the session as she wanted to know exactly what was going on. Participants who 
were unable to attend gave their permission to be contacted at home for an 
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interview, but due to timing only one further carer and a person with mild 
dementia participated in the study. 
3.5.1.4 Location Four 
This branch supported the organisation of a separate focus group for carers and 
for people with mild dementia who wanted to participate. The original focus 
group for carers was cancelled due to unforeseen circumstances and was 
rescheduled. There were 12 participants including the branch lead. 
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Table 3.1: Local Branch Specifications*

Factor 
Demographics 
Location One Location Two Location Three Location Four 
Total population 157,800 125,370 188,564 117,485 
Predicted Number of People 
with Dementia in this area 
Don’t know 1500 3217 1300 
Registered Members at 
Local Branch 
Carers and PWD Involved with approximately 
150 families including 
carers of PWD 
Figures for April to September 
2005: 224 carers, 225 PWD 
Carers, PWD and former 
carers 
Main Client group e.g. all 
ages, >65years 
All ages are welcome but 
no under 65’s at present 
Mainly over 65’s All ages All ages, but mainly >65’s 
Is there a local memory 
clinic? 
Two, about 20miles apart Yes run by local MH Trust Yes; one based at the city’s DGH 
and one to the north of the patch 
No 
Is there Day Centre provision 
locally? 
Three places provide 4 
days per week; two places 
provide one day per week 
General day centre, not 
specifically for PWD 
Yes, available in both localities Very little for PWD 
Is Consultant access readily 
available? 
Yes Yes Yes Yes, however some GPs 
reluctant to refer into 
service 
Local services/support 
offered by local branch 
Carers support group; 
including PWD 
Information; relief care 
service; carers group; home 
visits; on­going support and 
help­line 
Carer/family support (including 
home visits); carer support 
groups; support groups for PWD; 
befriending scheme and tea 
dances 
Monthly support group; 
monthly lunch club; 
outreach work; telephone 
support line; resource 
library 
Local services/support 
offered by local MH services 
Carers support workers 
attached to GP surgeries 
for ALL carers. Not sure but 
I think all are available. I am 
unaware of a problem now. 
Feel becoming less and 
less. Recent closure of 
specialist ward 
Local prescribing issues e.g. 
are all dementia medicines 
available or just one or two 
Unsure Not known, personal experience 
indicates most people prescribed 
Aricept; one consultant is known 
to prescribe memantine 
All available, very limited 
access to memantine 
*Taken verbatim from responses from local branch leader 
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There were 3 participants in the focus group for PWD. Each person with dementia 
was informed of the study by the branch lead, (with permission of their main carer) 
and was given the information leaflet (A3­3) to read and then discuss with her 
and/or their carer. Originally four PWD had indicated they would like to take part; 
but one had become so anxious about participating he had not slept the night 
before and was quite troubled. He was reassured that he didn’t have to take part 
and could just resume his usual activities at the group event. 
3.5.1.5 Non­participating Branches 
Branch 5 declined any interest in the study, with branches 6 and 8 offering to 
support the organisation of a focus group for carers, but due to changes in the 
national management of the Alzheimer’s Society branches were unable to support 
them to completion. Each was cancelled a few days before the event. Branch 7 
placed an advertisement for the study in their local newsletter but no expressions 
of interest were returned and branches 9 and 10 had changes of local 
management which precluded their ability to take part. 
3.5.2 Study Participants 
In all, five PWD took part in the study; two participated in face­to­face interviews 
(one in location one and the second in location 3) and the remaining three took 
part in the focus group at location 4. The branch at location 2 was unable to 
identify any PWD who would be suitable for the study. The local services had 
recently been cut for PWD and those that cared for them so there was also 
difficulty in general communication with and support of these people. In total 
twenty­three carers of PWD participated; 9 had face­to­face interviews in their own 
homes and 14 took part in one of two focus groups. 
The demographic details of the participants are laid out for clarity in table 3.2. 
Although two branch members observed sessions (location 3 and 4); their 
comments and details are not included in the results due to their observational role 
in the focus group. Where age ranges are given, these were supplied by the local 
branch lead for missing data. 
56 
Table 3.2: Participants in Phase One

Location 
Number 
Study 
Name 
Participant 
Number 
Person 
with 
Dementia 
Carer Gender Age 
Date of Session 
Focus 
group 
Interview 
1 Jack 1 Male 65 21.09.05 
Ann 2 Female 65 21.09.05 
Pat 3 Female 67 21.09.05 
Jill 4 Female 80 22.09.05 
Doris 5 Female 72 22.09.05 
2 Mavis 6 Female Early 70’s 05.10.05 
Sue 7 Female mid 60’s 05.10.05 
Lyn 8 Female Early 80’s 05.10.05 
Jenny 9 Female Late 70’s 05.10.05 
3 Jane 10 Female Early 50’s 12.10.05 
Mary 11 Female 74 12.10.05 
Wendy 12 Female 78 12.10.05 
Peter 24 Male 60 04.11.05 
Thomas 28 Male 77 01.02.06 
4 Andrea 13 Female 79 03.11.05 
Liz 14 Female 79 03.11.05 
Bob 15 Male 85 03.11.05 
Diane 16 Female 80 03.11.05 
Mandy 17 Female 63 03.11.05 
Steve 18 Male 86 03.11.05 
Fred 19 Male 82 03.11.05 
Sarah 20 Female 79 03.11.05 
Angela 21 Female 68 03.11.05 
Paul 22 Male 77 03.11.05 
Helen 23 Female 61 03.11.05 
Tim 25 Male 76 17.11.05 
Sandy 26 Female 72 17.11.05 
Philip 27 Male 73 17.11.05 
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CHAPTER FOUR: RESULTS AND DISCUSSION PHASE 
ONE 
This chapter will briefly explain the analytical process using Interpretative 
Phenomenological Analysis and then discuss key findings from phase one in 
each of the three identified superordinate themes 
4.1 Data Coding 
After the final transcription was passed as complete by the researcher it was 
time to start the data analysis. Analysis started in order with the very first 
interview before moving on to the next transcript. The transcripts of carers and 
PWD were analysed separately to explore any differences in attitudes and 
beliefs arising from the data. Once data analysis was completed for carers and 
PWD, superordinate themes were compared and interrogated across both 
groups. 
The process was methodical and time consuming. The first interview was 
read through twice by the researcher prior to starting any analytical process. 
Then it was read a third time and notes were made about concepts arising 
out of the data that seemed of interest. At all times the underlying philosophy 
of Interpretative Phenomenological Analysis (IPA) was referred to in order to 
ensure that the phenomenon being explored was being described by the 
researcher in terms of the effect on the life experience of the participants. 273­
276 By doing this it became clearer to see the actual effects of medicines for 
dementia on participants’ day to day lives. The transcript was read a further 
time and then an attempt to code these concepts into themes was made. The 
difficulty became actually ensuring that the theme descriptor reflected 
accurately the life meaning to the participant. 
After the first transcript was completed the codes and themes were grouped 
together in historical order prior to a further arrangement under descriptive 
codes. Then the second transcript was analysed as above with new themes 
and descriptor codes being added to the master list. At the end of the final 
transcription analysis the master code list was arranged into descriptor code 
headings and themes sorted accordingly. At this point all transcripts were 
reviewed and re­analysed against the final master list to ensure that all 
relevant data was highlighted. Following this, there were five further data 
sorting sessions where each theme was reviewed and questioned by the 
researcher to ensure that it was appropriately described by the superordinate 
or sub­code delineator. 
NVivo® was used only as a means of coding and managing thematic data.282 
Ongoing questioning and interrogation of the data took place by the writing of 
each theme on a ‘post­it’ note and then placing these on large pieces of 
paper titled with the superordinate theme. Visual exploration allowed a 
greater internalisation process of the data to occur, resulting in the cross 
interrogation of sub­codes across each superordinate theme. Coding 
validation was achieved by sharing the thought processes behind the 
analysis and the development of the superordinate themes with a colleague, 
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Dr Jane Sutton, who has a wealth of experience in IPA. Further details of this 
process can be found in Appendix A4­1. 
4.1.1 Coding for Carer Participants 
There were 18 female carers and 5 male carers involved in the carer interviews 
or focus group sessions. (See Table 3.2 for further information). The age range 
was from 60 to the late 70’s. It is unclear why more female carers participated in 
the study, but this seemed to be a reflection of the branch membership activity 
in terms of gender and attendance at local meetings. 
Coding for carer participants was completed separately from PWD to ensure 
that analysis was specific to the participant group. A total of 131 codes emerged 
from the data and on exploration, as described above in 4.1; data was sorted 
into 5 superordinate codes, each of which had sub­code analyses. 
These were: 
1.	 Carer Expertise 
2.	 On Being a Carer 
3.	 Living with a Degenerative Illness 
4.	 Interaction with Healthcare Professionals 
5.	 Trials and Tribulations of Medicines 
Point of 
Reflexivity 
The original coding process took place in January 2007 and 
due to a period of suspension from June 2007 to February 
2008 required a re­analysis of the results as a means of re­
familiarisation with the data. During the re­analysis I had a 
moment of absolute clarity of the difference between IPA and 
modified grounded theory (another analytical method used 
frequently in our department). IPA is the interpretative 
analysis of the phenomena being studied (in this case the 
experience of taking medicines for dementia or living with 
those that do so) that is the psychological effect on the 
persons self or inner world as interpreted by the researcher 
whilst always relating this to the narrative used. Modified 
grounded theory is the interpretation of themes that arise 
from the data but which are constructed by the researcher. 
Both processes are iterative and arise from the data but IPA 
is looking for effect of this on the lifeworld (subjective 
experience) of a person and how they make sense of this. It 
requires a subtle shift in mindset or approach by the 
researcher so that the results are seen as experienced by the 
participant not as experienced by the researcher. 
The original superordinate themes for carer participants were: 
1.	 keeping loved ones at home. 
2.	 accessing the appropriate medication 
3.	 diagnostic communication processes (healthcare 
professional consultation process) 
4.	 access to information. 
5.	 quality of life benefits 
6.	 being a carer. 
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My original coding for the carer data really reflected my own 
interests as the researcher; that it was the medication and its 
benefits which allowed the carer to keep their loved one safe 
at home for as long as possible. Whereas on re­analysis the 
medication was still important but it was just one of the key 
support structures for effective care­giving to take place 
enabling the carer to continue living with a person with a 
degenerative illness and cope with being a carer. One could 
argue that it is the same finding; however I feel that the 
second re­analysis is more from the participants’ unique 
experiential perspective of being someone who is living with a 
degenerative illness and all that entails. 
An overall summation of how these themes affected day­to­day lives of carers of 
people with dementia follows. 
The over riding concern of carers seemed to be the need to find the appropriate 
information, medication and/or support in order to keep their loved one at home. 
In their role of being a carer they developed expertise in some areas but for 
many there was an uncertainty in how they should care for a person with a 
degenerative illness. This affected decision­making in many areas of caring 
and also highlighted areas which they had less expertise and required more 
information. Information seeking behaviour generally arose from a lack of 
proactive information given within a therapeutic relationship and this resulted in 
further interactions with healthcare professionals, not all with perceived 
acceptable outcomes. The perceived beneficial effects of the medicines for 
dementia on their loved one and the resultant quality of life benefits enabled 
them to continue living with a person with a degenerative illness and in their 
role of being a carer. The medicines however, were not without their own trials 
and tribulations as carers battled with ensuring compliance and continuation of 
prescriptions. Carers also needed a framework of support for caring in order to 
be able to continue in this role, which required further access to information and 
interaction with healthcare professionals. 
4.1.2 Coding for People with Dementia 
Of the five participants who had dementia and were taking medication for it, four 
were male and one female. This does not depict the prevalence of dementia 
where it is commonly understood to have a greater female to male ratio.51,63 A 
proposed reason for this is that the incidence of dementia peaks in the eighties 
age range, where it is more common for people to be of the female gender than 
male in that population group. 51,63 Perhaps the findings of this study reflect the 
incidence of dementia in the younger age group (60 to 70’s). 
The participants with dementia were all capable of giving informed consent to 
take part in the study but were probably all at different stages in the continuum 
of dementia. What was interesting about the three PWD taking part in the focus 
group was their narratives could be linked to supporting statements from their 
carers who had a separate focus group two weeks later. Tim was married to Liz; 
Philip was married to Mandy and Sandy was married to Paul. 
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Four of the five participants were cared for by their spouse in their own home 
and the spouse was also responsible for the day­to­day organisation of living 
and caring arrangements. Thomas was the only one living independently, but 
he also had appointments to see the nurse at the local hospital and had 
made contact with the local Alzheimer’s Society branch but did not regularly 
attend any meetings or receive support. He was quite happy with this 
arrangement as he felt he was coping quite well at the present time and he 
had many friends in the local church. 
Point of 
Reflexivity 
As a researcher it was interesting facilitating a focus group 
with people with dementia for many reasons; the first was 
the ability to observe how they interacted together and 
were able to support each other with their experiences 
and knowledge; the second was to note how well they 
could function socially and as part of a group with fairly 
impaired memory. They joked with each other and also 
explained concepts if a participant seemed to be 
floundering in their comprehension. It is often said that 
PWD who have good social skills can hide behind this 
façade for some time (in terms of evading recognition and 
diagnosis) so it was interesting to see their social 
communication skills. One could argue that there was less 
depth and breadth to their conversation but it was still 
enjoyed by all participants. 
As mentioned previously, coding for participants with dementia was completed 
separately from carer participants and a total of 32 codes emerged from the 
data. On further interrogation, data was sorted into 5 superordinate codes, each 
of which had sub­code analyses. 
These were: 
1. Living with Dementia 
2. Perceptual Processing 
3. Interactions with Healthcare Professionals 
4. Relationships with Close Others/Carers 
5. Trials and Tribulations of Medicines. 
People with dementia were able to speak about what it was like to live with 
dementia and how they felt this affected their relationships with close others. 
For some their carer was seen as the main support in day­to­day life and helped 
them with the interface at interactions with healthcare professionals and also 
to deal with the trial and tribulations of medicines. The medicines however 
were viewed as a very important part of their lives and some remembered 
distinctly the difference between their day­to­day abilities prior to and after 
starting them. It was interesting how people with dementia still retained their 
ability for perceptual processing and how this was independent of memory. 
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4.1.3 Cross Coding for All Participants 
Some of the superordinate themes were similar for both participant groups and 
all superordinate themes will be discussed together as appropriate to explore 
the same theme from each perspective. 
The final themes for carers and participants with dementia (PaWD) were as 
follows: 
1.	 On Being a Carer (Carer Expertise and supporting data from PaWD) 
2.	 Interactions with Healthcare Professionals (Carers and PaWD) 
3.	 Living with a Degenerative Illness (Carers and PaWD, and includes 
Perceptual Processing and Relationships with Close Others/Carers and 
Trials and Tribulations of Medicines (Carers and PaWD)) 
The explanation or definition of each superordinate theme can be found in 
Appendix 4­2. 
When quotes are used to describe the participant experience, their assigned 
pseudonym is used (see table 3.2), followed by their location. The location area 
will be referred to as L for location and the number of the site e.g. L1 for 
Location 1.If a quotation includes a question from the interviewer; this is 
represented by “I” for interviewer and the narrative in bold font. Phrases to aid 
sense of the quotation (if used) will be in non­italic font and contained inside 
brackets. A … indicates a section of the quote is has been deleted to aid clarity 
and understanding. 
4.2 On Being A Carer 
Being a carer seemed to involve stepping out of a usual life role and taking on a 
new persona. Duties and responsibilities included becoming the person who: 
made all the household decisions and completed many of the household tasks 
as well as taking on a caring role. Carers needed to learn how to access 
supportive mechanisms, such as service organisations, peer support groups 
and specialist healthcare professionals. What was more unexpected was the 
experience of the darker side of caring and associated emotions of recognising 
their inability to continue as a carer. 
4.2.1 Generalities of Caring 
Caring required undertaking tasks to enable routine and daily activities to be 
completed, helping their loved one with personal activities and taking on new 
relationship and supervisory roles. 
4.2.1.1 The Day­to­Day Experience 
Carers described a complete change in their loved ones ability to perform the 
most simple of tasks and how this affected their caring role. 
“He doesn’t do anything for himself. Well he can eat with a spoon; he has 
got a special plate. He is all right still with a cup; mind you don’t fill it right 
up. But other than that he can’t put his shoes on or if he manages to get 
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his slippers on its just luck really that he has got them on the right feet. 
He couldn’t do his laces up or buttons, he can’t do anything. I have to 
take him to the toilet and he has got a catheter.” Pat, L1 
Carers perceived there was a need for routine to orientate loved ones and 
establish a sense of normality. Many included daily walking in this routine to 
keep loved ones as active and fit as possible. The second carer focus group 
linked a change in routine to possibly worsening an already variable mood 
status. 
Angela: “They still have bad mood swings, don’t they and days when 
they’re very low their memory’s worse than other days.” 
Helen: “Yes, yes.” 
Liz: “And if it’s out of routine then they get very agitated.” 
Sarah: “(Husband)… whenever we go out anywhere, when we go 
home he is always very lost he never knows where he is. And he is 
always asking to go home.” 
Carer Focus Group 2, L4 
Thomas had a greater level of insight and general functioning than other 
participants with dementia. At the time of the interview he still travelled within 
Europe to visit one of his daughters and took winter sun breaks. What he 
showed most insight into was the maintenance of his current level of 
functioning and interaction was dependent on his weekly routine. His main 
area of cognitive loss was in short term memory; corroborated by his 
forgetting the interview which eventually took place on the fourth date it was 
arranged. 
“I go out for a walk and spend a fair bit of time round at the church 
either doing the garden, looking after the presbytery and I go to mass 
one day a week and on Sunday. I realise that it’s easy to hibernate and 
not see anybody and once you start doing that I feel that you hesitate to 
go out and start not interacting with people and you’re isolated. I’m not 
as daft as a brush.” Thomas, L3 
These changes associated with living with a person with dementia and 
resultant full­time caring role meant an acceptance of change in their own life 
circumstance. Their previous life had gone and a new life was being shaped 
by the changing daily demands of a degenerative illness. 
“I mean your whole life revolves about caring for that person, actually 
you haven’t got another life at all anymore, so all you do all you think 
about is how that can be improved and how the person is on that day 
and how it worries you.” Jane, L3 
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There seemed to be little information available for carers on how best to support 
the continued integration of their loved one in daily activities and engagement 
with previous interests and prolonging mental stimulation. In 2003 the 
Alzheimer’s Society Book of Activities was published which may have helped 
many of the carers. 284 
4.2.1.2 Gender Role Changes 
In the two carer focus groups there was discussion about the effect of role 
changes with the consensus that it was “worse for men” to be a carer than it 
was for women. Sue also thought it was worse “for a man to have to cope and 
to get a woman dressed and take her to the toilet and do all the things for her.” 
This is supported in the literature where males perceived daily caring activities 
such as washing and dressing as diminishing their wife as a female person and 
resulted in reduced intimacy within the relationship.131 Paul explained below his 
frustration at an almost complete reversal of roles. 
“I mean when I was young, I was the breadwinner in our house and I 
used to go to work. And the wife used to do all the cleaning and all the 
cooking and everything, I done hardly anything. But now it’s changed; 
now I’m doing all the lot! Not only the cooking, I mean she can’t even 
make a cup of tea or do anything properly.” 
Paul, L4 
Ann (L1) also explained that she had “turned out to be a DIYer, shelver, cut the 
grass, change light bulbs, everything” kind of person but admitted that this was 
more to do with Jack having left­sided weakness following transient ischaemic 
attacks, than his dementia. Although there is a wealth of research on female 
aspects of caring as it is perhaps more accepted for females to have caring 
roles,285 there is little research on male gender role reversals in caring. Hirst 
has suggested that men over the age of 65 years were more likely to be caring 
for their spouse than were women.286 This is an interesting point because the 
response rates in this study do not reflect this. However research suggests 
that men “are often reluctant to use services” 285 and other authors comment 
this may be related to masculinity and its negative effect on seeking help.284 
They go onto to state that if men did not seek and/or use support services they 
would be less likely to be recruited in gender­related research (or one could 
argue, any research).287 It has been proposed that male carers were more 
likely to give up their caring roles and institutionalise their spouse due to 
“relational deprivation.”171 The author’s hypothesis was that men receive all of 
their emotional support from their wives and as the disease progressed, this 
integral support for their intimate relationship diminished and caused 
underlying feelings of deprivation within and about their relationship.171 
Interestingly in this study, all male care givers had or were considering 
admitting their spouse to a long­term care organisation. 
4.2.1.3 Keeping Loved Ones Safe 
An observed caring role was the need to keep loved ones safe; a finding 
supported by Aneshensel et al who found it could also be linked to carer 
burden if the supervisory role was too great.177 This included trying to protect 
them from adverse medication effects or from getting lost in public or from 
admission to a nursing home. It has been suggested that 60% of all PWD 
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wander or “feel compelled to walk about” with 40% getting lost.288 
Unfortunately wandering can also lead to disappearance of the individual 
and/or accidental death.289 Recently the Alzheimer’s Society, supported by the 
Department of Health have called for safer walking schemes for PWD which 
could include tagging with satellite monitoring.290 Tagging for PWD is relatively 
common in care home facilities291 but up until recently not used extensively in 
community settings. Possible tagging of PWD could enable people who get 
lost to be quickly found and hopefully before putting themselves at risk. 
However, there are several ethical issues associated with this proposal such 
as possible deprivation of liberty and whether this makes it easier for carers or 
PWD.290 
Ann (L1) had lost Jack in a strange town the previous year and described how 
the medication made her feel “not so worrying that I’m going to lose him.” 
Due to PWD losing insight into their own safety, carers spent a lot of their time 
in a supervisory role. As Doris (L1) explained this could get very time 
consuming as “The only time I can leave him for a moment is when he’s fast 
asleep.” This obviously limits a carer’s ability to complete any of their own 
personal activities. A recent survey illustrated how the numbers of hours per 
day for this supervisory role increased in line with increasing severity of 
dementia.172 
Another concern was the adverse effects of medication; with Jill (L1) explaining 
that the medication used to help her husband sleep were actually dangerous 
because they had “such a long effect and I think it is more dangerous for him 
because he staggers when he gets up to go to the bathroom.” Jill had been a 
nurse before she retired and she knew that unsteadiness could result in a fall 
and possibly unnecessary admission to hospital.292 The reduction in falls 
experienced by older people is one of the Department of Health’s major focuses 
for improving long­term care outcomes for older people. 66, 292 
As well as keeping loved ones safe, carers needed to consider the safety of 
others in terms of the person with dementia continuing to drive. Tim was 
unusual as he was the only participant with dementia who was still driving. 
He never drove without his wife in case he got lost but said “If I didn’t have 
that thing to do, my wife wouldn’t get very far” as she didn’t drive. He thought 
his ability to still drive safely was because “it’s just ingrained, which I’m glad 
to say” from driving since he was 17 (at the time of the focus group he was 
76). 
“But I suppose that goes back for many many years. I’ve driven all me 
life. I was an instructor you know a driving instructor in the army and 
out in civvy street. And it just comes natural.” 
Tim, L4 
Some tasks which are ingrained and habitual can be retained for some time. 
Problems arise when the person is no longer able to recognise where they are 
but the actual mechanical process involved with driving may be still be being 
performed relatively well. There are also associated problems of an ageing 
driver such as delayed reaction; difficulty in assessing distance and speed and 
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reduced hearing and visual acuity. However Morgan proposes that older 
drivers may actually be safer because they take fewer chances; they drive 
more slowly and consider their decisions more carefully.77 
For PWD there may be major emotional attachments to driving such as 
independence and self­determination even in view of an increased risk of road 
traffic accidents. It is important that these factors are addressed within the 
consultation process.293­295 
But perhaps the biggest concern for nearly all carers was the need to continue 
to care for their loved one at home as Angela (L4), expressed as “long as 
possible.” 
“I know I probably will need some help later on as the disease progresses 
but I don’t want him comatosed in the chair, not now anyway, not at the 
moment because he likes the garden, he likes to go for a ride in the car, 
he enjoys that. And while he can enjoy things like that, I want to stay here 
as long as we can.” Jill, L1 
Generally carers did their utmost to continue caring for the person they loved at 
home as long as possible. This was made possible by good supporting 
structures for the carer to reduce overall burden. 
4.2.1.4 Uncertainty and Decision­making in Caring 
A key theme was how carers held uncertainty about the illness and associated 
caring issues and this affected decision­making. Overall they were keen to do 
the right thing but uncertainty about past decisions persisted for many years. 
Lyn didn’t see any medical clinicians (including her husband’s GP) but thought 
she might be able to if there was a real need. It is unclear how this lack of 
knowledge of key members of a healthcare team can exist and perhaps could 
be addressed by the carer having a written document outlining the team 
members, their contact details and their role. 
“I haven’t sort of asked who’s on this board that meets and discusses each 
case. I don’t know if there are any difficulties in seeing (GP) again, you know 
to talk to. But I don’t think he can do anything more than any of the others.” 
Lyn, L2 
This uncertainty also extended to the actual diagnosis of a dementia as for 
some carers the signs and symptoms of dementia were noted in relation to an 
unrelated hospital admission. Lyn described how her husband had been 
hospitalised with encephalitis which seemed to be the trigger. 
“I wondered if that might have been the start of it. Cos he went very 
peculiar as you would; you know he didn’t know where he was and 
couldn’t remember what he was doing in hospital. I often wonder if it’s 
really what they say it is, vascular dementia. That’s different from 
Alzheimer’s disease. We don’t know.” Lyn, L2 
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This doubt and uncertainty about diagnosis was also expressed by Thomas (L3) 
a participant with dementia. He described himself as “just old and a bit 
dilapidated that’s the way I see it.” 
Mostly carers’ expressed retrospective self­doubt of previous decisions and 
whether they still held up to scrutiny. 
“Cos then I wonder you see, should I have taken him sooner? If we’d 
gone sooner and accepted some drugs would we have been a bit better 
off? I often think should I have done it sooner.” Lyn, L2 
However decision­making on the behalf of others is a difficult situation to be in 
and clarity gained from hindsight is not something we have access to at the time 
of making a decision. The Alzheimer’s Society published a useful guide for all 
carers of PWD in 2005 which covered caring­related decisions from early to 
later stages of the illness.296 
Pat had been asked to be involved in a decision that was unexpected and she 
had been less than prepared for. The local research memory clinic that her 
husband had attended while he was on a trial medication had telephoned to ask 
her if she would agree to donate his brain once he died. 
“If when anything happened to (husband) if I would be prepared to let 
them look at his brain and then I said ‘well I didn’t really know, he can’t 
make the decision so it’s going to have to be up to me.’ Umm and then 
she was looking at her paperwork she said ‘I really shouldn’t be ringing 
you because he was on the placebo.’” Pat, L1 
The impact of such a telephone call cannot be underestimated; firstly the call 
could be taken to imply her husband was going to die imminently; secondly she 
had been given very little information or time in order to make an informed 
decision; thirdly she now knew her husband had been on placebo and this may 
be why his condition was now so advanced and finally the caller was 
unprepared and if she had read the notes thoroughly prior to dialling she would 
have realised there was no need to call. 
In summary carers and participants with dementia experienced uncertainty in 
their day­to­day lives and for carers this was also compounded by having to 
make decisions on behalf of others, which affected their own lives as well as 
challenged their health beliefs and ethical principles. 
4.2.1.5 Information Seeking Behaviour 
Carers held an individual repertoire of knowledge, which they added to and 
checked the validity of. This concept of carer expertise has been commented on 
by Nolan et al who also established that carers proactively sought information if 
they felt there knowledge was lacking.187 An important consideration was the 
content and depth of knowledge, changed from individual to individual and topic 
to topic; that is being knowledgeable in one area did not imply being 
knowledgeable in others. Because of their membership to the Alzheimer’s 
Society, carers were privy to sharing information and received Living with 
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Dementia from the Society.297 When information was not forthcoming from 
HCPs people accessed the following sources: libraries, the internet, 
newspapers, television, the Alzheimer’s Society and people in a similar situation 
to their own. Previous research suggests that non­sharing of or vague 
information was experienced as confusing and upsetting.298 It could also be 
suggested that this can also undermine the therapeutic relationship and creates 
one of co­dependency or paternalism; not one of person­centred care. Seeking 
information and support was perceived as ‘a battle’ or ‘struggle’ by carers. 
Jane: “So you are constantly thinking ‘am I doing the right thing? Am I 
upsetting the person in the memory clinic because I am now seeing Dr 
X?’ You know nobody told me anything else so you, I feel you are 
constantly fighting, trying to get information. It’s just a constant struggle to 
do the right things” 
Mary: “It’s a battle isn’t it?” Jane & Mary, L3 
In general participants spoke about a lack of information at the point of 
prescribing which resulted in them having to actively seek out further 
information. 
”No information at all was given when (husband) was put on to Aricept®. 
We had been going to the memory clinic for 3 or 4 months maybe and 
this particular doctor said ‘Well I think we will try him on Aricept®’ but no 
information about it whatsoever he just went on it, but there was a distinct 
improvement.” Mary, L3 
Both Jack (L1) and Thomas (L3) commented that they had sufficient information 
on the medicines and in Jack’s case he said “I am not afraid of asking 
questions; from my point of view it’s necessary.” Thomas couldn’t remember 
anyone telling him what was wrong with him so he had to find out for himself. 
“Obviously I knew they were for my brain function. Then of course you 
get the bit of paper in the back and I always read things like that and I 
look them up in the medical book.” Thomas, L3 
On being recommended any new treatment, part of the decision­making 
process is being given sufficient information about potential risks and benefits to 
make an informed decision about whether to take them or not. This has been 
well described in the Mental Capacity Act299 and also in the NICE guidance on 
medication adherence. 300 As carers were responsible for the compliance to 
medication regimens and they were making decisions on behalf of loved ones, it 
could be argued that they were poorly informed due to the paucity of information 
received. In a national survey only 50% (n=2030) of all respondents said they 
received sufficient information about medicines and the disease at the time of 
diagnosis, a finding supported by these results.30 
The variability in the provision of information even in the same location implied it 
would be hard to recommend a particular level or standard of information 
provision because the experience of participants was so different. 
68 
4.2.1.6 Sharing Information 
Several interactions within focus groups illustrated that carers used local branch 
meetings as opportunities to share knowledge with others. In this example 
below, group members discussed that medicines were a help but not a cure. 
Angela: “But we went on umm Exelon®, which did no good whatsoever, 
so we went back on that (Aricept®) and he seems to be fine. But as 
people are saying, he’s going down hill with certain things, so I just don’t 
know whether the tablets stopped working, or whether (pause) …… if you 
asked him he’d say ‘oh no the tablets are working’” 
Paul: “They don’t stop it though love, do they?” 
Angela: “It doesn’t stop it, it slows it, (lots of agreement) so you don’t 
really know….” 
Andrea: “What they’d be like without” 
Sarah: “Yes. The trouble is once they’re stopped you would then notice a 
difference and quickly they go down hill. You don’t know until you stop 
them, do you?” (General agreement) 
Angela: “They’d never recover then would they?” 
Sarah: “No, no they don’t not according to research anyway. Once they 
go down hill they can’t put them back on them because it doesn’t bring 
them back up to the level they were.” 
Carer Focus Group 2, L4 
Evidence suggests that if a medicine for dementia is withdrawn, then the person 
needs to be closely monitored for the next two weeks and if signs of 
deterioration occur the medication is reinstated as soon as possible to halt 
further decline.111,112 Because the medicines act on all cholinergic functioning, it 
is not just memory that is affected but behaviour, activities of daily living, 
problem solving and communication. These positive effects are often not 
attributed to the medication especially if carers may be more focussed on 
memory or behavioural issues. 
It has been identified that all carers want information on dementia, how to get 
help and the best way to interact with services.79 The authors recommended 
that the best information was related to the specific needs of the individual,79 a 
finding also endorsed by others.182, 301 Lyn, in her early 80’s described a 
situation of only finding out support services were available after talking to a 
neighbour who had respite and sitting services. When she asked the 
professional involved in her care (the same professional as her neighbour) why 
she didn’t have these services she was told that she had never asked for them. 
“I said, ‘they came after me, how come they have a good sitter and I 
haven’t?’ She looked me in the eye and said ‘you never asked’. So now I 
ask for what I want, for what I need, that’s more like it.” 
Lyn, L2. 
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Point of 
Reflexivity 
Jane and Mary spoke of their lack of knowledge of basic 
support service such as memory clinics or day centres and 
how they could access care in the first place. Not knowing the 
availability of services precluded people from asking for them. 
As mentioned above, it seemed that information was often 
only given in a response to a carer’s lack of ability to cope 
rather than in a proactive manner, which would be supportive 
to carer health and caring ability. 
4.2.1.7 Misinformation and Bureaucracy 
There were many shared experiences of carers receiving incorrect information. 
This resulted in loss of confidence in the HCP but also a reluctance to speak out 
in case they were seen to be ‘rocking the boat’ and were removed from patient 
lists. Most commonly carers were told that all AChEIs were the same or that 
memantine was the same as an AChEI. This provision of misinformation could 
also seriously undermine trust within a therapeutic relationship as illustrated by 
Mary (L3) when she said “But when I asked him about Ebixa® he told me it was 
the same drug (previously on Aricept®) and it isn’t. And I knew that it wasn’t.” 
A continued lack of information can result in great frustration and anger for 
carers who described their days as being completely absorbed by caring for 
another and worrying continually whether they were doing the right thing. 
“Why do we have to fight? I mean dementia is just, is an illness just like 
any other. Why do we have to fight for everything and why do we get so 
little information and why do GP’s really know so little about this illness, 
and how it affects people and carers?” Jane, L3 
Perceived misinformation or a complete lack of information received from HCPs’ 
forced people to access other organisations such as support groups or the 
internet. In this study, the internet was used by most carers and by Thomas (L3) 
as an information source. People with dementia often require further information 
as demonstrated in a study where all calls to the Alzheimer’s Society were 
logged to explore the nature and frequency of calls.302 The authors were 
surprised to find PWD regularly called help lines to ask for information or 
practical help.302 A large internet study in America highlighted that support 
seekers (carers) were the second largest group of people to access the internet 
for medical advice about the person they were supporting.303 
It seemed that relevant, individualised information presented in a suitable format 
and repeated at various stages throughout the illness was necessary for carers 
to feel they had sufficient to make informed decisions. The NDS suggests that 
information provided should be both verbal and written and supported by an 
information co­ordinator for each person so there is always an open line to 
relevant and timely information and support.51 This seems to be an imminently 
useful proposal if sufficient workforce resources are allocated.208 Most important 
is the need for access to specialist services at an early stage of the disease to 
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allow for greater planning of the inevitable with on­going access to support and 
information as the illness progresses. One of the problems with current access 
to specialist services being limited to people on a medicine for dementia is that it 
creates inequity, as only generalist care seems the option for many. 
4.2.2 Caring: Darkness and Light 
Carers recognised that they had to be aware of their own needs and develop 
coping strategies to support this new role. They were able to recognise when 
they were coping and when they needed support from the local branch, GPs, 
respite care and from specialist services. 
4.2.2.1 Supportive Structures 
What carers appreciated most was the provision of proactive support, even if as 
Ann (L1) shared, it was just a question from the clinician such as ‘how are you 
coping?’ Carers recognised when they could cope but also realised there would 
come a time when they might not. Some felt that the ability to cope may be age­
related and although they could cope now they surmised they may not in the 
future. 
“I mean if I was 80 it would be different you probably can’t feel like it you 
know? I am 67 so I still feel as though I can do what I need to do.” 
Pat, L1 
Peter explained that caring for someone with dementia “can be lonely, quite 
truthfully and I think that’s what a lot of people find.” This is often exaggerated 
when the person being cared for is younger because most services are aimed at 
the 70plus age group and the activities may not seem suitable for those people 
in their fifties with dementia. Peter’s wife was first diagnosed with dementia 
when she was 55 and they found there were few activities available for this age 
group and consequently had set up an informal support group called the “Half 
Dozen Club.” (A group of 6 younger carers and their spouses who met at each 
other’s houses once every month or so to share food and company). 
“Especially in the early days it was a very good release valve because 
you’ve all got same or similar problems and it was marvellous. Ringing 
each other up, so on and so forth.” Peter, L3 
The participants also valued the support they received from the local branch of 
the Alzheimer’s Society. As Andrea opined, it was “absolutely invaluable” for 
both themselves and the person they cared for. At these carer support events 
there was the ability to spend time away from the person they cared for and also 
a joint refreshment event where activities were done together. 
Liz: “I think this is the only thing that Tim remembers, coming here. 
Definitely; that this is where he comes. He loves coming here.” 
Paul: “They all do don’t they?” 
Polly: “(Husband) does remember every time he’s coming.” 
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Mandy: “It something they all enjoy.” 
Carer Focus Group 2, L4 
These joint sessions were enjoyed by both and allowed a semblance of 
normality of shared social interaction within their relationship. It is an important 
point that shared enjoyable activities can reduce the carer from feeling 
undermined as a person and undervalued within the 
relationship.131,166,167,171,177,304 
Support from Family and General Practitioners 
Family was also a great support to many, with children of carers providing extra 
free time by having their loved one over for an afternoon or evening once a 
week, or taking them out food shopping. Many however did not like to bother 
their children too much because as Mavis suggested, “they have got their own 
lives anyway haven’t they?” 
Although it has been proposed that wider family relationships could cause 
conflict for the caregiver and become a secondary stressor in the care­giving 
process; this was not supported from the findings of this study.170,171 
Generally carers’ first point of call was their spouse’s General Practitioner (GP) 
who in some locations, seemed to be able to arrange support more directly than 
in others. 
“I went to my GP and sat down with him and said ‘Look I can’t cope any 
longer like this.’ He wrote a letter to the Consultant, because that’s all he 
can do he can’t do anything, and said ‘look this woman is at the end of 
her tether she is beginning to hate her husband and something needs to 
be done about this.’ Nothing happened. No response at all, nothing. 
(silence) Sue L2 
Other carers, like Lyn (L2), explained that although they had asked their GP for 
practical and medical help “letters got lost” and help was not forthcoming for 
over a year. Lyn expanded “I was a bit peeved by that, I couldn’t really work it 
out” but now “someone comes every morning to wash him and dress him.” 
Respite and Day Care 
Respite care provision was seen as a key element of support in order to give the 
carer a sustained break over a number of days rather than hours. This did not 
mean that it was without problems with many speaking of how guilty they felt 
sending their loved one away. As Jenny (L2) shared “I don’t like to see him go, 
you know. But you got to think about yourself as well.” 
Frequently it took some crisis in care in order for day or respite care services to 
be initiated. Day care was provided according to individual needs of the carer 
however some carers of people with moderately severe dementia received no 
day care whereas other participants in the same location received up to four 
days a week. This discrepancy was also observed in the provision of respite 
care, where some received a weekend every few months, with others receiving 
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one or two week respite session every six week to thirteen weeks. The provision 
of day and respite care is dependent on local availability and individual needs; 
however on reflection those carers who were able to vocalise their needs 
seemed to have a greater influence on receiving a service. 
“I think in this area we’re probably a lot luckier than a lot of areas. Some 
areas I know are really bad and there aren’t day care places. You get two 
days a week. I was lucky. (Sue received four days a week)” 
Sue, L2 
Sue had received the greatest amount of support in both day and respite care 
services prior to her husband being admitted to a care home. She was the 
youngest of the carers in this location and seemed to have found it more difficult 
than others to sustain a caring role. Other participants in the same location 
seemed more stoical. This difference may be due to secondary subjective 
pressors such that the subjective experience of caring was one of relational 
deprivation.170,171,177 As Baker and Robertson propose it may be the perception 
of the stress of caring rather than the amount of support that is involved which 
results in care­giving breakdown. 285 Perhaps in Sue’s experience the role 
reversal was so great and she was receiving so little reciprocation of care and 
support from her husband in return for her perceived personal sacrifices as a 
care­giver that it became too difficult for her to sustain a caring role. This would 
be supported by Pearlin’s model of caregiver stress which indicates that the 
different characteristic backgrounds’ of carers plus their psychological response 
to caring are key components in the experience of carer burden and 
170,177 stress.
It seems services were generally only provided in response to crisis and crisis 
management is a poor option in the provision of quality healthcare services. 
Evidence suggests that crisis management leads to greater institutionalisation 
and greater spending on health and social care and that proactive care and 
holistic support can result in cost savings in the long–term.51,206 
Specialist Services 
Access to memory clinics was seen as one of the greatest supports because of 
the expertise available and central co­ordination of support services including 
access to medication. As Mavis (L2) explained “they are so nice and they are so 
helpful and they are there, I know they are there if I need them.” Sometimes a 
CPN was assigned for routine monitoring of the person with dementia in their 
own home, which then saved arranging transport to attend assessment clinics. 
Some consultants were held in great regard when they provided carers with a 
telephone number to call if they were ever worried as illustrated by the narrative 
below. 
“But you can ring them at anytime He said ‘you must ring at anytime if 
you’re worried about anything at all I’m on the end of the phone’. I mean 
they can’t do anything more than that really, can they? 
Angela, L4. 
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Unfortunately this was not common and other carers present felt deprived 
because they had not been offered the same sort of support. This variability in 
experiences of living with and caring for a person with dementia was prevalent 
throughout phase one findings. 
4.2.3.2 The Darker Side of Caring 
As previously mentioned, the caring role has more frequently been thought of as 
a female role, although this did not mean that it sat easier with either female or 
male carers. A caring role which is not asked for and is unrelenting and 
demanding on emotional, physical and psychological levels can seriously 
damage ones health.173­175,178­181 The darker side of caring was associated with 
the care­giver reaching the end of their resources. 
The Struggle of Caring 
This relentless nature of caring was perhaps expressed best by Jenny who at 
the time of the interview qualified for a respite break once every 13 weeks but 
had her last break cancelled due to a cut in local service provision. 
“When they come and talk they (local social worker) say ‘we finish at 5 
o’clock’. I got it 24 hours a day 7 days a week. I think they’ll probably set 
it up again, (the respite break) they said probably getting him in once 
every five or six weeks which would be better” Jenny, L2 
This struggle was enhanced by the continual need carers had to find out more 
information about the care­giving structure. As discussed previously much of 
this information or support was not pro­actively offered and so had to be actively 
sought out by carers. 
“Everyday is a struggle dealing with people with dementia and if you have 
to struggle with the medical profession as well to get the right medication 
or to at least try the medication it is just another thing that you don’t 
need.” Jane, L3 
It is unsurprising that carers expressed their darker feelings within narratives; in 
fact one could argue it would be less healthy if they did not. Sue struggled hard 
to adapt to her caring role even though HCPs had intimated to her that “others 
were good at caring” which left her feeling even more inadequate. 
“I mean I kept thinking ‘I’m a failure I’m a failure’ because I can’t do this 
and some people they’re good at it. There are people, and they told me, 
there are people that do not like doing it but are very good at nursing their 
partners and I’m not.” Sue, L3 
It may be that the severity or the stage of the illness and/or the duration of the 
carer coping on their own affected the intensity of these feelings. Perhaps as 
others suggest, it is even more complex and includes prior relationship 
issues.167,170,171,177 For whatever reason Sue started to hate her husband and 
admitted this on tape (see below); hoping I think that her distress and 
experience would perhaps aid detection in others at an earlier stage. 
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“To cut a long story short he (husband) went in the next day (to a care 
home) and has been in ever since. I felt really really guilty for a month or 
so. I mean I still do now but he’s in the best place because I was 
beginning to hate him. Not only was I beginning to hate him, but I admit 
and I admit it on the tape that I had thoughts going through my mind ‘can 
I push this man down the stairs?’ I really couldn’t cope but nobody was 
helping me and there must be hundreds of people out there that are in 
the same situation.” Sue, L3 
The above narrative depicts just how destructive continual caring can be for 
some people and their relationships and of course for the person with dementia. 
What was interesting was that these feelings of despair and anguish were not 
seen in carers older than Sue, who seemed to adopt a more 
stoical/philosophical approach as reflected by Lyn below: 
“I don’t want too much detail as long as I have the facts and know how to 
deal with them, that’s all. So we have a situation we can’t alter, so no 
good fussing about. Accepting what you have and get on with it. That’s 
my angle anyway.” Lyn, L2 
It was difficult to say whether these differences were related to the older age of 
the carers, who came from a generation with perhaps fewer expectations from 
life and healthcare from those ten to twenty years younger. However, secondary 
stressors associated with the caring process include psychological responses 
such as role captivity.170,171,177,188,285 Role captivity is the response to a role that 
was not asked for, not wanted and yet has to be done. Seen from this 
perspective it becomes easier to understand that even basic caring roles could 
seem cumbersome and onerous to a carer with such a response. 
The adverse effects of a full­time caring role are well recognised and the Carers 
Act of 2005305 was an attempt to ensure that carers’ own needs were assessed 
and taken into account as part of the total care package for an individual patient. 
A healthier carer can support the patient longer in the community and there is 
then less of a financial burden placed on the wider health and social care 
budget.51,206 However many carers struggled to gain any support at all and the 
majority had not received individual care needs assessment. 
4.2.3.3 Asking for Help 
The perceived adverse social stigma associated with caring for PWD was raised 
by one carer. Fundamentally it meant admitting that the person being cared for 
has a problem considered to be a mental illness. Dementia has double stigma in 
reality as it embraces ageism and mental illness; two concepts that the NDS 
and memory clinics may be able to reduce by educating both the public and 
HCPs. 51,204 This double stigma can negatively influence successful access to 
medical care perhaps due to the institutionalised ageism embedded within the 
NHS.64­68 
Sue shared that it had taken her some time to realise that she needed help as 
she had been embarrassed and too proud to admit this to others. 
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“I was too proud and not only proud but embarrassed because you’ve got 
a husband or a husband has got a wife that’s not quite right in the head, 
you’re embarrassed about it and you want to hide it and you don’t want to 
admit to anybody that you can’t cope.” Sue, L2 
Before you can ask for support for caring duties, you first have to recognise that 
you are a carer and not a spouse or a child of the person being cared for. This 
can be a defining moment as described by Sue when she read a poster at her 
GP surgery which asked “’Are you a carer?” 
“I saw a notice (in the GP surgery) that said “are you a carer?” and it said 
“carers coffee evening where you can discuss your problems.” So I said 
to the receptionist ‘I don’t know if I’m a carer or not’ and she said ‘well 
what do you do?’ and I said ‘I have to look after my husband’ and so she 
said ‘you are a carer’ so I went to that coffee and that actually started it.” 
Sue, L2 
The majority of participants in this study perceived that proactive information 
improved coping ability and prevented a crisis in care. In 1995 it was observed 
that services often arrived too late to avoid carer distress and some were 
counter productive.306 In 2002 Bailey reflected that services were few and that 
you needed to fight for them if you were a carer;307 as still seems the case with 
these findings. The consequences of carer needs not being assessed can have 
major negative impact on their physical and mental health178­181,189 and this 
distress is associated with increased morbidity, mortality and rates of 
institutionalisation for PWD.173,184,186,189 
4.3 Interaction with Healthcare Professionals 
This section describes how participants, both PWD and carers, experienced 
interactions with healthcare processionals (HCPs) when they sought advice 
and/or support. They described less than person­centred therapeutic 
relationships and their frustration at the complexity and duration of the 
diagnostic process. 
4.3.1 Consultation Etiquette 
Consultation etiquette is a descriptor for relationship dynamics within a 
consultation. Increasingly more emphasis is placed on HCPs having good 
communication skills to ensure satisfactory outcomes of consultations.211,213,214 
All carers were involved in the day­to­day care of their loved one so by default 
were perhaps the best informed on the persons condition. However some were 
able to make more of a contribution than others within a consultation whereas 
others felt excluded. Carers often perceived their views and concerns were 
ignored or of no interest to the clinician, which unsurprisingly resulted in carers 
feeling isolated. 
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4.3.1.1 Differing Approaches 
Communication within a consultation can be a very difficult process to get right, 
and this can be reflected in the lack of therapeutic engagement by people not 
establishing successful relationships with their prescriber. 308 Compounding this 
perceived lack of effective communication from HCPs was the experience that it 
changed with individual clinicians. Within locations it was clear that carers 
shared their experiences of good and less effective experiences with HCPs and 
within each location identified the HCP with the perceived best approach. This 
resulted in carers switching clinicians and then becoming anxious about 
associated politics and possible negative outcomes for the person they cared 
for. More importantly it illustrated inequity and variability of resultant care offered 
from different HCPs and the potential for stress this had on the carer, and 
therefore potentially the person with dementia. 
There were examples of very supportive HCPs which left some listeners feeling 
less satisfied with their own. 
Helen: “A lot of doctors ignore us don’t they?” 
Angela: “I think Dr X is, the Consultant, is very good because he does 
say to you ‘if you’re worried about anything at all I’m on the end of the 
phone. All you have to do is ring and somebody will come.’ They can’t do 
more than that can they?” 
Paul: “No, they can’t.” 
Steve: “No, but I suppose different consultants are different. We don’t 
ever get that. We never.” 
A bit later 
Steve: “Our GP is very good.” 
Andrea: “So’s ours.” 
Liz:” When we’ve needed help.” 
Helen: “We’ve had two GP’s over the last few years and they’ve both 
been excellent.” Carer Focus Group, L4 
This variability in responses from HCPs in therapeutic consultations has been 
commented on by others who found that people consulting a GP rated the 
interaction dependent on the amount of information given and the manner in 
which it was delivered.79,80,190 
4.3.1.2 Lack of Knowledge 
As mentioned previously GPs were generally the first port of call for information 
and support in order to seek out the reason for their loved one’s behavioural 
changes. However there was a perceived sense that the GP lacked appropriate 
training and knowledge. 
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“I just feel the GP, if we were just in the GP’s hands we would get nothing 
at all because they haven't got a clue really, what’s going on.” 
Mary, L3 
Depending on the setting carers were offered either no or insufficient 
information about medication or support services. GPs were seen as being 
useful for the management of other medical conditions but generally not helpful 
for dementia care. For those people on medicines for dementia this meant 3 to 6 
monthly reviews with a specialist service and perhaps telephone contacts in 
case of emergency. For people who had been withdrawn from or were never 
suitable for medication there was no regular support offered. 
“We don’t go to the memory clinic any more because when he was 
taken off Aricept® and I enquired about further medication and I was 
told no it wasn’t possible. The doctor said ‘and I shan’t need to see you 
any more’ and that was it, I was finished, we were finished.” 
Wendy, L3 
4.3.1.3 Carer Involvement 
Carers perceived they had a very good idea of what was going on due to their 
full­time caring role. However if they felt excluded from the consultation they 
perceived that the clinician was getting an incomplete picture on which to base 
decision­making. 
Mary: “Well I used to go in with him when he was having this memory test 
and the doctor would start off by saying ‘so how are things?’ And I mean 
to begin with I was saying ‘a tremendous improvement.’ But there was 
nothing, I don’t know he just didn’t seem terribly interested in that side of 
it. He seemed to be more anxious to get on with giving him the memory 
test again and I don’t know it was a, it was a difficult situation.” 
I: “And how did that make you feel?” 
Mary: “It made me feel very angry actually, yes in fact I mentioned to 
(branch lead) several times. I said “I am very, very upset with doctor 
… he is giving (husband) the Aricept®, but I don’t feel he is taking the 
interest in what is happening with (husband) since taking it.” 
Mary, L3 
Interestingly the experience of therapeutic relationships varied within and across 
locations and age groups. Carers often described situations where their 
thoughts and viewpoints were ignored. This finding is supported by others who 
described carers as feeling squeezed out of the consultation process due to the 
traditional medical orientation which focuses on the patient.190 
Carers were asked whether they felt they had sufficient input into decision­
making processes within a consultation and the majority thought they would like 
the chance to have more input. They viewed themselves as the expert on the 
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day­to­day life of the person they cared for and therefore their views should be 
sought and respected. 
“I think that we should have a big part in the decision­making because I 
mean we know the person that we are caring for don’t we? And I think 
that we should be allowed a big decision but obviously the ultimate 
decision is the doctor’s of course, the medical one. But yes I think we 
should be given more chance of a decision than we get at the moment.” 
Mary, L3 
The consultation is a complex undertaking for any HCP and it requires excellent 
person­centred communication skills to ensure that both patient and carers’ 
agenda is voiced and understood. This may be very different from the agenda of 
the HCP who may want to complete specific tasks within the allotted timeframe. 
Somehow a mutually agreeable outcome needs to be negotiated within the 
consultation period. Interestingly a qualitative study in 2005, established that 
what mattered most for people with chronic mental illness in primary care 
consultations was not specific knowledge of an illness but the ability to 
communicate the following: optimism in the treatment; continuity of care and 
demonstration of listening skills.308 These are key communication skills for every 
HCP consultation delivering a patient­centred focus.211 
Other carers felt they had good relationships with HCPs and had good input into 
care­related decisions, as Lyn explained: 
“I think I get plenty of input into his care anyway. When we go to the 
doctor I go in as well, you know. I have to ‘cos he can’t, he doesn’t know 
what he’s gone for sometimes.” Lyn, L2 
The three younger carers (Sue, Helen and Peter) seemed very adept at 
interacting with HCPs to get the treatment and/or care support that they wanted. 
This age­related difference is an interesting finding within this study. Perhaps 
highlighting the difference in expectations of patient and doctor relationships 
from those people born in the 1920’s as compared to those born in the 1940’s. 
The concept of ageism in service provision has been discussed in 2.1.2.1. 
4.3.1.4 People with Dementia and Consultations 
Carers described the fluctuating changes of their loved ones’ behaviour in many 
dimensions and interestingly, some of this demonstrated retention of insight as 
they changed their social skills and usual behaviours in company or within a 
consultation. This perception of self­preservation was demonstrated beautifully 
by this next quote, which described what happened on the day of a visit to the 
memory clinic for a routine assessment. 
Wendy: “I will tell you what I do find with the memory clinic, he seems to 
get geared up somehow and he will answer questions there that he 
wouldn’t answer at home, like what day is it, what month is it, it is as if he 
is putting on a bit of an act.” 
Jane: “They always put on a front don’t they?” 
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Wendy: “As if he is trying to do something so clever and I think well you 
wouldn’t have said that at home. He might have said it before we went 
there, what month is it and as soon as they ask him he will say the month 
you know. You know I can’t believe it, I can’t believe this, it is like two 
different people talking.” Wendy & Jane, L3 
Jack’s opinion was that HCPs involved in consultations with PWD needed to 
develop their communication skills in order to pass on relevant information to 
the individual. 
“The difficulty there is actually whether the interviewer can actually put 
things over properly, without talking down and without leaving things out 
or without complicating it…the best ones have an understanding to ask 
the right questions at the right level (but) most of them can’t seem to.” 
Jack, L1 
This was an insightful comment, as many people do have difficulty 
communicating with a person with dementia. There seems to be a perception 
that PWD cannot understand anything, but this is not explored within the 
consultation.141 HCPs need to simplify sentences, ask one question at a time 
and wait for an answer to be constructed and then spoken. Often 
communication takes longer with PWD and more time and patience is 
needed.151 To complicate things people with advanced disease often lose verbal 
fluency and use more non­verbal communication skills. HCPs may need to 
increase observation skills of the person and their body language and facial 
expressions to communicate effectively. 
4.3.1.5 Consultations: together or apart? 
Carers expressed concern about having to talk about the activities and 
behaviour of their loved one in front of the person themselves within a 
consultation. They felt this upset the person that they cared for and their 
behaviour was more subdued afterwards. What carer participants wanted, was 
a chance to talk with the HCP on their own either before or after the consultation 
with the care­recipient in order to give a realistic picture of the day­to­day. In this 
study only four carers had the person that they cared for present at the time of 
the interview. Jack and Ann were interviewed in their own home and Jack was 
able to give informed consent to participate. Mavis, Jenny and Penny had their 
respective spouse’s present on the day but this was because they were at the 
stage where there was little or no insight into the content of conversation. The 
remaining carer participants took part because their loved one was at a respite 
or day care facility and they would not have to speak in front of them. 
Helen: “Sometimes when the nurse comes to talk to us and occasionally, 
well I did last week, I’d had a bad week, and I rang the nurse and chatted 
to her when my husband was out for the day somewhere. Specifically 
because I just hate talking in front of him.” 
Lots of agreement 
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Helen:” I do think he’s a little bit down after I’ve talked about things in 
front of him.” 
(Lots of agreement) 
Helen: “And after we’ve been to the specialist there is just something that 
he’s not quite so bright, if you could say bright, but, as usual, as if he’s 
absorbed something from the conversation and it’s affected him.” 
Mandy: “I think they resent the fact that you are saying something 
about them.” Carer Focus Group 2, L4 
The above comments typify carer experience and it seemed there was a need 
for a change in the way in which consultations are managed for PWD and their 
carers. 
Interestingly there were opposite views of who should be included in the 
consultation process from the participants with dementia. Thomas, who was 
widowed and lived on his own, normally saw his youngest daughter once every 
two or three months for a few hours at a time. The first consultation with a 
consultant had been organised by this daughter and as he described below, he 
had little input to the consultation or any decisions. 
“I was sat beside his desk…and my daughter stood behind me and he 
was firing questions at me ­ I can’t remember how many questions it was 
… but every time I answered, his eyes went over my head and my 
daughter was signalling to him ‘Oh God no’ that kind of thing. And then 
he said ‘right okay Mr X you can go now.” 
Thomas, L3 
For subsequent consultations he had been told he needed “to have somebody 
with me,” but he had since decided it was not going to be his daughter but 
someone who knew him on a day­to­day basis because he experienced the 
consultation as “annoying the way it was done.” This was in contrast to Jack 
who thought it was good that his wife Ann accompanied him into consultations 
as it helped to get the most accurate information. 
“It is important as well, sort of to have both sides because if I suddenly 
can’t think of the next word that I am going to use, then Ann sometimes 
knows what I’m going to say.” Jack, L1 
This seems an area that HCPs working with PWD and their carers need to 
address within their own consultations; whether the patient and carer should be 
seen together or apart or both. Fundamental to this decision is the need to 
explore how the person with dementia would like to be involved, who else they 
would like to be involved and who they trust to take those decisions on their 
behalf. Obviously any agreement needs to be flexible to respond to the changes 
brought about by disease progression. The Mental Capacity Act 299 and 
Dementia Care Mapping199­203 supports the concept that PWD should always be 
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considered as having capacity to make or be involved with decisions about their 
own care. 
4.3.1.6 Conflict with Healthcare Professionals 
Due to the nature of full­time caring and wanting what was perceived as the best 
treatment and support for your loved one; carers often came into conflict with 
HCPs. Examples centred on access to support or medication. Mary (L3) was 
trying to get her husband prescribed memantine as the AChEIs had been 
withdrawn 12months previously. Since then her husband had become 
increasingly restless, wanting to walk outside for hours and he had lost sense of 
the night­day cycle. This is a common behavioural change exhibited by PWD 
sometimes referred to as ‘sun­downing’ or diurnal variation.146 Mary was not 
sleeping either as she kept her husband company on his nightly walks; she was 
literally exhausted. 
“And at night he gets up and he wanders, and he wants to go out and he 
wants to go walking and he wants to know where his mother is and all 
these usual sort of things…I have got another appointment with Doctor X 
(specialist) in the first week in November, and he said if the sleeping is 
stabilised then he will start him on Ebixa®.” Mary, L3 
This specialist supplied her with Zimovane® (a non­benzodiazepine hypnotic) to 
try and establish a day­night cycle.306 It seemed to work effectively for two 
weeks before tolerance was seen; the dose increased and again tolerance 
resulted. The risks of tolerance and addiction are well known pharmacological 
effects as are the risks to the person in terms of confusion and possible falls.206 
It is perhaps an inappropriate treatment for sun­downing; but one that Mary felt 
she had to give to possibly receive memantine. It also seems inappropriate that 
therapeutic trade offs are being made for people at this stage of the illness. If an 
asthmatic were kept awake at night by their wheeze or cough they would not be 
prescribed a hypnotic in order to make them sleep; they would have the 
appropriate treatment for their symptoms prescribed. As mentioned in 2.1.2.1 
the clinician should feel able to prescribe in the patients’ best interest and it 
would seem that evidence would support the prescribing of memantine ahead of 
Zimovane®.110,119,120,230 
Because most carers felt that the medicines were positively effective in many 
areas of daily living they often had difficulty accepting judgements obtained from 
clinic assessment tools. Pat’s husband was taken off an AChEI because his 
MMSE score stayed the same. Another way of looking at a static MMSE score 
is the medication is holding the neurodegenerative process, and preventing 
further deterioration at this particular point. 
“Well I thought he sort of stayed the same when he was on that. He 
didn’t seem to get any worse. But I suppose he didn’t improve either 
so they said it wasn’t doing him any good.” Pat, L1 
Others ignored well meant advice from HCPs that the person they cared for was 
potentially dangerous and they should not take them home. Sue explained that 
this occurred twice; once after her husband had an inpatient stay (for an 
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unrelated medical problem) where he had become very confused, disorientated 
and aggressive with staff when they had tried to restrain him and the second 
after his first admission to a respite service. 
“(They said) ‘I don’t know whether you should have him back he’s very 
aggressive.’ And I said well I’ve been married to him for 49 years he’s not 
going to do anything to me I know. So anyway then we went and got him 
and he walked in the front door and he said ‘It’s all right I’m home.’” 
Sue, L2 
In reality these behavioural changes displayed by PWD when moved from a 
familiar environment to one that is less so are well documented as triggers to 
agitated and aggressive behaviour.310 People with dementia need familiar 
objects in their environment to help orientate them to time, place and/or space. 
Without familiar objects, orientation is lost, sometimes on all three levels and 
this can be a frightening and confusing experience. It seems that more formal 
carers are less able to help orientate people without specific training and this 
lack of skilling increases agitation and anxiety of the transposed person.50,51 
These interactions with HCPs, for many carers, were an interaction with a 
powerful other. That is, someone who was perceived as having control over 
their ability to care and their loved ones day­to­day mood and behaviour. This 
powerful other held the possibility of information, appropriate medication, and 
carer support. 
4.3.2 Ageism 
Carers’ generally recognised subtle prodromal changes in their partner, such as 
uncharacteristic behaviour, fuzzy heads; difficulty in telling the time, mood 
changes and/or loss of interest in usual hobbies. This prodromal period lasted 
from 5 to 12 years and carers’ related stories of frustration at the lack of 
response from GPs and other HCPs when they sought advice and/or guidance 
and their concerns were dismissed as being age­related. 
4.3.2.1 Recognition and Diagnosis 
Carers experienced the disinterest and dismissal of concerns displayed by 
HCPs as therapeutic nihilism, which compounded the feeling of not being heard. 
As Wendy described in the narrative below, this lack of concern for the effects of 
symptoms on the lives of carers could be distressing and lead to mental and 
physical stress. 
“As far as my own GP is concerned it was a case of well he is 80, he is 
doing quite well in getting to 80 and that was it you know. No matter what 
goes on it was nothing really because of his age, you know. I thought 
there was a line drawn because he was 80 years of age and as long as 
he was on his feet it didn’t matter about what else was going on or how I 
was coping that sort of thing.” Wendy, L 3 
“So I knew sometime really before he was diagnosed and before the 
doctors really took it up because I even mentioned it to one doctor and he 
said ‘oh well that’s old age’ you know, because it wasn’t that much. 
Doris, L2 
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As mentioned previously in 2.1.2.1, for older PWD there was a double stigma, 
with it being perceived as a mental illness and affecting older people. Dementia 
continues to be one of the most under funded and under­supported of the major 
therapeutic conditions in today’s health services. Although it is hoped that 
funding of £150million in support of the NDS implementation may help to 
address issues such as stigma and therapeutic nihilism.51,79,80 Currently many 
services are attached to Old Age Psychiatry units and continued and/or 
adequate funding may be dependent on local resources for Mental Health 
services. The Cinderella of modern medicine, Mental Health services are well 
known for being inadequately funded and also having funding taken from their 
budgets in order to support debt ridden general medical services.311 
Point of 
Reflexivity 
The branch lead from location one and each of the 
participants had asked to be kept informed about the findings 
from the study. Two of the interim findings had been around 
the variability in the provision of information, medication 
and/or services and the experience of ageism in this 
aforementioned process. The carer participants’ age range 
was between 65 and 80 in this location and each asked the 
branch lead to feed back to me that this was something they 
had found upsetting and frustrating when seeking help from 
healthcare services. 
Non­recognition of symptoms by frontline HCPs meant that many PWD were not 
referred to specialist services for some years. Not only did this preclude the 
usefulness of an early diagnosis in terms of allowing the person to prepare for 
the time they would no longer have insight into their treatment and perhaps 
complete an Advanced Directive, but it meant useful treatments, services and 
educational interventions were not accessible.192,194­8 Patients and their families 
need time to understand what is going on before it is too late and prepare in 
advance for potential financial, social and mobility issues. 
Ann had recognised something was not quite right with Jack over 12 years 
before the diagnosis was finally made. They bounced from GP to GP to 
specialist GPs to consultants before a diagnosis was finally made. Jack, had 
been a University lecturer, with previous high intellect and she had been sure 
that this was the reason for the delay in her husbands’ diagnosis as illustrated 
below. 
“So you know she (the consultant) confirmed what I’d been saying all 
along that yes there was a problem and she actually sent an email to this 
GP Specialist to say ‘you’ve got to look for the very intelligent patients to 
see what their drop is’ because he’s had a massive drop but because he 
started at a higher level.” Ann, L1 
Often getting the diagnosis was not actually seen as helpful by carers as it didn’t 
actually change anything. 
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“(Husband) did have a brain scan though to see if it was anything. They 
say, if it’s Alzheimer’s the brain shrinks or something and if it’s vascular 
there’s other signs, you know. It still doesn’t alter the fact of how you are 
does it?” Lynn, L2 
Many people find it very difficult to take a lot of information on board at the time 
of diagnosis and perhaps even forgetting they have been told certain facts.211 In 
fact, the diagnosis given in an off­hand manner can cause distress, humiliation 
and anger at the process of diagnosis, the lack of support and “the system of 
so­called ‘care.’” 312 Pat described the off­hand way in which she and her 
husband received his diagnosis, when there had been no expectation of such a 
prognosis. 
“We had to see the consultant and he said to me “You must have 
guessed he’s got Alzheimer’s?” I said well I hadn’t because I thought with 
Alzheimer’s once it had gone it had gone and (husband) would remember 
another time and it didn’t sort of cross my mind.” Pat, L1 
4.3.2.2 Complexity and Duration 
As mentioned in 2.1.2.4, diagnosis of dementia is one of exclusion with no 
routinely available simple blood or tissue tests.313,314 Unsurprisingly, this 
resulted in a large number of visits to different HCPs, often in different 
healthcare settings. One could predict that there would be miscommunication; 
lost results, incorrect procedures being undertaken; all of which delayed time to 
diagnosis further. This diagnostic process was experienced as being time 
consuming and frustrating. 
Ann: “It was frustrating for me, I got very uptight. They lost the CAT scan 
from (the hospital). At that time he had what seemed to be a stroke 
which now turns out to be several TIA’s but when we went to see the 
specialist about that he hadn’t got the figures to hand because the scan 
was missing. It’s a long cycle of things that went wrong.” 
Ann, L1 
This diagnostic process was also associated with a large time commitment for 
both the carer and the person with dementia as Jack related below: 
“I don’t think we went really a day, a week rather, when we weren’t 
seeing somebody, we are more used to that than anything else. That 
was normal.” Jack, L1 
The duration of time between the initial contact with a HCP with respect to 
presenting memory problems and a confirmed diagnosis, was counted in years 
rather than months. These experiences contrasted with the proposal that the 
duration of the diagnostic process in primary care took 18 months, 61 which did 
not seem to take into account the years of delay from an ageist response at first 
presentation. 
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This delay in access to services and active treatment was perceived by carers 
to have negatively affected their loved ones current health status. 
“ In all the years and she (her mother) has been here, six and a half 
years and it is only this year she has gone there (memory clinic). If she 
had taken Aricept® five to six years ago she may have been you know in 
a much better state than she is now.” Jane, L3 
Point of 
Reflexivity 
Jane’s comment above illustrated the extreme desire that 
carers had to hold the disease in a specific timeframe and 
halt further progression so that the person they remembered 
and loved was kept safe in the present. It was very moving to 
witness the emotions displayed by the participant carers and 
their perceived impotence to contribute to this yearning. 
4.3.3 Accessing Medicines for Dementia 
As mentioned previously, carers were reasonably well informed as they 
received the quarterly magazine Living with Dementia297 which enabled them to 
form their own opinions on efficacy and use of medicines for dementia. 
Consequently there were associated hopes and fears associated with these 
treatments. 
4.3.3.1 Hopes and Fears of Medication 
There were four main fears or hopes associated with medicines for dementia. 
These were: 
1. the chance for their loved one to try a perceived effective treatment, 
2. how to overcome the barriers to accessing a medicine for dementia, 
3. being able to start the medication sufficiently early to ensure a good and 
prolonged response, and 
4. the hope it would not be discontinued if they felt the medication was 
helping. 
A Chance to Try 
Receiving a diagnosis of Alzheimer’s, vascular or a mixed dementia, did not 
guarantee access to medicines for dementia. Prescribing criteria between 
locations was different, with two of the four sites not routinely prescribing 
memantine. This meant that those people who were not eligible for AChEIs 
because of concomitant medical problems or because their MMSE score were 
too low, were not eligible for any medicine for dementia. In locations 3 and 4 
some people were prescribed memantine but others were not; this variability 
resulted in inequity in access to treatment and another thing a carer felt they 
needed to fight for. 
“I think they should be given the chance even if it is not going to work, I 
feel that they should be given the chance. I mean it may not work for 
(husband) but you know I shall feel happy that he has been given the 
chance to try which hopefully he will but as you say, you fight every step 
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of the way don’t you?” Mary, L3 
There was great frustration expressed that the treatment of dementia was not 
regarded in the same way as which physical health conditions were and this 
raised undercurrents of feeling neglected by the NHS. This could also be linked 
to institutionalised ageism having possibly pervaded the auspices of NICE in 
terms of the inappropriate use of QALYs as an outcome measure for a terminal 
illness in older people.64­68 
“I mean if somebody has some sort of other physical illness like angina 
the doctor wouldn’t think about not giving him the right medication which 
might help that person.” Jane, L3 
When carers spoke of their hopes for a medicine for dementia to be prescribed 
for their loved one there were always mixed emotions present. Some were very 
anxious about it, not wanting to push too hard and the rock the boat; whereas 
others were angry and saw it as their loved ones’ right to be able to try a 
treatment that was available. Listening to the benefits seen in some PWD, 
carers experienced great hope tempered by the knowledge that it might not be 
effective for their loved one. 
Mary: “I know I am sat hear almost drooling over the

improvements.”

Wendy: “We have tears. I am so worried…we are told aren’t we, we 
mustn’t pin our hopes on it. I must be realistic, it may not work and I think 
to myself ‘well the Aricept worked I am sure it will if he ever gets on 
Ebixa®.’” Mary & Wendy, L3 
Barriers 
As outlined in 2.3.3.1 the review of the NICE guideline was overdue and a draft 
suggested reduced availability of AChEIs and although it was not a question on 
the topic guide; carers expressed their disapproval of the impending decision. 
This decision­making process was seen as long and arduous, resulting in many 
participants feeling anxious about the effect of the impending decision on their 
own situation but also the effect it would have on others not currently receiving 
treatment. It all added to their sense of disempowerment and helplessness 
within the current biomedical framework. 
“That’s why I’m so angry about this NICE proposal. Because they say 
‘well you haven’t got a worry because (wife) is already on it she’ll carry 
on.’ That’s not the thing. It’s people not been given the opportunity 
because it’s so dramatic, altered every one of our lives. Anyone even 
remotely connected with (wife), it’s so totally different even her sister who 
only sees (wife) probably once a month; she wouldn’t have anything to do 
with her, now she strokes her and everything. Peter, L3 
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Another point of concern was the perception that the prescribing of these 
medicines was rationed locally and that somehow; they and the person they 
cared for had to pass an unknown test before a prescription was written. 
“Well he did come out here and see me in our own home before 
prescribing the medicine…So he came out here and he saw us and 
chatted to us and was very pleasant. And probably deciding whether it 
was worth spending the money. Oh God isn’t it awful? But maybe their 
hands are tied and they’re told you can only have so many patients that 
are allowed to be prescribed it.” Sue, L2 
Some carers were concerned that their continued demands on behalf of their 
loved one would end with them being removed from surgery lists as a patient. 
“I do feel like I have been making waves for quite a while about this 
Ebixa® and I mean when the, my husband’s GP said well I don’t think 
they’re, any of these things are any good anyway, you know that really 
got me going (pause) not to him. I don’t want to be taken off the list.” 
Mary, L3 
It could be considered that memantine’s place in therapy would be once the 
AChEIs were no longer effective; or if they had been an inappropriate choice 
due to concomitant illness. Many carers had difficulty accepting the NHS could 
refuse to prescribe a medicines costing £2.50 per day to enable PWD to be 
cared for at home for longer, but were willing to pay £400 per week for the same 
person to go into a care home. Carers were quite open that they wouldn’t be 
able to contribute much if at all to the care home costs as explained by Mavis 
(L2) “we couldn’t do it, which would mean it would be on the NHS” and Peter 
below: 
“I’d swear I’d never do it, I can’t say you will never do it but I was 
reaching the end of my tether with her (his wife). It was going to cost 
somebody a lot of money because I couldn’t carry on looking after (wife), 
bearing in mind I’d done if for 8 years. But there is no problem now, she’s 
fine, aren’t you (wife since starting memantine)?” 
Peter, L3 
Others looked at it from a slightly different viewpoint and thought the 
government was making money out of informal carers and by implication the 
government should be more prepared to prescribe medicines for dementia. This 
became a debated point in the second carer focus group (L4). 
Paul: “Well if the governments got all this money what they’re making out 
of all of us sick people; the millions of pounds that they’re making.” 
Diane: “With us caring for them?” 
Paul: “Yeah with us caring for ‘em like.” 
General: “Yes, yes” 
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Paul: “They’d spend a lot more if they had to go in a home wouldn’t 
they?” 
General Agreement: “Yes” “Yes” “True” 
Carer Focus Group 2, L4 
As mentioned earlier, Informal carers have been estimated to save the 
government £6billion pounds each year by bypassing the need to implement 
more formal caring arrangements.51,191 Although the Carers Act305 outlines the 
legal rights of informal carers; it is not widely publicised and local health 
organisations struggle to assess individual carer needs.48­50,192 Many carers feel 
undervalued and unsupported; leading to increased carer burden, stress and 
ultimately institutionalisation of the person they care for and increased heath 
and social care costs.192 
Participants realised that money in the health service was limited and that NICE 
was there to “sort out the good from the bad” but they felt the decision was 
hasty to stop access when the medication actually caused improvement in some 
people. 
“I wrote when we had the big push for the latest drug I wrote to the MP 
because I thought it was important that when you could see what it could do 
for some people. It doesn’t suit everybody, not everybody it works for. I feel 
that they were a bit hasty. I know money is a problem but it seemed rather 
hard to just sort of stop.” Lynn, L2 
Starting Medicines Early 
A number of carers voiced opinions that ‘they were not keen on tablets’ and that 
this influenced their decisions on whether to start recommended medication for 
their loved one. This also raised an interesting ethical dilemma in terms of what 
the best interests of the person with dementia actually were. In the following 
example it was unclear whose beliefs were being addressed and whether the 
best interests of the patient were being protected. 
“I can’t remember which one it was it was, but it was one of the three 
main ones. And it was quite clear it was all experimental. They wanted to 
monitor so on and so forth. I’ve never been keen on drugs, we’ve never 
been keen, so we didn’t actually do it.” Peter, L3 
Who has the best interest of the person with dementia at heart? Can there ever 
be true concordance with a medication regimen when PWD may not be given 
the chance to voice their opinion? 
In terms of starting a medicine for dementia carers generally felt the medicines 
were not started soon enough. Evidence8­12,23,27 supports that starting AChEIs in 
mild dementia can be beneficial for some people; but larger differences in 
response from baseline measurements are witnessed when the medicines are 
started at moderate stages.31 
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“Perhaps if they had been a year earlier, you don’t know. But I think they 
do pick up on it more now. I mean it’s, I don’t know, maybe its seven 
years (since first symptoms appeared).” Pat, L1 
All the participants with dementia knew that they had been started a medication 
for “brain function” and Jack (L1) believed that the medicines should be started 
as soon as possible as long as the diagnosis was correct. 
“ASAP except you should maybe be sure that they are appropriately 
prescribed, and identification of the condition.” Jack, L1 
In summary HCPs were perceived as powerful gatekeepers to the access of 
medicines for dementia and support services. Variability in communication skills 
and knowledge across and within locations demonstrated a resultant inequity in 
support and service provision. 
4.4 Living With A Degenerative Illness 
Living with a degenerative illness as a carer meant the daily witness of a loved 
ones’ decline in cognitive; social, psychological and physical functioning. 
Section 4.3.1 discussed the general role changes and associated challenges of 
caring. This section will discuss the lived experience of participants and how 
they perceived the medicines for dementia supported this. 
4.4.1 The Lived Experience 
This section describes how dementia affected and shaped the lives of those 
involved. The lived experience was the daily recognition that what once was had 
changed forever. Participants expressed sadness and frustration at perceived 
individual losses, but there were some signs of illness acceptance. 
4.4.1.1 Sense Making and Acceptance 
Both care­givers and recipients expressed difficulties in understanding why 
people were affected and many narratives described participant’s sense­making 
of their lived experience. A large part of this process was trying to establish 
exactly what dementia was. 
“…what started this originally has got nothing to do with what this is 
about. He had one of those TIA’s. And they say that’s what caused this.” 
Doris, L1 
There were contrasting views on whether dementia was a disease or an illness 
as illustrated below: 
“They still don’t know what it is really. Because it’s not an illness is it?” 
Jenny, L2 
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“I mean it is an illness. If you have got cancer you go in hospital and you 
have your treatment free. I mean I know they don’t need to be in hospital 
but they still need care if they are in a (their) home.” Pat, L1 
Point of 
Reflexivity 
The concept of whether dementia is an illness or a disease is 
one I struggled with as well. Disease is defined as “any 
alteration of the normal vital processes of man, any disorder 
or morbid condition.” Illness as “the state of being ill, 
sickness, physical indisposition.”315 The signs and symptoms 
seemed to traverse across the two descriptors as cognition 
negatively impacted on physical health. It seemed carers felt 
an illness was taken more seriously in terms of the treatment 
proffered. 
A common narrative from carers was incomprehension of how dementia could 
occur in someone who was otherwise fit: almost as if it would be easier to bear if 
a loved one had some other medical condition. 
“It’s just the mental part, I mean actually he’s well in his self and he eats 
ever so well I mean he’s 82 but he eats well and that, there is nothing 
wrong with him really. (Husband interjects; non­sensical) This is the part; 
(the distress of living with a person with dementia) when you can’t hold a 
conversation with him.” Jenny, L2 
As with any chronic illness there needs to be adjustment and acceptance made 
by those living with it that the situation cannot be changed and therefore need to 
be accepted in order to move on.135,136,142 Tim (L4) had experienced difficulty 
dealing with the frustration of his poor memory on daily activities and stated 
“you’ve got to be I suppose philosophical is the right word. You can’t let it bother 
you too much otherwise you’d go bonkers wouldn’t you?” 
Philip (L4) talked about how his ability to complete tasks was “all right for a while 
now, then it dies away” and how frustrating this was. He expanded saying the 
hardest thing “I found was you couldn’t do what you were capable of doing, 
that’s what was the worst bit of the lot, you know. But I got over it.” 
It is interesting to consider whether these illustrate a true acceptance of living 
with memory problems or whether participants forgot to get concerned about not 
remembering, or as the disease progressed their insight into previous abilities 
lessened. However the frustration was still evident as they remembered the 
extent of their cognitive limitations. 
4.4.1.2 Living with a Poor Memory 
Poor short­term memory is a prominent factor of most dementias, and especially 
those diagnosed with an Alzheimer­type. The participants with dementia 
described how this symptom affected them and their daily routines. Thomas 
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found it difficult to accept his diagnosis of AD because he felt that there was not 
a great difference in his memory from when he was a younger man. He said that 
he had always been absent minded as “my brain was away up in the sky 
somewhere.” He continued with the following explanation: 
“My wife always reckoned I had a bad memory. There were lots of things 
she liked to trot out like ‘What’s your name, Mary Jane, where do you 
live, down the lane.’ So, it still is that, but a little bit worse.” 
Thomas L3 
In the focus group for PWD (L4), participants shared their frustration about 
being able to remember distant but not recent events. 
Tim: “It’s just the memory at times, you want to remember, and it’s 
always the things you want to remember you can’t!” 
Philip: “And the more you try the worse it is.” 
Tim: “The worse it is! So I go into my memory bank, my wife. Most people 
find it very hard, people like us. They’ve sort of lost their memories and 
yet you can go back years ago, I can remember all that.” 
I: It’s all there, so it’s just the recent sort of things 
Tim: “Yes, you can walk down the road and if you ask me tomorrow ‘what 
did we do?’ I can’t tell you we walked down the road. Strange isn’t it? It 
used to frustrate me a lot...” 
Philip: “It used to with me as well.” 
Tim: “but the wife said ‘forget it, I know what you’ve done’” 
PWD Focus Group L4 
Some carers accepted short term memory problems as part of the condition and 
adjusted conversational content to more distant shared memories. 
“His long term memory is excellent but you ask him about something that 
happened yesterday and he can’t remember but that is one of the 
symptoms anyway but apparently he is not doing too badly so I have got 
nothing really to complain about have I?” Wendy, L3 
Participants with dementia acknowledged their reliance on carers to confirm 
their memories but Jack found it difficult that sometimes he could not remember 
a shared memory at all causing him some frustration as he explained: 
“It’s not only that I forget what’s been said I forget that it was said. It’s 
irritating and exasperating.” Jack, L1 
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Although Jack said that he sometimes felt “over dependent” relying on Ann to do 
things, he accepted that this was necessary and qualified it by saying “I don’t 
believe in shooting myself.” He continued by saying that “we’re quite good 
friends. And always have been.” This seems to be an important factor in the 
caring relationship, the maintenance of friendship and social intimacy through 
talking and social contact. This concept about the quality of the previous 
relationship influencing the quality of the subsequent caring relationship is well 
known and perhaps should also help to shape support packages for the person 
with dementia.167,170,171,177,188 
4.4.1.3 Changing Relationships 
Participants with dementia generally spoke warmly and with affection and 
gratitude for the support of their carer as Jack shared “Imagine, it would be 
impossible to work things out at all without help of a carer.” Carers felt a sense 
of loss for the person they loved and the associated deterioration in their 
personality.166 As has been suggested, if there are unresolved issues or 
disappointments then it may become increasingly difficult for caring to continue 
and/or the relationship to survive. 167,170,171,177 For the person with dementia this 
can obviously present a number of difficulties especially as the illness 
progresses and dependence increases. 
Sandy (L4) was an anxious lady who knew her poor memory was causing her 
husband Paul great irritation; although she said “He’s been very good though; 
my husband has. Really, very good.” Paul was finding it increasingly difficult to 
care for her and she shared “he’s getting a bit frustrated.” Other statements 
were repeated during the focus group creating a dilemma as to whether Sandy 
was safe at home. 
Point of 
Reflexivity 
As a researcher this was cause for ethical deliberation. 
Sandy repeatedly stated how her husband was frequently 
irritated with her and that she thought she needed some more 
of the medicines for dementia as she thought these may help 
her and by inference, her husband. She became quite 
anxious through the latter stage of the group session and I 
became concerned for her well­being at home. Did I break 
the confidentiality of the sharing within the group? Was I 
picking up incorrect information? Was it any of my business 
as the researcher? 
In the end I asked to speak to the lead social worker at the 
branch and shared my concerns. They were well aware of the 
increasing irritation and frustrations experienced by Paul in 
response to Sandy’s inability to complete simple tasks and 
were doing their best to support them both. However, Paul 
was proceeding with enquiries to have Sandy admitted to a 
care home and Sandy was very anxious as she did not want 
this to happen. 
Jack (L1) spoke about his concerns of his behaviour and memory before the 
diagnosis was made as he realised that “everything was going wrong, physically 
and mentally and I was a bit concerned. It affected other people as well.” 
93 
On a more personal and emotional level for carers intimacy was lost within the 
relationship, as the person they had fallen in love seemed to disappear; 
resulting in profound sadness. 
“He doesn’t even remember when we were courting or anything. We’ve 
just had our 60th wedding anniversary and he’d completely forgotten 
about that; he didn’t even know what it was all about. It’s pretty awful 
really.” Doris, L2 
This loss of being able to share personal, intimate relationship memories has 
been proposed as a key subjective stressor affecting the ability for caring to 
continue.131,166,177 
“There is something to be said from a heart attack. I know it is a shock for 
people left behind but there’s a lot to be said for it. I had a friend and, her 
husband died of cancer and he had in about four months and she said 
‘well at least you still got him,’ but you haven’t, you haven’t got him at all.” 
Pat, L1 
Sue experienced such a complete change in the relationship with her husband 
that there was almost a felt sense of the anger, loss and perceived unfairness of 
the resultant situation. 
“I had a husband that did pay the bills, made the arrangements in our 
lives, looked after me and suddenly he went and I didn’t have that person 
any more. He couldn’t make the decisions, he couldn’t pay the bills, he 
couldn’t talk to me at all and it was absolutely appalling to live with 
somebody…who isn’t that person anymore. It’s been the worst time in 
my life I would say, it was terrible absolutely terrible.” Sue, L2 
This perceived loss of the person carers’ loved can be distressing resulting in 
increased carer burden 131,166,177,285 however it has been suggested that perhaps 
this is due to the inability of the carer to live with the person as they are now 
rather than the person they once were.141 
4.4.1.4 Progression and Behavioural Changes 
Dementia is an insidiously progressive disease and it has been suggested 
carers want to be forewarned of possible outcomes61 as Jenny stated: 
“Oh no I think it was the right thing (being told about progression). You 
know it gets worse don’t you? I mean when he first had it, it’s no good 
saying he’s going to get better from it. You really hope that he is.” 
Jenny, L2 
On or off a medicine for dementia PWD exhibited fluctuations in cognition and 
behaviour as Jill voiced “you see their condition changes so much I find you 
know, every week is something different.” Others like Helen Mary, Bob, Steve 
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and Fred (L4) observed a decrease in confidence which was experienced as 
their loved ones “becoming more clingy.” Fred shared “she’s (his wife) always 
looking for me. She gets quite obsessed.” 
Fluctuations in mood impacted greatly on care­givers as Jane described below: 
“I always think the worst thing for carers, it is not so much that people 
get more and more forgetful or do strange things, it’s to see when they 
are unhappy and when they are miserable because that really pulls on 
the heart strings and you’re sort of living with this unhappiness in the 
house all day long.” Jane, L3 
Communication became increasingly difficult both for the person with dementia 
and for the care­giver trying to adjust to and live with these changes. This was 
illustrated by a discussion at the second carer focus group (L4). 
Bob: “You can’t tell from day to day where she’s at. If you argue about 
things you may as well forget about it but if you agree and go along with 
the flow then it’s ok. Strange.” 
Mandy: “I think we’re all like that aren’t we? Don’t argue, you can’t argue 
with them, because they’re never wrong.” 
Bob: “That’s it they’re never wrong.” 
Polly: “Never wrong.” 
Bob: “And don’t tell me what to do.” 
Mandy: “Not their fault.” 
Steve: “Don’t tell me what to do.” 
Mandy: “That’s right.” 
Bob: “Strange.” 
Steve: “Yes that seems to be the case of male and female. You daren’t 
sort of try and correct them, because if they’re in a state where you’d call 
them apparently normal, they can flip over to being aggressive.” 
Carer Focus Group, L4 
Good communication skills become increasingly important when caring for 
someone with dementia. If a person can no longer reason or understand logic 
then no amount of debate will shift their viewpoint. Guidance suggests that 
agreement and then distraction from the topic may be the best way to handle 
these situations.151,316,317 The person with dementia does not become frustrated 
in their ability to understand and the carer does not become embroiled in an 
argument that can never be won.151,316,317 Interestingly Pat linked this decrease 
in communication skills to progression of the illness. 
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“I think he is getting into another stage now, he’s not so amenable as he 
used to be, he’s not violent or anything like that but he gets very, he gets 
frustrated because he wants to say things and he can’t communicate, he 
gets cross about it.” Pat, L2 
Carers described aggression as being either internally or externally directed. 
Internally directed behaviour was described as “jittery” and externally directed 
behaviour was often associated with people lashing out or hitting others. 
“The aggression went (after memantine started) because he was getting 
very aggressive and agitated all the time, sort of jittery and wanting to run 
away from himself.” Sue, L2 
“…if you came with in striking distance, you’d get a biff. You weren’t 
allowed to touch her or anything (before memantine).” Peter, L3 
Other carers such as Helen experienced disease progression as increasing 
resistance to completing small tasks or their approach becoming more 
aggressive. 
“I would say it (Aricept®) held the position as it was for about a year at 
least without any deterioration at all and then gradually things started to 
deteriorate with doing tasks, that sort of thing and then after about 3 
years or so I suppose, he started becoming a little bit more aggressive 
himself.” Helen, L4 
Another change experienced in people with advancing dementia was the 
inability to orientate to time and place in terms of their environment and/or in 
recognition of their loved ones and family. This has been described as one of 
the most difficult things for carers to accept as illustrated by Jill below: 
“He doesn’t live in the here and now and you know he sees things. He 
thinks I am his mother most of the time, or I can be his father sometimes, 
if I’ve been in the garden working he thinks I am his father. I can be 
sitting watching him and we’re having tea and he’ll say ‘when’s Jill 
coming home?’ and I say ‘I am Jill.’ You know, and then I’ll say ‘well who 
do you think I am?’ “Well you’re my father.” You know, it’s very weird. 
Jill L1 
In summary the lived experience of degenerative illness challenged care givers 
and receiver on many levels; completely changing the previous relationships 
and lives they once shared. 
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4.4.2 After Medicines for Dementia 
Carer participants described wide­ranging effects of medicines for dementia. 
Because dementia causes progressive impairment in areas of memory, 
language, visuospatial and perceptual ability, thinking and problem­solving or 
personality; it could perhaps be foreseen that these agents could have a more 
global affect than just improving memory. More important was how these 
effects were experienced by carers and by those who took them and resultant 
effects on mood, functioning, daily activities and carers’ ability to cope. 
4.4.2.1 Effects on People with Dementia 
In terms of effect on memory there was variability; with carers reporting 
improvement, holding or no effect. More important seemed to be global 
improvements in functioning. Sue for example perceived the main effect was 
improved behaviour. 
“I would say mostly behaviour, but I don’t think he was on them early 
enough. I think it probably did hold it sort of stop the memory getting 
quickly worse which it would have done without them, but I wouldn’t say it 
improved the memory.” Sue, L2 
“It didn’t help his memory but it helped him in other ways. … again he’d 
stopped being quite so outgoing, but he’s back to that again and he’s 
much more friendly and talking to everybody in there (day centre) and he 
has little jokes now and that sort of thing.” 
Mandy (about Philip), L4 
Behaviour was a generic term used to include anything from perceived 
aggression, agitation, repeated questioning to increased sociability and 
friendliness. 
“And he had been becoming more aggressive and really questioning 
everything that we did ‘why?’ ‘Why do I have to do this?’ ‘Why do we 
have to do that?’ and this (memantine) controlled that. And it was really 
mood enhancing it’s not so much the tasks that these drugs help 
altogether, so much as the mood and the way they approach things and 
how much easier that makes it for me.” Helen, L4 
Participants described a wide range of improvements on mood including: the 
return of a sense of fun or humour; improved mood or mood stability; or mood 
alerting or calming affects. Many carers were pleased to see loved ones happier 
and more cheerful in themselves; this obviously helped to improve social 
interactions within the caring process as humour returned. Jane shared what 
she felt were the most important benefits of the treatment below. 
“Now I think there is a purpose for her because she gets up and she’s 
cheerful and she laughs and we have a joke and she does something 
silly, she has got a great sense of humour, she always had which 
disappeared for a while and it has come back and this is really very 
special to me.” Jane, L3 
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Prior to starting memantine Jenny’s husband was up all night and displayed 
very agitated and driven behaviour. He was unable to sit quietly and was always 
on the go, which was exhausting for Jenny, as she wasn’t sleeping well at night 
trying to get him upstairs to bed. 
“…this is the one that has calmed him down a bit. Where he used to be 
on the go and would never sit down and he’d be up and down and 
moving about and I don’t know never rest, but now this is great we sit like 
this (quietly side by side) in the evening, he really likes a sit down.” 
Jenny, L2 
Helen described how the introduction of memantine had enabled her husband to 
attempt every day tasks that Helen would normally be doing for him. 
“He had started being a bit more confident and for instance, I’d started 
shaving him just prior to that (starting memantine) everyday and he said 
‘oh I’ll try that, I’ll do that’ even though he couldn’t complete it properly he 
was having a go at some of the smaller tasks.” Helen, L4 
Jack described how the medicines made him feel more confident and therefore 
able to complete his usual daily activities. 
“I think the best way of putting it is to say that I feel more confident in 
going about my daily doings and there has been occasions where I 
haven’t been safe to be walking home on the side of the road, but I’m 
safe to take the dogs out (now) and so on but you know that’s where I’ve 
been feeling more confident and I don’t think it’s getting any worse.” 
Jack, L1 
In terms of the effects of the medicines on daily activities, the responses were 
varied both in terms of capabilities but also in terms of importance to the carer. 
For example Ann reported improvement in activities such as making a cup of 
tea and using the dishwasher but more important to her was the fact that Jack 
could now spend time on a previous hobby of railway modelling. 
“Well we still have a short­term memory loss. I don’t think it is as bad as 
it was. We’ve actually got Jack to start modelling again. He has a railway 
model and… before he would not have been able to do what he’s been 
doing now. Although what he is doing now is very simple.” Ann, L1 
Other carers reported a return to previously enjoyed activities such as 
crosswords; reading and listening to music, but for others it was toileting issues 
that were of more importance. 
“He likes listening to his music he has got all these videos that I put on 
because he likes all music. Irish, Scottish ones he’s got there. If there is 
nothing on the television I’ll put that on, even if you think he is asleep he 
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isn’t because you can see his foot tapping.” Pat, L1 
“So far as regards toilet that’s fine and that’s where I think this is helping 
him. I do think maybe I might have had more problems that way.” 
Mavis, L2 
The participants with dementia described daily activities which ranged from 
helping with household chores, to dog walking or collecting newspapers, to 
driving under supervision, and then on to arranging own travel and 
accommodation and cooking and cleaning for oneself. So a wide range of 
capabilities were demonstrated and this may reflect different individual’s stage 
of the illness and/or include a contribution from their prior capabilities and 
personal aptitudes. 
As Thomas (L3) explained, “Except for being a bit forgetful I think I’m coping 
alright. I keep myself clean, I keep the flat reasonably clean and tidy, I cook 
proper meals, I walk and get a lot of exercise.” However he confessed to 
forgetting to shower at one stage but had written reminders on the calendar to 
ensure that he showered regularly. He was also doing all his own laundry and 
ironing; although he admitted “I don’t iron the sheets very well mind you.” 
Tim (L4) liked to walk out for the paper when he could, as he liked the exercise. 
At this stage he felt safe enough to do that without getting lost as he explained, 
“I think, the roads round where we live are imprinted in me mind anyway.” 
Philip spoke frequently of his disbelief about how quickly and how well the 
Aricept® worked for him and comments such as “ I couldn’t believe it; I can still 
remember it today, the day I took them for the first time” were common. He 
described them as a “magic pill” and how he felt “completely new and better” 
after taking the medication which more than anything perhaps gives an 
indication of how badly he felt before. 
“When they first told me, before I had took it, (the medicine for dementia) 
I didn’t know what planet I was on or anything, you know. I was just a 
dead loss you know.” Philip, L4 
Mary (L3) described her husband as being “more alert, his speech was more 
coherent as it were and this went on for about a year.” In comparison Sarah (L4) 
had experienced her husbands slip into dementia as almost like a sleeping 
sickness, and after starting an AChEI she described him as having “been 
sleeping and suddenly he was more aware and he changed.” For Jill this 
increased alertness without improved insight decreased her ability to cope and 
as there were side effects of treatment it was decided to withdraw the 
medication. 
“I did notice he was brighter and you know more responsive and probably 
at the time I thought that I don’t want him that bright because he’ll want to 
go out and do Parish work, when he isn’t it, you know. He doesn’t, he 
has no self­awareness at the moment.” Jill, L1 
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All participants with dementia described episodes of insight into their own 
behaviour or needs, this included Sandy (L4) who commented, “I think I could 
do with some” after she heard about the dramatic benefits of the medication that 
Philip had experienced. Before starting the medication Philip described himself 
as “very contrary and things like that you know which I didn’t even know I was 
doing.” It seemed these medicines could also improve self awareness and 
insight into previous and present behaviour. As Jack told Ann in her interview, 
the “effects of stress on you made me upset as well” clearly demonstrating that 
PWD can be very much aware of how their illness may affect the health and 
well­being of others. This finding is supported by an observational study of PWD 
interacting with their carers in their own home with interview follow­up which 
noted how the effects of dementia on the spousal relationship were of great 
concern for some of the participants with dementia.133 
Also noted were positive benefits on visual perception, communication, retention 
of personality and ultimately quality of life. The changes in thought processing 
and communication were often seen as remarkable by carers as their loved one 
demonstrated greater insight and understanding than previously. It seemed 
unclear whether this insight and understanding was already present but just 
could not be accessed prior to a medicine for dementia. 
“Well with the Aricept® she had brief moments where I thought ‘where 
does that come from?’ …Did I tell you what she said one day? It was a 
nice sunny day and she said “oh isn’t this a lovely sunny day can you 
freeze it?” So I thought that was really sweet you know. You just think 
what a complicated thought pattern you know, to keep something sort of 
frozen and then you can keep it safe.” Jane, L3 
What was interesting from participants’ narratives was that PWD engaged more 
with visual stimuli which improved engagement in the world of their carer. 
“Within a month of going on to memantine she was doing things she 
hasn’t done for yonks. Like for instance if a hot air balloon went by she 
wouldn’t even see it but now ‘oh oh’ and the birds come down and will fly 
by and she notices that. We used to have the television on she’d look at it 
and go to sleep, (now) she argues with the television. She loves watching 
the kiddies programmes c­beebies, wildlife with animals, things with 
movement, she loves watching it.” Peter, L3 
An unexpected response for carers was observed improvements in mobility in 
two PWD. Prior to taking the medication they were either limited in walking by 
pains in their feet (Philip L4) or perceived discrepancies in the surface on which 
they were walking (Peter’s wife, L3). The latter perception is commonly 
associated with falls in older people and there is guidance on the types of 
flooring that should be used in care facilities to reduce risk of falls.292 For 
example, flooring with lined patterns are more frequently associated with falls as 
people with poor vision may mistake these for steps or changes in floor heights 
and hence trip or fall. 292 So these observed improvements may be related to 
improved visuospatial awareness, vision and/or physical and manual dexterity. 
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“We do a lot of walking in the woods and if she saw a leaf she’d be trying 
to pick it up and wouldn’t be able to pick it up and would keep missing it. 
Now she bends down and picks it up no trouble at all. She was starting 
to find trouble going from different colour surfaces, ‘cos it obviously was 
going to be a different height, all gone.” Peter, L3 
“Within a couple of days, he (Philip) could hardly walk before that 
(Aricept® being prescribed) because he felt his shoes were filled with 
gravel, and his feet were hurting, and he walked sideways all the time off 
the pavement and within a couple of days that stopped completely.” 
Mandy, L4 
Many carers spoke of improvements in clarity and content of speech and the 
resulting ability of their loved one to participate in conversations and become 
more sociable and friendly. Diane shared “people who came in said how much 
friendlier he was and chattier and all this sort of thing.” It is difficult to 
understand how these changes arise as they are quite complex interactions and 
it may be that this is the combination of increased confidence; clarity of thought 
processing and a deeper understanding of what is being said and/or awareness 
of their environment. Again this type of improvement helped the caring process, 
as they were then able to communicate on a deeper level with their caregiver 
than prior to treatment starting. The sharing of conversation is a core part of 
relationship building and it is a sorely missed aspect by carers in relationships 
as the illness progresses.133,166,167,177,304 
“Well he wasn’t taking anything else until he started on the Aricept® so I 
know quite well that the Aricept® was a great help for him. The change 
was really wonderful, you know with his speech and clarity and he was 
much more alert and asking me questions for a while which was unheard 
of. It was good. I was thrilled with it.” Mary, L3 
Carers frequently expressed their sadness at living with a person who was ‘not 
them’ and did not engage with life or their family as they had previously. An 
important experience for some carers was the return of ‘them’ and preservation 
or return of previous personality traits. Helen was a younger carer and had 
experienced her husbands’ loss of his former personality as ‘losing him as he 
was.’ 
“With the Aricept® I did feel it kept his personality somehow, I felt once or 
twice prior to taking it that I was sort of losing him, I can’t explain why, but 
that’s about losing him as he was. And I think that that retained his 
personality for a long, long time.” Helen, L4 
Obviously these are important experiences for carers to have: the perception of 
the person they now care for still being the person they fell in love with and not 
an empty shell. If we relate this as being a reduction in subjective stressors in 
the care­giving process170,171,177 we can see then that these medicines reduce 
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caregiver burden by decreasing the subjective experience of stress related to 
the caring process.171 
4.4.2.2 Effects on Care­givers 
Consensus opinion was that the medicines for dementia were an integral part of 
the care structure support system enabling caring to continue. Positive effects 
included the perception that the care­recipient was easier to care for and 
improved sociability impacted positively on relationships and quality of life. 
However sometimes carers felt it difficult to describe exactly how the medicines 
had helped as Ann expressed 
“I feel there’s been a slight improvement but I can’t actually specifically 
say what that improvement is except that life is not quite so bad.” 
Ann (L1) 
Others were much more aware of how the medication had affected their ability 
to cope with caring as Jane noted below; 
“She is happy, she sleeps well which is wonderful as a carer to get a 
decent night’s sleep and she is just really happy and cheerful.” 
Jane, L3 
Peter, who had been caring for his wife since she was 55, described his life after 
memantine was prescribed for his wife at age 63 as having “been cushy.” The 
eight years he had been caring for his wife prior to memantine had become 
increasingly stressful to the point where his GP was concerned for Peter’s 
cardiovascular health. 
“But if I tell you now that my blood pressure is normally about 137 over 
70 something and I don’t think that’s just the drugs (bendroflumethiazide). 
That is I’m feeling better, I’m not under pressure. I feel better enough to 
do exercise. I go on the bike, which I was doing anyway, trying to do. But 
I’m losing weight again, you know, I don’t mind admitting I was comfort 
eating. I was absolutely worn out” Peter, L3 
This finding of being less worn out was supported by Ann who felt although she 
was still tired she wasn’t so weary and she put this down to not having to watch 
Jack to the same extent. His increased awareness meant that she could leave 
him alone at home for short periods “as long as I’m on the end of the phone it 
tends to be alright.” These are important and significant improvements in the 
quality of a carer’s life and the resultant positive effects on their own physical 
and mental health. Caring has long been associated with negative health 
outcomes for carers174,175,189,191 and interventions that minimise these stressors 
have an important role in supporting continued caring.180,181 Educational,194,196 
respite,180 day care181 and formal care service51 interventions have also shown 
to improve the quality of life and associated levels of stress related with caring. 
It is important that any support package addresses all relevant needs to enable 
caring to continue. 
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Another consensus was how the medicines affected not only their lives but also 
the lives of others. PWD have interactions with healthcare and related 
professionals as well as family and friends. Peter thought the wider circle of 
people involved with caring for a PWD should be consulted in any monitoring 
process monitoring efficacy. 
“I think it’s two pronged. It’s on the person it’s been given and also the 
people caring for them because I, people say I look younger now than I 
have for years. I was worn out. I feel better now than I’ve felt for the last 
five or six years. I know I keep using the work dramatic but it is. So no I 
think both the carer or carers and the person having the drug need to be 
monitored see how it’s affecting their lives.” Peter, L3 
As mentioned earlier carers described loved ones as calmer, more relaxed and 
less aggressive; this helped day­to­day caring at home but also interactions at 
day and respite care facilities. This is an important concept to take in to 
consideration when measuring the benefits of these medicines; the 
improvements in behaviours, mood and cognitive functioning benefit all those 
involved; not just the carer and the person with dementia but wider family and 
caring support networks. 
“I haven’t noticed her doing any more better things or being brighter at all 
but her attitude has changed and, like she went to respite care for a week 
and they said that she is just a different person and it just makes such a 
difference.” Jane, L3 
Others spoke of how prior to starting the medication they could see the 
progression of the illness in their loved one and how this halted on the start of 
the medication. 
“…at the very beginning I could see quite a difference, because you 
could see it, you could see it progressing, going down hill and then 
suddenly that stopped when he went on to this drug.” 
Wendy, L3 
The overall value or worth of these medicines was talked about by a number of 
participants, mainly with respect to delaying the progression of the illness. This 
in itself is an interesting concept; that carers would prefer to have their loved 
ones with them longer even at a moderate to moderately severe stage rather 
than not treated at all. This is in contradiction to NICE who see medicines for 
dementia as an inevitable delay in the terminal outcome.31 These highlight the 
need for decision­makers rationing access to treatments to take greater account 
of the values that people taking medicines and those that care for them believe 
are important.55 
“I think it’s important for quality of life to remain on them for as long as 
possible. I think if he hadn’t gone on them he would have dropped off. 
You don’t know do you because you don’t have control. I think they 
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should be on it for as long as possible to maintain that quality of life.” 
Ann, L1 
“I: So would you say that your quality of life as well as your 
mother’s quality of life has improved? 
Oh god yes, oh it’s so much better. I mean if you cared for someone who 
was constantly unhappy and unwell you would think what is the purpose 
of their life if they are this unhappy? But now I think there is a purpose for 
her because she gets up and she’s cheerful and she laughs and we have 
… she has got a great sense of humour, she always had which 
disappeared for a while and it has come back and this is really very 
special to me.” Jane, L3 
The way in which the participants with dementia spoke about the positive effects 
of their medicines on their day­to­day lives implied quality of life benefits. When 
Jack (L1) was asked what he understood by the term ‘quality of life’ he replied 
that it was “When you can do the things you want to be able to do” and that in 
relation to the tablets he felt this was “immeasurably better.” He went on to say 
that it was “especially the confidence, presumably this is mostly due to the 
Aricept.® I don’t know what state I’d be in without them.” 
A qualitative study proposed the hypothetical introduction of a new medicine for 
dementia to 102 caregivers of PWD in the severe stages of dementia and 
described that it wasn’t a cure and it may also cause gastrointestinal side effects 
in 3% of people who took it.318 Carers expressed their opinion that they would 
risk these side effects if it had beneficial effects on the care­recipient’s quality of 
life (QoL); even if it prolonged time spent in a particular stage of the illness.318 
This is an important viewpoint for NICE to consider when it next reviews the 
guidance on the use of AChEIs, as their value­based decision­making is not 
reflected by PWD and their carers. 
Overall carers believed that the medication had positively affected their quality 
of life; however for some it was difficult to accept that the illness and associated 
symptoms had not been completely removed. When Jenny (L2) was asked if the 
medication had affected her own quality of life she replied that it had but “it is 
still hard for me because I have got it all the time you are never rested either.” 
However Helen thought any improvement helped, even if it was for a short 
period of time. 
“It’s still that five or six months that he was more confident a bit more 
confident and so on it was a big help. I mean anything that helps, for any 
period of time, is just wonderful really when you’re in this situation.” 
Helen, L4 
Previous research has demonstrated the ability to undertake activities of daily 
living is strongly associated with improved QoL scores for both PWD and their 
carers. 144 This is an important consideration for decision and policy makers who 
act as gateway keepers to these medicines. 
104 
In summary the medicines for dementia were seen to be a positive part of the 
process of living with a degenerative illness; improving the ability to care and 
also the ability for people with dementia to take part in daily activities. 
4.4.3 Issues with Medicines 
Although carers and participants with dementia perceived the medicines to have 
positive benefits on their lives and those supporting them, medicines were not 
without their problems. These included the experience of adverse effects, being 
assessed for response to treatment, the complications of concomitant 
medications and ensuring compliance. 
4.4.3.1 Managing Side Effects 
As previously mentioned in 2.1.4 the medicines for dementia are associated 
with many side effects.1­3,33 Interestingly people either experienced no side 
effects or they were severe enough to warrant co­prescribing of other 
medicines. Jack (L1) experienced a continually streaming nose and cramps in 
his feet which were severe enough for him to be prescribed concomitant 
medication to help alleviate these. Jack felt that “mostly the effects are now 
positive and you don’t mind side effects if they (the medicines) are working.” 
For some though the adverse effects experienced were sufficient for the 
medication to be stopped. Pat (L1) spoke of how her husband had felt so sick 
that “he couldn’t lift his feet up, you know he was quite disorientated.” Her 
husband then said “if this is what they are going to make me feel like I don’t 
want to take them” so they were stopped and subsequently Reminyl® (an 
alternative AChEI) was prescribed. 
Jill (L1) described how she decided to stop her husband’s medication after he 
had 3 months of gastrointestinal side effects and “he was feeling stressed and 
feeling really ill.” Many prescribers are reluctant to prescribe medicines for side 
effects in elderly people as it can lead to a cascade effect and resultant 
polypharmacy.319 Supporting evidence from the literature demonstrates that 
when side effects or lack of response to one AChEI is experienced then a trial 
with one or both of the remaining agents could lead to an improvement without 
adverse effect. This allows both carer and the person with dementia to possibly 
experience the benefits from treatment. 
There was variability in how prescribers managed side effects associated with 
AChEIs; some locations offered an alternative agent and others did not. Steve 
(L4) explained that his wife had been started on Aricept® but could not tolerate 
the associated nausea and vomiting however when “she was prescribed 
Reminyl® that didn’t upset her at all.” An experience supported by Mavis (L2) 
who said “when this one came through it was okay, he has no side effects at 
all.” 
Diane described a severe reaction by her husband, to the starting of Reminyl®, 
a medication that takes some time to titrate up to an effective dose. What is 
unclear from her description of the event was whether this panic, anxiety and 
fear experienced by her husband was due to some return of insight into his 
illness. 
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“My husband can’t take them, they put him on Reminyl® and he just went 
out of his mind completely. He was almost normal before that, just a little 
memory problem. He’d done the first month, ‘cos there were three 
stages wasn’t there? As soon as he went on to the second one he was 
suicidal. He was crying, he was frightened, he couldn’t breathe and very 
ill, they had to take him off them so he’s on nothing now”. 
Diane, L4 
This overarching theme of variability in provision of care, medication, 
information and services is prevalent throughout the data. Each participants’ 
experience was individual and therefore it became increasingly apparent that 
generalisations within and across locations could not be made as service 
provision was so variable. 
Peter had a very pragmatic approach to risks of medication; he balanced these 
with potential benefit in quality of life for himself and his wife for whom he cared, 
as well as relating these to his concepts of how the illness progressed. This is 
illustrated in the narrative below when I asked if he had received any information 
about side effects of the memantine or when it might be withdrawn: 
“No she mentioned that there were possibly side effects, well the same 
with risperidone, the thing of possibly strokes. You know and my 
argument was that in theory that is what is happening all the time, 
strokes, little mini strokes, so my attitude is and I made it very clear that 
it’s quality of life when we’ve got it. You know it’s no good going on 
forever in hell you might as well as have perhaps a shorter period of time, 
a very pleasant time, which is what we’ve got but touch wood there 
doesn’t appear to be any side­effects for (wife) at all.” 
Peter, L3. 
4.4.3.2 Monitoring and Assessment of Response 
A medicine for dementia can only be prescribed with regular monitoring and 
assessment; with NICE guidance placing an emphasis on the use of the 
Folstein MMSE.81 However in practice there is often a battery of tests used to 
gain a more holistic assessment of response. Carers soon learned the potential 
limitations and implications of the tests. For example that answers may be 
easier depending on where the test actually took place and they also knew at 
what score their loved one was at risk of being taken off the medication. 
“But he had one of those mini­mental tests on Monday (3 days previous), 
the nurse came and did it at home, and he’d gone down to 12 and I know 
if he had had that done at (Day Hospital) where the consultant is, he 
wouldn’t have answered as well, cos she said ‘where are you? Do you 
know what this place is called?’ Well he knew it was his home and that 
sort of thing but if you go to (Day Hospital) and he never knows where he 
is or what level, you know, so that was a good score. Because I then said 
to her ‘well 12 is the borderline, isn’t it for stopping Aricept®’ but she said 
‘well they wouldn’t do because its doing him, good, everybody can see 
that it is.’” Mandy, L4 
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Mandy’s quote above, highlights a limitation of the MMSE being dependent on 
where the assessment takes place and not reflecting improvements observed 
by others. Carers were distressed to think that the decision to continue a 
medicine could be based on a memory or psychological test score on a specific 
day as a snapshot when PWD fluctuated on a daily basis. 
“People with dementia can have very bad days. If they have a really bad 
day when they go to the memory clinic; you know they (the prescriber) 
might not do anything. My mother has been very confused this morning, 
I got up this morning and she is stuffing all her stuff down the toilet and 
she has never done this before and this is a very odd thing to do you 
know and these things just happen on the day. So it’s, this memory clinic 
is every 6 months don’t really tell you an awful lot I don’t think.” 
Jane, L3 
Of the participants with dementia, only Thomas could remember the test he had 
completed. He remembered being told the names of three objects and told he 
would have to repeat those names back at the end of the consultation. 
“When I go down there, well he said “I want you to remember three words 
and I’ll ask you them at the end” and he forgot to ask me. And he also 
asked me to draw some shapes and….he asked me about them; “which 
is the top, which is the bottom,” and he turned it upside down and said 
“where is the top now” and things like that...I’m not quite sure what he 
was trying to prove but I think I got them all right and didn’t have a 
problem with them.” Thomas, L3 
Of the remaining participants with dementia Philip (L4) could not remember 
what kind of test he had received but he knew that he had to have his dose of 
Aricept® increased because of the results. Jack and Ann (L1) felt the tests were 
not appropriate for his level of intelligence. 
Ann: “Jack actually got one more point out last time on the short­term 
memory part of it, so she (psychologist) was quite pleased, but it’s too 
easy a test for him.” 
Jack: “Especially for me ’cos I found them too simple and straight 
forward.” 
Ann: “I think he should be having at some stage the tests he had at the 
beginning to see the improvement I mean there has been.” 
Ann & Jack, L1 
It is an interesting concept to consider whether people with higher intellect prior 
to their diagnosis of dementia, should have a different set of tests during 
diagnostic and assessment. It has been suggested by others that the MMSE is 
not an appropriate tool for the continuum for a neurodegenerative illness as it is 
not sufficiently sensitive in the earlier stages to pick up changes.124­128,130 
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4.4.3.3 Uncertainly of response 
Due to the heterogeneity of dementia PWD exhibit different signs and symptoms 
which are prominent or problematic for them. For whatever reason not everyone 
responds overtly to these medicines. Although the benefits of medicines for 
dementia on care­giver and recipient have been discussed earlier, some carers 
were unable to clarify exactly how and in what way the medicines were 
effective. This uncertainty seemed to arise from trying to make a judgement in 
improvement on a background of disease progression. Was the rate in decline 
due to the disease or the medication or was it a combination of both? 
“Well what I did for a while is wrote everything in my diary and see how 
she (mother) was on the day. Things that I noticed that were better or 
worse and I think perhaps they should just give you a piece of paper 
really and ask you to write something down everyday or whatever to help 
you along with that. You know I think that is the only way.” 
Jane, L3 
“But it’s difficult to know what action it does have on the patient, because 
unless you give it them for x number of months and then stop it, and note 
any difference, you can’t really tell. Because I mean there’s a downward 
trend.” Fred, L4 
This latter perception was one that Thomas agreed with when he was asked 
about how effective he thought his medicine for dementia was. 
“I can’t make a comparison on that. The only way I could do that would 
be say to go a fortnight without and make notes and a fortnight back on 
again.” Thomas, L3 
Perhaps the difficulty when talking about the effectiveness of a medicine is that 
it depends on an individuals’ definition of ‘effective’. For many people a 
medication is seen as a cure, an agent that will fix the problem. For example 
antibiotics and analgesics are commonly considered to be ‘cures’ for a particular 
condition. Medicines that ameliorate symptoms are more difficult to judge, 
especially if the symptoms they ameliorate change on a daily basis. This 
concept is an interesting one as NICE suggested that as the medicines were not 
a cure and just delayed the inevitable then perhaps any utility value associated 
with their use should not be applied. 31 This viewpoint is difficult to uphold when 
the majority of pharmacological treatments available for cardiovascular disease 
(for example) are not a cure either; they ameliorate symptoms and improve 
outcomes. 
Jenny (L2) and others however, voiced opinions that “it’s not a cure though is it? 
I suppose in time they will find one but not in our time. I don’t think there will be 
a cure for it really, not a complete cure.” This was an interesting concept for 
some who compared the treatment of dementia to cancer treatment twenty 
years ago. 
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“I suppose eventually they might find a cure or at least be able to help 
more like they do with cancer. So many people survive that now; you 
know eventually they will won’t they? At one time there was nothing for 
cancer.” Mavis, L2 
The NDS highlighted the national lack of research co­ordination and funding and 
suggested it was a similar position to that of cancer research in England in the 
mid nineties.51 This theme has been expanded in the NDS for greater linking of 
research on the three key care strategies that have been laid out. 
These are: 
1. Ensure better knowledge about dementia and remove the stigma 
2. Ensure early diagnosis, support and treatment for people with 
dementia and their family and carers 
3. Develop services to meet changing needs better.51 
4.4.3.4 Stopping treatment 
The thought of stopping these medicines left the majority of participants feeling 
anxious. Mavis described the medicines as a support ‘helping even when they 
say it isn’t.” However NICE 2001 guidance suggests that the concept of 
stopping the medication should be discussed at the point of prescribing.27 The 
excerpt below from a carer focus group (L4) illustrated the reservations 
participants held about stopping the medication. 
I: “When do you think that these agents should be stopped?” 
Sarah: “Never, they go down hill so fast, they are deteriorating all the 
time and without them their memory will go so much quicker. They’re 
going down hill with the drug and if that was stopped…” 
Paul: “They should keep on ‘em” 
Sarah: “You know, we’d never cope. We want to keep them home with us 
long as possible, don’t we?” 
And later 
Helen: “It is related isn’t it? Because if we don’t get the support and we 
go down hill then that worries my children. They’re worried and their 
families and they’re more involved and so on and it just goes down 
through the family, affecting everybody involved. Unfortunately it affects 
everybody’s health really.” 
Carer Focus Group 2, L4 
It seemed that the medicines were seen as a core part of the support structure 
to enable caring. As the medicines were perceived to improve activities of daily 
living, behaviours, mood and communication these were all improvements 
which could mitigate the associated stressors of caring170,171,177 and the sense of 
loss experienced as a carer.166,304 Although carers were aware that the 
medication had to be stopped at some stage there was great uncertainty and 
fear associated with this thought. 
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“I’m too terrified to stop it because of the adverse effects. I’m quite happy 
for it to carry on.” Doris L1 
Ann felt that stopping the medication would adversely affect both Jacks’ and her 
quality of life as she narrated below: 
“I think it’s important for quality of life to remain on them for as long as 
possible. I think if he hadn’t gone on them he would have dropped off. 
You don’t know do you because you don’t have control. I think they 
should be on it for as long as possible to maintain that quality of life.” 
Ann, L1 
When participants with dementia were asked how they felt about the possibility 
of having their medication for dementia stopped Thomas (L3) replied that he 
would “probably do a test on myself by stopping it for a week to see if there was 
any difference in my behaviour and then go back on them perhaps.” 
Jack thought the medication should only be stopped “when you die. They should 
ask other people as well.” He went on to explain that all those involved in the 
support of PWD should be involved in any decision to stop medication. 
“Carers, friends and family. Other people that are involved like 
grandchildren, and our children and I hope they will be asked as well.” 
Jack, L1 
This is a very interesting comment because without exception, all participants 
with dementia recognised that their behaviour affected other people as well as 
their carers and that this was, or could be, modified by the medication. Again an 
important concept for policy and decision­makers to consider in the next 
guidance review.31 
4.4.3.5 Concomitant Illness and Medication 
With concomitant illness came concomitant medication and when there were a 
number of medicines being taken together it was difficult for carers and 
participant with dementia to know which agent was causing which effect. 
“But it is a concoction of tablets, the things they take now you don’t know 
whether they are working against one another.” 
Wendy, L3 
Concomitant medication was a problem for Jack because three other medicines 
had been started at the same time as his medicine for dementia. To add further 
difficulty there had been subsequent changes to his medication regimen as well. 
“It is difficult to know which ones are the side effects of the condition and 
which ones are side effects of the medication. They have actually 
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changed medication. It’s sort of evolved since we started. There are 
certain ones we don’t take now.” Jack, L1 
In summary the presence of concomitant illness and associated medication 
complicated not only knowing which medication was causing which good or 
adverse effect but also affected the overall physical frailty of the individual and 
carer workload. 
4.4.3.6 Ensuring Compliance 
Before a medication can be taken, a prescription needs to be generated so that 
it can be cashed at a pharmacy. Obtaining a repeat prescription could be a very 
complex task as in most locations the medicines for dementia had to be ordered 
via a specialist prescriber. There was great variability in how these were 
accessed; some prescriptions were posted directly to peoples’ homes, others 
had to be collected from specialist services and yet others from their GP. 
In terms of keeping track of medication, prescriptions from hospital consultants 
invariably had insufficient quantities ordered to last until their next appointment. 
Some carers newly started on medicines were unsure about how to get further 
supplies and other carers spoke of how they had to telephone the consultant’s 
secretary to ensure sufficient supply. 
“Luckily I kept the appointment card and on the appointment card it says 
the consultant’s secretary’s name. So I had to ring her and get her to 
send me a prescription through the post and then it didn’t come. So then I 
would have to ring again and she was on holiday so you would have to 
talk to somebody else and they’ve huge huge files because otherwise he 
would have no tablets and this happened, I would think, at least half a 
dozen times and that is so bad, just unbelievable.” Sue, L2 
Thomas was the only participant with dementia who had responsibility for 
ordering and cashing in his own prescriptions for his medicines. His experience 
was that even once you had a prescription it didn’t necessarily mean it could be 
filled. He had to remember to order at least a week in advance so his local 
pharmacy could order the medicines in. 
“I just go down to the surgery and get a prescription, take it round and 
they say come back, because they take four or five or 5 days to get, 
because they don’t keep them in stock, my little chemist.” 
Thomas, L3 
NICE 2001 stated that the issue of compliance needed to be discussed with the 
patient and their carer prior to an AChEI being prescribed.27 This guidance does 
not speak of adherence, a term which suggests that the person taking a 
medication is fully informed of the treatment and able to ensure continued self 
administration; rather it talks of compliance which is a more paternalistic 
approach where a medication is prescribed and the directions have to be 
complied with.300 Carer participants spoke about a general assumption that they 
would take responsibility to supervise medication taking and the whole process 
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involved with this; for example the ordering, collection and cashing of 
prescriptions. 
In most relationships there is generally one partner who takes care of the 
medication associated responsibilities and as Wendy (L3) explained “it’s just as 
we are together, yes they assume that” carers will ensure compliance with the 
medication regimen. Mary stated “I have always done his tablets” and continued 
she had to take responsibility for compliance to ensure the medicine was 
actually taken. 
“He doesn’t remember to take anything at all, he wouldn’t take any drugs 
if I didn’t give them to him, you know they have got no idea about drugs, 
he wouldn’t know he was on this drug unless I give it to him at night 
before he goes to bed.” Mary, L3 
Thomas lived alone and had developed a system of having a piece of paper 
with a weekly grid on as a medicine reminder. (Thomas took three medicines in 
total and could remember their names and the dosing frequency.) As he took 
each of his medicines, he would put a tick in the appropriate weekday next to 
the medication name. 
“I have a piece of paper on the kitchen table. I take three pills. Aricept®, and 
aspirin; that I’ve been taking since I had a TIA many years ago, I was told to 
keep on taking it for life, it won’t do you any harm, and omega­3 (fish oil). 
And a piece of paper in the kitchen and there is Monday, Tuesday, 
Wednesday, Thursday, Friday, three different columns and as I take them I 
tick them off. I know I don’t take them twice and I know I don’t miss them.” 
Thomas L3 
A medication regimen becomes more complex with concomitant illness. It is well 
known that many older people have greater than one medical condition and 
consequently take a number of regular medicines each day.300,319 Some of 
these medicines have a narrow therapeutic range, for example digoxin and 
warfarin as highlighted in the transcript below, and adverse effects can be 
potentially life threatening if the correct dose is not given. 
“I would say probably two years ago I started putting them in those little 
boxes for the day and I would leave them on top of the fridge and he 
would take them. Then I discovered he was taking double lots in one day 
and he was taking none for two days. So then I had to start leaving them 
on top of the fridge and me doing it. Then I found that he would find them 
so then I had to hide them and I had to keep hiding them in different 
places. Oh dear, and I couldn’t remember where I put them myself. 
Anyway we did cope; we did cope with administering them, so that was 
ok.” Sue, L2 
Ensuring the correct medication was taken became an onerous duty for some 
carers and Ann explained that even by using compliance devices for medication 
did not ensure the person gets the right medication at the right time. 
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“I wasn’t told I had to do it (administer the medicine) but Jack was having 
such trouble opening all the packets in the morning and in the end we’ve 
been on this tablet tower* now for nine months or something.” 
Ann, L1 
* (compliance­aid type device with daily slots for taking medicines at four different times 
during the day) 
Jack said he found the tablet tower very helpful and added “I generally 
remember them but I have to get her to check sometimes.” However filling the 
tablet tower was time consuming taking an hour and a half every week. Ann 
viewed this as a negative effect of the medication for dementia, although to be 
fair Jack was on ten medicines in total; only three of those related to the 
dementia. Further complications arise if concomitant prescriptions have not 
been started at the same time as they will then be out of synch with each other 
and not ordered at the same time each month. The ability to deal with these 
issues can become quite taxing for some people and as Jane explained, 
“Now I am capable to do this but there are a lot of elderly partners caring 
for their spouses they might lose track somewhere along the line.” 
Jane, L3 
As dementia progresses people may lose their ability to swallow solid forms of 
medication and so carers were given liquid options and/or they decided to crush 
medication in food. 
“No, we have got a lot now in liquid because it was beginning to get 
where he wouldn’t swallow them and so what we can we get in liquid. 
…The quetiapine and these; I got a grinder now and I put it in, so I grind 
the two together and put them into yoghurt, smooth yoghurt because he’ll 
even find a pip and go puh (spits it out).” Pat, L1 
Point of 
Reflexivity 
As can be ascertained from the above examples there is a 
large responsibility associated with compliance; but one that 
was seen as important by both carers and PWD. A study of 
people with chronic illness found that if people perceived a 
higher necessity for the medicine (in terms of potential 
benefits) then they were more likely to also report higher 
rates of adherence to a treatment regimen.28,29 What was 
interesting from my perspective was that there had been no 
proactive advice from pharmacists on either medication 
administration or managing adherence to the prescribed 
regimen. Some of these situations, especially the crushing of 
medication into food can have negative effect on the efficacy 
of the medication and possible adverse effects for the 
individual. 
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From the narratives of carers the following practice areas

could be helped or supported by community and primary care

pharmacists becoming involved in the provision of medicines

for dementia.

These were:

­ The appropriateness of concomitant medication,

­ swallowing difficulties and the safe administration of

medicines,

­ helping compliance issues proactively, addressing repeat

prescribing problems, and

­ ensuring proactive provision of information.

4.5 Summary of Key Findings 
What was striking was the sheer hard work that being a carer entailed. It 
seemed to be a life changing event which was all encompassing. The most 
distressing part of this was the variability in support, access to treatment or 
information and/or specialist services all of which were complicated by the 
variability in response by healthcare professionals. The objectives of phase one 
are discussed in relation to the findings next. 
Delayed access to support services such as respite or day care led to a 
breakdown in the carers’ ability to continue coping. Support and information 
needs to be offered earlier and at frequent intervals throughout the caring 
process as the experienced burden does change over time in response to the 
degenerative process and its effect on the person being cared for. There also 
needs to be some method of ensuring equity in treatment access, services and 
information offered. 
Participants reported a diverse range of improvements to medicines for 
dementia including: effects on personality, mood and behaviour and quality of 
life. There were also improvements in activities of daily living, mobility, 
socialisation and communication skills and engagement in their environment. 
There was a perception that these benefits were apparent for some time before 
lessening. 
People with dementia were, in the main, able to talk about the benefits of the 
medication and how it had enabled them to take part in life again. Important 
outcomes for them and their carers seemed to be an increase in sociability and 
taking part in daily routine activities around the house. Carers experienced the 
medicines as making it easier to care for their loved one because of improved 
mood, sociability and attitude. Even though memory did not seem to improve 
much overall, this seemed mitigated by the ability of PWD to take part in 
conversations and interact with people. These perceptions were endorsed by 
family, friends and healthcare professionals. 
It also seemed that healthcare professionals required education and training in 
the very basic skills of consultation etiquette and determination of whether 
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consultations needed to be together or apart or both. The expectations and 
needs of both the person with dementia and their carer need to be addressed 
within a consultation to ensure that the therapeutic relationship can develop and 
be trusted and also that all parties arrive at a mutually agreeable decision. 
However there is a need for healthcare professionals to be proactive in 
providing support and information. Findings suggest that community 
pharmacists could have a role in supporting medicine management issues such 
as the management of side effects; compliance, administration of medicines and 
ensuring the appropriateness of concomitant medication. Provision of general 
information on maintaining good physical and mental health as well as 
information about local dementia services would also be appropriate. 
There was a perception of incomprehension of the methods used to monitor the 
effects of the treatment and the environment in which this took place. This was 
compounded when carers felt their viewpoints were ignored or not sough within 
a consultation especially if the person they cared for fluctuated in ability on a 
daily basis. It seems that further research is needed to agree outcomes to 
treatment that are important to the person with dementia, their carer and the 
prescriber. 
Caring can be an onerous and lonely task; good supportive therapeutic 
relationships can help ease the perception of this burden by the carer and 
support the continued ability for caring at home. 
The findings from this phase of the study were paramount in designing the 
second phase of the study, which explored the longitudinal affect and effects of 
medicines for dementia in people with early disease. This will be explained in 
greater depth in Chapter Five. 
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CHAPTER FIVE: METHODOLOGY & METHODS PHASE 
TWO 
5.1 Introduction 
Findings from phase one suggested that the effects produced by a medicine for 
dementia were similar for all agents and that key concerns were side effects, 
withdrawal and access to treatment and information. Concerns were also raised 
about the appropriateness of the objective measures used to assess efficacy 
and the perceived poor level of participation in decision­making. 
The second phase of the study was a longitudinal study which aimed to explore 
what happened in actual clinical practice in mild dementia when any medicine 
for dementia was started, with­held or withdrawn. Case study research 
methodology is designed to explore a situation in which an intervention being 
evaluated has no clear single set of outcomes.320 In this research the situation 
was the day­to­day lives of the person taking the medication and their carer. 
The intervention was the initiation of a medicine for dementia (or not). The 
outcomes were multifactorial, as these medicines are known and were shown in 
the previous chapter to affect a range of domains including: the physical, 
mental, social and behavioural health of the person taking these agents and 
those of their carer. These domains can also affect quality of life and the wider 
social environment such as interaction with family and friends. 
5.2 Case Study Methodology 
Case study methodology allows a combination of methods to be used to explore 
a given situation; for example data resulting from both qualitative and 
quantitative methods can be used to triangulate results. Historically triangulation 
with quantitative methods has been used in qualitative research as an attempt 
to justify the robustness of findings and improve transferability or generalisability 
of findings.321,322 Another perspective is that methodological triangulation can 
offer “a more holistic perspective” of findings in complex situations.321,322 
Case study methodology can be explanatory, descriptive or exploratory.320,323,324 
This flexibility is one of the reasons why it has been used for a diversity of 
research subjects as it can support investigation and interrogation of events 
within contexts such as large organisations; individual case events; or political 
and historical events. 320,323,324 However it is increasingly being used in 
educational research17 and health services research.323­326,327­330 
5.2.1 Case Study Methodology in Health Service Research 
At the focus of any healthcare intervention is a patient and in the delivery or 
monitoring of the intervention is a HCP. So from the start there may be at least 
two viewpoints on outcome success or failure. As with any healthcare 
intervention; there are ripple effects of the treatment as experienced by family, 
carers, relatives, friends and other HCPs. Healthcare research can be very 
complex and by using different methodologies within a case study framework; 
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complexities of healthcare interventions can be explored from a number of 
perspectives. This enables a holistic interpretation of the findings and may 
improve transferability of findings.321 lt has been suggested that a case study 
approach is suitable for palliative care research because it “is a realistic study of 
practice” and that it “has the potential to contribute to knowledge 
accumulation.”325 This ethos could be applied to most healthcare specialties. 
The majority of studies published using single case study design attempted to 
develop a greater understanding of the reasons behind why a particular 
process, 330 event,327 or care intervention,328 worked effectively or otherwise 
within a single environment. Multiple case study design was used when 
differences in behaviours and attitudes towards the intervention being studied 
was suspected.331­333 However case study methodology should not be viewed 
as a “catch all,” for a mixed methods approach but as the best choice after a 
rigorous investigation of other potential methodologies has been made by the 
researcher.320,322­324 
There are at least three views on the methodological implications of case study 
research: those proposed by Yin,326 Walshe,325 and Mayes and Pope331 will be 
briefly outlined here. Yin holds the view that case study research is a 
methodology in its own right stating that qualitative and quantitative techniques 
“are part of the case study arsenal.” 326 Mays and Pope331 suggest case study 
research falls under the umbrella of qualitative methodology, with Walshe325 
describing it as “an approach or strategy, not a methodology.” This viewpoint 
enables researchers to use a number of different data collection methods as 
long as they are appropriate to the study question.325 
Point of 
Reflexivity 
I can see the different perspectives outlined above with their 
associated benefits and theoretical constructs. To me, Yin 
seems to want to replicate theory and if opposite theories are 
found he suggests changing criteria and/or sites until there is 
one theoretical truth. 320,326 However the ethos of qualitative 
methodology is to explore all truths, not just one. I don’t 
believe that case study research falls into just the qualitative 
or quantitative camp as an entirety either331 and perhaps 
favour Walshe’s325 hypothesis that case study research is an 
approach rather than a methodology. With this approach I 
can as the researcher choose the most appropriate methods 
and methodologies for the research question whilst still being 
aware for the need for quality throughout the research 
process. 
5.2.2 Quality Issues in Case Research Methodology 
Interestingly a widespread misunderstanding of the validity and quality of 
findings from case study methodology has been reported,320,326,334 with Yin326 
calling for increased attention to the need for quality in case study design. It is 
therefore important to ensure that the underlying principles for improving the 
quality of research are followed. These principles have been well defined by 
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many 320,331­335 and research design should include attention to: construct 
validity, internal validity, external validity and reliability. 
5.2.2.1Construct Validity 
In case study design, construct validity requires the researcher to ensure they 
employ the most appropriate tool (or set of) to measure outcomes being 
investigated. Criticism can arise if all measures are completely subjective as 
findings can be experienced as having no real tangible objective standpoint. 
320,324,328 In fact, there has been misunderstanding of the value of qualitative 
methodology in health services reserach.322 It has been proposed that 
qualitative data can describe and explain behaviours behind results of 
randomised controlled trials to improve understanding of findings.331 That is the 
use of methodological triangulation can improve construct validity of the 
research design and understanding of findings.320,321,323,324,326,336 
Point of 
Reflexivity 
It is my belief that if the views and beliefs of a healthcare, 
educational or social intervention is required then a 
qualitative methodology is the most appropriate. 
Unfortunately for some readers of such research there are 
few numbers to compute relevance in a way which is 
meaningful for them. It is interesting that I now feel that every 
randomised controlled trial or clinical study needs a 
qualitative arm to actually explore things that are important to 
the subject receiving the intervention, as well as those 
outcome measures important to the researcher or prescriber. 
In this study, there were 4 sources of evidence which could be linked to one of 
the study objectives (see 5.3). These were: 
1.	 Interview data from up to four participant sub­groups. 
2.	 Observation of consultations to observe the extent of shared decision­
making. 
3.	 Patient shared care records to access objective documentation. 
4.	 Diary records of participants. 
5.2.2.2 Internal Validity (for explanatory and causal design) 
Internal validity in case study design is to ensure that the method of analysis is 
decided prior to starting data collection to ensure data collection is 
focussed.320,326,328 Yin has suggested that the use of pattern­making (thematic 
analysis); explanation building (theory building) or logic models can help to 
ensure internal validity.320 
These suggestions can be viewed as equivalent to the inductive thematic 
analytical process involved with interpretative phenomenological analysis.273­276 
In IPA findings are interrogated and re­analysed until an overall thematic picture 
of the findings evolves.273­276 These findings are described in the narrative of the 
research participants and can be linked to individuals’ life experience. The 
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subsequent layers of analysis results in a taxonomy (classification system) of 
superordinate and subordinate themes (see 3.4.3.2 and 4.1). 277,278 
Each individual case was to be analysed separately to ensure that there was 
both descriptive and explanatory discussion on the findings. This taxonomy or 
thematic overview also in a sense uses ‘pattern­making’ as a form of analysis in 
that it looks for ‘patterns’ (i.e. themes), which emerge from the data as a result 
of the participant experience.278 This in turn leads to a synthesis and discussion 
of the findings to offer an explanation of the participant perspective.323,329,337,338 
5.2.2.3 External Validity 
If the internal validity processes are robust then there is the generation of 
analytical theory which can lead to an understanding of which contexts and/or 
domains the study findings can be generalised or applied to.320,337,338 Yin states 
that single case studies are like experiments, in that the results cannot be 
generalised to population groups but they can be generalised in terms of the 
analytical theory developed.320 This analytical theory if replicated in one or more 
case study sites with similar findings could lend itself to supporting the theory 
and by inference may be generalisable to other similar contexts. (i.e. ‘replication 
logic’ as termed by Yin).320 This stance is heavily dependent on using replication 
logic (which could possibly be perceived as interrogating data for supportive 
and/or deviant themes). Other researchers339 believe that qualitative findings 
cannot be generalisable because they relate to a specific group of participants 
at a specific point in time. However Lewis and Ritchie340 propose that 
qualitative findings can have ‘inferential transferability’ (i.e. that one could infer 
findings would be similar in a similar population group. Similarly the term 
‘naturalistc generalisation’ by Lincoln and Guba341 has been used to describe 
generalisability as dependent on the location or site findings are being 
transferred from and then to. 
5.2.2.4 Reliability 
An important principle for ensuring the validity and quality of the results is to 
ensure that the approach to data collection and the process of data collection is 
the same within and across each case study. If data collection procedures are 
the same for each it means that the study can theoretically be repeated and the 
same results obtained. However in qualitative analysis much is dependent on 
the background and life experience of the researcher involved in the 
interpretation of findings, so this is not always the case. 
In case study research it has been recommended that a Case Study Protocol is 
produced prior to starting data collection to ensure a thorough investigation of 
the proposed data collection and analytical methodologies has 
occurred.320,326,330 The Case Study Protocol should provide an overview of the 
case study project; the procedures for field work; the research questions and an 
outline for the preparation of the Case Study Report. 320 The Case Study 
Protocol for this study can be found at Appendix A5­1. 
Another recommendation to improve quality of case study research is to keep a 
clearly defined Case Study Database.320,326,329 Theoretically this is so that any 
researcher with access to the Case Study Database could replicate the ethos of 
the study in different locations.317,339 
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The Case Study Database for this study includes; taped interview recordings; 
digital recordings of interviews; all interview transcripts (anonymised); the 
observation tool; the observation data recorded as field notes; diary records and 
relevant anonymised data accessed from patient shared records in tabular 
format. Where possible the electronic data is in a separate folder on the 
University hard drive and also backed up on a password protected data stick. 
Written data is filed in a secure and locked cupboard within a locked room along 
with the original tape recordings to fulfil Data Protection Act requirements.265,267 
5.2.2.5 Alternative Quality Structures 
An alternative method of assessing the quality of qualitative research in its 
independent components (i.e. the interview or observational data) has been 
described by Mays and Pope.331,342 They suggest that “systematic and self­
conscious research design, data collection, interpretations and communication” 
will ensure rigour and quality. 331,342 The authors suggest that an account of the 
method, process and data should also be kept (akin to the Case Study 
Protocol).343 Interestingly in 2000 they debate the relativist criteria for quality 
and suggest that triangulation, respondent validation, an account of the process 
of the data collection and analysis, attention to negative cases and reflexivity as 
a researcher can all contribute to improving the validity of findings.342 
Point of 
Reflexivity 
Researcher reflexivity defines the process of continually 
acknowledging the dynamic between the researcher, data 
collection and interaction with participants of the study. IPA 
demands that the researcher views findings from the 
perspective of the lived experience of the participant and not 
from their own perspective. This can be challenging as it 
means being aware of your own lived experience and 
ensuring this does not colour interpretation of the 
participants.’ 
5.2.3 Case Study Design for Phase Two 
In 4.5 the findings from phase one were briefly discussed with relation to how 
they influenced the study design for phase two. The findings were diverse and 
what was wanted was to explore these in greater depth within a set context; the 
context of taking (or not) a specific pharmacological agent for dementia. 
“A case study is an empirical inquiry that; investigates a contemporary 
phenomenon within its real­life context, especially when the boundaries 
between phenomenon and context are not clearly evident.” 320 
People with newly diagnosed mild dementia were to be recruited from 
participating memory clinics using purposeful sampling332 to complete the 
proposed case study framework. It could be argued that in case study 
methodology, there is no real sampling process as the design of the case study 
itself is pre­determined by theory development (i.e. the unanswered research 
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questions). Theory development in turn leads to case selection to fulfil the 
specific aims of the research. 
In this phase the underlying premise was that the effect on daily life 
(phenomenon) of the person taking the medicine for dementia was similar no 
matter which of the four licensed medicines were taken (context). The remaining 
3 cases were purposefully selected to represent common care scenarios 
described by clinicians working within memory clinics which challenged 
decision­making and clinical management. It was proposed the case study 
framework would consist of 8 case studies in total: 
1.	 one where the medicine for dementia was donepezil; 
2.	 one where the medicine for dementia was rivastigmine; 
3.	 one where the medicine for dementia was galantamine; 
4.	 one where the medicine for dementia was is memantine; 
5.	 one where a cholinesterase inhibitor was taken in combination with 
memantine; 
6.	 one where the medicine for dementia has been withdrawn due either to 
adverse effects or lack of efficacy; 
7.	 one where the person refused treatment, and 
8.	 one where the person was ineligible for treatment (perhaps due to an 
unproven condition such as mild cognitive impairment). 
Point of 
Reflexivity 
Originally it was proposed to recruit to 7 case studies; the 
extra one was case study 5 which was suggested by a 
clinician as an area which challenged prescribing decisions 
and also an area where there was limited evidence of 
efficacy. 
The potential participant members of each case study group included: the 
person with dementia, their carer; the prescriber of the medicine for dementia 
and a HCP providing dementia­related support if appropriate (e.g. a community 
psychiatric nurse, psychologist). 
5.3 Aims and Objectives 
The second phase was a longitudinal study designed to explore the effects of 
medicines on the daily lives of people with early dementia and their carers over 
time. The objectives of this part of the study were to: 
1.	 explore lay and healthcare professional perceptions of the outcomes of 
medicines for dementia. 
2.	 explore whether there was consensus on perceived efficacy over time. 
3.	 explore perceptions on how medicines for dementia should be used in 
early dementia. 
4.	 to highlight the potential role of the pharmacist in supporting medication 
use in people with early dementia and their carers. 
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5.	 to identify possible areas of educational need for healthcare

professionals.

It was proposed that findings from this study would provide qualitative and 
quantitative evidence of perceived effects of medicines for dementia in a 
naturalistic setting. It might also establish insight into the perceived effect on 
carer’s ability to cope. The results could also provide information to aid in the 
education and training of HCPs involved in the prescribing process. 
5.4 Methodology 
As previously mentioned a case study approach was chosen as a means of 
being able to explore and describe the contextual event of a medicine for 
dementia being prescribed (or not) on the phenomenon of day­to­day life. Eight 
case studies were to be recruited to and the participants of each case study 
group were to be followed­up over a period of up to 12 months (dependent on 
the emergence of new findings). 
5.4.1 Methods 
In this case study qualitative data would be gained from face­to­face interviews; 
observation of prescribing consultations and diary entries. Quantitative data 
would include objective measurements of neuropsychiatric testing found in the 
shared care record. 
5.4.1.1 Face­to­face Interviews 
The participants with dementia or a memory problem were the hub of the case 
and in all there were up to four units of analysis in terms of the interviews, 
embedded in each case study. These were data from people with the memory 
problem; their carers; their prescriber and if appropriate a HCP involved in 
dementia­related care. 
The purpose of the interviews with prescribers and HCPs was to explore 
whether findings from lay participant interviews were supported and to explore 
HCP viewpoints on medicines for dementia. This group were to be interviewed 
on a single occasion. Interview methodology was the most suitable for this part 
of the study as it would allow greater exploration of the individuals experience 
and beliefs. Qualitative research has been described as “reaching the parts 
other methods cannot reach” so that greater understanding of people’s 
experiences within healthcare may be gained. 343 
Timeframe of Interviews for People with Dementia and their Carers 
Originally interviews were planned at: 
•	 Baseline: to explore expectations and hopes associated with taking a 
medicine for dementia 
•	 At 3 to 4 weeks after starting a medicine for dementia: to explore 
occurrence of side effects; severity and management if appropriate. This 
time period was chosen as it can take at least 3 to 4 weeks to titrate to an 
effective dose and often people taking these medicines experience side 
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effects at this time. Also at the start of the study people were recalled at 
this time for follow­up and monitoring. 
• At 3 months: to explore effects on day to day life 
• At 6 months: to explore effects over time. 
However the actual number of interviews completed per participant would be 
dependent on new findings arising from the data. 
Development of the Topic Guide 
The Topic Guide can be found in Appendix A5­2 and was designed to explore 
the following: 
• Expectations of the medication 
• Information given about the medication 
• Any compliance issues 
• Positive and negative effects on day­to­day life 
• Any other concerns or thoughts 
The Topic Guide was a tool used to cover the research area of interest rather 
than a didactic process of interaction. Questions could be reworded according to 
understanding and arrive in any order dependent on the flow of the current 
conversation. Case study research is focussed on what is happening in context; 
i.e. in real life so an open, semi­structured approach was proposed to facilitate a 
conversational style of interaction. 320 
5.4.1.2 Observation of Consultations 
It has been suggested observational research methods provide us with insight 
into “why they (people) do what they do.”344 As part of the data collection, the 
intention was to observe one consultation with the prescriber to explore the level 
of decision­making and involvement lay participants had. This was an area 
which participants from phase one had reported as being a challenge. Rather 
than accepting individuals accounts of behaviours and events that occur within a 
consultation; an observation study allows the researcher to observe and 
document those that actually happen.345­347 It was proposed to use a non­
participant observer approach to directly (but discretely) observe behaviours 
and social interactions within the consultation to develop an explanation of what 
behaviours were exhibited by each participant. 
It is important to note that participants may naturally change their behaviour 
when they know they are being observed,345,347 however it is increasingly 
common in healthcare settings that there is an observer present as a matter of 
routine. It seems that patients and HCPs seem less disturbed by a non­
participant observer than individuals in other settings.347 Dallos suggests that it 
may be difficult for some observers in naturalistic settings to remain wholly non­
participant or wholly participant.347 To reduce the risk of this occurrence I would 
be seated in a discrete position out of eye contact of each of the consultation 
participants. 
It was proposed that 3­months into the case study, participants would be asked 
for their consent and written permission to be observed in a consultation with 
their prescriber. (A5­3) Once this had been established the next appointment 
would be ascertained and then the prescriber approached separately for written 
consent. (A5­3) 
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The observations were not to be audio­recorded but an observation tool (See 
Appendix A5­4) and field notes were to be used to collect data on shared 
decision­making and patient­centredness of the consultation. 
Development of the Observation Tool 
One of the pivotal frameworks for measuring and teaching patient­centred 
consultations with an emphasis on shared decision­making has been the 
Calgary Cambridge Guide (CCG). This was primarily introduced as a teaching 
aid in primary care general medicine211 but is now used in undergraduate 
medical and some postgraduate pharmacy curricula’s. 
There has been one tool designed to capture shared decision­making within 
primary care consultations for people with a mental illness.348 The OPTION tool 
contains questions which both observer and the patient use to rate perceived 
level of shared decision­making at the end of the consultation. 348 However the 
phrases were difficult to define meaning in a reliable manner so it appeared an 
inappropriate tool for this study. The study observation tool drew on content 
from the CCG, and an assessment tool for patient­centredness of a consultation 
used in postgraduate communication skills teaching. It can be found in A5­4). 
5.4.1.3 Diary Records 
A finding from phase one (4.4.2.2) highlighted that it was difficult for carers to 
identify exactly what had changed after medication was started. It seemed 
appropriate to suggest that participants kept a written record of their progress 
soon after starting a medicine for dementia. At the first interview carer 
participants were given the option of using a diary in between interviews to 
record thoughts and feelings of medication effects. 
The use of diary records has frequently been used in qualitative research as a 
means of attempting to develop explanatory accounts for behaviours and events 
and/or evidence to support an intervention.349,350 They are increasingly being 
used in health services research as a means of recording patient responses to 
care interventions such as surgery351 or asthma,352 with evidence to show that 
people prefer electronic diaries for ease of access.349,350 
The advantages of using diary records is their flexibility in design, their ability to 
be used in combination with other methods and that they can minimise memory 
problems if used immediately after event.349 The limitations have been 
described as cost, selection and inaccuracy biases.349 
In this study the diaries were to be offered to carers as a means of recording 
response to any pre­selected goals of the treatment they may have chosen. 
5.4.1.4 Patient Shared Care Records 
Patient shared care records would be accessed at the end of the qualitative 
data collection and objective data such as the results from neuropsychiatric 
testing and comments made by the data entrant would be collated. As memory 
clinics use validated tests to measure an objective response a method of 
substantiating claims of lay participants would be to access these data and 
relate these objective findings to the subjective phenomenon experienced. 
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5.4.2 Recruitment 
5.4.2.1 Selection of Recruitment Sites 
It was proposed to recruit people newly diagnosed with dementia from specialist 
memory clinics. This was because at the time of the study all diagnostic and 
prescribing decisions had to be made by a specialist at a specialist centre and 
these were often made at memory clinics. 
Point of 
Reflexivity 
I had already been involved in some collaborative grant 
proposals at a local research memory clinic and attended a 
number of their Carer Advisory Group meetings as a 
consequence. The staff at the centre were supportive of the 
proposed research and their increased activity into 
recruitment was seen to be as a trade off (if you like) for my 
involvement in study steering groups and in design of 
research proposals. I had also made links to another local 
memory clinic where staff positively encouraged a qualitative 
approach as they felt this was an area which was under­
represented in dementia research. It seemed that these 
would be appropriate sites for recruitment of potential 
participants for Phase Two. 
Unexpectedly slow recruitment necessitated an increase in the number of 
locations to recruit from; finally resulting in a total of 6 sites (see 5.7). Three 
sites provided memory clinic services from community hospitals and two from 
general hospital sites as part of the local Mental Health Trust and one was a 
charity­based memory clinic. 
5.4.2.2 Participant Recruitment 
Participants with dementia and their carers were to be recruited from one of the 
above sites. At each site a gatekeeper to the research was responsible for 
identifying possible participants who attended their clinic and informing them of 
the study and providing an information pack if appropriate. (See A5­5). This 
process meant the gatekeeper could identify people with capacity for informed 
consent and who fulfilled inclusion and exclusion criteria. If people were 
interested in the study they were invited to contact the lead researcher directly. 
Alternatively gatekeepers could opt to recruit possible participants via a joint 
letter from themselves and the researcher. (See A5­6) 
Once contacted either after receiving an expression of interest the lead 
researcher would then speak directly to the potential participant and give further 
information and discuss the need for informed consent. If participants agreed to 
take part then an interview was arranged. 
5.4.2.3 Inclusion and Exclusion Criteria 
All people who attended a participating memory clinic with newly diagnosed mild 
dementia and satisfied the inclusion criteria of being able to give informed 
consent were eligible to take part. The carers, prescribers and dementia­related 
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HCPs who supported the person agreeing to participate were also eligible to 
take part; but approached after the person with dementia or a memory problem 
had been recruited. 
Memory clinic staff excluded potential participants who they felt did not fulfil 
inclusion criteria, or who did not speak English or who were deaf as the use of 
interpreters and/or signers would have brought an added dimension we did not 
wish to pursue. 
5.4.3 Data Collection and Management 
In summary both subjective and objective data was to be collected. Subjective 
data included: 
•	 the experiences and viewpoints of the person with dementia, their carer, 
prescriber and/or HCPs about the efficacy of the medication and/or 
treatment success over time (interviews and diary records), and 
•	 the observational findings from a consultation between the prescriber and 
the person with the memory problem or dementia. 
The objective data would be the results of in­house measurement scales of 
treatment efficacy accessed via the shared care record. 
5.4.3.1 Interview data 
Recording and Transcribing 
All interviews were to be recorded with informed signed consent and transcribed 
verbatim removing identifiable phrases and organisations. (A5­7) If consent for 
recording was not given then hand written notes would be taken. Interviews 
were intended to be completed separately to minimise any possible negative 
effect of narrative spoken in front of others. The recording devices used were a 
cassette and digital recorder with multi­directional microphone. 
The transcribing, verification and confidentiality processes followed the same 
process as outlined in 3.4.3.1. 
Coding and Analysis 
After transcription the data was to be sorted, organised and indexed into 
categories. These categories would be further interrogated and grouped 
together in order to clarify the relationships between categories and to refine 
emerging ideas. The emerging theory was to be tested for deviant (that is data, 
ideas or relationships that did not fit the emerging pattern) and common themes 
arising. The analysis of the qualitative data analysis would be via the same 
process as outlined in 4.1. 
5.4.3.2 Observation Data 
Recording of Observed Data 
Although an observation tool was developed; the data collection would mainly 
be in narrative form so that a description of the event could be made347 and the 
behaviours associated with shared decision­making explored in greater detail. 
One drawback was the consultations were not to be audio or visually recorded 
and this could mean observer selectivity and perhaps missing salient points.347 
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Point of 
Reflexivity 
As a means of reducing this risk, I spoke into the recording 
device immediately after a consultation in order to note down 
feelings, thoughts and findings from the observed session 
before the event reduced in clarity in my mind. Dallos 
describes this process as “self­reflection” and feels that this 
may aid the researcher to understand what the experience of 
being the observer felt like and associated atmospheres and 
behaviours before they were lost in time. 347 
Analysis of Coded Data 
Although the process of self­reflection described above is an important aspect of 
supporting field notes; the researcher must not start making interpretative 
inferences about the nature of the observation before all data has been 
gathered and the analytical process started. 347 This is so that memorable 
events within the observed period (for example distress; or disagreements) do 
not cloud the perspective of the rest of the session which may have been based 
on sound and appropriate social and psychological interaction. 347 
The data from the observed consultations would arise from the narrative within 
the observation tool to provide a descriptive and explanatory account of how 
individual behaviours supported (or otherwise) a shared decision­making focus. 
5.4.3.3 Diary Data 
Small A5 sized notebooks would be offered to all participants for them to record 
any thoughts or feelings about their experiences of a medicine for dementia 
throughout the study. Notebooks were used as diaries as the delayed 
recruitment process affected the proposed start and the use of a dated diary 
format. 
As the diary would form a naturalistic approach to data collection the text or 
narrative would be appropriate to support qualitative findings from other parts of 
the study. The narrative could be seen as a means of adding depth and 
explanation to findings. Narrative within diaries can be transcribed verbatim and 
then analysis aided by a qualitative data handling package such as NVivo® so 
that thematic interpretation can occur as another level of data enquiry.282 
5.4.3.4 Patient Shared Record Data 
A data collection form was prepared (see Appendix A5­8) to collect relevant 
participant data from the specific time frame of the study. All data collected was 
anonymised and to take place at the appropriate study site. Access to shared 
care records was possible because participants signed a consent forms 
requesting their permission (see A5­7) and the researcher had an honorary 
contract with the healthcare trust. 
An application process had to be made to gain access to the records and this 
stage of the data collection was completed once all qualitative data from 
interviews and consultation observations was concluded. Data findings would be 
tabulated and used as a strand within the case analysis to lend depth and 
description to the qualitative findings. A diagrammatic overview can be found in 
table 5.1 below. 
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Figure 5.1: Overview of Case Study Methodology
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5.5 Ethical Considerations 
As discussed in 3.3, both people with dementia and their carers are described 
as vulnerable subjects in research,260 and as NHS HCPs were to be recruited, 
research ethics approval was needed. 
5.5.1 The Process 
The study protocol had been submitted to the Department of Pharmacy and 
Pharmacology Ethics Approval of Research Proposals ­ Peer Review Process 
and reviewed by Dr Jenny Scott and a photocopy of her comments can be 
found in Appendix A5­9]. The study proposal had also been successfully 
submitted for funding as a Galen Award managed by the Pharmacy Practice 
Research Trust (PPRT) at the Royal Pharmaceutical Society of Great Britain 
(RPSGB) in August 2005.353 This process of application provided for an external 
review of the study design and methodology by the PPRT panel. 
The study was discussed at the Swindon LREC meeting on 1st December 2005 
and eventual approval was granted on 1st February 2006. (A5­10) In the 
intervening period procedural changes in the two original recruitment sites 
required a substantial amendment to approve changes to revised information 
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leaflets and recruitment process. This was granted on 21st April 2006 allowing 
recruitment to begin. (A5­11). Subsequent to this recruitment was poor and one 
of the recruitment sites dropped out requiring further substantial amendments to 
allow for 4 further sites and changes in recruitment procedures. (A5­12, A5­13). 
Due to the delay in starting and recruitment three further substantial 
amendments were needed to extend the study duration. (A5­14 to A5­16). A 
more detailed outline of this process can be found in the Case Study Report. 
(A5­17) 
5.5.2 Research and Development Approval 
Research and development approval (R&D approval) was needed for the 
proposed recruitment sites. Of the two original sites one had clear R&D 
application processes but for the second it was less clear as it was a charity. 
The charity clinic felt it did not need R&D approval as it had its own research 
governance processes but the local primary care trust (PCT) thought otherwise. 
Three weeks later the PCT agreed it had no research governance jurisdiction. 
Similarly for another proposed recruitment site there was also confusion about 
which NHS Trust it actually belonged to. Three weeks after first contact it was 
decided the site came under the umbrella of the trust which already held R&D 
approval for the study. It transpired that all three recruitment sites were part of 
the same R&D Trust. These also required amendment to the original 
agreement. 
R&D approval allowed the researcher to receive an honorary research contract 
for the period of the study and to enter NHS property and be involved in 
research activities. It also meant the researcher could access patient shared 
records with the patient’s permission. 
Point of 
Reflexivity 
There were times when it has seemed this part of the study 
would never be completed. I was fortunate that I had an 
encouraging supervisor and supportive clinicians to work with 
who suggested further routes to enhance recruitment and 
also an understanding sponsor of the research. The Swindon 
LREC and the R&D trust have also been very supportive and 
responsive to requests for change. 
5.5.3 Potential Ethical Dilemmas 
Due to the nature of this research there were a number of ethical considerations 
that were documented and explained within the research ethics application. The 
recruitment method has been explained earlier and was designed to ensure the 
researcher could not potentially coerce people to take part. 
Participant interviews were to be held in the participant’s own home following 
the University of Bath’s Research in Private Residence Policy and needed 
informed signed consent at each interview.261 (See A5­7) Consultations were 
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observed at the appropriate memory clinic, with informed signed consent from 
all participants (See A5­3), and interviews with HCPs and prescribers occurred 
at their place of work. (See A5­7) 
As explained in 3.3.1, people with mild dementia are often able to give informed 
consent. The same process of assessing capacity for consent was followed in 
this phase of the study and potential participants were informed of their potential 
involvement. 
5.6 Recruitment 
As explained earlier recruitment was slow and the first participant was recruited 
in October 2006, some six months after the study first started (and eleven 
months after the original LREC submission). Although it had been proposed that 
there would be eight potential case studies, only seven were recruited to by 
April 2007, and as the agreed study extension was until September 2007 (at 
that time point) it was decided to stop any further recruitment activity. 
5.6.1 Description of Recruitment Locations 
Case study participants were recruited from three of six potential sites, with a 
total recruitment of six people with dementia or a memory problem (one 
individual fulfilled the requirements of two case studies); six carers; four different 
prescribers and two different HCPs. These locations were actually in three 
different health authorities but services were provided by one mental health 
trust. A round trip from location one to three to two (in a direct line) totalled 
52miles. 
5.6.1.1 Location One 
This memory clinic ran from a hospital unit providing health services for older 
people, near to the centre of a large city. People could self refer or be referred 
by their GP or another medical clinician. People had an initial meeting for a brief 
assessment and then were brought to a session where they had a full 
neuropsychiatric workup; physical examination and referral for other clinical 
examinations as appropriate. At the time of the study psychologists performed 
all the neuropsychiatric testing which were then analysed by a senior 
psychologist who made a decision based on probability related to findings. This 
was then discussed with the appropriate psychiatrist and a probable diagnosis 
made. The individual would then be brought back to the clinic to be given the 
diagnosis and treatment started if appropriate. At the time of the study there 
were three psychiatrists (one at consultant level) providing this service. 
5.6.1.2 Location Two 
This memory clinic ran from a small community hospital providing general 
healthcare services for the local population. It included service provision for 
older people with mental health problems. Patients could be referred by their GP 
or another medical clinician. The memory clinic staff included a psychiatrist; a 
junior doctor and a psychologist (who complete the neuropsychiatric testing). 
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5.6.1.3 Location Three 
This memory clinic ran from a small community hospital providing general 
healthcare service for the local population. Service provision included that for 
older people with mental health problems. Generally people were referred by 
their GP or another medical practitioner. This service was provided by a 
consultant psychiatrist and a rotational junior doctor with the support of 
community psychiatric nurses as appropriate. 
5.7 Reporting Case Study Findings 
It was decided that each case study would be analysed and described 
separately in its entirety before a cross­case synthesis occurred. This would 
ensure that thematic frameworks were finalised and interrogated within each 
case study before comparing findings across case studies. 
This would allow comparison of findings across the proposed case studies 1 to 
5 (see 5.2.3) and findings from the experimental case studies 6 to 8.320,326 
Negative and positive findings could be seen as a means of gaining a more 
holistic overview of the complexities associated with prescribing a medicine for 
dementia.320,321,326 
The Case Study Report (Appendix A5­17) presents a discussion and analysis of 
each individual case study and was submitted to the PPRT in June 2008. A 
detailed analysis and discussion of cross­case thematic findings will be 
presented in Chapter Six. 
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CHAPTER SIX: RESULTS AND DISCUSSION OF 
PHASE TWO 
This chapter will present a brief description of individual case studies, followed 
by cross­case analysis of all findings. The full description of individual case 
studies can be found in the Case Study Report in Appendix A5­17. Phase two 
was a longitudinal study exploring the effects of a medicine being prescribed (or 
not) in the early stages of a dementia. In comparison phase one highlighted 
associated chronicity and severity of dementia and its affects and effects on 
carers and caring. 
6.1 Description of Case Studies 
The following section gives a brief description of the seven case studies and 
participants. In total six people with dementia or a memory problem (one 
individual fulfilled the requirements of two case studies); six carers; four different 
prescribers and two different HCPs were recruited. Interestingly all people with a 
dementia or memory problem were male; a similar finding to phase one. It is 
unclear why this was but may be related to male carers being less likely to take 
part in research287 as discussed previously in 4.2.1.2. The case study not 
recruited to was the prescribing of donepezil, which was unexpected as 
donepezil has been viewed as the first­line AChEI because of its duration on the 
market and resultant familiarity of use by clinicians. 
The demographic data of the case study sites can be found in Table 6.1. Please 
note ALL participants have received a pseudonym to protect anonymity and 
confidentiality. Narratives from the interviews and observed consultations will be 
quoted as outlined in 4.1.3. 
6.1.1 Case Study One: Ineligible for a medicine for dementia 
Mr George Black was not eligible for treatment with an AChEI because the 
memory loss was diagnosed as being mild cognitive impairment possibly 
attributed to the effects of heart bypass surgery. He lived with his wife (Mildred) 
who was known for her poor memory and had relied on her husband as almost 
a walking memory bank for most of their married life. George’s problems were 
recognised because he could no longer remember people’s names or telephone 
numbers; things that he was previously very good at. This resulted in George 
being made redundant as he could no longer keep up with his work. George and 
his wife lived on a council estate on the outskirts of a large city. In George’s 
case study there was his wife Mildred and the following healthcare 
professionals: James, a psychologist who performed the diagnostic and routine 
follow­up neuropsychiatric testing at location one and the potential prescriber Dr 
North a specialist registrar in dementia. 
6.1.2 Case Study Two: Intolerable side effects 
Mr Harry Smith was eligible because he had not been able to tolerate two 
different AChEIs. Harry lived with his wife Joan, who herself had arthritis of long 
standing and needed assistance on stairs (they had a chairlift fitted about 
10years previously because of her increasing immobility). As Harry became 
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increasingly frail and less mobile it became more of a struggle for Joan and he 
eventually needed a wheelchair for mobility. He needed knee replacements but 
was not considered eligible because of his dementia and concomitant 
cardiovascular problems. Harry was long retired and he and his wife lived on the 
outskirts of a medium­sized country town. In Harry’s case study there was his 
wife Joan and the prescriber Dr South as they received no other home 
assessment in relation to the dementia. 
6.1.3 Case Study Three: Rivastigmine 
Mr Robert Jones had been prescribed rivastigmine (off­license) for vascular 
dementia. He lived with his wife Judy who had found it very difficult to account 
for her husband’s increasingly withdrawn state. Robert’s ability to communicate 
and socialise had greatly decreased which had caused great friction within the 
relationship. Robert and Judy lived in a small town on a private estate in a semi­
rural area. In Robert’s case study there was his wife Judy and his prescriber Dr 
West; they had no other home visits in relation to his care. 
6.1.4 Case Study Four: Co­prescription of Memantine and an 
Acetylcholinesterase Inhibitor 
Mr David White had been co­prescribed memantine when he was already stable 
on rivastigmine. He had been diagnosed with Alzheimer’s disease in 2003. Prior 
to the memantine being started he had begun to deteriorate quite markedly in 
terms of cognitive functioning and verbal fluency. He lived with his wife Annabel, 
who was the main carer and looked after him on her own. Annabel was a very 
organised person and believed in routine to keep David functioning as well as 
possible. David and Annabel lived on a residential caravan park on the outskirts 
of a large city. Mr White’s case study included his wife Annabel, Mary a 
community psychiatric nurse (CPN) who visited them on a three­monthly basis 
to monitor progress and his prescriber, Dr West. 
6.1.5 Case Study Five: Galantamine 
Mr Chris Green was prescribed galantamine for Alzheimer’s disease. After 
retiring from a high powered engineers post it became increasingly obvious that 
his memory was causing severe impairment in his ability to carry out day­to­day 
activities. He was well spoken with good social skills and this enabled him to 
seemingly function at quite a high level on casual observation. He lived with his 
second wife, Vicky who did all the caring duties and found this increasingly 
difficult because of the social isolation it incurred. His children from his first 
marriage had not accepted him remarrying and now declined to have any further 
contact. Chris and Vicky lived in a small village in a rural area. Mr Green’s case 
study included his wife Vicky and his prescriber Dr East. They had been 
assigned a CPN but had refused them entry to the house. 
6.1. 6 Case Study Six: Refused to take Medication 
Mr John Johnson was originally recruited because he had refused to take any 
medicines for his memory problems. He had even had all his mercury dental 
fillings replaced in order to reduce the risk of Alzheimer’s disease being the 
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cause of his problem. However between the time of consenting to participate in 
the study and the interview taking place his wife Janet had convinced him that 
he should take the medication being offered (galantamine). 
John and Janet lived on the edge of a busy rural town in their own home. In Mr 
Johnson’s case study there was his wife Janet and his prescriber Dr West, but 
no CPN visit as Mr Johnson had dismissed this as “a waste of time.” 
6.1.7 Case Study Seven: Memantine 
Case study seven was the original case study two participant; Mr Harry Smith 
who had not been able to tolerate AChEIs. He had not been deemed suitable for 
memantine at the time of these being withdrawn because his dementia was 
classified as mild. However at the time of the observed consultation his 
condition had progressed and it was decided with the agreement of himself, his 
wife and son­in­law, to start memantine. In this case study there was Mr and 
Mrs Smith and his prescriber Dr South. 
6.2 DATA COLLECTION and ANALYSIS 
As described in 5.4.1, data collection comprised of qualitative data from 
interviews with patients, carers, prescribers and appropriate HCPs and 
observational data from consultations. Patients and carers had been asked if 
they would be willing to keep a small diary to write pointers in to discuss at the 
next interview and any changes that they had noticed after the medicine was 
started. 
Quantitative data collected by the memory clinic staff which ‘formally’ monitored 
patient’s progress (objective data) was collated from participant’s medical record 
(with consent) as a comparator with the qualitative picture (subjective data). 
In total 22 interviews were completed; 16 patient and carer sessions; four 
prescriber sessions and two healthcare professional sessions. Four observed 
consultations took place with three different prescribers. 
All interviews of the person with dementia or a memory problem and their carer 
took place in the participants own homes. All the HCPs and prescribers were 
interviewed at their place of work. 
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Table 6.1: The Case Studies

Type Participant Carer Contact Time in Study Prescriber HCP 
Case 1 Not suitable 
(has mild cognitive 
impairment) 
George Black 
Age 60 
Recruited from 
location 1 
Mildred 
(Wife) 
1
st 
IV: 4.10.06 
2
nd 
IV: 15.01.07 
3
rd 
IV: 14.06.07 
Consult: 
24.08.07* 
10months Dr North 
IV: 23.01.07 
Consult: 24.08.07 
James 
(Psychologist) 
IV: 15.12.06 
Case 2 Withdrawn due to 
adverse effects 
Harry Smith 
Age 83 
Recruited from 
location 2 
Joan (Wife) 1
st 
IV: 13.12.06 
2
nd 
IV: 04.04.07 
Consult: 11.04.07 
10 months Dr South 
IV: 18.01.07 
Consult: 11.04.07 
None involved 
Case 3 Rivastigmine Robert Jones 
Age 70 
Recruited from 
location 3 
Judy (wife) 1
st 
IV: 19.12.06 
2
nd 
IV:08.03.07 
3rdIV: 18.01.08 
Consult:5.4.07 
13months Dr West 
IV: 15.02.07 
Consult: 5.04.07 
None involved 
Case 4 Co­prescribing of 
rivastigmine and 
memantine 
David White 
Age 80 
Recruited from 
location 3 
Annabel 
(Wife) 
1
st 
IV: 21.12.06 
2
nd 
IV:09.03.07 
3rdIV: 31.01.08 
Consult: 5.4.07 
13months Dr West 
IV: 15.02.07 
Consult: 5.04.07 
Mary (CPN) 
IV:27.02.07 
Case 5 Galantamine Chris Green 
Age 81 
Recruited from 
location 3 
Vicky (Wife) 1
st 
IV: 17.01.07 
2
nd 
IV: 10.04.07 
3rdIV:28.01.08 
Consult: 12.04.07 
12months Dr East 
IV: 16.05.07 
Consult:12.04.07 
None Involved 
(Refused) 
Case 6 Refused John Johnson 
Age 76 
Recruited from 
Janet (wife) 1
st 
IV: 11.06.07 1 month Dr West Refused CPN visit 
location 3 
Case 7 Memantine Harry 
Age 84 
Recruited from 
Joan (Wife) 1
st 
IV: 19.06.07* 
Consult: 11.04.07 
RIP: 15.10.07 
Dr Q None involved 
location 2 
Case 8 Donepezil Did Not Recruit To 
* Researcher unable to attend IV = Interview; Consult = Consultation
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6.2.1 The Data 
6.2.1.1 Interviews of Participants and their Carer 
Although it was intended to interview the person with dementia or memory 
problem and their spouse separately, all participants wished to be interviewed 
together. In the case of Mr and Mrs Black (Case 1), there was a very frank 
exchange of what was going on in terms of the affect and effects of the memory 
problems on his life and how that made him feel and it was the first time his wife 
had heard him really talk about it. So there was a sharing of each others 
experience, which resulted in a deeper understanding of what it was like for each 
other. This was the case for each of the other case studies as well, with the person 
with dementia and their carer expressing a wish to be interviewed together. For all 
but one there were similar sharing experiences as with Mr and Mrs Black, but for 
Mr and Mrs Green (Case 5) it seemed they were afraid of what their other half may 
say about them if they were interviewed apart. 
6.2.1.2 Interviews with all Healthcare Professionals 
Although it had been expected that each person recruited would possibly have a 
HCP other than a psychiatrist or a medic involved in their monitoring; because of 
the differences in the way in which locations were organised this was not the case. 
(See 5.5.1.1 to 5.5.1.3) Each of the HCPs participating expressed a wish not to 
talk explicitly about the person they cared for, but to express their views in a more 
generic way and use the participant as a reference if and when appropriate. By 
engaging in the study in this manner they felt they were best able to protect the 
confidentiality of their relationship with the patient even though they understood 
the patient and their carer had given consent for the interview to be about their 
care. 
6.2.1.3 Observed Consultations 
Four observed consultations took place at two different locations. The consultation 
arranged for location one was not able to be attended by the researcher due to 
unforeseen circumstances. The findings presented here focus mainly on data from 
interviews with all participants; however the observation findings are presented in 
greater detail in the Case Study Report (A5­17). The reason for this is that findings 
from phase one (see 4.3.1.3) indicated participant dissatisfaction with 
consultations and their involvement in decision­making processes. This was not 
supported by phase two findings; however one could propose that HCPs working 
from specialist memory services may have greater awareness of consultation 
etiquette. 
6.2.1.4 Diary Records 
All participants were asked if they would like to record their thoughts and feelings 
in a notebook in between planned interviews. Only Judy Jones (Case 3) 
completed this on behalf of her husband Robert (see 6.5.2.3). 
6.2.2 Data Analysis 
Each interview was transcribed verbatim by a departmental secretary and then 
checked and edited by the researcher in order to clarify confidentiality and sound 
quality issues and problems arising with unfamiliar medical jargon. The data was 
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(See Case Study Report A5­17) then formatted for import to NVivo® and coded 
using interpretative phenomenological analysis.273­276 Themes arising from the 
data were sorted and then categorised into over­arching superordinate themes. 
Case study sites were analysed separately before being analysed across sites. 
Healthcare professionals and prescribers were analysed separately linking 
relevant data to the cross­case analysis as appropriate. 
Qualitative data was enhanced by accessing participant’s medical records and 
comparing objective findings from the clinician with subjective findings arising from 
the data (see 6.4.3.1). Observational data from the observed consultations was 
analysed in a descriptive manner linking to the use of consultation skills and the 
way in which responses to medication were assessed in both a subjective and 
objective manner. 
6.2.2.1 Thematic Taxonomy from Individual Case Studies 
Descriptive information on each of the individual case studies in A5­17 outlines the 
overall nature of each case study, including findings from interviews; observed 
consultations, diary records (where appropriate) and from the shared care records. 
Following these descriptive case studies is an overview of findings from the 
prescribers and then the HCPs involved in the study. Prescribers were analysed 
separately as they did not wish to make specific comments on individual patients 
but on general prescribing issues. The HCPs were analysed separately from 
prescriber data as their roles in follow­up patient care were so different. 
In Table 6.2 the superordinate themes from each case study are listed for visual 
comparison. It was found that living with a memory problem or dementia had a 
profound effect on the relationship dynamics between the couple, their families’ 
and friends. For some, interacting with healthcare professionals was arduous 
but others found it very supportive. There were contrasting experiences of 
medicines for dementia; with some being very positive; one experiencing 
intolerable side effects and yet another resisting the need to take them for some 
time. 
Prescribers perceived their therapeutic relationship with their patients and carers 
as being very important and to be protected. It was via this relationship that they 
learned about how people lived with dementia and that there was a need for 
careful decision­making in prescribing a medicine for dementia either on 
stopping, starting or continuing a prescription. They realised that careful and 
holistic monitoring of response was important but often felt constrained in their 
decision­making in prescribing by national and local policy. 
The healthcare professionals involved (a community psychiatric nurse and a 
psychologist) were interesting in that their findings settled into two superordinate 
themes of medicines for dementia and procedural issues. Although obviously 
competent at their own role within the prescribing pathway of medicines for 
dementia; theirs was a role that did not make final decisions but just contributed to 
these. This was reflected in much of their discussion and narrative focusing on 
procedural issues and how this related in their experience to medicines for 
dementia. 
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6.2.2.2 Cross­case Analysis 
In terms of cross­case analysis it was first proposed to compare those cases 
where a medication for dementia was prescribed (Case 3 Robert Jones; Case 4 
David White and Case 5 Chris Green) with findings from those cases who were 
not prescribed a medicine for dementia (Case 1 George Black; Case 2 Harry 
Smith and Case 6 John Johnson). This was to follow Yin’s guidance that 
theoretical analysis should be transferable across sites.320 However the 
individuality of experiences described by participants precluded just contrasting 
findings between two arbitrarily defined groups as originally planned (see 5.7). As 
a result thematic findings were interrogated across all cases. As appropriate; 
findings from the prescribers’ and HCPs were incorporated into the analysis to 
support and/or contrast findings from the people with a memory problem or 
dementia and their carers. 
The inductive process of interpretative phenomenology was used as described 
earlier in 4.1 with overall themes described in Table 6.2 resulting in a final 
thematic taxonomy for the results and discussion as: 
1.	 Living with a memory problem or dementia (including relationship

dynamics)

2.	 Interacting with healthcare professionals (including therapeutic 
relationships; decision­making in prescribing and procedural issues) 
3.	 Medicines for memory problems or dementia 
Point of 
Reflexivity 
The individual case analysis took place in May and June 2008 
for the Final Report to the Pharmacy Practice Research Trust 
who funded phase two. The first cross­case analysis took place 
in May 2009 and the original superordinate themes for carer 
participants were: 
1.	 Living with a memory problem or dementia 
2.	 Relationship Dynamics 
3.	 Interacting with Healthcare Professionals (including 
therapeutic relationships; decision­making in prescribing and 
procedural issues), and 
4.	 Medicines for memory problems or dementia 
As the analysis progressed it became clear that ‘Relationship 
Dynamics’ was a sub­code analysis of ‘Living with a memory 
problem or a dementia.’ 
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Table 6.2: Comparison of Taxonomy Between Individual Case Studies

Superordinate Themes Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 
7 
Rx HCPs 
Total number of themes 69 31 66 65 61 59 0* 85 41 
Living with a memory problem or 
dementia 
Relationship Dynamics 
Interacting with Healthcare 
Professionals 
Medicines for Dementia 
Therapeutic Relationship Dynamics 
Decision­making in Prescribing 
Procedural Issues 
KEY 
Rx = Prescriber 
HCP = Healthcare Profesional 
*Point of 
Reflexivity 
On the 11th April 2007 at a follow­up consultation with their prescriber, Mr Harry Smith agreed to try 
memantine for his dementia. The couple had previously expressed a wish to try another medicine to see if that 
might help them cope. Because they knew me they were happy to continue with the study but as a new case 
where Mr Smith became a person with dementia taking memantine. A follow­up interview was arranged for the 
19th June 2007 as by then they would have been able to titrate the medication up to an effective dose. I was 
on my way to the interview when I was involved in a road traffic collision which resulted in an extended period 
of sick leave. Unfortunately by the time I was capable of returning to work­related activities Harry had passed 
away and his wife no longer wished to take part in the study. May he rest in peace. 
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The final coding sheet can be found in Appendix A6­1 and an explanation of each 
superordinate theme can be found in Appendix A6­2. 
The overarching theoretical analysis was that living with a memory problem or 
dementia opened Pandora’s Box in terms of its effect on relationship dynamics. 
Changes in behaviours, roles, activities and social interactions stressed 
relationships to almost breaking point. Acceptance that there was a problem which 
required attention resulted in interacting with healthcare professionals for 
advice, support and information. The ultimate hope was for access to medicines 
for memory problems or dementia which were perceived as a means of 
controlling or holding the disease. Healthcare professionals were empathic and 
positive about the possible effects of medicines for memory problems or 
dementia. These medicines also improved relationship dynamics which resulted 
in an increased ability for both the person with the memory problem or dementia 
and their carer to live together with the memory problem or dementia. 
Figure 6.1: Interaction of Superordinate Themes 
MEDICINES FOR DEMENTIA 
• Prescribing hindrances 
• Responding 
• Medication issues 
INTERACTING WITH HEALTHCARE 
PROFESSIONALS 
•	 Therapeutic relationship 
•	 Therapeutic decision­making 
•	 Assessment, follow­up and 
support 
LIVING WITH a MEMORY PROBLEM OR

DEMENTIA

• Personal changes 
• Comparative changes 
• Relationship dynamics 
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6.3 Living With A Memory Problem Or Dementia 
Figure 6.2: Diagrammatic Representation of Living with a Memory 
Problem or Dementia 
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6.3.1 Personal Changes 
There were many personal changes attributed to the dementia or the memory 
problem with resultant changes in behaviours and activities. Living with these 
personal changes challenged both the sense of self131,134,137­143 and also 
personal and social relationships.166­169 This section will explore these 
changes in further detail. 
6.3.1.1Ageing and Concomitant Illness 
The age range of the participants with a memory problem or dementia was 60 to 
84 years. Dr West described three age ranges when providing care for older 
people; “the young old, the old and then the old old.” He went on to define the 
age ranges as “young old is 65 to 75; old is 75 to 85 and old old is 85 plus.” So 
George Black, the youngest at 60 fell outside even the ‘young old’ category; 
(which Robert Jones was a member of) and the remaining participants were in 
the ‘old’ category. This age difference was interesting in terms of the results 
because participants had an increasing package of concomitant medical 
conditions and associated medication as well as increasing physical frailty 
associated with older age. 
As mentioned in 6.1.2, both Joan and Harry experienced reduced physical 
capacity. As a result they were confined to the house and relied on family for 
help for outings and hospital appointments. This also meant that what Harry 
wanted from his medication was more focussed on his physical pain than his 
cognition. 
Harry: “The medicines for my knee that’s the most important thing to me.” 
Joan: “I think he’d be completely lost without them to be perfectly truthful, 
just at the moment.” Harry & Joan, Case 2 
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John had worked hard all his life and Janet shared “work was his life” and he 
had only in the last couple of years handed his business completely over to his 
son. 
“He doesn’t take old age easily, he doesn’t. What I say to him is he is 
lucky to have got to this age (75). Lots of his friends died of cancer, heart 
attacks and that’s life isn’t it? But he’s still here so you have to be 
thankful for that.” Janet, Case 6 
A lack of mental stimulus can lead to poor engagement in the external world and 
a decreased level of functioning so the reduced stimulus from fewer social 
interactions with friends and relatives can be a negative factor in maintaining 
and improving social functioning.76,354 Many of the carers in phase two were 
aware of and tried their best to increase opportunities for mental stimulus (see 
6.3.2.2). 
Chris had cardiovascular problems, diabetes and about 18months prior to the 
study had suffered a major stroke which had required removal of a brain clot 
to preserve arm and leg function. He said that “old age never comes easy” 
and what upset him most was the macular degeneration which in his view 
had robbed him of being able to drive and play golf at a level he was happy 
with. 
Sometimes it was difficult for the participants to know whether it was the 
dementia or their age slowing them up; which was reflected by Robert below. 
“But I still don’t have to me I don’t have the power I would like. Whether 
that is because of the age I’ve got to I don’t know.” 
Robert, Case 3 
This experience of ageing and its associated medical conditions resulted in 
trips to hospital and for some, operations and procedures. For all couples 
except George and Mildred, there had been gradual decline in mental 
functioning over time as reflected by Judy below. 
“I don’t now how much it’s been coming on like this. I think over the last 
couple of years I’ve compensated by talking and he’s just given up.” 
Judy, Case 3 
Janet commented that they had been told by their GP that John had been 
having “mini strokes that he wouldn’t have known that he had them” and 
continued with “we didn’t notice it too much at first.” Vicky reiterated this 
perception when she said they had first noticed problems after the brain 
surgery but added “I suspect it had been building up for a long time without us 
being aware.” These possible prodromal changes will be discussed further in 
Section 6.3.2.1. 
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Robert and John were treated for depression prior to being formally 
assessed for possible dementia because of their increasing social 
withdrawal. Depression may cause some symptoms associated with 
dementia, although it may be part of the dementia prodromal period.96,146 
Robert never thought he was depressed but his GP prescribed a 
antidepressant anyway where as John put his low mood down to not being 
able to “go go go” all the time. 
“Then first of all he started going quiet and our GP thought he was 
depressed, we didn’t think he was depressed but they put him on 
antidepressants.” Judy, Case 3 
These concomitant medical problems muddied the waters for people in terms of 
knowing what was actually causing what in terms of day­to­day experience. 
“Some days can be quite bad, I get tired that is another thing I mean 
there are so many things going on with me personally you know health 
wise as well.” George, Case 1 
Point of 
Reflexivity 
Not only were there physical effects of concomitant illness, 
but participants also spoke about the effects of concomitant 
medication. All participants took between 6 and 10 medicines 
per day and I could only wonder at the different 
pharmacodynamic and pharmacokinetic interactions that 
could negatively effect their cognitive functioning. The elderly 
are susceptible to experiencing medication­induced delirium 
with estimates ranging from 11 to 30% of hospital 
inpatients.319 Medicines that are centrally active with a high 
anticholinergic load are well known to cause confusion and 
delirium so regular medication review and assessment of 
continued need should occur This was not an activity that I 
witnessed or I was informed of. 
The burden of concomitant illness and medication is illustrated by Robert below 
who tried to make sense of the number of medicines. 
“I feel I’ve got to the stage now where I take approximately 20 tablets a 
day; you know shake me I rattle. You don’t mind a joke but I just hope 
and I keep asking ‘am I benefited by these or can I reduce them?’ ‘Oh no 
not at the minute sir,’ they turn to me and say ‘oh have you tried these?’” 
Robert, Case 4 
Harry summed up the associated frustration of medicine taking well when he 
said: “I have been taking so many bloody tablets.” This concept of taking too 
many medicines is also referred to as polypharmacy which describes the 
situation of taking more than one medication regularly.319 Multiple users of 
medicines have described a dichotomy of feelings; gratitude that they were still 
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alive because of the medication but concern about whether it was actually good 
for their body.355 Interestingly, it has been suggested that different forms of 
dementia may be related to higher rates of polypharmacy and co­morbidities.356 
These findings suggest that many people with dementia may require an overall 
holistic assessment of co­morbidities and medication to reduce associated 
negative cognitive effects of medication and promote overall well­being. 
6.3.1.2 An elusive memory 
George Black, had a past history of a heart attack followed by a heart bypass 
with a seemingly devastating effect on his memory. Previously he had prided 
himself on his memory and his ability to remember complex numbers; 
appointments and tasks that needed completing. Mildred, his wife, described it 
as a “brilliant, brilliant memory” and their relationship roles were built around this 
fact as her memory had never been good. George took care of business, all the 
paperwork and remembering historical and current events. 
George: “But it is, I don’t know what all these different factors what they 
are doing to me, what they are doing to my mental state I haven’t got a 
clue. All I know is that my memory has been getting chronic. For me it is, 
you know. I am not getting senile I am not getting…” 
Mildred: “He had such a brilliant, brilliant memory.” 
George: “That is the annoying thing.” 
Mildred: “You know it was like opening a book. Ask him and it was there 
instantly and he knew you know. And now if I asked him something he 
snaps because he tends to do that. It’s his way of saying he don’t know.” 
George & Mildred, Case 1 
Prior to the bypass George had been warned that his memory might be affected 
but it was not until he started back at work that he realised the extent of the 
change. 
“I was missing appointments; I was not doing the things I was asked to 
do…You know sometimes I had to be quite truthful and say ‘sorry, it 
completely slipped my mind.’ I didn’t do this, I didn’t do that. So I got to 
the state where every time I spoke to someone I had to carry my book 
around with me, (and) write it down.” George, Case 1 
The other gentlemen in the study were aged between 70 and 84 years of age, 
so it seemed that the impact of a poor memory on their sense of self was less 
devastating for them than it was for George. In this age group the key concerns 
were the day­to­day and sometimes hour­to­hour fluctuations in their ability to 
access their memory. 
Chris: “I know I’m losing my memory, that’s what worries me but it comes 
back after probably an hour or two hours but sometimes it is a nuisance 
actually.” Chris, Case 5 
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A common source of irritation for carers167,169 is the continued repetition of 
questions; stories or phrases. This was experienced by Vicky, who shared that 
when she understood the reason it no longer became a problem. 
“First of all, which would be about two years ago when I started having to 
say things twice. I got terribly annoyed about that ‘I just told you that’. 
Then of course I understood.” Vicky, Case 4 
Both carers and people living with a memory problem or dementia spoke about 
the differences in long and short term memory, but overall seemed puzzled by 
how one memory retrieval system could be so good and yet the other was so 
poor. This was perhaps best summed up by David below: 
“My short­term memory is very bad. Long­term is quite good, but a 
person will say something to me and two or three minutes later it’s gone 
but not all the time. It’s peculiar. Things come back from the past which I 
haven’t been thinking about at all and my wife asks me something and 
two or three days later I’ll suddenly come out with a name. It’s odd and 
it’s nothing to do with what I’m thinking about you know in the brain (at 
the time).” David, Case 4 
Of greater concern for three participants was when their memories differed to 
those of their spouse or were completely nonexistent for a given event. As 
Robert stated “I couldn’t remember doing things.” George experienced his poor 
memory as frustrating and it completely shook his belief of what he thought was 
truth. 
“…that is when it really gets frustrating when I am told about things and I 
hope to me, it has never happened. I have never said it, never done it, 
no one has done it for me or given it to me or said it to me you know. I 
thought black was black and white was white and now I am not sure, now 
I am not sure at all.” George, Case 1 
An observational study recorded the progression of dementia symptoms over a 
12­month period in 58 patient­carer dyads. A major problem experienced by 
participants was the inability to “rely upon the memory of, or consciously 
recollect and relive, a past experience.” 357 The authors went on to argue that 
“memory is simultaneously individual and social, and that memorabilities are 
shared co­constructed events and experiences.” 357 This viewpoint perhaps 
explains why carer frustration can be so great when stories are mixed up or 
incorrect because these ill­remembered memories could be experienced as 
unpicking shared history and experiences as a couple. 
6.3.1.3 Fluctuations and progression 
David and Annabel in their first interview described how the time of day and 
different days affected David’s ability to function and cope with daily activities as 
narrated below. 
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Annabel: “We had a slightly dodgy Monday and Tuesday didn’t we of this 
week…but then from Wednesday and today he is so much brighter you 
really can’t tell from one day to the next.” 
David: “Yes and it varies what time of day. I don’t know why this should 
be ‘cos I’m not very good after 11 o’clock …It’s the same time each day 
and I am all right at the moment. We were in Asda and my head was 
constantly spinning and I couldn’t focus on anything at all…Then it wears 
off and by the afternoon and evening I’m fine.” 
Annabel & David, Case 4 
Mary (CPN) had been to check David’s blood pressure and pulse after the event 
but had found nothing unusual. David described it more as ‘turmoil’ in his head 
than actually feeling dizzy, which resulted in him not being able to concentrate 
or focus. 
Both carers and people with a memory problem or dementia spoke about their 
fears of progression and for the future. For David it was a fear of nursing home 
admission after friends of his had been admitted on a permanent basis. 
“I’ve got three friends …they all moved into a home recently they are all 
our age with the same problem and they won’t come out again. I think to 
myself how lucky I am that I am not in a home.” 
David, Case 4 
In contrast, at his first interview George had not seen Dr North for the possible 
diagnosis. His concerns included not being diagnosed as senile and wanting to 
be told that his memory would not get any worse. 
“I would like to know what he has come up with you know. Is it my 
memory has gone or is it just me just bloody ga ga you know? I don’t 
think it is me going ga, ga either.” George Case 1 
This fear of progression has been highlighted in a previous study which 
investigated what the perceived threats to self were for people living with early 
dementia.135 The two overarching themes were “It will get worse” and “I want to 
be me” and these were linked to the participant wishing to retain their own 
sense of identity or self­hood.135 After his first appointment with Dr North, 
George received a diagnosis of mild cognitive impairment and was told there 
may be some improvement in the future. 
“He ruled out a lot of things but he said, the short term memory might 
improve but there is no guarantee to it and I must admit it hasn’t yet.” 
George, Case 1 
Mild cognitive impairment (MCI) has been postulated as being a stepping stone 
in the continuum of dementia for some of those diagnosed; especially those with 
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amnestic MCI.92 It has been proposed that 44% of people with amnestic MCI will 
proceed to a diagnosis of AD over 19months. 92 The possible implications of 
giving a diagnosis of amnestic MCI to people and its effect on their resultant 
health behaviours is unclear at present.358 For George there was no recognition 
of a possible link to dementia in the future or any information on reducing 
possible risk factors. 
Point of 
Reflexivity 
Interviewing people with a memory problem or a dementia is 
an interesting experience. It requires great attention to the 
way in which a question is formed and what kind of questions 
need to be directed to the carer and not the individual with 
the problem.359 For example I was reminded of this when I 
asked Harry Smith in his first interview if he could remember 
taking his medicines for dementia and just received a blank 
expression and withdrawal. His wife, Joan tried to explain his 
reaction by saying 
“I don’t think he took a lot of notice of them quite truthfully 
himself, you know but, he doesn’t remember very much, his 
memory is not very good at the best of times.” 
But really it was my gaffe and I learned to adapt my questions 
so that they related to their personal experience in the 
moment. This was made difficult when some people like 
David who had a great memory for things that he was 
interested in such as current or family­related affairs but 
could not remember things he perceived as less important. 
David could tell me about the benefits of the co­prescribing of 
rivastigmine and memantine but when I asked him how long 
he had been taking his rivastigmine he replied: 
“I can’t remember when that was. I would have thought it was 
about 2 years but that is the sort of thing I can’t remember.” 
In a way there was a need to explore an individual’s ability to 
remember and learn the areas in which their memory was 
less functional. 
6.3.2 Comparative Changes 
In this section the changes in behaviours and activities of the individual with a 
memory problem or a dementia will be presented. From the narratives an insight 
into the effect and affect of these changes on the day­to­day relationship of 
each couple can be seen as well as resultant affects on their personal 
relationship. 
6.3.2.1Behaviours 
Chapter Two introduced the concept of a prodromal period for people with 
dementia with resultant behavioural or personality changes. Interestingly John 
exhibited many of these earlier symptoms such as depression, anxiety, worry 
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and suspicion (paranoia) as related by his wife and own narrative throughout the 
interview. 
“Before we had a problem, you were very anxious and very worried about 
everything and that is where the citalopram that helps. You did get a bit 
down sometimes didn’t you?” Janet, Case 6 
The following excerpt demonstrated how John tried to make sense of his own 
anxiety and tendencies towards low mood; as well as sharing how difficult it was 
for him to contain ‘the man inside.’ 
John: “…my anxiousness is based probably on a bit of temper do you 
know what I mean? An anxious person can become down and down 
and down because you are anxious.” 
Janet: “Oh you don’t get in a temper at all you are very..” (Interrupted by 
John) 
John: “You don’t know what the man inside is saying do you?” 
Janet: “No but..” (Interrupted by John) 
John: “And nor does anyone else.” 
John & Janet Case 6 
Point of 
Reflexivity 
From Janet’s interruptions to and comments on her 
husbands narrative it was clear that she was very worried 
at the start of the interview about how I might feel about 
him being bad tempered and angry; trying to deflect him 
from admitting this. At one point she said to John “But I 
don’t want Denise to think that you get in a temper and 
you get nasty.” By my response I tried to allay her fears 
that I thought any less of her husband or her as his wife 
and that such reactions to dementia were relatively 
common. This was in great contrast to the first interviews 
with George and Mildred, and Robert and Judy who 
shared openly their frustrations and anger about each 
other, throughout the interviews. 
John also had a great dislike of being on his own, and was not keen on going 
out (present prior to starting medication). This put a great strain on Janet’s 
activities and ability to function as an independent person. 
Janet: “The biggest draw back is he doesn’t want to be far away from me, 
that’s the..(Interrupted by John)” 
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John: “No I always cuss and grunt when I am sat on my own and that 
is the truth I don’t make any bones about that, I say ‘I think I might go 
down Lyme and see if there is a bird about’ (to pick up a woman).” 
And a little later 
Janet: “The thing I notice, I can’t have a private telephone 
conversation. If I am in one room he will come in ‘who’s that, what 
were they saying, what did they want? Don’t you?” 
John: “Well yes. But it’s probably some crony running me down or 
something like that. You might as well find out mighten you?” 
Janet & John, Case 6 
These early behavioural changes can cause great disruption of the spousal 
relationship and result in increased carer stress. As mentioned previously 
heightened carer stress can also result in heightened stress in the person 
with the memory problem.180,181,183 It has also been described how in early 
stages of memory impairment carers may feel any or all of the following: 
irritated, frustrated, angry, impatient, argumentative, amused, unloved and 
under­appreciated.61,166­167 Again these can be seen as secondary stressors 
which increase the carer burden.170,171,177,188, 285 It has been suggested that 
what needs to happen is a psychological adjustment to the actual lived 
experience of living with dementia.141,142 This adjustment includes jointly 
trying to make sense of the experience and developing ways of coping 
together.142 
Another early change for some was social withdrawal and Judy became very 
agitated about this in the first interview as she felt Robert was “just sitting 
there not doing anything” and “it was getting me depressed.” Robert tried to 
explain his feelings about this but Judy dismissed these as excuses. 
Robert: “I walk down to the paper shop post office and there’s quite a 
number of people in there that I talk to and I see on a regular basis, 
but at the same time once I’ve left there and come back I’m on my 
own. I admit I should see more people in a 24hr period, I accept that 
but until recently I have felt that I had work to do around the house 
which I’ve not achieved and I can take more on but of course at the 
minute don’t want to push myself too hard.” 
Judy: “I just think that you don’t want to get involved in anything 
outside Robert. This excuse of jobs having to be done in the house 
and this that and the other it’s just an excuse. If you wanted to go out 
and do something else you would do.” 
Robert & Judy, Case 3 
Anger and frustration in response to changes in memory or abilities was 
common. Chris said “it makes me so cross at times really” but George was quite 
open as he shared how it turned him into a ‘nasty person.’ 
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.“Initially it was making me very bad tempered you know it really made 
me bad tempered I was a nasty person…(continued later)…I noticed it 
and frustration started getting in and the more I was getting frustrated, I 
was getting stressed, I was getting tense, the worse it became.” 
George, Case 1 
This impacted on carer functioning as well. Mildred had always been known 
for her poor memory and found it very distressing when she knew that 
George had said or done something which he later denied knowledge of. 
“So I would say to him that you did say that and he would deny it and I 
would think to myself ‘well alright fine I am not going to argue with 
you.’ but then George was getting angry, really, really angry with me 
and I am thinking ‘I am near to tears here because I would stake my 
life on it that he said it or done it.” Mildred, Case 1 
Judy frequently described her husband Robert as being agitated in response 
to every day situations which tested him, saying “he soon gets agitated“ 
continuing with “he’s got a very short fuse” Robert agreed saying “I do, well 
it’s frustration really,” and perhaps frustration was a better term to use. 
Another concern mentioned (6.3.1.1) was the associated slowing down of 
ageing, but David perceived this as AD itself with Annabel reflecting it affected 
everything that David did. 
David: “And it slows me down a lot.” 
Annabel: “That is very significant very, very slow yes.”

.

I: “Is this the tablets do you think or the disease?” 
David: “I would have thought it was the disease actually.” 
And a little later 
Annabel: “I would say so, I think it’s because it is somehow there being a 
lack of concentration and he seems to me he’s slowing down and trying 
to work out what’s to be done next. It’s almost as if each step is a 
deliberate effort…he doesn’t do anything at even remotely normal speed 
now.” David & Annabel, Case 4 
This is an interesting finding as it highlights the need for HCPs, carers and 
family members involved in the care of PWD to allow time for individuals to think 
and respond to questions and/or to complete tasks and activities. This was 
highlighted in 4.4.1.4 as an important concept in developing good 
communication skills with PWD. HCPs need to be aware that the slowing in 
mental processing is caused by a reduction in the short term memory capacity 
for new information.360 This means there is less available capacity for 
processing and sense­making, which sometimes can be interpreted as the 
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person having lost conceptual knowledge.359 Bayles argues that it is the 
reduction in the available working memory which can affect information 
processing and retrieval. If the capacity is diminished this can result in a wrong 
or incomplete answer.359 The author goes on to suggest there are seven steps 
which can improve memory and conversation with PWD and these are outlined 
in the Table 6.3 below.359 
Table 6.3: Improving Memory Deficits to Aid Communication359 
Step for Improving 
Linguistic Memory 
How to do This 
1. Work within memory span 
capacity 
Use a series of short commands in order to 
complete an instruction; only giving the next 
when the patient has completed the first 
command. 
2. Simplify language Reduce syntactical constructions and use 
simple, active and declarative sentences and 
speak at a moderate rate. Rephrase if the 
person is confused. Don’t use open­ended 
questions in people with poor searching 
memory 
3. Put Conversation into 
Context 
Photographs or toys or models can be used to 
increase meaningful utterances 
4. Provide Repetition if 
Recall is needed 
This has been found to improve picture and 
story recall, sentence comprehension 
5. Ensure Learning is 
errorless 
If a person cannot remember do not make 
them guess as this will be the word that they 
remember next time. 
6. Priming A prior stimuli can result in the facilitation of s 
response (this is known as priming and is 
considered an unconscious form of memory) 
7. Reducing Cognitive Load Reducing task complexity and thereby the 
cognitive effort needed to complete a task can 
be successful. Multitasking is more demanding 
and can be frustrating for the individual; so 
eliminate distractions, provide written 
instructions to support oral instructions 
Point of 
Reflexivity 
The first interviews with each couple were very much a 
getting to know each other event, but also a chance for many 
of the couples to share with each other how it had really been 
for them over the past months. Harry and Joan were very self 
contained and of few words and seemed very accepting of 
their situation. Interactions with the other participants were 
often very frank and honest to the point I felt for each person 
and their own individual suffering. Much of the friction was 
built on the misunderstanding of what living with a dementia 
or a memory problem entailed and the damage of this to their 
own perception of their identity, independence and their 
relationship. 
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6.3.2.2 Activities 
As might be expected participants with the dementia or a memory problem 
spoke of their past prowess on the cricket pitch, golf course, or about the house 
or as a do­it­yourself­er. The lament was really a yearning for past times and 
past enjoyment and satisfaction. 
“I played golf extremely well. I was a cricketer from the age of 7. I went all 
over the world playing cricket. The moment they saw me they said you’ve 
got to play for us you’ve got to play for us which was great.” 
Chris, Case 5 
David described the confusion and frustration arising from living with a dementia 
well in the following narrative: 
“I felt very frustrated (before the medication) and as my wife says I used 
to be quite keen at do it yourself, after that I couldn’t have tackled a job at 
all. I would just sit and look at it and think ‘well what on earth am I meant 
to be doing’” David, Case 4 
More distress can also arise when simple tasks become problematic. Prior to 
starting memantine David went through a phase of not being able to dress 
properly. He was always particular about being dressed in a shirt and tie with a 
jumper and trousers, but this fell apart when he could no longer remember how 
to tie a tie. 
Annabel: “You referred to the fact that you couldn’t work out how to tie a 
tie. You were also at that point, dressing in a most odd fashion. He was 
putting on trousers upside down and that sort of thing. So it was an 
overall situation with dressing together with the tying of the tie wasn’t it?” 
David: “Yes, putting my pyjamas on top of my trousers.” 
Annabel: “It got to that sort of situation which was very distressing really 
but that is all behind us now (since memantine).” 
David & Annabel, Case 4 
Robert found it very difficult to cope with having to change from one plan to 
another and described it as “frustration, you know diversifying” and 
it caused great friction within his relationship with Judy. 
Robert: “Invariably I’ve been in the garage and I’ve been getting things 
ready to take out into the garden. The good lady will say “have you a 
minute (interrupted). ” 
Judy: “You keep saying that I always interrupt you.” 
Robert: “No just a minute, let me finish before you go on. Oh dear. Umm, 
that distracts me to a given degree not because I want to get in the 
garage but because I want to do what she wants so I’m torn if you will 
and as I said she has priority.” 
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Robert & Judy Case 3

This was quite amusing because Judy did actually interrupt Robert frequently; 
probably due to her lack of understanding for the need to give a person with 
dementia time to think about a subject, formulate a response and then vocalise 
it. This was illustrated again in an excerpt between Janet and John below 
Janet: “Can I step in there a minute?”

John: “Well you seem to be, I don’t know.”

Janet: “Because I know when it started.”

John: “Well I am not having a chance to think.”

Janet: “Well you think a minute and I’ll say when it started.”

John: “Well you carry on now.”

Janet & John, Case 6 
This is also an important concept for HCPs working with PWD; to give them 
sufficient time to respond and even longer if an adaptation to a plan or task is 
needed (see 6.3.2.1). This perception of slowed processing has been explained 
in terms of reduced working memory span and that account of this deficit needs 
to be considered when communicating with any person with dementia or 
memory problem. 359 
Point of 
Reflexivity 
This has been very interesting for me to analyse as I have 
been able to relate it in some way to my own recovery from 
rather a severe head injury with its own associated memory 
dysfunction. Not only that but it was the unexpected finding 
that thinking is actually quite hard work and if you are 
completing a physical task (e.g. gardening) that requires 
some mental activity as well, the outcome is drained physical 
and mental energy reserves. 
6.3.3 Relationship Dynamics 
This section describes how living with a memory problem or dementia can affect 
spousal and family relationships as well as the ability to cope on a daily basis. 
6.3.3.1Perspectives of day­to­day living 
Both the participants with a memory problem or dementia and their spouses had 
to learn to live with this problem and develop coping and sense­making 
strategies. (This was similar to participant experiences presented in 4.4). These 
changes affected all communication and social interactions. In the first interview, 
Judy explained her frustration with what she perceived as lack of initiative which 
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resulted in Robert’s inactivity and perhaps suggested Judy thought it was 
deliberate. 
Judy: “You don’t seem to activate something, seems you’ve got to the 
stage where you react on somebody saying something asking you to do 
something but you don’t do it on your own.” 
Robert: ““I just feel that at the minute I’ve been going round in ever 
decreasing circles and not knowing anything what so ever. You could 
argue I used to be very bright, positive in what I did, but now I’m quite 
sort of lethargic. Just hoping I can get back on track.” 
Judy & Robert, Case 3 
This perception of “not knowing anything” was also experienced by David and 
Chris. This inability to be pro­active or take initiative in conversation, tasks and 
their relationships is probably what made respective carers frustrated. The 
machinations of the mind are so complex it seems almost dramatic that a 
medication could help improve these complexities to an extent perceived as 
beneficial by both the individual and their carer (see 6.5.2.2 to 6.5.2.4). 
Roles changed in response to the dynamics of living with a memory problem or 
dementia. As could be expected this inability to think or initiate activity impacted 
on their relationships especially spousal interactions. Judy had set up a number 
of lists around the house to prompt Robert to do or remember things; however 
these only worked if Robert remembered to look. 
“You could help yourself by just referring to it (the list) before you went 
out but I have to do it at the door, I say ‘have you got this, have you got 
that, have you got your tablets, have you got?’ everywhere we go… So 
it’s like a constant checking all the time.” 
Judy Case 3 
This depth of frustration seemed linked to a lack of understanding about what 
having dementia actually meant and how roles had had to change in response 
to Robert’s behaviours as well as a yearning for things to be as they were so 
that normality could return. 
In order to combat this lack of initiative or inertia, Judy, Annabel and Vicky tried 
hard to provide stimulus and activities which improved mental stimulation and 
be interesting. These were not always successful and depending on the 
individual spouse finding new ideas for activities was hard work. 
“I tried to get you to do crosswords, showed you how to do that sudoku, 
but just everything mentally to make your brain hurt you won’t do.” 
Judy, Case 6 
“The dominos is good yes that was a brilliant idea on my part, it is trying 
to have these ideas, that is only one, I need dozens more.” 
Vicky, Case 5 
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Vicky felt that she was unable to give Chris the stimulation he needed as in her 
experience Chris became more socially interactive in male company. She 
explained how her brother’s visit had resulted in Chris being animated and 
involved with conversation and tasks. She believed this was because her 
brother “was able to give you a stimulus that I can’t, you know being female.” 
She continued “So that’s really what Chris needs but I don’t know how to supply 
it to him.” 
This need to find stimulating activities was a different aspect to findings in 
4.2.1.1 where carer participants tried to involve their loved one in routine 
activities of daily living rather than in mind stimulation. 
Coping Strategies 
There are many strategies to support a poor memory, ranging from writing lists; 
using diaries, calendars, mobile phones as alarms etc and increasingly 
computer or handheld programmes to stimulate brain function.360 Interestingly 
none of the participants had any formal direction on this from their respective 
memory clinics and so had adopted various strategies that worked for them. 
George at interview one was writing everything down saying “I am having to 
adapt everything you know” and by interview he described his “normal code of 
practice in the morning is getting up looking at the calendar see what is on.” 
Judy had three lists on the go saying “I think you have to do it, it’s a lot of 
organisation really.” Robert added they also used a diary to enable them to work 
together. 
“We have a diary in there and that’s the only way to do it to put things in 
the diary …you know what I mean cos we’ve got to work together.” 
Robert, Case 3 
Annabel believed strongly in motivation and routine stating that “we have quite a 
regime here, we have a set pattern for our day otherwise things don’t work out.” 
She believed that this approach was “good for both of us actually” as it gave her 
time to do things on her own whilst David had been taken to either his camera 
club or art class by friends. When asked whether he liked the routine David said 
“yes I enjoy it” although Annabel appreciated that “it must be very frustrating to 
be told or asked if you like to do this or that...” She did confide that she wasn’t 
trained at all and often worried if she had the right approach. 
“When you are looking after somebody in this situation and you are not 
experienced in it you do what you think is the right thing and I talk over 
with Mary or when Doctor West comes and they haven’t yet told me ‘you 
shouldn’t be doing that or the other’ and so we keep going and with me 
rather driving is a too strong a word but motivating David I think is better 
and if I find that he’s going down a little bit and a bit lethargic then I try to 
give him something else to concentrate on. And I personally think the 
combination of the drugs and how I contend with things works.” 
Annabel, Case 4 
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6.3.3.2 Communicating with a memory problem 
One of the main areas of distress for Judy in the first interview was the inability 
of Robert to initiate or take part in a conversation. It also highlighted Judy’s lack 
of knowledge and/or understanding about why this might be so. Robert tried to 
explain why he felt unable to maintain a conversation, but he had also been 
trying to tell Judy that he wasn’t able to remember recent events sufficiently well 
enough to put these into conversation. The narratives below highlight their 
frustration with the other not being able to see their point of view. 
Robert: “Sometimes I feel that I’m in a conversation and I suddenly dry 
up because I feel I’ve run out of things to say, I need a digit pressing to 
sort of get back on track.” 
Judy: “Robert what I want is your conversation to be about present and 
future not things about (interrupted).” 
Robert: “I was just saying what I was capable of; not present day and I 
admit that (vehemently)!” Robert & Judy Case 3 
The EUROCARE study highlighted that two of the most difficult experiences as 
a carer of a person with dementia was the “loss of companionship through 
diminished quality of communication” and changes in social behaviour.361 (See 
Section 6.3.1.4) A finding that Judy’s narratives support. 
What most annoyed George was the effect that his poor memory for names had 
on his ability to take part in conversation. He was so busy trying to remember a 
person’s name that he wasn’t able to concentrate on what was being said and 
then had no idea how to respond. 
“…I can contend with not being at work, I contend with not having the 
money that I used to have, but all that doesn’t really bother me you know 
what bothers me is not being able to go out in that street meeting 
somebody, knowing who I am talking to and not being stressed out 
because I can’t remember what they had said five minutes ago because 
my mind is trying to work on something else.” 
George Case 1 
David and Robert both had hearing problems and needed bilateral hearing aids. 
However hearing aids tend not to be selective in what they make louder and the 
wearer can find themselves “bombarded from all sides and you can’t really pick 
out anything” as David explained. Annabel observed that this made 
communicating as part of a large group quite difficult. 
“He does have a problem with fairly largish groups of people and I can 
appreciate that obviously because with his hearing problems as well he 
finds it difficult.” Annabel, Case 4 
This finding was supported by Judy who at the second interview thought that 
Robert still tended “to be quiet in company I don’t think you’ve got these hearing 
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aids sorted well enough yet.” Chris had no problem hearing but had very poor 
vision. There is evidence that reduced visual acuity can affect communication 
due to reduced visual clues.362 However both visual and hearing impairment can 
negatively effect cognitive function so such people may need greater support.363 
These are important concepts for HCPs to take into account when 
communicating with PWD with visual or hearing impairments as these will also 
exacerbate the slowing in mental processing. 
6.3.3.3 Effects on Others 
A change in mood of the person experiencing the memory problem can affect 
everyone around them and result in damaged relationships between spouses 
and other family members. Mildred recounted below how George’s bad 
temperedness had caused her embarrassment and stress and had also affected 
his relationship with their sons. 
“I am not normally a nasty person you know I don’t normally bite the boys 
head off but I have been… one of my sons he took me aside and said 
‘that was out of order dad.’ I don’t even remember what I have done you 
know…I mean at first I didn’t realise how bad I was. It is only because of 
just everyone threatening to leave me two or three times…I have had to 
rethink myself and the way I behave and try to control myself it is hard, it 
is hard.” George, Case 1 
Mary commented that on her home visits she often perceived evidence of 
discord in a relationship but it was hard to get to the bottom of things if there 
was not the opportunity to speak to people on their own. 
“Sometimes you get a clue that they’re going to be defensive or they will 
say things are fine if they can’t talk in front of the individuals, some kind 
of scheme (is needed) where you can talk to them separately.” 
Mary, CPN 
Point of 
Reflexivity 
As mentioned earlier Robert and Judy; George and Mildred 
spoke very frankly about their relationship difficulties, but for 
Chris and Vicky this was a very different story. The first 
interview with them was very difficult as they were both so 
careful about what they were saying; plus also I was a 
stranger to them. Vicky seemed very agitated and fidgety 
during the interview and at the end as she walked me to my 
car she said that she found it very hard, very distressing and 
very awful and that she would like to talk to me on her own 
but she would upset Chris by doing so. In the end she 
actually wrote her thoughts to Dr West in a private letter. In 
the subsequent interviews they were both much more 
relaxed; perhaps some of this due to Chris improving slightly; 
and also because they felt they knew me a bit better. 
Interestingly Chris shared his worries about Vicky with me 
and her future in interview 3 when she was out of the room 
and he thought she couldn’t hear. I felt so much for them both 
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and perhaps their relationship was best summed up by Dr 
West who said “the couple shared a special relationship and 
one gets the impression that one would be lost without the 
other.” 
Another issue for carers was how the changes associated with the memory 
problem resulted in the person changing from the person they fell in love; a 
finding also highlighted in 4.4.2.1. This is reflected by Judy and Robert’s 
narrative below. 
Judy: “Sometimes you think you’ve lost the person that you married, don’t 
say you’ve been like this all the time.” 
Robert: “I appreciate I haven’t been like this all the time, don’t ask me 
why.” 
Judy: “No I just wish sometimes it was like that (before).” 
Judy & Robert, Case 3 
The participants spoke of their appreciation for their respective spouses’ care 
and concern as reflected by Robert’s comments below. 
“I married a good lady, my mentor, that’s all I live for really plus the 
family. Whilst I’ve been in this state I’ll admit I haven’t felt right, don’t 
know why just something that happens and …I’m gratified that I’ve now 
got to this stage with the help of good lady.” 
Robert, Case 3 
George had more to reflect on and his response below is perhaps indicative of 
one of the differences between male and female acceptance of living with 
dementia and associated relationship changes.131,285 
“I have sat down and thought about what has happened in the last year 
18 months and if I had been Mildred I would have been gone a long time 
ago and would have left me.” George, Case 1 
However the illness didn’t just affect spouses but also family as Janet described 
how prior to the medicine for dementia she needed extra help around the house 
in order to care for John and that his increasing social withdrawal made it 
difficult for family events. 
“This time last year, John was entirely different. My sister used to come 
everyday, my son used to come twice a day, my niece used to come and 
help do the housework and things were difficult…John, last year come 9 
o’clock he wants to go home, he was quite agitated. Christmas we got 
there at 1 o’clock we had to leave at 4 he wanted to come home.” 
Janet, Case 6 
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For Chris it wasn’t the dementia which caused friction with his children but his 
marriage to Vicky some twenty years earlier, twelve years after his first wife 
died. At the first interview he said “unfortunately my children…we just fell out. 
They didn’t get on with Vicky…so my two children don’t keep in contact.” It is 
very difficult to make sense of family histories as they are always more complex 
than they first seem. His adult children refused to see him in hospital when he 
had his stroke telling Vicky “they were too busy.” Chris said that he found the 
situation “very difficult actually.” 
At the third interview, while Vicky was out of the room he shared “I have a 
problem is that my children which are all very good but they don’t have anything 
to do with Vicky” and “what I’m worried about is her.” Vicky entered the room 
shortly afterwards and said “Chris’s great tragedy is that his children won’t have 
anything to do with him, was he telling you that? It is a huge, huge sadness.” 
Unresolved issues can cause a great deal of suffering and distress for people 
and it has been linked to the presence of behavioural changes in advanced 
disease.147­149 Problems within the family can act as secondary stressors to the 
caring and coping process, thereby increasing carer burden.170 Interestingly this 
family discord seen in second marriages in older couples where the step­mother 
is caring for a person with AD has been described by others.364 They describe 
the findings from nine ‘late­life remarried women’ as encompassing rejection 
from their partner’s adult children and a general disinterest in them wanting to 
be involved in care­giving. 364 The authors reflected that these women also 
inherited unresolved issues which were increasingly difficult to address and 
suggest such couples may need greater social input and support. 364 
6.3.3.5 Acceptance and Living Together 
Although developing coping strategies seemed to improve relationships and the 
ability to live together; this had to be underpinned by acceptance of the memory 
problem or dementia by both. 
George: “I accepted it there and then, I knew I had a problem before but I 
hadn’t said to myself ‘oi you have got a problem get it sorted.’” 
Mildred: “But he is coming back to it, he is coming back to the person that 
I used to know and I love that person. I didn’t love the person that took 
over from him if you get my drift. …and I couldn’t even nail it down to 
why he was like it to begin with until I realised that he did have a problem 
and he said he was waiting for this thing so hopefully fingers crossed we 
will go forward. We both understand it a bit now.” 
George & Mildred, Case 
1 
Acceptance of chronic illness is perhaps one of the most difficult things for 
individuals to do especially if it is associated with progression and few treatment 
options.132,135,136,142,143 The concept of acceptance of the diagnosis and then the 
consequences of living with its symptoms was commented on by Dr South 
below 
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“Often I think people get the diagnosis and they first realise that there is a 
significant problem and they get very worried that things are going to 
change very quickly…and then actually a year down the line things aren’t 
necessarily that different they settle in to a sort of acceptance, you know 
realisation that actually things usually happen fairly slowly and you have 
time to adjust.” Dr South 
This acceptance enabled couples to relate to each other with understanding and 
empathy as reflected by Janet. 
“When John couldn’t remember things I used to try desperately hard to 
get him to remember, sometimes I would get a bit irritated because I 
couldn’t get through to him. The minute he (Dr West) said what it was I 
saw things completely differently, I didn’t get so cross, don’t ask me why 
but I seemed to know there was a reason.” Janet, Case 6 
Point of 
Reflexivity 
As a researcher building increasing rapport with the 
participants over a period of time, it was clear that couples 
became more relaxed and perhaps shared increasingly more 
personal views. It seemed at times I was almost put in a role 
of mediator or therapist and I needed to work hard at 
objectivity and not becoming involved. After each interview I 
off­loaded all my feelings and concerns into the recording 
device so that I cold regain a sense of perspective as a 
researcher. As a human being caring about others, I found 
this more challenging. 
Living with a memory problem or dementia will severely test the strength of any 
relationship and this is reflected well by the excerpt from the second interview 
with Chris and Vicky. 
Chris: “But it’s all in the past we’ve got to live together and get on with 
ourselves, have we not Madame?” 
Vicky: “Absolutely.” 
Chris: “Cause there’s nobody else; it’s just the two of us. Cos Vicky is on 
her own.” 
Vicky: “I never had any children so.” 
Chris: “Well it’s a problem. But we get on with it, we’re friends aren’t 
we?” 
Both cackle with laughter

Vicky: “It’s a case you have to be or all else.” Both laugh
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Chris: “I have to say that don’t I? You know me. We have mini fights 
occasionally don’t we?” 
Vicky: “We do, we do have an argument. We break it down very quickly.” 
Vicky & Chris, Case 5 
In summary the effects of living with the changes associated with a memory 
problem or a dementia tested social and personal relationships to the full. 
Improved understanding of the problem including carers realising that things 
were not being done deliberately done helped acceptance and empathy toward 
the person they cared for. These are important concepts for those providing 
healthcare that more information is needed about the reasons why people 
exhibit the behaviours that they do and how these could best be managed. 
6.4 Interacting With Healthcare Professionals 
Figure 6.3: Diagrammatic Representation of Interacting with Healthcare 
Professionals 
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6.4.1 The Therapeutic Relationship 
This section describes the interaction between communication skills, different 
consultation styles and how lay participant expectations and beliefs of 
medication could affect dynamics within the therapeutic relationship. 
6.4.1.1 Consultation Etiquette 
The therapeutic relationship was a concept which prescribers and healthcare 
professionals (HCPs) participating in the study found important and protected in 
terms of confidentiality. As mentioned in 6.2.1.2 prescribers and HCPs 
expressed a wish to talk generically about prescribing medicines for dementia to 
maintain patent confidentiality. They also re­checked consent for the 
researcher’s attendance at the consultation before the consultation took place. 
Consultation Types 
A total of four consultations with three different prescribers were observed. In 
the main there were two different styles in terms of eliciting information from the 
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person with the memory problem and their carer. Drs West and East had both 
the person with the memory problem and respective spouse in the consultation 
together at the same time. Dr South consulted with Joan and her son­in­law first 
whilst Harry completed his neuropsychiatric testing with the psychologist. Then 
Harry joined everyone once he had finished his tests. 
In both of the above scenarios there are benefits and possible problems; when 
seeing people together there is the risk that the dominant person gets to do all 
the talking and the more reticent participant’s story remains untold. It takes a 
skilful practitioner to redirect questions and pick up on non­verbal clues and 
changes in body language. Obviously there is the risk that people may feel 
inhibited about speaking their truth in front of the other in case there is resultant 
discord and also in theory breach of confidentiality for the individual being seen. 
In all consultations there was no prescriber time spent only with the person with 
dementia. In Harry’s case he joined his wife and son­in­law and was asked his 
view on the decision to start memantine previously made by Dr South, Joan and 
their son­law. 
Communication 
The style of each prescriber was formal, with patients and carers being greeted 
in the waiting area using formal titles and in direct conversation using the word 
‘sir’ when addressing the individual. This possibly reflected the age group being 
seen but also rooted the consultation in formality and implicitly set boundaries. 
Drs West and East had similar consultation styles in that they started the 
consultation with general every day questions to put participants at ease before 
moving on to the main reason for the consultation which was to assess the 
response to the medicine for dementia using a series of neuropsychiatric tests. 
Dr West saw Robert and Judy Jones plus David and Annabel White on the 
same day. Dr West varied his assessments depending on the person he saw. 
With David; he was interested in evaluating how the combination of memantine 
and rivastigmine was holding David’s cognitive functioning. Because one of 
David’s problem areas was speech and language, Dr South started off a 
conversation with David about what he had been doing recently in the garden 
and around the home. As an observer this seemed like quite a random piece of 
conversation. But Dr South explained afterwards that actually he was testing 
memory; his ability to interpret what was being said; think and formulate an 
answer and then interact within and maintain a conversation. When viewed in 
this manner the interactive dialogue made complete sense and also meant that 
the person was being assessed to do a reasonably complex task without ever 
feeling they were. This is important because in comparison Chris and Robert 
both reacted to more formal testing with increasing anxiety and distress both of 
which exacerbate memory dysfunction. The tests had to be stopped in Chris’s 
case to avoid him becoming even more distressed. 
Dr West commented that in Robert’s case he was using more formal and in­
depth tests because Robert had been prescribed rivastigmine off­license for 
vascular dementia. In order for Dr West to justify continued expenditure he 
needed to demonstrate continuing improvement. Although it was clear Robert 
had ‘holes’ in his memory he scored better than previously and it transpired that 
Robert had only been taking 3mg once daily (sub­therapeutic), due to an 
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incorrectly written prescription. This problem in the titration of medication doses 
is discussed further in 6.5.3.5. 
Communication Processes 
All prescribers spoke more clearly and slowly, using simple words and phrases 
when talking to the person with the dementia. This makes imminent sense in 
allowing time for mental processing to occur as mentioned in 6.3.2.1. However 
Bayles warned that if the rate of speech was too slow it became more difficult to 
understand as PWD had to keep more information in their compromised working 
memory for longer and therefore may forget earlier information.359 Interestingly 
Vicky had a problem with this slowed speech pattern used by Dr West and 
thought this slowness was a reflection of Dr West’s inability to converse with 
them. (Chris had originally been assessed and diagnosed by Dr West but in the 
observed consultation had been seen by Dr East). 
“He was very slow but he tried to explain things you could tell he would 
be swimming around in the dark, he didn’t know what on earth to say to 
these strange people on the other side of the room.” 
Vicky, Case 5 
Janet thought Dr West was “so nice, so easy to talk to” and Chris said that “I 
could talk to him and he would understand (what I meant)” so it is interesting 
how perspectives differ. It was also interesting observing the participants within 
the consultation. In the observed consultation with Vicky, Chris and Dr East, 
Vicky’s body language was very tense and she became tenser as the 
consultation went on. This was in response to Dr East exploring how they were 
coping on a day­to­day basis and trying to ascertain if they needed extra 
support at home. Vicky became quite agitated at the thought of a ‘stranger’ 
coming into the house. Dr East had to repeat several times they would leave 
this for now but would revisit this in the future, before she visibly relaxed. She 
also became very annoyed (not verbally but demonstrated amply by her body 
language) when Dr East suggested to Chris that it didn’t matter if he couldn’t 
drive as he had “someone (nodding to Vicky) to take you around wherever you 
want.” Being a taxi driver appeared not to be a role Vicky had any aspirations 
for. 
6.4.1.2 Expectations within the Consultation 
At the time of the first interview all but George had met their prospective 
prescriber and received a diagnosis. For George a lot hinged on this future 
appointment; as since his consultation with James both he and Mildred had 
realised there may be something wrong which could possibly be treated. This 
realisation in itself had improved their relationship, however George remained 
anxious. Mildred however was hopeful about the results of the consultation with 
Dr North the following week. 
George: “Just wait and see what Doctor North (says), hopefully 
something positive will come out but I just, my fears I just don’t want to 
get any worse. I take pride in myself in a lot of things but now (shrugs).” 
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Mildred: “If George can come out being the person that I married and not 
the person he turned into our quality of life will be perfect but if he goes 
back to being that person I don’t think we’d have a life.” 
George & Mildred, Case 1 
When prescribers and HCPs spoke about their consultations in general, it was 
clear they also held perceptions about the expectations of their patients. The 
consultation was perceived as a gateway to a medication people felt would help 
them in their daily struggle. The perceived expectations of the medication were 
eloquently described by Dr West below. 
“I do think the hardest bit is balancing its (the medication) expectations 
and not giving too much hope, where some people will expect the drugs 
to perform miracles. Interestingly older old people are more happy with 
anything that helps; younger old people are expecting more of the 
magical hit. In my expectations, older old are just happy you know their 
expectations are much lower; younger old are more assertive.” 
Dr West 
This perception of differing expectations dependent on age is interesting and 
perhaps reflects findings in 1.4.2.2 where younger old participants seemed to 
struggle more with coping as a carer and the older old participants were more 
stoical and accepting. It is unclear whether these findings reflect societal 
changes and expectations of health delivery and well­being. 
Mary felt there was also an expectation or hope on the carer’s behalf that the 
medicines would bring their old familiar way of life back as she explained below: 
“I would think that they would want to be released from a carer role that 
they would really rather be a spouse a daughter a son to the person that 
gives the drugs that they would rather have a different relationship rather 
than a carer.” Mary, CPN 
6.4.1.3 Beliefs and Expectation of Medication 
John, George and Mildred expressed reservations about taking medication. 
George had refused to take any form of medication as a young man and had 
only started to take them to control angina and related heart conditions. Mildred 
had similar views and felt that medication should be a last option to keep a 
person alive. 
George: “It is like being experimented on, like these tablets every time we 
get tablets now we sit and read..(Interrupted by Mildred)” 
Mildred: “Read what it says because I have had two really bad 
experiences from tablets. My attitude towards medicine is it is fine to give 
a person the medicine if it is their life line, if they have got to keep that 
medicine to keep them alive then fine they have got to take it but if they 
can get by without having to have that thing then it is not important for 
them to have it.” George & Mildred Case 1 
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In terms of medicines for dementia, John initially refused medication (and 
possibly refuted the diagnosis) and had all his mercury fillings replaced in an 
attempt to lessen his worsening memory. John had only agreed to take 
medication if it was going to help. 
“I think it was just as plain as that for me on any subject, if it is doing me 
good I am all for it and that’s it really. I can’t elaborate on that because I 
mean it and if it weren’t doing me good I would be saying to him quickly 
‘here this stuff isn’t any good at all to me I am getting bloody worse!’” 
John, Case 6 
At the time of the first interview, Robert, Chris and John had fairly recently 
started their AChEI so it was early days in terms of noticing a response to the 
medication. Robert had become increasingly quiet and socially withdrawn and 
this had negatively affected his relationship with Judy who desperately missed 
their conversations and social activities. Consequently her expectations of the 
medication were quite different to Robert’s who was more concerned about his 
perceived lack of “power.” 
“Well for him to join in more, with the family things rather than sitting 
there quietly and watching things….I wish he had more interest in things 
and do more…He doesn’t go out and join in to anything, he hasn’t got 
any conversation about him so his whole world is sat watching television 
so he doesn’t talk about anything.” Judy, Case 3 
However the prescribers and HCPs also had expectations of how medicines 
could help their patients as a result of their clinical experience. James 
(psychologist) said his “impression (was) that they seem to have mood 
improvement.” Dr South thought that people mainly commented on “the 
improvement that they see is a sort of increased motivation a sort of 
improvement in the apathy.” Whereas Mary (CPN) said that “Some people I’ve 
seen live entirely on their own and are enabled to live on their own because 
they’ve taken cognitive enhancers.” 
6.4.2 Therapeutic Decision­making 
This section will briefly describe the processes involved in therapeutic decision­
making related to medicines for dementia. This includes the processes of a 
diagnosis and how prescribing decisions were made. 
6.4.2.1Diagnostic Processes 
The National Dementia Strategy highlights the importance of early detection and 
diagnosis of a dementia so that appropriate treatment options with supportive 
educational interventions can be offered.51 
Across the case studies there was a variation in time to diagnosis; with George 
receiving a diagnosis of mild cognitive impairment (MCI) within months of his 
referral and investigation; but 2 years after the bypass which was suspected of 
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causing this. John had been followed up for 5 years by his memory clinic after 
his initial diagnosis of MCI before a diagnosis of Alzheimer’s disease was made 
and at this point he refused medication and tried other avenues. 
Robert, David and Chris were investigated in response to memory deficits 
noticed after a cerebral haemorrhage (Chris) and cerebral ischaemia (Robert 
and David). Harry did have atrial fibrillation but his diagnosis of Alzheimer’s 
disease was not thought to be linked to this. However it is interesting that in all 
case studies there is damage to the cerebral vasculature system. It can only be 
hoped that the Department of Health’s drive to reduce cardiovascular disease 
by preventative methods and public health initiatives will reduce incidence in the 
future.103­106 
As previously mentioned in 2.1.2.4 the diagnostic process of AD is 
fundamentally one of exclusion and the duration of the process can seem 
infuriatingly slow to those involved. This is reflected by Vicky who described a 
series of consultations over an 18month period before a diagnosis was made 
and a possible treatment offered. 
“Four times if not five I can’t quite remember and the last time brought us 
to the beginning of August when he finally gave a prescription. Inside 
myself without saying anything; ‘why this hesitation for heaven’s sake? 
Get on with it you know the sooner you’ve got the medication the better. 
Why are you hesitating? Why all this?’” Vicky, Case 5 
Neuropsychiatric testing can be quite an involved procedure sometimes lasting 
for an hour or longer. Individuals can find the tests quite threatening and can 
become quite nervous. For some, the actual questions involved seemed a little 
ridiculous and non­sensical and made people feel dismissive of the results. One 
of the Folstein questions involves asking the person to draw two intersecting 
pentagons (A1­2), the usefulness of which was questioned by John below. 
Janet: “When he first went up to Dr West and he had to do some 
drawings and things well he…thought it was absolutely ridiculous what 
they asked him to do and he more or less told them as well, ‘what the hell 
have I got to do that for?’” 
John: “Well yes I think that would be me because some of these things, 
to be a free hand I am no good drawing; what’s good drawing from bad 
ones? And I never once, I never had the patience to be able to do good 
free hand drawings I would always get a wiggly line come somewhere.” 
Janet & John, Case 6 
This is an interesting point as the ability to draw the face of a clock has been 
shown to have increased sensitivity and specificity at demonstrating higher 
executive dysfunction in people with normal MMSE scores than the replication 
of intersecting pentagons.365 
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Chris had difficulty with questions which were specifically oriented to memory 
and comprehension such as remembering shopping lists or series of numbers, 
or even what he had to do next, leaving him feeling flustered and unsure. 
“I have to think about it and eventually I get there but when they were 
asking me once or twice I just couldn’t understand what they were asking 
me. That’s where I felt I wasn’t (sigh) I wasn’t in the system and 
eventually after not saying anything I realised that I should have been 
doing something.” Chris, Case 5 
As previously mentioned, the MMSE is recommended to classify severity of AD 
and response to medication.31 Dr North thought it was probably better as a 
screening tool to be used in conjunction with other assessment scales. 
“It’s a good screening instrument but…although my study guidance does 
say MMSE assesses all the skills. It’s alright. I just use it, (as) a 
reasonable reflection. I think in a way needs to be used with other scales 
rather than just use it on its own in isolation.” 
Dr North 
The limitations of the MMSE in detecting dementia in people of previously high 
intellect is well known.124,126 This was illustrated by David who scored between 
27 and 30 (indicating normal cognitive function) throughout the period of the 
study, yet it was plain to see that he was not functioning well (see 6.4.3.1 Figure 
6.5). Dr West suggested (6.4.2.3) that people with a previously high level of 
intelligence seemed to have a more aggressive illness; but perhaps this is due 
to the insensitivity of current diagnostic tools to identify the presence of 
dementia at an earlier stage. 
“I mean obviously MMSE is not the tool to do on somebody with high 
intellectual functioning. They could still get thirty and still have really 
gross functioning…It does let them down and goes against them to a 
point.” Dr North 
The three AChEIs (see 2.1.4.1) are licensed for the symptomatic treatment of 
mild to moderate AD but since 2006 are only recommended for treatment of 
moderate disease (i.e. when the MMSE score is between 10 and 20).31 For 
prescribers this meant there was no licensed treatment for people in the milder 
stages of dementia or those with mild cognitive impairment. 
“With people who we think have MCI we have to say to them ‘I don’t feel 
a diagnosis of Alzheimer’s is appropriate at the moment, come back in 6 
months.’ Really what you’re saying is we’ll have to see if it gets worse 
then maybe we’ll give that diagnosis and then give the treatment.” 
Dr South 
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6.4.2.2 Prescribing Decisions 
Once a diagnosis and a decision to prescribe was made there needed to be a 
decision about which of the agent was most suitable. Each of the prescribers 
had their own selection process encompassing a wide number of variables. 
Decisions seemed dependent on the need for once daily dosing, adverse effects 
and concomitant illness. 
“I suppose I often start donepezil, because in our experience we found it 
easier in terms of plotting the dosing partly that it’s only two different dose 
levels. And that I think we feel that people tend not to have side­effects 
but …whether that would actually be the case (shrug) but I guess 
because we’ve used donepezil probably more we kind of feel we know it 
better.” Dr South 
As mentioned key considerations such as concomitant illness or gastrointestinal 
sensitivities may preclude a certain agent. For example these agents can 
exacerbate respiratory problems such as chronic obstructive airways disease or 
asthma, but if it was thought appropriate a trial with a short acting agent such as 
rivastigmine may be an option. 
“There have been instances where people have had quite bad asthma or 
chronic obstructive airways disease and we’ve maybe then started with 
rivastigmine because it has a shorter half life so that if people do get side 
effects of exacerbating their airway problems that it obviously washed out 
quicker.” Dr South 
“Somebody where you predict that because they are quite frail they may 
have problems with their balance, potential side effects of drugs then we 
might lean to donepezil.” Dr West 
Drs North, South and East felt that AChEIs were equal in terms of efficacy with 
Dr North proposing that “all three are fairly similar but just with minor variations.” 
However Dr West had been a researcher involved in clinical trials of AChEIs 
prior to becoming a Consultant and his views and experience were quite 
different. He maintained there was a difference in toxicity and duration of effect 
between the three agents. 
“I think there is differences in tolerance you know rivastigmine most toxic 
galantamine middle. I do think there is a difference in the length. I mean 
galantamine works for a longer duration particularly (compared) with 
donepezil. It’s hard to judge but it’s my perception over the years, 
comparing the three together there is a difference there as well.” 
Dr West 
Discussions with individuals and their carers prior to starting a treatment for 
dementia are very important as they need to be warned not only of the possible 
side effects and how to deal with these but also that these medicines do not 
help everyone. 
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“I do talk about there is a one in three chance (of responding well) and I 
do also say that if they do not respond to the first one there is still fifty­
fifty to respond to the second and make it clear about that you don’t just 
have one shot.” Dr West 
The different perceptions of the prescribers about the efficacy of AChEIs were 
interesting with Dr South stating that “the drugs aren’t wonder drugs by any 
means” in contrast with Dr East’s comments below. 
“I think overall, in the initial stages at least it does have an effect on the 
person’s ability to manage his own work or the carer’s ability to cope. … I 
think there is a lot of things which these medications help rather than just 
orientation in time place and person.” Dr East 
It has been suggested that the evidence to date “is overwhelmingly in favour of 
the benefits of AChEIs” with the authors discussing the uncontrolled evidence 
available which support the earlier use of these agents in AD.114 The authors 
suggest the evidence base “would favour an early diagnosis and prompt 
treatment to maximise the cognitive and functional abilities” of people with AD 
for as long as is possible.114 
Participant and carers perceived that more information could have been given at 
the time of prescribing about possible side effects or what to expect. Joan stated 
“I just read the leaflet right through and that’s all more or less” and Janet could 
not remember receiving any particular information either. In contrast Robert and 
Judy could remember being told about possible side effects, but then there was 
some concern about whether they may not be working effectively if there wasn’t 
a side effect. 
Robert: “I’m alright on them. The doctor said ‘you might feel nausea or a 
little sick.’ I don’t, whether that’s a good thing I don’t know.” 
Judy: “I was worried about side effects, but touch wood you haven’t seen 
any side effects.” 
Robert & Judy, Case 3 
Dr West explained that he “would always give them the common side effects 
and they always have our phone number to phone me if they have any 
concerns” and this was corroborated by Vicky who said “he talked to us for a 
long time.” 
However, Annabel probably summed it up best below when she put the 
perceived lack of information into context of the gratitude of receiving the 
medication. 
“I wouldn’t have said there was any in­depth discussion about each one 
(medication for dementia), it’s just we were so grateful at the time I think 
to get something that was going to possibly do some good.” 
Annabel, Case 4 
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This is an interesting comment as evidence suggests that patients’ prefer to be 
given a positive explanation about their treatment which improves their 
satisfaction rating.366 Provision of negative information was associated with 
decreased compliance to treatment and decreased satisfaction with the 
information. 366 This is the perception of what Dr West’s thought people actually 
remembered from a consultation as he related below: 
“The problem is the difference of what comes out of my mouth and what 
the patient and carer hear and can take a day later. The reality you are 
only going to take three points from a consultation and so you may well 
take the three best ones, so I do my best but sometimes it’s hard to judge 
the difference between mine and the judgement of patients and carers.” 
Dr West 
6.4.2.3 Predicting Response 
Prescribers were asked if they were able to predict which individuals would 
respond to treatment because anecdotal evidence suggests that one­third of 
those treated respond very well and one­third respond somewhat. In terms of 
medicine budgets and the risks of exposing people to medication unnecessarily 
it may be useful to know which people not to start on treatment. 
“That is a difficult one, I would say no to that because it is very, very 
difficult to pinpoint a great response from individual patients until you start 
them on a monitor…with some people you get a brilliant response and 
others it doesn’t change it doesn’t make a difference so it is difficult to 
say.” Dr North 
Although the general consensus was that a clinician could not predict 
responders, Dr North indicated he thought age affected depth of response and 
Dr East proposed that people who were highly anxious fared worse. Dr West’s 
experience indicated that those people with higher pre­morbid intelligence 
responded less well. 
“I think …the slightly younger patients, not totally young not under 65’s 
but I would say in their early 70’s they seem to respond slightly better at 
least initially.” Dr North 
“I don’t know if it is just observation by me or it is just a coincidence but 
people who are anxious as a sort of personality...it seems that it might 
not be that effective.” Dr East 
“I think we realise that highly educated people diagnosed with dementia 
have a more aggressive course, so that group I’d still treat with a bit less 
optimism. But no I still find it hard to know whether the person will 
respond well or not.” Dr West: 
In summary there was a great deal dependent on these consultations for 
participants because the outcome dictated whether they would gain access to a 
medication with perceived potential of improving daily functioning. Prescribers 
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and HCPs held their own perspectives on treatment outcome and how these 
were measured but were in favour of treating the disease at an earlier stage. 
6.4.3 Assessment, follow­up & support 
This section describes how the response to a medicine for dementia was tested 
and assessed and the resultant follow­up options of care that were available. 
6.4.3.1 Testing for response 
Once a medicine for dementia was prescribed there began a process of routine 
follow­up to measure any clinical response and assess for the presence of side 
effects. The first follow­up appointment was generally led by the prescriber and 
Dr West thought this was probably the most important consultation. 
“The follow up after 3 to 4 months you would normally be able to gauge if 
the person’s better, stable or still deteriorating and that’s often most, in 
just pure medical side that’s the most important consultation of all.” 
Dr West 
A very interesting concept raised was that of a possible placebo response to 
treatment at the first follow­up appointment. This was explained by Dr South as 
perhaps due to the high expectations of the individual and their carer; Dr West 
thought it may be due to the fact that finally something was being done and also 
the differing pharmacokinetic profiles of the medicines prescribed. If the 
rivastigmine and galantamine doses were still being titrated, the person may not 
have reached an effective dose, so a clinical response may not be expected. 
Another perspective is that the variability of response is well known as are the 
limitations of the assessment tools; perhaps these need accounting for as well 
within the term ‘placebo response?’ 
“It is difficult because that becomes a very subjective thing and obviously 
that again depends a lot on the mind­set of the patient and their relative 
or friend because you know, if they are hoping against hope that this is 
going to do something then it’s positive thinking and they come back and 
say ‘oh he’s much better’ and yet all testing’s worse you have to think 
‘well is that just wishful thinking?’ ..Because you can’t deny what people 
are telling you. You can’t say well if they feel better and the relatives they 
say ‘oh yes things have been much easier and other people have 
commented’ you can’t say ‘oh well no they haven’t.’ So it is quite hard 
and I often feel that are we just, is this just placebo? Is this just a 
response that ‘yes that having the tablets we must be better’ but you 
know that’s hard to say.” Dr South 
“I think there’s a danger in that first follow up consultation, there may well 
be a degree of placebo effect within that something’s getting cracking in 
the pot and is therapeutic and the original trials show this. The placebo 
group improved as well at 6 months, that’s when the placebo and 
treatment group really separated…Sometimes with older patients their 
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conditions and expectations (are less) and actually those are the people 
that I think have less of a placebo effect.” Dr West 
These are interesting comments and perhaps some credence can be given to 
each as people who have been worrying over an undiagnosed condition may 
feel relief and some sense of hope when a diagnosis has been made and a 
treatment offered. As Dr West implied by ‘something cooking in the pot’ people 
feel that people are being taken seriously, something is indeed wrong and more 
importantly something is being done about it. It is interesting that in many 
studies evaluating the efficacy of medicines in psychiatry such as 
antidepressants or AChEIs, there is a high placebo response. Many different 
explanations have been proposed for this; better supportive care from trial 
arrangements; regular follow­up with concerned HCPs and the positive 
expectations of a new treatment. Nunn proposes that if the actual interventions 
were described in greater detail there would be increased transparency into 
what actually happened and what was responsible for causing the so­called 
‘placebo’ effect.367 Perhaps a better term to use if improvements are temporary 
(that is they are not apparent on next measurement) is the Hawthorne effect. 368 
Perhaps also the limitations of current measurement tools fail to capture the 
personal and social improvements that PWD and their carers’ find so important. 
George’s comments below reflect his feelings since he realised there was a 
chance that Dr North may be able to help him. 
“I think for me since I actually came up to the hospital and the tests and 
all that I think that is when something in the mind suddenly said ‘maybe 
there is something going to get done now’ and I wasn’t just waiting in 
limbo. ” George, Case 1 
This sense of being helped by an expert seems a powerful driver for people to 
seek help and information perhaps leading to unrealistic expectations of the 
expert and any provided treatment. However there may also be some incorrect 
use of the word ‘placebo’ as implied by the comment below from Dr West. What 
he is really saying is that rivastigmine and galantamine have not reached a 
therapeutic dose in the majority of cases by the first follow­up consultation 
because of titration difficulties. This is not a ‘placebo’ dose; it is an ineffective 
dose. 
“The other time when we donepezil first line is when we need a quicker 
speed of onset because the 5 milligrams the initial dose of donepezil is a 
working dose where for the other two the first month is a placebo dose.” 
Dr West 
6.4.3.2 Assessing the response 
There were many different tests used for assessing response to a medicine for 
dementia and/or to stage severity. The Folstein MMSE was only part of this 
assessment process as the prescribers and Mary all felt that it did not give a 
complete picture of the clinical response. These findings are similar to those 
found in 4.4.3.2 and highlighted in the literature review. 
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“Daily­activity scales are not very good. They don’t pick up changes very 
well and on the first follow­up visit, when they’ve been on them four 
months or so, we don’t just do the mini­mental we do camcord which has 
more in it than the mini­mental. The mini­mental doesn’t capture things 
and often you see that some areas have improved and others have 
dropped and again people vary from day to day so I think one has to take 
a little bit of license with it and yes, yeah sure testing doesn’t necessarily 
pick up the slight thing that maybe has improved, or a bit of initiative.” 
Dr South 
“I don’t think MMSE is the perfect set of tests at times we do have 
patients who have scored more than 20 but you have the gut feeling that 
their cognitive ability is much worse than that.” Dr East 
In this study data from the participants shared care record (SCR) was accessed 
to establish findings from objective measures of response. This was to explore 
further whether the subjective findings from interviews and observation were 
supported by objective scores. Two figures follow Figure 6.4 and 6.5 which 
depict the change of the MMSE score over time, with comments from interviews 
and the prescriber for Harry Smith and David White respectively. 
Figure 6.4: Harry’s MMSE Timeline 
Interview 1: Joan: “he 
doesn’t talk an awful lot, SCR: Increasing memory 
he talks to me but he problems, lack of initiative SCR: Memory not 
doesn’t hold the	 & conversation. Start improved, diarrhoea a 
conversation he ever used	 memantine. problem, donepezil 
to hold.” stopped 
SCR: Probable

AD; donepezil SCR: Confused & Observed Consultation:

Date: 12.04.06 26.07.06 04.11.06 28.11.06 20.03.07 08.05.07 
MMSE: 17 20 14 20 18.5 12 
started	 disorientated, start Harry: “no sense in being 
galantamine miserable” 
(stopped after 2 doses) 
Harry’s changing MMSE scores indicated the fluctuating nature and increasing 
severity of his disease and were probably an accurate reflection of his 
capabilities at home. 
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Figure 6.5: David’s MMSE Timeline

Interview 1: David: “I know there 
are some things I can’t do I just Observed Consultation: 
SCR: 
accept them and I don’t get so Annabel: ““socialising very 
Rivastigmine 
frustrated about it now cos I know I much more at ease.” 
increased to 6mg 
can’t do anything about it.” 
twice daily 
Interview 2. David: “My short­
term memory is very bad, 
long­term is quite good.” 
Date: 10.04.03 Feb 05 16.02.05 19.12.06 19.02.07 04.09.07 
MMSE: 29 27 30 27 29 
SCR: Probable AD; 
rivastigmine started SCR: Confused, 
disorientated, speech & 
dressing problems. Start 
memantine 
For David; his behavioural changes such as poor speech, problems with 
washing and dressing occurred with a MMSE score of 27; the NICE definition of 
which is ‘mild cognitive impairment.’27 In fact for the whole of this study David’s 
scores were 27 or above. This finding supported the limitations of the MMSE 
used in people with higher intellect and potentially it can discriminate access to 
medicines and services for dementia until the disease, for that individual, is at a 
very advanced level. 
Further information on other individual assessment scores in relation to their 
daily abilities can be found in the Case Study Report in A5­17. 
As an alternative approach, Mary often agreed target symptoms that individuals 
would like to see respond to the medication rather than use a standardised tool. 
These have also been referred to as goal assessments248 and could also form 
the basis of patient reported outcomes for dementia.54,369,370 
“I guess it’s classed as subjective really but we check with the carer or 
the individual…and how they’re progressing; they’re either the same, 
they’re improved or obviously they deteriorate.” Mary CPN 
Lay experiences of completing these tests differed with David being able to 
remember how he had improved in some of the questions over time and Judy 
being able to tell that even by the way her husband answered the question he 
was never going to get it right. 
David: “When he came to do those tests which he does, there were two

of them I got 30 out of 30 and another one I got 28 out of 30.” (MMSE)*

Annabel; “And he said you’re doing very well.”

David: “Yes and there was a distinct sign of improvement.”

David & Annabel, Case 4
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*These scores were for the two methods of completing the MMSE; one where the question is to 
subtract serial seven’s from a 100 and the other version is to spell world backwards. 
Judy: “It was quite interesting those test things that Dr West did like; ‘how 
many things can you name in a supermarket in a minute’ and you just got 
stuck after half a dozen things and I could tell the way his (Robert’s) mind 
was working by what he said.” 
Robert: “I was going round the shelf.” 
Judy: “No no you weren’t going around the shelves. The things that you 
were saying were the things that have been on a shopping list recently 
(at home).” Judy & Robert, Case 3 
Another problem with objective assessment scores such as the MMSE being 
taken on a particular day was that it did not account for fluctuations in people’s 
functioning. Drs North and West commented that many PWD had ‘bad’ days 
and this meant that readings from the subjective tests probably did not reflect a 
true account. This resulted in greater emphasis being placed on what the 
individual’s and their carers thought were important in terms of change or 
response. 
“…the same with memory it might have been a hard day when they are 
doing the mini­mental or the ADAS­cog and it probably is not the same 
results testing at that point in time and I tend to go by what the carers and 
the patients feel important as well.” Dr North 
When pressed as to his actions if a person scored poorly on the MMSE, (and 
according to the guidance it should be withdrawn) but the individual and carer 
both reported improvements, Dr North replied: 
“I would be inclined to continue the medication because obviously the 
functionality is maintained and the quality of life is maintained and I 
wouldn’t go by an objective testing at that point in time, the MMSE, I 
wouldn’t go by that mentality. It’s just more an augmentation tool.” 
Dr North 
As mentioned in 2.3.4.1 there seems no consensus on the prediction of which 
individuals may respond more overtly to a medicine for dementia, or agreement 
on how to measure response. However it is not just the overt response of the 
PWD but also the impact on carer quality of life that allows PWD to be cared at 
home for longer that needs to be accounted for.49,51 It seems that this very 
complex area of response may need further research and ultimately redefinition. 
6.4.3.3 Follow­up and Support 
Once it had been decided that there had indeed been a clinical response and 
the medication was to be continued then follow­up was arranged. This differed 
in each location and was also dependent on the complexity of the case. 
Generally people were followed up annually by the prescriber (unless there was 
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a problem or a complex issue and in­between at 6­monthly intervals by the clinic 
nurse or psychologist. 
“Then it would all depend on the service capacity; if the person is 
stabilised on treatment it may well be taken over by one of the memory 
monitoring nurses or junior doctors. If they haven’t got capacity, I’d still 
take them and if anybody’s on a quite a complex combination of 
medication and diagnoses I would then carry on with treating them.” 
Dr West 
The participants found this system worked well and in­between times there were 
calls to or from the memory clinic about repeat prescriptions 
John: “What we have been able to achieve now is to keep it rolling and to 
go and see Doctor West however often, is it twice a year? I don’t know.” 
Janet: “Probably more than that.” 
John: “But to be able to go there and sit and have a discussion with him 
and then go off, it’s good.” John & Janet, Case 6 
In terms of disease severity, perhaps Harry was the most advanced, followed by 
David, then Chris, Robert and then George. Over the time of the study Harry 
had progressed from needing healthcare assistants to help him get up and 
dressed in the morning to needing assistance twice daily. It must be said that at 
the start Harry’s main problem was his physical mobility and because of Joan’s 
rheumatoid problems she was unable to physically help him with some tasks. As 
the disease progressed Harry also became increasingly lethargic and 
recalcitrant. (Further details can be found in the Case Study Report A5­17). 
Joan: “We have a carer comes every morning and in the evenings, help 
get him up or to be put into bed again….they are very pleasant all the 
carers are lovely to him really nice. I’d be lost without them. I can’t cope 
every day, push around pull around you know.” Joan, Case 2 
Mary visited David and Annabel every three months to complete assessments, 
but apart from that they had no other care support. John and Chris had been 
offered CPN support but had refused. 
“Somebody offered to come but it was a strange voice that I’d never 
heard before and didn’t know anything about it and I thought rather than I 
let strange people in the house I want to know something about them and 
we didn’t see them that time. …So I suppose at some time or another it 
would be nice to talk to him now that I know who he is” 
Vicky, Case 5 
This is quite interesting because although Vicky felt she didn’t want a stranger 
coming to their home related to the hospital memory clinic; she initiated a 
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cleaning person to ease the pressure on her household tasks, explaining “we 
have got a cleaning lady now to my huge relief she’s coming tomorrow 
afternoon.” In contrast to phase one findings (4.2.2.3) it seemed the participants 
were not as severe and/or their carers had yet to be weighed down by the 
chronicity of caring as there was only positive comment about support services. 
This was from Joan who had perhaps had more exposure than the other 
spouses participating in the study. 
“I don’t think there is anything anybody else can really do for us. 
Everyone has been very very good, we haven’t any complaints about 
anybody at all or the NHS. I wouldn’t run them down for the world. “ 
Joan, Case 2 
In summary the healthcare professionals involved in the care of the participants 
were caring and empathic towards their daily predicament and where possible 
helped as much as they could in terms of access to medicines and information. 
6.5 Medicines For Dementia 
Figure 6.6: Diagrammatic Representation of Medicines for Dementia 
PRESCRIBING HINDRANCES 
MEDICINES FOR 
DEMENTIA 
RESPONDING 
MEDICATION ISSUES 
6.5.1 Prescribing Hindrances 
The study participants were interviewed between October 2006 and the end of 
January 2008, and the NICE revised guidance was published in November 
2006.31 There was frequent coverage by the media both on local and national 
television as well as local radio and newspapers. So for some participants there 
was the worry that the revised guidance would mean they came off the 
medicines they were already on or that other people at the same stage of illness 
would be denied access. 
6.5.1.1Access to Acetylcholinesterase Inhibitors 
Janet had eventually begged Dr West for the chance for John to try a 
medication for dementia and she related that “I know it’s not easy for him (Dr 
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West) to get” but they felt lucky they had a chance to try them because “I think 
anybody with that problem, they do want them but they can’t get them. “ 
Judy agreed with the above sentiment saying “I think it’s a shame when they 
start doing this not letting people have tablets that are available.” To which 
Robert replied that he felt “I’ve been very lucky to get on that road” and Judy 
replying “Dr West was good wasn’t he because it was just before they got taken 
off.” Anecdotally many clinics screened more people prior to the final NICE 
decision so they could start people who satisfied the old criteria of having mild 
disease. 
The NICE decision to withdraw recommendations for the use of the AChEIs in 
the mild stages of Alzheimer’s disease really wound David up in particular who 
was very animated and cross as he spoke about how he felt about this decision. 
David: “What I find is so bad that and bureaucracy gone mad really. I 
have two hearing aids and they supply all the batteries; now they’re 
expensive batteries and I only have to send off a pack of used ones and 
they’ll send me back a brand new pack. Why don’t they charge for it? 
They say they’ve got no money and yet they’re giving them away! 
…Ridiculous! They’re not organised with things like that and somebody 
said “it would cost too much to collect.” 
Annabel: “Yes, I think it boils down to the admin doesn’t it?” 
David: “I think they want to get it sorted out, they say they can’t afford 
these tablets and yet they give batteries out like…” 
David & Annabel, Case 4 
But David still felt aggrieved about his perceived injustice of it all and went on to 
mention “the bonuses some of these directors are getting at the end of each 
year are phenomenal” implying this was not right if there was insufficient money 
in the health service. His perception was that if public sector monies were re­
organised there could be money available for treatment. 
“We were reading an article the other day, weren’t we? Somebody in the 
paper and it quoted the price it costs to keep a prisoner in jail for a week 
and how much it costs for these tablets and there’s no comparison.” 
David, Case 4 
Annabel thought David’s discourse was marvellous and indicative of how well 
he was doing on both the rivastigmine and memantine in combination. 
“This is what is so good, David wouldn’t have been able to remember or 
think or converse on a particular subject like that. I find it amazing when 
he comes out with something like that.” Annabel, Case 4 
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It wasn’t just the participants with dementia and their spouses who felt 
aggrieved, the prescribers felt at times hampered in their clinical decision­
making. 
“I think with the recent NICE guidelines, I feel that it should be provided 
at an earlier stage rather than the moderate at least to an extent where 
we could help some of the proportion of these people to maintain this for 
a longer period of time rather than giving it when their MMSE is 20.” 
Dr East 
“The treatments are licensed for Alzheimer’s; you think once you’ve 
made the diagnosis you should be able to use them.” 
Dr South 
The concept of rationing healthcare is not a new one and NICE was 
implemented to help prevent postcode lottery of access to medication and 
healthcare in England. Whether this has been a success or not is yet to be 
proven. The NDS clearly highlights a continuing postcode lottery for access to 
medicines for dementia.51 It has been proposed that NICE “can make or break a 
drug – and, consequently, make or break the lives of many people who may 
benefit from the drug.”55 The authors continue that NICE does not sufficiently 
take into account patients opinions or costs outside of the NHS and implications 
for the wider population. 55 
6.5.1.2 Prescribing and Co­prescribing of Memantine 
The prescribers had clinical experience in the use of memantine either as a 
single agent or more commonly in combination with an AChEI (as in David’s 
case). 
“Most clinicians would say it seems to be useful for, in earlier people is 
expressive language … the memantine coincides with them being able to 
speak clearer and that was chosen partly for that reason (in David’s 
case).” Dr West 
David was started on memantine when functionally he started deteriorating, 
even though his MMSE scores reflected a seemingly high level of cognitive 
ability at 27. Annabel described the combination as “brilliant really marvellous” 
and that he now seemed to be “more or less sort of holding his own.” She went 
on to say “the change is remarkable.” (See section 6.4.3.1 Figure 6.5). 
Although the NICE guidelines are only guidelines PCT Prescribing Advisors 
work hard to ensure that implementation and associated audit takes place. 
However, guidelines cannot be applied to every individual; there is always 
someone who does not fit the criteria because of individual idiosyncrasies; 
concomitant illness, allergy or clinical need. As mentioned earlier, clinician’s had 
been guided to make treatment decisions based on what was in their patient’s 
best interest even if this was outside NICE guidance.230 However prescribers in 
this study felt that their ability to make clinical decisions on the needs of the 
patient may be compromised by the new decision as narrated below. 
179 
“Just that it’s going to be hard if we do have to follow the NICE guidelines 
but we’ll see what happens. Because you know it is nice that there is 
something to offer and basically you know if we’re not allowed to use 
memantine then there is nothing to offer the more severe people and to 
be only able to treat people once they reach a certain level of dysfunction 
seems very wrong as a clinician.” Dr South 
In terms of noted response rate to memantine the clinicians varied in their 
assessment with Dr East claiming “probably about 80% of the people have 
benefited at least to an extent.” Whereas Dr North thought it was “about 60%” 
as an add on therapy and “about 30­40% pushed” as a single agent for 
moderate cognitive impairment. His narrative demonstrates the heterogeneity of 
observed response to memantine. 
“Doesn’t happen with everybody, it is really hard to give a statistic but 
some people respond brilliantly and you can’t rate the response and 
others it doesn’t make a difference and you use it for awhile, (and) if it 
doesn’t make a difference stop it.” Dr North 
6.5.2 Responding to a Medicine for Dementia 
This section will discuss findings related to the actual type of responses 
observed and/or experienced by lay participants and the duration. 
6.5.2.1Response Rate and Duration 
One of the controversies of the use of AChEIs is the interpretation of a 
response. What does an improvement of two points on the MMSE mean (or any 
other scale for that matter?) For those measuring a response on an objective 
scale such as the MMSE there is no inherent experience or understanding of 
what this means for the person taking the medicine and those caring for that 
person. This is where the experiential (subjective) effect of these medicines on 
daily lives seems to differ widely from the clinical (objective) assessment of the 
effect. The response rate was best described by Dr West below. 
“I’d say it’s the rule of thirds; a third of people improve the third people 
stabilise and a third of people don’t benefit. The improvement can go 
from really dramatic to mild, but mild can be just the one straw that 
breaks the camels back, the remaining one straw is the camels back (that 
is) sometimes a mild improvement in function can still be the difference 
between staying at home and being in care.” 
Dr West 
Prescribers spoke about an average duration of sustained response, of 2 years 
but shared experiences of individuals still responding to the medicines at 4 to 7 
years. 
“I would normally tell people that if they are in the two­thirds who are 
benefiting I would normally try and achieve 2 years of stability…The max 
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at the moment is about 7 years so we’ve got quite a few patients who are 
on four years.” Dr West 
6.5.2.2 Beneficial Response 
Dr West previously described the follow­up consultation at 3 to 4 months as 
probably “the most important consultation of all” but continued with: 
“that often at 2 months you can begin to see signs not improving so much 
in cognition but in the attention, concentration…it sounds very trite but 
sometimes the early sign is that you just see the person looks more alert 
and bright.” Dr West 
Interestingly Dr West’s observations support findings from the Alzheimer survey 
in 2004 where respondents described people as being “brighter / happier/ more 
aware / more active” to “calmer / less aggressive” to improved concentration / 
speech.”30 
This increased alertness and interest in their environment was mentioned by 
many of the carers. Judy at their first interview shared “at least his interest is 
coming back in things. It affects every part of your life.” This was endorsed by 
Joan who felt that the Aricept® (donepezil) had somehow lifted Harry out of his 
shell he had withdrawn to. 
“I would say that the Aricept was one tablet that did sort of bring him out 
of himself more, you know because he is back in his shell and doesn’t 
say very much but that one Aricept® it was (a) wonderful tablet.” 
Joan, Case 2 
Increased alertness was also highlighted by phase one findings as improving 
the ability of carers’ to cope. This increased alertness in Robert’s case seemed 
to be still improving at the third interview when he told me “last time you called 
I’d tend to be a bit more lethargic.” He went on to say that he felt “more alert 
for the want of it” and that when he woke in the morning he was able to plan 
his day. 
“I wake up in the morning and I come round and I’m thinking ‘what day is 
it? How am I going to do it?’ like that. If I’m here (in the living area) then 
I’m thinking ‘well that needs doing’ but I’m more alert.” 
Robert, Case 3 
This improved alertness translated into improved awareness of their 
environment and recognising what needed doing and the initiative to complete 
tasks without being asked. 
“I was able to see a job in the house and go and do it and before that I 
wouldn’t even think about it, I would walk past it and not know there was 
anything to do anyway, but I even made the bed this morning.” 
David, Case 4 
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Robert had also been a very keen handyman and had always been painting, 
repairing and gardening prior to the onset of dementia. He then withdrew and 
sat watching television, not able to complete any tasks. At interview one about 3 
weeks after the medicines had been started he had been out mowing the lawn 
and doing other garden activities without prompting. Judy was pleasantly 
surprised as she said “so he’s going back to how he was, you know wanting to 
do things which has been amazing really.” 
For some participants the changes were less dramatic but were seen in 
improved behaviour or return to previous activities. Janet described “John is 
better on these” and then went on to explain that he knew what day it was when 
he woke up and that there were “lots of little things I notice like that, you know, 
they are really nothing very much but I think ‘oh that’s good.’” John endorsed 
this general improvement when he said: 
“I am 75 and I am functioning quite well amongst people much younger, 
so I think in that respect and I am quite satisfied with what is happening 
now with (what) Doctor West’s supplied. And I am going along quite well 
I think.” John, Case 6 
People also spoke in more general terms about how they felt since the 
medication was started. Robert said “life’s fantastic now” and Janet said that 
there had been “a vast improvement, everybody can see it and not only that he 
looks better.” To which John replied “Blimey they are doing well aren’t they?” I 
felt this was a nice indicator of attention to the conversation and appropriate 
processing with a sense of humour in the response. He went on to say that 
“because the memory, the mind is better, you (meaning himself) are not a 
miserable old devil.” 
Many of the participants also became more involved with household tasks now 
that they were at home full­time. John drove down to the local shops to do the 
shopping, and helped out with peeling vegetables; emptying dishwashers and 
changing the beds. David had been involved in spring cleaning and Chris had 
regular household chores that he helped with. 
Chris: “Well I do the washing and the ironing don’t I, all the time?” 
Vicky: “Yes you do dear yes you do you’re very good at it.” 
Chris: “And the cooking.” 
Vicky: “Yes and he does washing up and drying, you don’t actually do the 
cooking. But you do the ironing.” 
Chris & Vicky, Case 5 
Chris also thought the medication was helping him to cope with living with his 
memory problems, saying “I feel I can cope now whereas at one time I couldn’t 
but now I can. I can cope now.” However, Vicky seemed unsure whether there 
had been progression since the medicines had been started. 
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Vicky: “Well as I understood it it’s supposed to stabilise Chris’s situation 
and it’s not going to cure it but it will prevent it getting worse, that’s what I 
understand and I’d say that’s what’s happened as far as I can tell” 
Vicky, Case 5 
This uncertainty remained at interview 3 and in some respects it was easy to 
see her predicament. Since the medication had started about 14 months 
previously, Chris had become blind in one eye due to macular degeneration and 
was partially sighted in the other; this had increased her supervisory role 
enormously and also curtailed any independent activities such as walking or golf 
that Chris used to do. 
“They seem to be as far as, I mean I don’t know how to judge but I can’t 
find anything to say yay or nay, I mean you could be feeding him talcum 
powder for all I know. I mean how do you judge? He just carries on as he 
always does carry on.” Vicky, Case 5 
David was taking other medication for concomitant illness as well so had 
problems knowing which was responsible for what. 
“If you were to put the tablets out in a line I couldn’t tell you which was 
which. I find it difficult to say about a particular drug is doing a particular 
job (pause) but overall it’s improving and it’s better than before.” 
David, Case 4 
This very general level of improvement is perhaps the reason why objective 
assessment of response is so difficult. This may also be why the non­specialist 
viewpoint is that the medicines are not cost­effective as they are not 
appreciative of the unmeasured benefits on daily lives. The response seemed to 
be different for each person and the importance of that response to individuals 
was also different. 
As outlined earlier the prescribers all had different ways of measuring response 
and some of the most important were just the ability to continue with usual every 
day tasks as outlined by Dr North below. 
“I tend to ask of the general activities of daily living; in more sort of things 
they can do for themselves and how independent they are, maybe 
shopping finances, do they drive, do they manage to pay their own bills, 
how is their personal care, using the telephone, how do you manage 
various things like that you get a good feel for things.” 
Dr North 
6.5.2.3 Sociability and Returning to Old self 
Perhaps the most remarked upon improvement for spouses was the increased 
ability of their loved one to take part in conversations and social activities again. 
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They shared how their husbands were getting back to their old self and the 
improvements this had on their lives and the wider family. 
Social interactions are important as part of a couple continuing their own 
personal relationship and if people can no longer converse it can cause great 
friction between them. In their first interview Judy was quite fraught about the 
situation and she mentioned how Robert would previously “just sit there silent 
you now, wouldn’t speak to me, wouldn’t speak if we went out” but that now 
“he’ll actually have a conversation instead of just sitting there and watching TV.” 
At the second interview things had improved even more and they were back to 
going out to dinner or away for the weekend and having fun together. Robert 
tried to explain the difference in his behaviour. 
Judy: “That was really nice because it was a nice restaurant and a nice 
meal and it was really sociable whereas we got out of that because it was 
no fun going to anything like that.” 
Robert: “I would sit I would not talk, I don’t know why I can’t say I was 
struck dumb but I just didn’t want to talk and that was it, now I talk the 
hind leg of a donkey.” Judy & Robert, Case 3 
Janet mentioned how John’s impatience to be back at home had lessened and 
when they had been out recently at a family event he was happy to stay and 
take part in the conversation. 
“Last Friday when we went (to family function) he didn’t even mention 
coming home; we were still there at half past ten and he was quite happy 
and joined n the conversation.” Janet, Case 6 
Along with this improvement in conversation and perceived sociability was the 
perception of the person returning to their old self again. This was related to 
personality, previous activities and interactions with family. These improvements 
seemed to impact positively on quality of life and carer well­being. 
In interview one Robert said he felt “that these tablets have helped quite 
dramatically” and Judy replied that “since he’s taken these tablets he’s getting 
back to how he was.” Robert went on to describe his thoughts of how he had 
been after taking the tablets below. 
“I came back. Sat down there for a while (pointing to sofa) until these 
tablets decided to take effect and then I thought ‘yes I can do things,’ 
which I’m grateful for because I’m usually a do­it­yourself’ fiend and I just 
lost me nerve hadn’t been doing that much at all.” 
At the second interview Robert said 
“I would say I think the presence they’ve given me for want of a word 
have brought me back into the world really.” 
Robert, Case 3 
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In section 6.5.5.1 David had been talking with knowledge and passion about his 
feelings of the NICE decision on the access to medicines for dementia and he 
attributed his ability to do so to the medicines. He said “when I am talking like 
that I feel everything is normal and as I used to be.” 
In the first interview Judy was asked what key things she hoped the medicines 
would improve in terms of Robert’s behaviour on a day­to­day basis. Firstly she 
wanted Robert to “join in with family things rather than sitting there quietly and 
watching things” and also that he “took more interest in things and do more” as 
well as converse more with her. Robert just felt he needed more power in order 
to be able to do things. 
At the second interview Judy was thrilled that he was interacting more with the 
family; especially the grandchildren. 
Judy: “And the children have said ‘goodness sake what’s up with him he 
won’t shut up’. He keeps going on so much they’d noticed. And he 
actually takes more interest in the grandchildren now; he’ll sit and play 
with them now where he wouldn’t before.” 
Judy Case 3 
In her diary recordings Judy had listed a number of things she hoped would 
improve and then later on had given examples of activities that Robert was now 
involved with. These were not tabulated or linked together; but presenting in a 
tabular format demonstrates clearly the improvements in sociability; initiative 
and self motivation which were lacking prior to taking the medication. See table 
6.4 below. 
Table 6.4: Diary Notes by Judy Jones 
Symptoms Noted after First Interview Improvement Since taking Exelon® 
Lack of conversation Went to hotel with relatives over New 
Year and held conversations at table 
over meals 
Quietness 
Wanting to sit quietly Repaired water barrel pump which has 
been broken for over a year 
Visited Coventry cathedral and went 
shopping 
Not going to bowling club Has shown interest in starting to play 
bowls again next season 
Aggressiveness 
Stopped gardening Has mowed the lawn and done some 
gardening. Has raked the path 
Can’t have a discussion without arguing 
Makes more effort talking with family 
Doesn’t join in conversations with friends 
& family prefers to sit quietly 
No conversation on a car journey 
No interest in money/family/finances etc 
Doesn’t play with grandson (age 2) Now plays with two grandsons 
Bad memory of recent things 
Keeps raking up the past 
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6.5.2.4 Perceived Quality of Life 
These improvements also affected perceived quality of life with David saying 
“It’s affected me very well, it’s made me think in a way how lucky I am” and John 
saying that he did “not feel too bad for an old chap” Mary described quality of life 
nicely as the perceived ability of people to be able to do every day things. 
“I mean yes it does improve their quality of life I think the hope 
sometimes as well improves their self esteem that they’re able to do little 
things.” Mary, CPN 
It is a complex thing to measure a person’s perceived quality of life (QoL). There 
are a number of dementia­specific QoL measures available;371­373 but 
controversy still remains about whether these scales should be completed by 
the individual or by proxy.371,374­377 This is because PWD generally rate their 
QoL higher than proxy informants.253,374,375,377 However it has been suggested 
that this lack of insight and disagreement with their caregivers’ rating perhaps 
reflected a “legitimate self­perception of mood and function that are associated 
with co­morbidities rather than AD.” 377 
This is an interesting point, because all participants had at least two other co­
morbidities which affected their QoL; physically, emotionally and 
psychologically. How can it be decided which concomitant illness or medication 
is responsible for what? There are also many external events that impact on a 
person’s perception of their QoL that perhaps in a sense makes disease or 
medicine­specific measurement meaningless. For example George spoke about 
his distress over his concomitant medical and memory problems and how these 
were adversely affecting him in terms of health. At the second interview he had 
received a court summons due to a loan non­payment as a result of his 
redundancy. The worry and anxiety of that event took precedence over all his 
other worries to the extent that he was having angina pains during the interview. 
(The interview was terminated early while George took a nitrate spray 
successfully and was then sent off to the medical centre with his wife). 
One proxy measurement for the value that people place on medicines for 
dementia is whether they would purchase them themselves if they could. 
John: “Well what I was going to say was I would if I could get hold of what 
I wanted, I would go and buy it if I could.” 
I: “Would you?” 
John: “I mean you can’t go on for ever like that you’d go bust wouldn’t 
you but saying that I mean if I have got something which is doing me 
good I would try very hard even if it cost money to keep it going. (To 
interviewer) I don’t want a bill from West next week.” 
John, Case 6 
There was an issue raised by Judy about how she felt they had been robbed of 
quality time together because of the time it took to get the medicine for dementia 
prescribed. 
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“If he could have gone on these instead of the antidepressants straight 
away we just feel as though we’ve had 12 months taken away you know 
which could have been avoided if these tablets had been prescribed 
sooner. I suppose they have to eliminate certain things but I think they 
certainly make a difference.” Judy, Case 3 
Point of 
Reflexivity 
This is interesting because according to the current NICE 
guidance John, David, Robert, David and Chris would not 
have been eligible for an AChEI as they had mild disease. 
These medicines were perceived to have produced positive 
effects on the person taking them which in turn meant 
improved relationships with their spouse and families. These 
improvements helped the carer to be able to cope with their 
new caring role. It is hard and perhaps inappropriate to reflect 
on what may have happened to these already straining 
relationships if a medication had not been started. I find it 
difficult to think about people in the early stages of dementia 
who now have no access to an effective treatment. 
However medication is a double­edged word, there are always negative aspects 
and these will be discussed next in 6.5.3 Medication Issues. 
6.5.3 Medication Issues 
This section will describe the experience and management of medication­
related issues such as side effects associated with treatment; obtaining stocks 
of the medication; dispensing errors and concerns around compliance. 
6.5.3.1Experiencing Side Effects 
As previously mentioned the most common side effects of AChEIs are 
cholinergic, affecting mainly gastrointestinal, cardiovascular and respiratory 
systems.1­3,33 Prescribing another medicine for the side effect of one already 
prescribed brings added risks for the individual;319,378 the reason why many 
clinicians do not co­prescribe for adverse effects but instead slow the titration 
rate. There are a number of ways of viewing this; firstly the reduction in 
exposure to any medication is beneficial to the patient; secondly co­prescribing 
and/or slowing the titration may alleviate initial symptoms until tolerance occurs; 
thirdly not prescribing for symptoms may mean the person has to stop taking the 
medication and forgo any benefits to cognition. As more people are being 
prescribed these medicines; bradycardia and possible effects on balance are 
increasingly being recognised with some people having pacemakers fitted so 
that the benefits of the medication are continued.379 The HCPs, prescribers and 
participants all described their experience of side effects and how these affected 
day­to­day lives. 
“I would think the gastrointestinal side effects are the most common. But 
we do have people who have more vivid dreams and don’t sleep as well 
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and then we would change the timing they take to the morning and that 
often helps. But I would think that diarrhoea would probably be the most 
common.” Dr South 
“Nausea, followed by decreased appetite. There’s a toss up between 
whether it’s a slight balance disorder or whether it is the medication 
…Now that we’ve got people on more we tend to see more bradycardias 
or slowing of pulse or something.” Dr West 
Harry had experienced almost continuous diarrhoea when he was started on 
Aricept® and this continued until his follow­up appointment at 3 months with Dr 
South who stopped the medication. Harry had continued with the medication in 
spite of diarrhoea because the leaflet had “said that diarrhoea was one the side 
effects.” Because of this Joan thought Harry just needed to carry on taking them 
and it may resolve. This stoicism was remarkable, but not always the case as Dr 
South commented below. 
“People often after a fortnight three weeks of taking it say ‘I’m not taking 
this anymore and I don’t want to try another one because I felt so ill.’ so 
some people really do feel quite ill, that’s unusual but it does happen.” 
Dr South 
As mentioned earlier some people experienced severe side effects which 
eventually necessitated withdrawal of the agent; as in Harry’s case. All 
prescribers agreed they would use non­pharmacological methods first­line for 
side effects and only co­prescribe if they were severe and cognitive benefits 
were present. Dr South said “I really don’t want to go on adding more and more 
tablets in to treat side effects” which was supported by Dr East when he said “I 
do discuss but prefer not to prescribe just because, another tablet, another side 
effect you know.” 
This reluctance to prescribe another medicine for a side effect is common for 
clinicians caring for older people as it can start what is commonly termed a 
‘prescribing cascade’319,378 and end with polypharmacy319,380 all of which may 
cause an increase in the morbidity and mortality of the older person.319,378­382 
With this knowledge in mind, the prescribers were very careful about taking a 
decision to prescribe for a side effect with the majority deciding to withdraw the 
agent and try another AChEI, as Dr South summed up below. 
“The feeling is that we would try people on two but not usually on three; 
so if they haven’t had a good response on two of them we wouldn’t even 
try a third one. But we have some people who have side effects with one 
and not with another so yeah it does happen.” Dr South 
This ‘switching’ of agents can also be a treatment strategy if there has been 
poor response to an agent, with evidence supporting that different people 
respond to or tolerate different agents within the same class.38­41 At some point 
AChEIs need to be withdrawn and discontinued; sometimes for lack of 
response; or intolerable side effects or when it is obvious they are no longer 
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holding disease progression. NICE 2001 suggested that end points should be 
discussed prior to starting the medication, but it seemed this was not explicit 
during consultations.27 
The participants all had different understandings of when the medicine would be 
withdrawn or stopped with Janet saying that they hadn’t been told when it would 
be stopped but “what he said was they could work for 2 years, they could work 
for longer but there is no set time but he did say that we have got stronger 
ones.” This unknown about the duration of response was a fear echoed by 
Annabel who said “how long it will last I don’t know but I hope it continues.” 
The prescribers and HCPs expressed some interesting thoughts on when these 
medicines should be withdrawn or stopped; with Dr North seeming the most 
reluctant due to his experience of witnessing a worsening of cognitive function in 
people who had stopped treatment. 
“I have seen this before. Some of the carers feel that they may not be 
working and they think let’s try and stop it and with the patient being 
lower in their mental state you say try and stop it and you can see a 
dramatic difference in the people and you (need to) reinstate it back.” 
Dr North. 
Now when Dr North withdraws an AChEI he warns carers that “if there are any 
differences come back to me straightaway so I can put it back on.” In Harry’s 
case because the diarrhoea was so severe it seemed that stopping the tablets 
as suggested by Dr South was a good idea, but Joan reflected “I thought it was 
better when he was on Aricept®; definitely he went down hill after he stopped 
taking it.” 
The clinicians expressed sadness about not being able to offer treatment at the 
later stages of the disease with Dr North outlining that all they could do was to 
“just put an extra social support and get social interventions, we make sure they 
have a support package.” 
“I feel very sad basically knowing that they would deteriorate if they stop 
but eventually we have to stop because of all the other aspects of duty of 
care. It’s sad but at some point of time we do accept this.” 
Dr East 
An important observation from these interviews was that the prescribers and 
HCPs strived for a holistic approach to the assessment of response to 
medication and disease progression. Where possible they involved PWD and 
their carers in the decision­making process but often felt sad at the lack of 
options available for caring for people in the later stages of the disease. These 
findings seemed in great contrast from participant perspectives described in 
4.3.1.3. 
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6.5.3.2 Getting the prescription and the medication 
Once the medication was prescribed and a decision was made to continue it, 
the prescriptions had to be obtained from the various memory clinics, with 
Annabel, Vicky and Judy telephoning the secretary for further prescriptions. 
“Most of David’s drugs come from our GP which is local, but those which 
Dr West prescribed came as a result of being in (Location 3). So I have a 
number where I can ring through and say I am down to the last month as 
it were. I like to be well prepared I don’t want to run out.” 
Annabel, Case 4 
However this was not without problems as often the prescriptions were 
incorrectly written and this meant that there was a need for further prescriptions 
so medication did not run out before the next appointment. In the narrative 
below Judy explains how she managed to get a prescription written for three 
months (3 stroke12) but only for once daily dosing instead of twice daily. 
“It (the prescription) said 3 stroke12, 3mg, so they look at it at the 
Chemist and (say) ‘I’ll give you 3 months of 1 tablet for 1 a day’ so he 
didn’t say twice a day, so you only get one.” 
Judy, Case 3 
The second time it happened they complained to the psychologist completing 
Robert’s neuropsychiatric testing who said to Judy she would “sort it out.” Judy 
continued “I mean they ought to put twice a day.” These echoed similar findings 
from phase one in 4.4.3.5. 
Point of 
Reflexivity 
This may be an incorrectly written prescription but the 
dispensing pharmacist also has a role to play in stopping 
these errors from being perpetuated. The licensed dose is 
twice daily; Judy told the pharmacist it was twice daily and yet 
the prescriber was not contacted to check the prescription 
was correct. This happened twice and is not reflective of 
demonstrating a duty of care by the pharmacist to the patient 
in that they receive an appropriate prescription.32 
Once the prescription was attained by Robert and Judy it was often difficult for 
the full supply to be received at the original point of dispensing or indeed for 
them to find a dispensary which stocked the medication as Judy shared below. 
“I think he’s been better on them; the only thing that concerns me is 
getting the prescription and getting it right from the chemist as well. Do 
you know why they won’t stock them?” 
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I: “Do you go to the same chemist every time?” 
Judy: “Well we try different ones to see if they’re any better…if you go 
into town, Boots down at (local village) don’t have them, we’ve tried 
Lloyds they didn’t have them at all, we tried the chemist in (another local 
village) and we had to go back because they sold out and this last time I 
said ‘let’s try the surgery at (local village).’ Well they said ‘well we’ll have 
to send away for them.’” 
Judy, Case 3 
6.5.3.3 Mislabelling 
Of more concern as a pharmacist was the extent of mislabelling errors reported 
in such a small study. Both Vicky and Judy reported labelling errors and 
highlighted their concerns for people with memory problems who may be trying 
to keep track of things on their own. 
“When he goes for his tablets they never have enough of them so they 
keep the prescription and at one point we had a box of tablets that said 
3mg twice a day and the other box said 3mg once a day and they were 
dated about a week apart and I thought somebody with a memory 
problem this is. It’s not good, obviously I’m keeping tracks on it, but they 
shouldn’t get this sort of thing wrong for people with memory, should 
they?” Judy, Case 3 
In the first interview Vicky had shown me a box of Robert’s medication which 
had just been issued after their 4­week follow­up appointment. When I read the 
label it said “Take two a day” whereas Chris had been telling me he took one a 
day (long acting galantamine). There was consternation about what the correct 
dose was which could only be ascertained by a telephone call to the prescriber 
and then the pharmacy; at the next visit Vicky recalled: 
“Well it was the Pharmacist’s fault as soon as you’d gone I phoned (local) 
hospital and they put me in touch with the doctor…and he checked in 
Chris’s notes and Chris was on the right dose it was the right medication 
so I went back to the Pharmacy and said ‘do you realise you’ve got it 
wrong?’” Vicky, Case 5 
Point of 
Reflexivity 
This is actually quite a serious error in the eyes of the law. 
Earlier in 2009 a pharmacist was struck from the register and 
received a 3month jail term suspended for 18months for a 
similar error.383 This was also experienced by Robert and 
Judy and for a small study indicates poor knowledge about 
the license prescribing indices of medicines for dementia. 
6.5.3.4 Compliance and Titration Problems 
Robert had been started on rivastigmine and because of his cardiovascular 
problems and the increased risk of gastrointestinal effects with rivastigmine had 
191 
been put on an increasing dose to be titrated upwards from 1.5mg twice daily for 
two weeks, increasing by 1.5mg once daily every four weeks to 4.5mg twice 
daily over the next couple of months. No written information was given to Robert 
and the increasing dosage was not written on the prescription so it didn’t get put 
on the label. Hence there was a lot of confusion about Robert’s dose and what 
he was supposed to be on. To complicate matters Robert still looked after his 
own medication and transferred medication from packets to a medication 
compliance device every week. He also was responsible for remembering to 
take his medication during the day. 
At interview one Robert reported that “this week I take two in the morning and 
one in the afternoon” with the aim of getting up to twice daily in a few weeks 
time. Between the first and second interview Robert had passed out in the 
kitchen, banged his head and spent two days in hospital while tests were done 
to see if it was a side effect of the medication or to do with his cardiovascular 
problems. (He was also on Warfarin which meant his head injury had bled 
profusely and needed stitching). So the medication had been reduced back to 
one in the morning and one at night. But somehow when the next prescription 
arrived from the memory clinic it had been written for 3mg for 3 months and this 
had been interpreted by the dispenser as 3mg once daily instead of 1.5mg twice 
daily (see Case Study Report A5­17). Dr West had been very apologetic and 
explained that Robert should now take 3mg in the morning and 1.5mg in the 
evening and increase to 3mg twice daily in two weeks. He was then to stay on 
this dose for 6 weeks when he would increase the dose to 4.5mg twice daily. 
However he did not explain why he wanted to increase the dose (for increased 
cognitive response) and because they had read in the literature that they could 
only go up to 6mg twice daily they didn’t want to reach it too soon in case they 
ran out of options; so they stayed at 3mg twice daily. 
“It’s a shame that Dr West left because we had faith in him. He didn’t 
sort of explain why he wanted to put them up and we were a bit 
frightened because of what had happened and if you get used to the 
increased dose you can only go up to 6 twice a day can’t you?” 
Judy, Case 3 
This is an important reminder for HCPs involved in the prescribing of any 
medication for PWD to always provide an explanation of what is happening and 
supporting written information. 
In terms of actually taking the medicine John thought that if the medication was 
“doing you some good you’d be a bit of a fool not to” take them. He added: 
“Well to do the best you can, what’s the point in going to see Doctor West 
years ago to see what can be done if you get the treatment not to do it 
justice? I am very positive and very certain that that requires to be done 
at all times as instructed. It would be just crazy not to, wouldn’t it? Just 
absolutely crazy.” John, Case 6 
This was quite an interesting stance after he had refused medication for so long, 
but as he experienced the medicines as being effective he felt they should be 
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taken. Judy mentioned in two interviews that she was concerned that Robert still 
had control of his medicines and that he couldn’t tell you what the name or 
strength of his medicines were, but Robert was adamant that he had them all 
under control. 
Judy: “One thing I’m not sort of happy with, Robert does his own tablets, 
which he wants to do and he puts them in his box but he couldn’t tell you 
what tablets he’s on.” 
Robert: “I could tell you quite a lot of them.” 
And later 
Judy: “But you can’t remember the names of them you see, that’s what 
worries me.” 
Robert: “Well they’ve all got packets or boxes or bottles up there so that’s 
it. I don’t think there’s any problem, I’m not going to take too many of 
one.” Robert & Judy, Case 3 
Point of 
Reflexivity 
The absence of any pro­active input from a pharmacist for 
these people with concomitant medical problems as well a 
dementia has been quite shocking. One would expect that 
basic advice would include information about titration issues; 
reminder cards to emphasise medication routine and perhaps 
a Medication Use Review session to see if there was any 
other help and information that people needed. I also found it 
difficult that healthcare professionals working with people with 
a memory problem or a dementia did not routinely provide 
written information to back­up dosage changes or titration 
information. Relying on carers’ memory cannot be an option 
as they are also taking on board much new information within 
a consultation. 
In a recent paper the authors discussed their concerns for a lack of evidence­
based strategies to promote medication adherence in PWD. 384Although there is 
a large literature base on general aspects of medication adherence, compliance 
and concordance; with national generic guidance published February 2009300 
there seems to be little pro­active involvement by community pharmacists in 
helping these people to take their medicines successfully. I would argue that as 
a clinician you could rarely achieve true concordance (definition of a shared 
decision between prescriber and individual to start a medication and agree to 
take it) with a person with dementia unless they were in the early stages of the 
illness and normally had full control of their medication. More often than not 
medicines are looked after by one person in a relationship and they ensure 
medicines are re­ordered; re­dispensed and taken. This is not concordance this 
is probably best described as compliance (complying with a direction), or if they 
agree with taking the medication, adherence.385 
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6.6 Summary of Findings 
In summary this section has discussed the expectations of and responses to the 
medicines for dementia from both lay and healthcare professional perspectives. 
The more important responses of efficacy from the lay perspective seemed to 
be increased sociability, initiative and interaction with others. These seem at 
direct odds to those responses measured by the MMSE. 
In Chapter Five it was proposed that findings from this study would provide 
qualitative and some quantitative evidence of the perceived effectiveness of 
medicines for dementia in a naturalistic setting. There was also the possibility 
that findings could inform information educational strategies for HCPs about 
communicating with PWD and their carers when starting a medicine for 
dementia. 
In relation to the objectives of the study the medicines for dementia were 
associated with global improvements in personality, quality of life; social skills, 
orientation and improved initiative which positively affected personal and wider 
relationships. These improvements were seen to outweigh lesser improvements 
in memory. Experiences of lay participants and healthcare professional 
supported the use of these medicines in early stages of dementia, although 
heterogeneity in response was raised by prescribers. Of more interest was the 
heterogeneity in the type of response and at times the very generality of it, 
resulting perhaps in a perception that the effect was in fact a ‘placebo’ 
response. However the longitudinal nature of this study demonstrated sustained 
efficacy over time in some cases. 
The MMSE recommended by NICE, was seen to tell only ‘half the story’ and did 
not accurately reflect for some participants; the true impact of the medication on 
day to day life; especially interactions and relationships with spouses, family and 
friends. For people like David the MMSE seemed not to accurately reflect the 
extent of functional impairment. NICE was seen to hinder appropriate access to 
medicines by lay participants, prescribers and HCPs. It seems that a wider 
range of patient reported responses may be important in determining efficacy of 
treatment. 
Of key importance is the need for education and information about the disease; 
its associated behaviours and how these progress over time at the early stages 
of the illness. As reflected by Vicky and Judy much of their frustration and 
associated negative effects on their respective relationships was related to not 
understanding common symptoms such as repetition and poor short term 
memory. Carers need to understand these are part of the disease and not a 
deliberate action on the part of the affected person. 
Pharmacists can be more involved in the support of people with dementia and 
their families. Key areas include provision of information, clearer labelling, 
provision of medication reviews and support with compliance and titration 
regimens. Inadequate knowledge about the correct prescribing for these agents 
was also highlighted which indicates an urgent need for educational input. 
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CHAPTER SEVEN: OVERARCHING DISCUSSION AND 
CONCLUSIONS 
This chapter will briefly summarise findings from both research phases and 
discuss the study limitations. Key findings will be presented and discussed and 
the implications for practice and future research will be explored. 
7.1 Summary of Findings 
Participants for phase one were recruited from four different branches of the 
Alzheimer’s Society in the South­west and for this reason the findings were 
more diverse in terms of the range of severity and chronicity of the disease and 
the effect of these on carer burden and personal relationships. Participants with 
early dementia or a memory problem in phase two were recruited from three 
different memory clinics. Findings illustrated longitudinal effects of the medicines 
prescribed for dementia on alertness, initiative, communication and improved 
relationships. 
Although there were surveys30,253 and clinical trials245,247,248 detailing the 
perspectives of people with dementia and their carers about the medicines for 
dementia, only one study incorporated a qualitative study which explored these 
findings in greater depth.253 Traynor et al have since outlined the importance of 
incorporating lay perspectives of treatment effects into measurements of 
medication response.386 In phase two of the aforementioned study there 
seemed to be a willingness of the HCP study participants to take account of 
subjective lay perceptions of response in some areas but not all,253 however this 
doesn’t seem to have filtered through to policy decision­makers.. Leibig has 
suggested that the incorporation of lay perspectives of important outcomes has 
been encompassed in the prescribing of medicines for dementia by specialist 
geriatricians but there remains an element of doubt because of the international 
387 controversy.
7.1.1 Phase One Summary 
The objectives of the study were to explore lay participant experiences of the 
use and effects of medicines for dementia; the experience of support and 
information provision and involvement in shared decision­making. What was 
striking was the sheer hard work that being a carer entailed. The most 
distressing part of this was the variability in support, access to treatment or 
information and/or specialist services all of which were complicated by the 
variability in response by HCPs. Delayed access to support services such as 
respite or day care led to breakdown in carers’ ability to continue coping. 
Findings suggested that support and information needs to be offered earlier and 
at frequent intervals throughout the caring process as the experienced burden 
changes over time. 
Not only was there variability in the aforementioned areas but also in the effects 
of the treatment in terms of efficacy; side effects and monitoring issues. 
Important outcomes for participants seemed to be an increase in sociability and 
taking part in daily activities around the home. These perceptions were 
corroborated by family, friends and supporting HCPs. 
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It seemed there was a need for some HCPs to complete further education and 
training in the very basic skills of communication and consultation etiquette. 
There was also a perceived need to explore whether consultations need to be 
conducted together with both patient and carer or apart or both. From 
pharmacists there was a paucity of proactive involvement but findings 
suggested there were many issues associated with medicines management and 
the illness that pharmacists could help support. 
7.1.2 Summary of Phase Two 
In summary this phase was a longitudinal study which explored the effects of 
the medicines for dementia from lay, prescriber and HCP perspectives in a 
naturalistic setting. Important outcomes noted from lay perspectives were 
increased sociability, initiative and interaction with others and the associated 
effects on acceptance and adjustment.136,142,143 These seem at direct odds to 
those responses measured by the MMSE with the MMSE perceived as only 
telling ‘half the story’ of the true impact of the medication on day­to­day life. 
Other key findings included a need for information and/or education for carers 
about how a dementia affects an individual and how this can result in changed 
behaviours. Other information required included suggestions for managing 
behaviours and support in suggestions for activities. Community pharmacists 
could be more proactively involved in the support of people with dementia and 
their families in the community especially in the areas of maintaining compliance 
and adequate and accurate medication supplies. 
7.2 Limitations of the Research 
In terms of actual participant numbers these were both small studies and the 
implications for transferability or generalisability of findings will be discussed 
later. In phase one, participants were recruited from local branches of the 
Alzheimer’s Society, but it could be argued that participants self­selected in 
order to tell their story. With the implication that those with the most grievances 
were those that signed up. However this is not reflected by the overarching 
variability in the provision of support, information, services and access to 
medication. These participants may also have had greater knowledge on 
treatment availability, current research and accessing support services, because 
of their membership. However again there was great variability in all of these 
areas and there seemed to be a paucity of support services in some locations. It 
could also be said that by recruiting from local branches there would be inherent 
bias in the participants’ perception that the local branch was a positive support. 
Participants in phase two were recruited from specialist memory clinics so 
perhaps findings of improved knowledge and communication skills from the 
prescribers and HCPs involved was not surprising. This was in contrast to 
interactions with HCPs by phase one participants which were variable and often 
unsatisfactory. 
In terms of the importance of medication­related responses such as improved 
communication and relationships, it is unclear whether these would have been 
different if there had been more male carer participants in each phase of the 
study. In phase one all male carers were or had contemplated placing their 
loved one in long­term care compared to one female participant. It has been 
196 
suggested that the daily completion of intimate caring tasks for their spouses by 
male carers could destroy their own perception of the spousal relationships such 
that it ended in institutionalisation.171,182,283 This seems in stark contrast with the 
female participant carers of this study who seemed to place greater emphasis 
on communication and sociability. 
In qualitative research and especially in face­to­face interviews the personal 
qualities of the researcher can have a direct effect on the interaction with 
participants and their involvement with the process. That is researchers’ can 
vary in their ability to form a relationship with the participant and this may affect 
shared narrative and therefore findings.57,268,270 It was evident that a number of 
interviews over a period of time can result in a relationship which may no longer 
be perceived as strictly participant and researcher. Participants may perceive 
the researcher more as an interested acquaintance rather than an objective 
researcher.57,268,270 This has implications for the resultant behaviour of the 
researcher which needs to remain objective.272,273 The participant invitation 
letters introduced me to potential participants as a pharmacist and this could 
also have affected the participant perception of the relationship. 
The design of phase two included attention to quality and validity with 
production of a Case Study Protocol (A5­1), a study database and generation of 
a Case Study Report (A5­17). The inherent use of multiple data sources in a 
case study approach can be seen as methodological triangulation to ensure all 
truths are discovered.321 The multiple data sources included; diary recordings 
from one participant willing to complete these; patient shared records; interview 
data and consultation observational data. Generally when multiple methods are 
used it is hoped that they will all produce the same results to improve the 
robustness and transferability of findings. The diary findings of this participant 
couple supported findings from the interviews, observed consultation and the 
patient shared record. However, the limitations of diary research such as 
inaccuracy of entry biases are well known.349 It is also a limitation that only one 
couple felt able to record their responses over time. However it could also be 
perceived that this could be a time consuming request for a carer who’s time is 
already constrained by caring responsibilities.132, 167,169 This supposition has 
been supported by Välimäki et al who found that although some caregivers 
perceived diary writing as ‘therapeutic,’ others felt it was “an extra source of 
stress.”388 
The different data collection methods in phase two indicated that some objective 
findings from disease rating scales did not actually reflect accurately what was 
happening in the real life­world of the individual. Does this matter? Others argue 
that disparate findings help to increase the depth and relevance of findings as 
they reflect more accurately the complexities of healthcare interventions and the 
heterogeneity of people.321,389 I would also agree with the complexity of 
healthcare interventions but more importantly on the heterogeneity of those 
involved and the individual reactions that people can have. The sheer 
interconnectedness of life implies that any intervention will have a myriad of 
effects and not just on the individual receiving it but those caring for and living 
with that individual. Although there were only six HCP participants in total in 
phase two their perspectives of the value of medicines for dementia generally 
reflected those of lay participants in phase two and other studies30,253 and 
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perhaps this could be explored in a larger study, looking at patient­reported 
outcomes. 
Are the findings of these small studies transferable or generalisable? Yin320 
argues it is not the transferability of results but the transferability of theory from 
findings that can be transferred. Perhaps the superordinate themes from each 
study phase could have ‘inferential transferability’ as proposed by Lewis and 
Ritchie so that one might infer the same findings could be found from a similar 
population group.340 Similarly if the context where the findings were being 
transferred to was similar to the context the findings came from then they would 
hold ‘naturalistic generalisation.’ 341 It could also be proposed that the findings 
would be likely to resonate with other PWD and their carers attending local 
branches of the Alzheimer’s Society and/or attending memory clinics for 
treatment of mild dementia. 
7.3 Key Findings 
This section will present the key findings from the study in order of importance 
and also link to the key healthcare policy literature. 
7.3.1 The Burden of Caring 
As a researcher an over­riding perception was of the sheer hard work that 
caring entailed. It completely changed any previous concepts of daily activities; 
roles and personal identity within that relationship. This was especially apparent 
in phase one where the chronicity of caring by participants seemed to have 
been longer than in phase two. In phase two came a personal recognition of the 
potentially devastating effects that mild dementia and cognitive impairment had 
on personal relationships. The improvements in spousal communication and 
social interactions that medicines for dementia and acceptance of illness 
brought were in some cases dramatic. 
Key pointers in reducing carer stress and sense of burden seemed to be the 
medicines’ for dementia’s affect on mood and initiative of the person with 
dementia and resultant affect on their ability to complete daily tasks. As 
mentioned in 2.2.2 behavioural changes and decreased ability to complete 
activities of daily living can be key factors which result in early 
institutionalisation of PWD by their carer.49­51,61,119,144,145 So it seemed the 
medicines for dementia by improving mood and initiative reduced the 
experienced burden of daily caring activities for some carers. Also a key part of 
this was the provision of appropriate support in terms of regular day and respite 
care. This is supported by Pearlin’s conceptual model of carer stress (see 2.2.3 
Figure 2.2) which demonstrates a connection between the provision of an 
interventional programme and an experience of mediation in the stressors 
associated with caring.170 
Coping with caring was also linked to perceptions of grief and anger at the loss 
of previous relationship dynamics between spouses and a taking on of an 
unwanted and unasked for role. This has been described by others as role 
captivity.170,177 The roles of stressors and secondary stressors in the magnitude 
of carer burden experienced have been well described170,171,188 and the 
perception of these stressors by individual carers seems important in how a 
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caring role is perceived.170,171,188,287 Pearlin suggested that the psychological 
experiences (intrapsychic strains)170 were shaped by the individual 
characteristics of the carer and these associated reactions by individual carers 
to caregiver burden were demonstrated within both phases of the study. Sue 
(location 2, phase 1) and Judy (Case 3, Phase 2) both struggled with their new 
roles and having to take on activities that had previously been performed by 
their respective husbands. It is important to note that the improvements in social 
skills after a medicine for dementia was prescribed made caring more bearable 
by mitigating other perceived dysfunctions such as memory loss. That is these 
medicines seemed to improve the ability to cope with everything else if there 
was a sense of gained relationship for the female carer. For many the concept 
of not being able to converse as usual with their partner was very distressing for 
both participants with dementia and carers and experienced as a major stressor 
within their own sense of self. This is entirely understandable, as Sue described 
it must be terrible to live with someone who you no longer know and recognise 
on a personal level. A return to a person’s former self or regaining their 
personality was also an important aspect of medication for some carers. It is 
however interesting that the older couples, and those with perhaps healthier 
relationships prior to the onset of dementia seemed to fare better with coping 
than others who were younger or who had previously more dependent roles on 
their respective spouse.166­169 
This of course relates well to Ablitt’s theoretical framework for well­being and 
relationships as depicted in Figure 2.3.188 It seems that the medicines for 
dementia could mediate the effect of living with dementia of the carer by 
improving relationship quality and as a result improving emotional well­being. As 
a result the proposed addition of a medicine for dementia taken by a PWD may 
mediate the well­being and relationships experience by the carer as postulated 
below in Figure 7.1. 
Dementia 
Quality of Prior 
Relationship 
Relationship 
Form 
Improved 
relationship quality 
Maintain relationship 
quality 
Higher 
emotional well­
being 
Improved 
experience of living 
with dementia 
Improved 
emotional well­
being 
Carer 
Person with 
dementia 
Medicine for 
Dementia 
Figure 7.1 Postulated mediation of medicines for dementia on carer ability 
to live with dementia. (Adapted from Ablitt188) 
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Whatever the relationship dynamic it was clear that people needed 
individualised support packages which were also backed up by written 
information and details of contacts for services in a crisis. These services 
needed to be offered proactively rather than in response to crisis so that 
relationships could be preserved and institutionalisation 
avoided.171,174,175,177,180,181,183 Once a carer has started to hate the person they 
are caring for, institutionalisation seems inevitably to be the next step.185,186 
Although there have been a number of government directives on the support of 
carers 45­51 it was clear from phase one findings that carer support was not 
equitable, generally not proactive and varied across and within locations. In July 
2009 the government published ‘Shaping the Future of Care Together’ which is 
an attempt to drive forward a more equitable care system across all areas 
where care and support is needed.391 It is hoped that this will improve carer 
experiences in the future. However if medicines for dementia are a positive 
mediating effect on the experience of caregiver burden and stress then a 
revised policy on how medicines for dementia are provided and the efficacy of 
these within the dyad of the PWD and the carer is urgently needed. (See later 
7.3.2) 
7.3.2 Accessing Medicines for Dementia 
Both lay and healthcare professional participant perceptions of the medicines for 
dementia were they had proven efficacy and beneficial effects were generally 
preserved for up to two years. Prescribers in phase two described how they felt 
their professional decision­making was compromised by the revised NICE 
guidance of 2006, in terms of caring for people at the mild and moderately 
severe to severe stages of the illness.31 The new economic costing model were 
upheld by Judicial Review232 even though discrepancies were noted such as the 
appropriateness of using QALY evaluations in older people and the decision not 
to include carer burden into the cost­effectiveness model.31,114,230 These 
decisions point to a misunderstanding on the behalf of NICE of what PWD and 
their families feel are important outcomes.30,55,247­250,253 
Point of 
Reflexivity 
Interestingly I was at an ESRC Economic Evaluation seminar 
in pharmacy practice in June 2009 where one of the 
members of the health economic modelling team for HTA 
1927,31 and another from the recent review of cancer 
therapies were presenting. I found it very difficult to 
understand the complete lack of compassion they had about 
the effects of the decisions their new cost models had on 
people’s lives. One of the comments went something like this: 
‘…if I have to listen to another bleating patient group about 
how these drugs help people to spend more time with their 
families when they are going to die anyway (I will be very 
angry).’ 
It is very easy to make decisions when you have complete 
disregard for the effect these might have on peoples’ lives. 
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We are all going to die at some point and if a medication can 
ease the pain of leaving this world for the next from the 
perspectives of patients, carers and families then there 
should be some real recognition of this. People need to have 
time with better levels of cognition and insight to plan in 
advance for their future care and end of life care plans. In 
great contrast was a wonderful presentation by Dr Jason 
Leitch (the National Clinical Lead for Safety and 
Improvement, Scottish Government)392 who presented at the 
2009 Health Services Research conference. He presented 
statistical data on a graph as patients’ names, ages and 
cause of death; making it personalised so the impact of these 
hospital acquired infections or accidents could be seen on the 
whole of the family and society. 
The participants of both phases held anxiety about whether the medications 
they or their loved one was taking may be withdrawn because of the impending 
NICE decision and/or their access to medication for the later stages of the 
disease would be closed. Participants from phase one described their 
perceptions of it being ‘a battle’ or a ‘fight’ to access what was perceived as the 
relevant medication, information or support. Those in phase two felt lucky they 
had been prescribed the medicines prior to the decision being made to limit 
prescribing. Perhaps a more eloquent indication of the perceived value of these 
medicines and the benefits they brought to the person taking them and those 
supporting them was participant’s anger about other people not being eligible for 
treatment after the final NICE decision (see Peter’s comments in 4.3.3 and 
David’s in 6.5.1.1) 
The media obviously has a great role in how the public view many things 
including healthcare and so another problem for HCPs and prescribers was how 
to manage expectations of these medicines. Medicines for dementia are only 
part of the treatment available for dementia, but they seem to be a part that 
helps support and ease the burden of caring through some of their more global 
improvements other than improved memory and cognition. Some of the 
prescribers talked about perceived placebo responses to treatment in the early 
follow­up consultations. This is interesting but perhaps raises more questions 
than can ever be answered; what exactly is the placebo? The medication? The 
fact that something is being done? The prescriber themselves? Does it really 
matter? Robin Nunn argues that once we describe the placebo it is no longer a 
placebo; it is a tangible effect and that perhaps we need to throw out all our own 
preconceptions and perceptions of what placebo is and look at what really is 
happening.367 
NICE guidance31 is actually due for a further review at the end of 2009; it will be 
interesting to see the approach taken. It has been proposed that the recognition 
of quality improvements in healthcare for older people may not best be reflected 
using QALYs.114,230,234­239 An interesting article by the researchers who 
developed the Assessment of Health Economics in Alzheimer’s Disease 
(AHEAD) model which NICE based their new economic model showed a great 
disparity in the cost per QALY.393 NICE 2006 estimated £46,000 per QALY for 
galantamine compared to £9000 per QALY in 2001. 393 The authors reflect that 
NICE used incorrect and unsubstantiated evidence to base their new economic 
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modelling and did not take into account the uncertainty in the estimates that 
they used.393 
At present there seems to be a great mismatch between lay perspectives of the 
efficacy of these medicines and the biomedical viewpoint gained from rating 
scales such as the MMSE, ADAS­cog and others.30,55,247­250 The improvements 
in sociability, initiative and attitude seem to be perceived by the current 
biomedical emphasis on memory retention as ‘soft’ outcomes for these 
medicines. As Woodarczyk et al pointed out the MMSE does not capture 
psychological and quality of life improvements;130 and just because it does not, 
does not mean improvements are not present or indeed that they should be 
ignored. Perhaps we need to revisit the attitude of Western culture which places 
an emphasis on memory and intelligence above all else and concentrate on 
social and relational outcomes associated with being human. 
It should be considered unethical now to have further placebo­randomised 
controlled trials with any of these medicines for dementia as their efficacy has 
been proven in certain groups of people beyond doubt.23,27,31,113,114,240­242 
However placebo­controlled trials continue394 in new research placing those on 
placebo at disadvantage in regaining lost cognitive function and preventing early 
progression. Perhaps what is needed is to revisit the way in which these 
response rates are measured and trust PWD and their carers to give PROs that 
reflect their response to medicines for dementia? (See 7.3.4 for further 
discussion). 
7.3.3 Perspectives of Responses 
What was apparent in both phases of the research was that the medicines for 
dementia had a diverse range of affects and effects with generally positive 
outcomes on activities of daily living; including those important to social 
relationships. Humans are basically a very social being who want/need to share 
experiences and thoughts with others, primarily through conversational 
interaction. Once this ability to converse declines or fades the resultant effect on 
personal relationships can be catastrophic.131,166­168,390 
Point of 
Reflexivity 
What I found interesting in phase two interviews was the 
depth of anger and frustration displayed by both the person 
with the memory problem and the carer as a result of 
cognitive impairment. The early social withdrawal displayed 
by those with a memory problem or dementia had an effect 
on social relationships; interactions with friends, family and 
grandchildren as well as the ability to socialise within a 
relationship in terms of just simple conversation. Participants 
with dementia spoke about how they were unaware of why 
they were behaving like this and that it wasn’t until they 
received a medicine for dementia they actually gained insight 
into their previous behaviour. Observing couples interacting 
together in their own homes over a period of up to 13months 
was very interesting as you could witness a range of 
responses not only to the medication but also the acceptance 
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and understanding of the illness itself. Observing the 
difference in insight and awareness of some of those taking 
the medicines and the resultant effects on their conversation, 
social skills and interactions with their grandchildren was very 
humbling. Dementia care is a very complex business 
requiring thoughtful, holistic and individualised support to 
those affected and their wider social circle of family and 
friends. 
This diverse range of improvements included: global effects on personality, 
mood and behaviour; quality of life; improved socialisation skills; 
communication; activities of daily living; mobility and engagement in their life 
world; and that these were apparent for some time before lessening. 
Participants commented on the fact that memory did not seem to improve that 
much but this was outweighed by other perceived benefits in day­to­day living. 
On the whole participants felt the medicines should be continued as long as 
they were perceived to be beneficial, the side effects were tolerable or when it 
was definitely proved they were no longer working. 
The findings from phase two suggest there is indeed a role for medicines for 
dementia in early disease, if just to ease the suffering associated with living with 
a memory problem and its resultant effects on communication and relationship 
dynamics and to decrease institutionalisation. (These are very important positive 
outcomes as they help to reduce carer burden and stress and these are well 
known to increase rates of institutionalisation).172­177,181,183,196 I believe that the 
decision to ration these medicines has increased unnecessary suffering for 
people with dementia and their families in early disease; a situation which 
seems grossly inappropriate in a so­called developed nation. This increased 
level of suffering can only grow and perhaps by the time moderate disease is 
reached permanent damage may be done to the spousal relationships and 
continued ability to care. It is indicative of institutionalised ageism, and 
associated stigma and misunderstanding of what it is to have to dementia. Li 
and Orleans proposed that the negative value­based judgments of HCPs 
pervaded all parts of the dementia treatment continuum and that a person with 
dementia became a non­person (just because they cannot remember what they 
did that morning).141 This ethos resulted in a complete disrespect for the 
individual with dementia and those caring for them.141 It is as if once a person 
has a diagnosis of dementia their opinion is no longer valuable, relevant or 
pertinent and not to be trusted. 
In both phases of the research, lay perceptions of the usefulness of the current 
tools available for rating the severity of dementia and response to 
pharmacological treatment were doubtful. Participants could not understand why 
a series of assessments testing their loved ones ability in areas where they had 
always been very good at; or alternatively very poor at were useful at all. The 
MMSE seemed to be associated with the most anxiety as this was also linked to 
the continuation of the medication. People with previously higher intellect 
generally scored highly whereas their actual functionality in terms of day­to­day 
activities and social interactions was grossly impaired. Prescribers and HCPs in 
specialist services were generally aware of the limitations of the MMSE in 
clinical practice and did not rely on it as a single rating tool. This resulted in a 
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battery of tests used to assess efficacy in some people whereas in others a 
more global and possibly subjective assessment of improvement was taken. 
This variability will be discussed further in 7.2.6. 
In June 2009 the 2006 guidance was updated again, not with respect to the 
economic costing model which was upheld (even in view of irregularities) but in 
terms of the use of the MMSE.31 It points out that the MMSE does not fairly 
reflect the diagnosis or staging of severity in those people with learning 
disability; sensory disability (such as hearing or blindness problems), or have 
English as a second language. It did not comment on the inappropriate use of 
this tool in people of higher intellect. In view of the fact that many of NICE 
decisions are based on trials using MMSE in all people (where pre­morbid level 
of intellect unknown) perhaps this underestimates treatment effects shown in 
studies and has implications for their next revision. 
Questions within the MMSE are location dependent126­128 with people scoring 
more highly in their own home than within an institutional setting. Perhaps as 
they are living in their own home, this is where the assessment should take 
place? Although many of the tools for assessing response to medicines were 
developed for use within a clinical trial setting it is less than clear of their 
usefulness in a naturalistic setting. It was also clear in both phases that many 
carers had little knowledge of the symptoms of AD (other than a poor memory) 
and how they manifested in day­to­day life. For example repetition and lack of 
initiative were seen almost as deliberate behaviours designed to annoy the 
carer. This ignorance points to a need for greater education for carers and PWD 
to inform them of the more global affects and effects of AD. This would enable 
them to understand more clearly how the medicines for dementia were affecting 
their loved one and perhaps reduce uncertainty in the area of response. 
It may therefore be more useful to develop a set of patient reported outcomes 
(PROs) for use in clinical settings which reflect the importance of response to 
these medicines from patient and carer perspective. As Frank reports “some 
treatment effects are known only to the patient” and “patients provide a unique 
perspective on treatment effectiveness.” 54 One could argue that this is common 
sense as the patient is living with the disease and is far more aware of the 
effects of change brought about by a treatment intervention than a medical 
observer. 
This research has provided the basis for a series of PROs which could be 
developed further and validated as a means of a more patient and carer­centred 
focus on measuring outcomes that are important in daily life. For example key 
PROs seem to be: social interaction; initiative; involvement in the 
environment/world and a returning or retention of self (personality). As 
mentioned in 7.3.1 and 7.3.2 these soft outcomes are important in their own 
right as the resultant improvements in social interaction seem to mitigate carer 
response to dealing with other aspects of caring, lessening burden and allowing 
adjustment to living with dementia. 
Currently the main use of PROs in dementia research is in the measurement of 
health­related quality of life (HRQOL) which suggest good correlation between 
PROs and those found on other QOL measurement tools in dementia.371­374 
They have also been used as a measure of the patient perspective in mild 
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cognitive impairment with some success.54 However there seems to be a 
reluctance to trust PROs in dementia as frequently their reporting differs from 
carer informant reporting in the same areas.374­377 Studies show that carers 
consistently rate HRQOL lower than PWD do, but this also occurs in other areas 
such as cardiac disease and breast cancer.374 However another perspective is 
that QoL PROs are also a valid perspective of the truth as experienced by the 
person with dementia. It has also been suggested that carers rate PROs lower 
if their carer burden and stress levels are high.373,375 This suggests to me that 
perhaps carers are rating their own QoL rather than that of the care­recipient. 
Lohr argues that as health is such a complex dynamic then perhaps more than 
one perspective is needed and that outcomes should be triangulated from the 
carer, patient and clinician perspective as well as other members of the 
multidisciplinary team if appropriate. 370 This seems imminently sensible, but 
what if the results are all different? More importantly does it matter if the person 
with dementia and their carer are happy? 
In terms of consistency NICE guidance can be construed as conflicting.31 
Although they suggest the use of MMSE81 and ADAS­cog82 tools in diagnosis, 
rating severity and response to treatment and base their cost models on these 
outcomes; in section 7.4 they go on to state that “surrogate measures of 
disease progression such as cognition do not correlate with clinically relevant 
outcomes such as behaviour, function and carer well­being…” 31This could be 
interpreted as mitigating reliance on such tools and encouraging clinicians’ to 
use their own clinical judgement, or just abdicating responsibility for the possible 
impact of supporting tools with acknowledged limitations. 
However this is an important statement which should be read by all decision and 
policy makers in PCTs in conjunction with key guidance points as it can directly 
affect patient and carer outcomes if medication is stopped or not started 
because of an arbitrary score on a rating scale. 
Point of 
Reflexivity 
As a clinical ward pharmacist in a previous career path I have 
completed many audits primarily looking at appropriate 
prescribing. I know of colleagues working in dementia 
services that routinely audit MMSE scores of PWD on 
AChEIs and recommend treatment withdrawal on the basis of 
a low score. Without a real understanding of the relevance of 
these scores and an understanding that these can fluctuate 
on a daily basis and may not truly reflect responses that are 
important to PWD and their carers; well meaning HCPs can 
actually do a lot of damage to a patients (and their carers’) 
well­being. This type of audit does not just occur in hospitals 
nationwide but also in outpatients and PCT as a means of 
cost­saving. I find the thought distressing in terms of the 
potential for increased suffering for PWD and their families. 
There is recognition that there is limited health funding but if overt rationing by 
NICE is to be upheld then greater acknowledgement of these treatments on 
family members and carers should be taken into account.55 It could be 
suggested that the NICE 2006 decision was based on personal value 
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judgements of the economic advisory panel involved and did not adequately 
reflect those of PWD and their families.31 Having licensed medicines available 
with proven efficacy yet not being able to prescribe them seems non­sensical in 
the 21st century. The fact that health and social care costs are separate makes it 
easier to target medicines expenditure as a soft option. It is far more palatable 
to ration medication than make redundancies or perhaps address the 
inadequacies of mismanaged and inequitable service provision (in both health 
and social care). It has been suggested that as soon as the current licensed 
medicines come off patent and there are generic alternatives the decision will 
change; but for many this will be too late.235 Too many people will have suffered 
unnecessarily and for too long in the intervening period. 
7.3.4 Educational Issues 
A number of findings pointed to the need for greater educational resources and 
training to be made available for HCPs; carers and PWD. The educational need 
of HCPs at the front­line (GPs) was one not only of knowledge but also in the 
best ways of communicating with PWD and their carers.80,81 GPs may not be 
experts in diagnosing dementia but there should be an awareness of the 
associated symptom pattern and an understanding of the difference from normal 
ageing. One of the underpinning tragedies of findings reported in the NDS was 
that although there is an estimated 700,000 people in the United Kingdom with 
dementia, only 400,000 of these are formally diagnosed and less than this 
number are receiving appropriate treatment and/or health and social service 
support.41 This information indicates there are a great many families and 
relationships suffering in silent despair from the effects of living with this 
disease. 
Findings from these two small studies highlight the anguish and burden of 
caring for a person with dementia that had been able to access treatment and 
support; what must it be like for those that have not? It is hard to tell if this lack 
of identification and referral to appropriate services is due to an underpinning 
ethos of ageism,67,68 the stigma of a mental illness and/ore therapeutic nihilism 
seemingly engrained in many front­line practitioners.80,81 Lay participants in 
phase one commented on these attitudes being less than helpful and generally 
obstructive in their search for information and support. 
In terms of communication skills and consultation etiquette it seems that some 
HCPs have a lot to learn about how to support people asking for help. There is 
also a need to revisit the structure of the consultation for PWD and their carers 
and to ascertain what type of engagement best suits participants needs. There 
is a need to protect the best interests of the person with dementia and maintain 
confidentiality where possible and this may best be done apart from their carer 
at times. However to ensure a complete picture of what the clinical situation is at 
home, carer views need to be explored, and again this may need to be 
completed alone to prevent discord or upset for those PWD retaining insight. To 
complicate things further shared decision­making may need to be negotiated 
between all parties together. This obviously could be seen as time consuming 
for the HCP involved but findings suggest that if carers’ viewpoints are not heard 
this builds resentment which ultimately negatively impinges on their continued 
ability to care. Interestingly a simple phrase like ‘how are you coping’ was seen 
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by Ann (L1) as making all the difference to how she felt within the consultation 
and in her role as a carer. 
People with dementia and their carers also needed information about the 
illness, its progression and what to expect in terms of changed behaviours and 
activities and how best to cope with these.41,301,302 This information needed to be 
also provided in a written format so that it could be referred to at a later date and 
the information needed to be tailored to the individual so that it helped their 
sense­making processes of what was actually happening.39­41 It was evident 
that some carers did not understand that the behaviours they found most 
annoying (repetition; lack of initiative; lack of conversation and mood changes) 
were in fact part of the dementia syndrome and not a deliberate attempt to 
annoy them. Being aware of disease­related changes with guidance on how to 
manage these can reduce frustration and anger in both care­giver and care­
recipient. 
7.3.5 Pharmacists and Medicines Management Issues 
Results from both phases of the research highlighted a large number of 
medicines management concerns for PWD and their carers. These included: 
difficulties in managing compliance and accessing the full supply of a 
prescription; problems with medicines administration, incorrectly labelled 
prescriptions, managing titration regimens and advice, information and support 
about side effects and disease management. 
All of these problems or difficulties could be covered by the pharmacist offering 
a medication usage review (MUR) service222 for PWD and their carers but there 
was no evidence of any proactive help or support by pharmacists. Bob and 
Judy’s and Chris and Sue’s experience in phase two of receiving incorrectly 
labelled medication and the lack of the dispensers initiative in checking an 
incorrectly written prescription are examples of levels of very poor knowledge in 
the area of medicines for dementia in community pharmacy. It also indicates a 
very poor level of duty of care by the pharmacist for the individual which 
conflicts directly with the professional practice guidance for pharmacist.32 
Point of 
Reflexivity 
After presenting an oral paper at the British Pharmaceutical 
Conference in 2006 about lay perspectives on the medicines 
for dementia I was commissioned to write an article on how to 
undertake a MUR in dementia for a national pharmacy 
magazine aimed primarily at community pharmacists.395 The 
article was also linked to the national CPD competency 
framework for pharmacists.396 However it remains unclear 
how effective these sorts of publications are and whether 
they actually change practice by enhancing knowledge. 
In terms of supporting people to achieve compliance the study findings showed 
no active input by pharmacists into the management of monitored dosage boxes 
(compliance aids) with these being filled either by the person with dementia or 
carers. As described in the findings, many PWD had concomitant illness and 
medication and were taking anywhere between one and 10 different medicines. 
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This can make for a very complex pharmacological cocktail with the potential for 
interactions, side effects and iatrogenic disease.397 It would seem that when 
dispensing a prescription for a medicine for dementia there was no active 
thought process by the pharmacist involved about giving advice on the 
medication or compliance, checking possible interactions with concomitant 
medication or obtaining repeat supplies. A compounding factor was that often 
these prescriptions were supplied by the specialist service and therefore would 
not be on the same prescription form as the person’s regular medication. This 
makes it important for pharmacists to check concomitant medication and illness 
if they do not have a record of it on pharmacy medication records. There 
perhaps is also a need for individuals to make a relationship with a specific 
pharmacy in order to maintain continuity of care. 
There are very few publications of the role of the pharmacist in dementia care 
and the majority are from the United States.384,398­400 In 1998 the potential for 
pharmacist involvement in medication review; input into care of people with 
behavioural symptoms and the promotion of AChEIs as an effective treatment 
was proposed.398 In 2008 the American Pharmacists Association published a 
‘White paper on the expanding role of the pharmacist in caring for individuals 
with Alzheimer’s disease.’ 399 It went on to give guidance for better education 
and training at undergraduate and postgraduate levels. 399 They authors 
described the top eight pharmacist roles and rated these out of a 100 in terms of 
perceived improvement to the care of people with AD. 399 These are listed in the 
Table 7.1 below. 
Table 7.1 Impact of Pharmacists’ activities on improving care for people 
with AD* 
Pharmacist Activity Impact of Care on 
People with AD (%) 
Providing general medication therapy review 69.2 
Incorporating pharmacists into support groups and 
education programmes 
69.2 
Counselling individuals with AD on medication 53.8 
Improving adherence and compliance to medication 
regimens 
53.8 
Delivering community education programmes 46.1 
Conducting memory services 38.4 
Serving as a source of referrals to other healthcare 
practitioners and local resources 
38.4 
Directing individuals with AD to pharmaceutical 
maintenance programmes 
23 
* Adapted from Skelton 2008399 
In the United Kingdom there is currently no guidance from the Royal 
Pharmaceutical Society of Great Britain (RPSGB) on the role of the pharmacist 
in the care of people with dementia or specific advice for training at 
undergraduate or postgraduate level. However in 2008, representing the United 
Kingdom Psychiatric Pharmacy group (UKPPG) I collaborated with the RPSGB 
to develop the response to the National Dementia Strategy (NDS) consultation 
for potential pharmacist input to the objectives of the NDS.401 I have also written 
Practice Guidance documentation for the Pharmaceutical Care of People with 
Dementia and the monitoring of medicines for dementia as part of a toolkit 
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aimed at enabling primary and community care pharmacists to support people 
with mental health problems.224 For each mental health area (including 
dementia) the toolkit links possible pharmacist roles at the essential, enhanced 
and advanced levels (see 2.3.2.1) as well as at pharmacist prescribing level. 
These correlate well with those suggestions proposed by the American White 
399 paper. 
However it is clear that there is a real need for increased education for UK 
pharmacists across all sectors in the recognition and management of dementia 
and their potential input. Two recent CPD papers published in the 
Pharmaceutical Journal (the mainstream publication of the RPSGB) outlined the 
background to AD402 and other dementias403 but there was no information about 
how best to support people and/or their carers and families. Perhaps the best 
indication of the narrow medication­related focus some pharmacy practitioners 
hold. There is a need to re­address this pharmacist­medication focus to a more 
holistic patient­focussed care if the aims of the Pharmacy White paper are to be 
fulfilled.223 
There also needs to be recognition of the need for specific education on 
dementia and the associated public, social and healthcare impacts at 
undergraduate level as well. This lack of knowledge may be reflected in a lack 
of proactive service provision to PWD and their families. A study in 2003 
highlighted that pharmacists were commonly involved in referral of people with 
concerns about probable dementia to dementia services. 404 However there was 
no indication of further involvement in multidisciplinary team working or at a 
specialist level in terms of medication review404 even though Wagner405 had 
previously highlighted the role of clinical pharmacists in secondary care in 
medication review services. 
7.3.6 Variability 
In phase one the results highlighted great variability across and within locations 
in a number of areas. These variability’s included: 
•	 access to treatment, information, support and/or specialist services, 
•	 differing responses and attitudes from HCPs, 
•	 differing effects of treatment, side effect rates, monitoring methods and 
follow­on treatment. 
In terms of variability in carer support it is hoped that the six key objectives of 
‘Shaping the Future of Care Together‘ document; which follow, will help to 
address this experienced inequity: 
1.	 the right for people to have support and care needs addressed to stay as 
independent for as long as possible 
2.	 access to an equitable care and support needs assessment 
3.	 a care service package that is seamless and holistic 
4.	 that people can find their way through the care and support system easily 
5.	 that services are based on personal circumstances and need, and 
6.	 people will have a say in how their own funding for care services is 
decided.391 
The implementation of the NDS will hopefully improve the awareness of 
dementia, lessen associated stigma, promote the need for holistic care and 
result in a more informed workforce with a better ability to support PWD and 
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their families.41 However more training is perhaps needed in communication and 
consultation skills needed to relate effectively with both PWD and their carer 
and also within wider health and social care services to address the issue of 
ageism that is currently perceived and experienced by many. 
The variability in access to treatment is something that will need greater input in 
terms of earlier recognition by frontline HCPs and increased awareness of the 
perceived benefits of these medicines by people who take them and those that 
care for them. The NDS highlighted the presence of postcode prescribing and 
this perhaps reflects the misunderstanding of the perceived benefits of these 
medicines by policy and decision­makers at a local level.41 However it may be 
difficult to address this issue when the value­based judgements of NICE are 
couched within a so­called evidence­based framework. 
The NDS has 17 objectives which it claims will improve dementia care services 
within England.41 These are outlined in Table 7.2 and linked to the findings from 
both phases of this research. Only objectives 9 (relating to intermediate care 
provision),10 (relating to technology) and 12 (relating to palliative care) were not 
mentioned by participants. This may be because they had no experience in 
these areas rather than no viewpoint. 
In terms of a national strategy the proposed NDS seems both comprehensive 
and far­sighted. It is also supported by government funding over the next two 
years which is a first for dementia care services. As mentioned earlier what will 
be needed is a change in the ethos of local PCTs and organisations supporting 
PWD and their families on how best to implement initiatives to achieve the 17 
objectives locally. This will need planning and coordination plus buy in from all 
stakeholders. 
What would seem imminently sensible would be the appointment of a champion 
trained in dementia care mapping (DCM) or patient­centred care to promote a 
patient­centred and holistic approach to care provision in each PCT and 
organisation providing dementia­related services.199,200 Along with this is the 
need to ensure that HCPs and related staff supporting PWD and their families 
are also adequately trained in the DCM approach. 
It is also important that as part of the NDS there is a concurrent drive to 
increase the general publics’ awareness of how they can best reduce their own 
risk of dementia in the future. This includes public health issues being 
addressed such as healthy eating and exercise for the mind and body406 and 
reduction of modifiable risk factors such as cardiovascular disease.102­105 It is 
also important that people understand that some protective factors such as 
drinking red wine are health risks in themselves.407 Community pharmacists 
would be ideally placed to support public health initiatives106 which should 
accompany the implementation of the NDS.41 
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Table 7.2 Linking Study Findings to the National Dementia Strategy Objectives

NDS Objective Research Findings & Implication for Practice 
1. Raise awareness of dementia and 
encourage people to seek help 
Training of frontline staff is needed to achieve this and also increased knowledge of 
referral and support systems for diseases management (pharmacological and non­
pharmacological) as the therapeutic nihilism experienced by many carers and PWD 
in phase one actually put people off seeking help. 
2. Good­quality, early diagnosis, support and 
treatment for people with dementia and their 
carers, explained in a sensitive way. 
Again phase one had many examples of people with diagnoses taking many years, 
then a perceived lack of access to effective treatment and support. Two carers spoke 
of their distress at the way in which the diagnosis was given 
3. Good­quality information for people with 
dementia and their carers 
Participants generally found this information from the Alzheimer’s Society or 
specialist services; with very little being available in general practice. 
4. Easy access to care, support and advice 
after diagnosis 
In phase two the participants were linked to specialist memory clinics so had ready 
access to advice and support. In phase one many participants had little or no access 
to advice and support because the person they cared for was not on a medicine for 
dementia. 
5. Develop structured peer support and 
learning networks 
The Alzheimer’s Society did this very well with participants from phase one 
developing other support groups for younger PWD which involved greater physical 
activity and social interaction. 
6. Improve community personal support 
services for people living at home 
There was evidence in phase one this was needed. 
7. Implement the New Deal for Carers There was evidence in phase one this was needed. 
8. Improve the quality of care for people with 
dementia in general hospitals 
Evidence from phase one indicated that perhaps earlier signs and symptoms could 
have been picked up in hospital for unrelated admissions so that referral and 
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investigation could occur. 
9. Improve intermediate care for people with 
dementia 
This was not discussed by any participant. 
10. Consider how housing support, housing­
related services, technology and telecare 
can help support people with dementia and 
their carers 
This was not discussed by any participant. 
11. Improve the quality of care for people 
with dementia in care homes 
Pat was keen to be more involved in deciding what type of homecare package she 
paid for so that her husband could be cared for at home. 
12. Improve end of life care for people with 
dementia 
This was not discussed by any participant. 
13. An informed and effective workforce for 
people with dementia 
There was evidence from both phases that the non­specialist workforce was 
generally was generally ill­informed. 
14. A joint commissioning strategy for 
dementia 
There was evidence from phase one that more effective interaction is needed 
15. Improve assessment and regulation of 
health and care services and of how systems 
are working 
Participants spoke of the fear of nursing home admission because of the perceived 
lack of appropriate care. 
16. Provide a clear picture of research about 
the causes and possible future treatments of 
dementia 
Participants spoke of the need for better research so that a ‘cure’ could be found and 
linked it to the specialty of cancer where cure rates seemed to better since greater 
research had been achieved. 
17. Effective national and regional support 
for local services to help them develop and 
carry out the Strategy. 
It seemed clear that there was a lack of a cohesive strategy for dementia care both 
across and within locations and that this probably reflected what was happening 
nationally. 
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7.4 Implications for Practice and Research 
In relation to the key findings summarised in 7.3 there are also important 
implications for practice and research and these will be briefly outlined next. 
7.4.1 Implications for Practice 
For those professionals working with and/or supporting PWD and their families 
there were a number of key implications for future practice; some of these have 
also been outlined in 7.3. These were related to support, medicines for 
dementia, therapeutic relationships, reducing carer burden, proactive input from 
HCPs and pharmacists especially, education and training and public health. 
The public in general and HCPs in particular need greater education about the 
signs and symptoms of dementia and the need for early referral and support. This 
support can be physical in terms of respite and day care or can be in the form of 
tailored information. This support and information needs to be offered proactively 
to prevent crisis and reflect the changing nature of the disease. (See 7.3.1 and 
7.3.4) 
Caring can be experienced and perceived as an onerous and lonely task; good 
supportive therapeutic relationships can help ease the perception of this burden 
by the carer and enable them to continue to care for the person with dementia 
at home for longer. Carers need individual assessment of needs so that 
identified stressors can be addressed and hopefully lessened. It is important 
that the individuals’ perspective of the carer burden is assessed as this seems 
to have the greater impact on the ability to continue caring.170,171,178,183,400 
These have implications for reduced rates of institutionalisation. (See 7.3.1 and 
7.3.4) 
The medicines for dementia are associated with global improvements impacting 
on sociability, relationships, mood and imitative all of which seem to mitigate 
the caring burden. Even though memory did not seem to improve much overall, 
this seemed less important than improvements in socialisation and the ability to 
complete tasks and activities of daily living. (See 7.3.1 and 7.3.3) 
The expectations and needs of both the person with dementia and their carer 
need to be addressed within a consultation to ensure that the therapeutic 
relationship can develop. There is a need for good communication skills with 
people with dementia and this may need to be addressed in further training. (See 
7.3.4) 
The findings suggest there is a need for increased and proactive input from 
pharmacists to ensure PWD and their carers have all their medicines 
management issues addressed. Pharmacists need to gain an increased 
awareness of the safer prescribing of these medicines and how to support 
compliance. 
For the above to occur there is a need for greater training and education in the 
awareness; the course of and the management (pharmacological and non­
pharmacological) of dementia. This needs to be across all sectors of the health 
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and social care service; the general community and embedded in 
undergraduate and postgraduate training of all HCPs. 
7.4.2 Implications for Future Research 
The findings from this research have highlighted a number of areas that could 
be pursued further and these are explained in brief detail below: 
1.	 I would like to explore the perceived effects of NICE 200631 on 
prescriber decision­making in dementia and the impact in terms of 
patient care. I would like to do this as a national study which uses both 
qualitative and quantitative methodologies. Qualitative methods such as 
focus groups and interviews would be used to explore perceptions and 
experiences and from these a series of research questions could be 
developed. These could be tested quantitatively as a national survey to 
investigate consensus of opinion and geographical differences. 
2.	 There is a part of me that since 2006 has wanted to interview each of the 
participants involved in the revision of NICE guidance; especially the 
economic modelling panel. I would like to explore in greater depth 
individual participant perceptions of evidence­based decision­making; 
value­based decision­making, and quality of life in relation to economic 
modelling. From a psychological perspective I would also be interested 
to explore their perceptions of the effect of their decisions on individuals. 
3.	 I would like to take forward preliminary patient and carer reported 
outcomes and explore these in relation to developing PROs as a means of 
understanding the experienced response to a medicine for dementia. This 
would involve a multi­centred study involving patient and carer user 
groups in the development and validation of this process alongside 
supportive clinicians. 
4.	 I would like to be involved with an educational intervention for community 
pharmacists to help improve the recognition of PWD and initiate 
proactive medicines management support services as appropriate. In 
reality the Centre for Postgraduate Pharmacist Education (CPPE) 
already host a learning event on dementia care in community pharmacy 
(which I helped to produce) however it seems not to have been reflected 
in findings from this research. However CPPE events are optional and if 
pharmacists do not have an interest they do not attend. Also due to 
stretched finances and time to deliver services pharmacists may not 
have viewed dementia as a priority in the past. However an enhanced 
educational event which links to key NDS objectives and commissioned 
service objectives from PCTs has the potential to support the 
implementation of the NDS and improve the provision of pharmaceutical 
care services to PWD and their carers. 
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7.5 In Conclusion 
The findings of this research present a qualitative picture of the lived 
experience of the perceived benefits of medicines for dementia and they 
support those from the literature which suggest that not enough consideration is 
given to the perspectives of PWD and their carers in terms of important 
outcomes of pharmacological treatment.253,386 What is surprising though is the 
seemingly institutionalised response of the inability to understand the 
importance of these global improvements in social skills, initiative; alertness, 
and maintaining relationships by policy makers. It is well known that dementia 
is a syndrome affecting many abilities such as speech; thinking, problem­
solving and visuospatial and perceptual ability, as well as memory.59 It seems 
less than compressible why the MMSE is still used as a means of deciding 
whether a medicine should be started, increased or withdrawn, when sensitivity 
to these softer improvements has not been demonstrated.31 Greater attention 
to the ‘softer’ global improvements is needed as these seem more important 
than improvements in memory and seem also to mitigate carer distress and 
perceived carer burden. In terms of the NDS objectives of reducing the stigma 
of dementia and the all pervading ageist response to older people presenting to 
services, it seems that there is a need for a national educational strategy which 
encompasses the community and all health and social care professionals 
related to dementia care service provision. It is also distressing to see that 
evidence­based decision­making is couched in such value­based judgements 
of the economic modelling panel.31 It seems outrageous that such a viewpoint 
can be held by policy decision makers who influence the lives and associated 
morbidity and mortality of people with dementia and their carers. 
Phase two is the first case study approach used in the exploration of the 
perceived benefits of medicines for dementia by people with dementia, their 
carers, prescribers and associated healthcare professionals. The findings 
supported a longitudinal and positive benefit of these medicines in the early 
stages of dementia and importantly enabled participants to salvage and repair 
relationships before the associated carer stress and burden became too great. 
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CHAPTER EIGHT: REFLEXIVITY ON RESEARCH 
In terms of my own reactions to designing and leading qualitative research 
studies; it has been a formidable learning curve. In Phase One I designed a 
qualitative study based on the use of interview and focus groups methods and 
IPA as an analytical methodology. As I had not led a research interview or a 
focus group before I had some learning to do. I attended a study day on 
designing and leading focus groups on campus and a study day on qualitative 
interviewing at the University of Surrey. I remember being very nervous for my 
first interviews. Luckily they were with Jack and Ann from location one and they 
were such lovely people it (the process of interviewing) became as natural as 
almost talking to them as old friends. I remember thinking that was probably a 
good thing to have happened as from an IPA perspective I was interested in their 
experiences and their interpretation of it and how this affected their own lifeworld. 
Throughout each of the interviews I was also aware of the possible affects of 
questions on the participant in terms of perhaps making them upset by reliving 
previously difficult experiences. However when people faltered or were tearful 
they were asked if they were alright to continue or wanted to stop; all of them 
continued. I understood that actually what was happening was a sharing of their 
experiences in terms of hurt, anger, frustration and disbelief so that perhaps their 
stories may be heard by someone who could possibly put a stop to it happening 
to others. I was also aware that because of who I am and the way I interact with 
people that possibly people opened up to me with a more frank response. But 
then again maybe they just wanted their story heard. 
At times I have found it very hard to contain my anger and frustration at health 
and social care policy and some of the professionals working in it after being 
privy to some of the stories that I was privileged to be told. I have struggled at 
times to maintain objectivity and not get emotionally or personally involved. In 
phase one there were times when I felt strongly there had been an injustice 
committed against both carers and PWD. My other half showed great patience 
with my post­interview or focus group ranting, but at times it was too much for us 
both. 
Phase Two was a more involved piece of research which my bench fee would 
not have been able to cover. I was fortunate to be awarded the Galen Award in 
July 2005 by the Pharmacy Practice Research Trust at the Royal Pharmaceutical 
Society of Great Britain which enabled the study to go ahead.350 Phase Two has 
seemed at times like it would never be completed; the first indication being the 4­
month period it took for LREC approval. This was then followed by very slow 
recruitment with the first patient being recruited after the study had been open 6 
months. Prior to this two other people had expressed an interest but one had 
withdrawn because ‘the doctor had said there was nothing wrong with him’ and 
the second person withdrew because he became very anxious about having to 
talk to someone he did not know. In Phase Two I learnt to speak about my 
feelings after an interview or observation into the recording device as it seemed 
to help more than off­loading to another person. It also has enabled me to track 
my thoughts and feelings about the changing relationship between the PWD and 
their carer over time; not something which always came through in the narrative. 
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However it has been an absolute privilege to be invited into the lives of the 
people in phase two and gain an insight of how things have progressed over 
time. I recently spoke to a friend of mine who is a Consultant psychiatrist who 
has refused to do outpatient clinics for twenty years as he always felt he got to 
know much more about the patient by visiting them in their own home. I couldn’t 
agree more. 
I found it incredibly interesting how some of the couple just carried on with their 
conversations (and arguments) with each other as if I wasn’t there; and in the 
first interviews almost used it as a means of sharing what things were like for 
each of them for the first time. I am very grateful for all the participants’ ability 
and willingness to share their experiences with me, as may of these were 
painful and distressing. Again I am also aware that by interviewing people three 
times over a 13month period, a sense of rapport was built up and at times it 
was difficult for them to still see me as a researcher. For me, it was difficult 
sometimes to not answer questions that were asked of me and respond as a 
clinical pharmacist (and at times as a therapist) but to direct them to their 
specialist or their GP because it was evident they actually needed the 
information then. I think the NDS objective of having a key contact person for 
information will be a great help in building continuity in information sharing but 
also strengthening a therapeutic relationship by familiarity. 
I have found that I have loved the face­to­face research contact with people and 
have also enjoyed the adventure into the world of IPA as a means of analysing 
qualitative data. I think because IPA is always asking you to view the narrative 
from the participant perspective I have gained a greater understanding and 
insight of what it is to live with someone with dementia. I find myself not 
understanding whether dementia is an illness or a disease; and perhaps feeling 
that it is more of a continuum of symptoms which ebb and change over a period 
of years. In some ways I feel a pejorative labelling of someone having a specific 
type of dementia is not really helpful; we should be thinking more of it being a 
degenerative process and where possible attempting to slow or halt progression 
and treat signs and symptoms appropriately as they occur (using 
pharmacological and/or non­pharmacological approaches). 
As a pharmacist I have gained a greater insight into the actual effect of dementia 
on communication and relationships and how this can totally destroy a carer’s 
ability to love the person they once did. I think it is a terrible thing that we cannot 
support carers earlier and more effectively so that this stage is not reached. In 
terms of the medicines for dementia, they are not a cure; but they seem 
associated with global improvements for many. These may not be easily 
recognised at the time; perhaps because some have been living with the 
degenerative process over a long period of time and have less feeling for how 
things were. What was clear was the experience of progression of one of these 
medicines was withdrawn. For other people these medicines were like ‘magic 
pills’ and impacted positively in all areas of their lives. For me the greatest impact 
was watching people being able to initiate and contribute to conversation and 
observe the relationship between the person with dementia and their family 
improve. Seeing how Bob’s interaction with his grandson improved over the time 
of the study was inspiring and hammered home how many people this disease 
actually affects. It is like a stone being thrown into a still pond; with the resultant 
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ripples being people affected by the loss of a person’s social and communication 
skills as well as the effects of the resultant behavioural and mood changes. 
Reflecting on my reflexivity I see that I have written it as a reflective piece on my 
journey from novice to more experienced qualitative researcher. But I am aware 
that my reflexivity has shaped and directed the flow of this research and the 
interpretation of the findings. My epiphany in the use of IPA has been previously 
described in Chapter 4 as a reflexive point and I can see that it has really driven 
my interpretation of the findings and ensured that they have been driven by the 
experience of the participants and not my interpretation of that. 
I feel a strong sense of responsibility for disseminating the results of both phases 
of this research in journals that will be read both by HCPs and those involved 
with policy change as it is important that the associated suffering of living with 
dementia is reduced. I have presented a number of oral and poster presentations 
on findings plus one commissioned article. Please see Appendix A8­1 for further 
details. 
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APPENDICES 
Appendix A1­1: Abbreviated Mini­mental Test 
Hodkins – an example of an Abbreviated Mini­mental Test Scale (AMTS) 
The following questions are asked: 
1.	 Age 
2.	 Time (to nearest hour) 
3.	 Address for recall at the end of the test e.g. 42 West Street. This address 
should be repeated by the patient, to ensure that it has been heard correctly. 
4.	 Year 
5.	 Name of the hospital 
6.	 Recognition of 2 persons (doctor/nurse), or 2 objects (watch and pen) 
7.	 Date of birth 
8.	 Year of First World War 
9. Name of present monarch 
10.Count backward from 20 to 1 
A score of 7 or greater is indicative of normal cognitive function. 
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Appendix A1­2: Mini­Mental State Examination 
(adapted from Folstein et al.) 
Patient Name ....................………………………………..

Date of birth...................…………… Date of test....................

Section Questions:	 Max Pt 
1. Orientation 
a) Can you tell me today's date/month/year? 
Which day of the week is it today? 
Can you also tell me which season it is? 5 
b) What city/town are we in? 
What is the county/country? 
What building are we in and on what floor? 5 
2.	 Registration 
I should like to test your memory. 
(name 3 common objects: e.g. “ball, car, man”) 
Can you repeat the words I said? 
(Score one point for each word)	 3 
(repeat up to 6 trials until all three are remembered)

(record number of trials needed here)

3.	 Attention & Calculation 
a)	 From 100 keep subtracting 7 and give each answer:

stop after 5 answers. (93­86­79­72­65­).

Alternatively 
b)	 Spell the word 'WORLD' backwards. (D­L­R­O­W). 5 
4. Recall 
What were the three words I asked you to say earlier? 3 
(Skip this test if all three objects were not remembered during registration test) 
5.	 Language 
Naming: Name these objects (show a watch) (show a pencil) 2 
Repeating: Repeat the following: "no ifs, ands or buts" 1 
6.	 Reading: 
(show card or write "CLOSE YOUR EYES”) 
Say “Read this sentence and do what it says” 1 
Writing: Now can you write a short sentence for me? 1 
7.	 Three stage 
(Present a piece of paper) 
Command: Take this paper in your left (or right) hand, 
fold it in half, and put it on the floor. 3 
8	 Construction Will you copy this drawing please? 1 
Examiner: Max Score 
Notes Patient Score 
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Scoring the Mini­mental State Examination (adapted from Folstein et al.)81 
1. Orientation 10 points 
a) Ask for specific facts omitted until a response has been given to all 10 parts of the

question. Score one point for each correct response.

b) Ask each question in turn. Score one point for each correct response.

2. Registration 3 points 
Name a sequence of three unrelated objects e.g. (apple, table, penny) or (ball, car, man) 
taking about a second to say each word. Ask the patient to repeat all three words. Score 
one point for each word remembered at first attempt. If response is incorrect after 
repeating the test five more times, recall cannot meaningfully be tested ­ skip section 4. 
3. Attention & Calculation 5 points 
a) Serial sevens: score one point for each correct subtraction of seven. 
OR 
b) Spelling backwards: one point is deducted if a letter is missing and one point is 
deducted for each remaining letter out of sequence (e.g. DLRW = 4; DLORW or DLW = 
3). 
4. Recall 3 points 
Score one point for each word recalled. 
5. Language ­ naming/repetition 3 points 
Score one point for each correct response. One trial only for the sentence. 
6. Language – reading/writing 2 points 
· Score one point only if patient actually closes their eyes. Score one point if 
sentence contains a subject and a verb and is sensible. Ignore mistakes such as 
grammar or punctuation. 
7. Language ­ three stage command 3 points 
Give the patient a piece of plain blank paper and follow the command. Score one point for 
each part correctly executed. 
8. Construction 2 points 
Score one point if each pentagon has five angles and two angles intersect. Ignore 
tremors or rotation of pentagon. 
The possible relationship between the MMSE and the progression of AD 
It has been suggested that the rate of cognitive decline as measured by the MMSE score

also correlates with the progression and severity of the disease itself.

Scores range from 0­30. (the lower the score the greater the impairment).

A score of 24 or greater is considered indicative of normal cognitive function. However, a

score of 27 in an individual with previously high intellect may be indicative of quite severe

intellectual impairment.

Table 1­1a: Interpreting MMSE scores 
27­30 Normal 
25­26 Possible dementia 
10­24 Mild­moderate dementia 
6­9 Moderate­severe dementia 
<6 Severe dementia 
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Appendix A3­3: Information Sheets 
(Patient only versions will be presented throughout to maintain brevity) 
(Patient Information Sheet Version 3 25th July 2005) 
Determining Attitudes to the Prescribing of 
Medicines for Dementia 
Lead Investigator: Miss Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath, BATH BA2 7AY 
Telephone: 01225 383677 (work) 
Telephone: 07891790025 (mobile) 
Email: prsdat@bath.ac.uk 
Information for People who take Medicines for Dementia on the 
Interview or Focus Group Study 
Dear Sir or Madam, 
We are inviting people who take (or have taken in the past) medicines for dementia to 
take part in a study. The study is to help us to find out what the attitudes and beliefs 
are of people that take these medicines may be. In the study we will use interviews 
and/or focus groups to help us find out this information. Focus groups are when 6 to 
10 people take part in a group discussion to share ideas, thoughts and beliefs about a 
particular subject. Interviews are when a person talks one­to­one with a researcher 
about their thoughts and beliefs on a particular subject. You are only being asked to 
take part in either a one­to­one interview or in a focus group; not both. 
You are being invited to take part in this study. Please take time to read the following 
information carefully. Please ask if there is anything that is not clear or if you would 
like more information. 
Thank you for reading this. 
1. Why are we doing this? 
We want to know your views on the medicines that you take for dementia including 
how effective you think these medicines are. We would also like to know your views on 
how these medicines affect your day­to­day life. 
2. Why do we ask you? 
You are being invited to take part in the study to give your views because you are a 
person who currently takes or has taken medicines for dementia. You also attend a 
local Alzheimer Society branch for support. We are planning to interview up to 6 
people in total who take medicines for dementia. Alternatively you may choose to 
attend a focus group session for people with dementia, which will be held at your local 
branch. If you agree to take part in the research, you would only be taking part in one 
interview session or attend one focus group session. We would expect an interview to 
last about 20 to 30 minutes and the focus group may last between 40 and 50minutes. 
3. Do I have to take part? 
No, it is up to you to decide whether or not to take part. If you do take part you can 
keep the information sheet and will be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. If you 
decide not to take part, any support that you receive at the local Alzheimer Society 
branch will not be affected. 
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4. What will happen during the study? 
If you agree to take part in the study, you will be contacted by Miss Denise Taylor, the 
person doing the research, who will explain things to you in further detail. She will ask 
you if you would prefer to have a face­to­face interview or to be part of a focus group 
session. 
If you would prefer to be part of a focus group session, Miss Denise Taylor will meet 
you at the local branch before the focus group begins. The researcher will explain 
what you have to do and if you agree to take part in the study you will then be asked 
to sign a consent form. The focus­group session will be tape­recorded and you will be 
asked for your consent for this to happen. When the tape is being written up, you will 
not be able to be identified in anyway from the recording. 
There may be up to 9 other people taking part in the focus group session and you will 
be introduced to the other participants before it starts. During the focus group the 
lead researcher will follow a guide in order that the aims of the research are met. We 
expect the session to last between 40 and 50 minutes 
If you decide that you would prefer an interview, the researcher will arrange a suitable 
time and place for the interview to occur. This could be in your own home or at the 
local Alzheimer Society branch. The interview will be tape­recorded to ensure the 
information is recorded accurately and you will be asked your consent for this to 
happen. You will be asked to sign a consent form if you agree to participate in the 
study and if you agree for this recording to take place. When the tape is being written 
up, you will not be able to be identified in anyway from the recording. During the 
interview the researcher will follow a guide so that the aims of the research are met. 
We expect the interview to last between 20 and 30 minutes. 
5. What are the possible disadvantages and risks of taking part? 
Taking part in the study is unlikely to put you at any risk. If you were to get upset by 
a question asked in the interview or focus group session, the researcher will deal with 
these sensitively. You may ask to discontinue the interview or to leave the focus group 
at any time. If this happens then Mr/Mrs X from the local branch and/or the lead 
researcher will contact you the next day to ensure that you are okay. 
6. What are the possible advantages of taking part? 
We do not expect there to be any advantages to you in taking part. However the 
information you give us will help us to understand what people who take medicines for 
dementia think and believe about their treatment. These findings will help us to 
educate healthcare professionals involved in the prescribing of these medicines. 
7. What if something goes wrong? 
In the unlikely event that you are harmed by taking part in this research project, there 
are no special compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have to pay for 
it. Regardless of this, if you wish to complain or have any concerns about any aspect 
of the way you have been approached or treated during the course of this study, you 
can contact the Lead Researcher; Miss Denise Taylor, Department of Pharmacy and 
Pharmacology, University of Bath, Bath BA2 7AY. Telephone: 01225­383677, or her 
supervisor Dr Marjorie Weiss at the same address on telephone 01225­386787. 
8. Will my taking part in the study be kept confidential? 
All information coming from the interview or focus group will not have your name on it 
and will not be shared with anyone else who is not part of the study. The Alzheimer’s 
Society will not know what you have said. The interviews will be typed up by a 
secretary who will not know who you are. If your name is mentioned on the tape­
recording it will not be typed up in the written report. Once the study is completed the 
interview tape will be kept in a secure place for 10 years and then destroyed. You can 
see the written report of your participation at any time. 
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9. What will happen to the results of the research study? 
We may have some quotes of what you say printed in a journal or magazine. If this 
happens your name and details and the local branch details will always be taken off, 
so that nobody will know whose words they are or where they came from. If you are 
interested to know more about the results, you should contact the Lead Researcher for 
further information. 
10.Who is organising and funding this research? 
The study is being organised as part of a doctoral thesis (PhD) by Miss Denise Taylor, 
the lead researcher. The study is funded by the University of Bath. 
11.Who has reviewed this study? 
This study has been approved by a research ethics committee (the Central Manchester 
Local Research Ethics Committee) and by the University of Bath. 
12.Who do I contact for further information? 
If you have any other questions, please contact Miss Denise Taylor at 
prsdat@bath.ac.uk , Department of Pharmacy and Pharmacology, University of Bath, 
Bath, BA2 7AY. Telephone 01225­383677 (office) or 07891­790025 (mobile). 
13.What do I do now? 
If you would like to take part, please complete the reply slip below and return it in the 
stamped addressed envelope provided. The researcher will contact you over the next 
few days to discuss the research with you. If you do not wish to take part you do not 
need to do anything. You will not be contacted again. 
Thank you for your time in reading this information 
I would be interested in helping with this research study about the 
prescribing of medicines for dementia. 
Name:

Address:

Alzheimer Society Local Branch:

Telephone: (please indicate when the best time to contact you is)

Thank you for your help! 
Please return to: 
Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath 
Claverton Down 
Bath BA2 7AY 
Telephone: 01225 383677 
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Appendix A3­4: TOPIC GUIDE Phase One 
(Only patient version will be presented) 
Patient Interview Topic Guide, Version 2 2nd June 2005. 
Determining Attitudes to the Prescribing of 
Medicines for Dementia 
PATIENT VIEWS ON MEDICINES TO TREAT DEMENTIA 
TOPIC GUIDE 
We are interested in finding out your views and beliefs about the medicines that are 
used to help treat the symptoms of dementia or Alzheimer’s disease. We would like to 
find out about your involvement in the prescribing process of these medicines and how 
effective you think they are. We are also interested in how these medicines may affect 
your day­to­day life. 
All information from the interview will be treated in the strictest confidence – so we 
will not use your name or refer to any people you might mention directly by their 
name. The tapes from this interview will be assigned a number and that is how we will 
refer to you when we present this information to other people. 
1.	 Background/Personal Information 
•	 Tell us the name of medicine for dementia that you are taking 
•	 Tell us about when you started taking it and how long you have taken it 
for now 
2.	 The prescribing process 
•	 Were you given sufficient information about the medicine prior to 
starting 
•	 Were you told about the effectiveness of the medicine? 
•	 How do you remember to take the medicine every day? 
•	 How do you monitor the effects of the medicine? For example for 
adverse effects; effectiveness of treatment etc 
•	 Before you were started on this treatment, did you discuss an end or 
withdrawal date with the prescriber? 
3.	 The effect of these medicines on day­to­day life 
•	 Tell us about how these medicines affect your day­to­day life in the 
following areas: 
­ Adverse effects 
­ Remembering to take the medicines 
­ Problems with increasing the dose 
­ Ordering and supply issues 
­ General effects on day­to­day life 
4.	 How effective are these medicines? 
•	 Tell us about the effects these medicines have on the ability for you to 
lead life as per your usual routine. For example what are the: 
­ Positive effects 
­ Negative effects 
­ Important improvements to you? 
­ Important effects for the person you care for? 
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Carer Focus Group Topic Guide, Version 2 2nd June 2005.
5.	 When should they be stopped/withdrawn? 
•	 Tell us about when you think these medicines should be stopped or 
withdrawn? For example:

­ Adverse effects?

­ No further improvements?

­ Other?

6.	 Role in decision­making process? 
•	 Tell us about your involvement with any decision­making about the 
medicine when you go to your clinic visits; 
•	 Is anyone who helps to care for you involved in any decision­making? 
•	 Do you think you get sufficient information to make decisions? 
7.	 Any other issues? 
•	 Is there anything else you would like to tell us about which is important 
to you and/or the person that may care for with respect to these 
medicines? 
THANK YOU FOR YOUR HELP 
If you would like to receive a summary of interview findings, please complete the reply 
slip below and return it in the stamped addressed envelope provided. The researcher 
will send you the summary details once they have been compiled. 
Thank you for your time 
I would like to receive a summary of the findings of this interview about the 
prescribing of medicines for dementia. 
Name: 
Address: 
Alzheimer Society Local Branch: 
Thank you for your help! 
Please return to: 
Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath 
Claverton Down 
Bath BA2 7AY 
Telephone: 01225 383677 
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_________________ ______________ ______________________ 
_________________ ______________ ______________________ 
_________________ ______________ ______________________ 
Appendix A3­5: Patient Consent forms 
(Only patient versions will be presented) 
Patient Consent Form Version 2 21st September 2005. 
Determining Attitudes to the Prescribing of 
Medicines for Dementia 
Lead Investigator: Miss Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath, BATH BA2 7AY 
Telephone: 01225 383677 (work) 
Telephone: 07891790025 (mobile) 
Email: prsdat@bath.ac.uk 
..................................................................................... .....................................................

Please initial the box 
1.	 I confirm that I have read and understood

the information sheet dated 25th July 2005

for the above study

2.	 I understand that my participation is voluntary

and that I am free to withdraw at any time

3.	 I am happy to have the interview

audio­tape recorded

4.	 I agree to take part in the above study 
Name of participant Date	 Signature 
Name of witness to Date Signature 
Consent process 
Name of researcher Date Signature 
1 for participant; 1 for researcher 
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Appendix A3­6: Branch Letter 
Branch letter, version 2 3rd June 2005 
Department of Pharmacy & Pharmacology 
Dear

I am a clinical pharmacist and Senior Teaching Fellow at the Department of Pharmacy

and Pharmacology at the University of Bath. I am currently registered to complete a

PhD as a part­time student.

My area of interest for some time has been the treatment and care of people with

dementia. I am particularly concerned about the role that the medicines used to treat

the symptoms of dementia have on the day­to­day lives of the people who take them

and the carers who care for these people. Also of interest is the fact that the carers of

people with dementia have to agree (according to NICE guidance 2001) to ensure

these medicines are taken by the person they care for and agree in principle to a time

when which these medicines will be withdrawn.

My research study consists of three phases; the first of which is a series of 5 or 6

focus group sessions to be run with carers of people taking medicines for dementia. I

would like these focus group sessions to be run in local branches of the Alzheimer

Society in the South­West who agree to participate in the study. I hadn’t wanted to

organise carer focus group sessions that were attached to a memory or research clinic

because of the possibility carers may feel that they ‘had to’ participate or felt that

their views may some how affect the treatment and support that they receive.

At this stage I hadn’t intended to invite people taking these medicines to the focus

group sessions because of possible problems in assessing capacity to consent. Plus I

feel that these people probably do better in face­to­face interviews with one person

rather than in a large group as it is easier to concentrate on one person speaking

rather than many. So I will be asking people with mild dementia who are taking

medicines for dementia if they would like to participate in the study by having a semi­

structured interview. I would expect to complete 5 interviews in total, perhaps one at

each of the participating branches.

What I am asking for is the opportunity for me to run a focus group session and

perhaps an interview (although these can also take place at the persons home if that

is more convenient) at one of your local branch meetings at some point over the next

3 to 4 months. A focus group lasts for about an hour and involves about 6 to 10

people being asked to give their views and beliefs on a certain topic.

To help you understand more clearly the content of this session, I enclose a copy of

my research protocol, a copy of the information sheet and topic guide for both the

interview and the focus group sessions plus an advertising flyer for the event.

The research is currently going through a MREC application at the Central Manchester

Research Ethics Committee, which considers whether any possible ethical dilemmas

have been considered by the researcher.

The ethical dilemmas as I see them are:

1.	 I can advertise the event but I cannot actively seek participants. To this end I 
need to ask for a contact person at the local branch who would be able to hand 
out information sheets to those people expressing an interest in joining the 
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session. (See attached). If the person does want to join the session they need 
to read the sheet and send me their contact details in a supplied stamped 
addressed envelope. I will then contact them and ensure they understand the 
study. 
2.	 I will need informed consent of the participants because I will be (with their 
permission) audio­taping the sessions to allow exact representation of their 
views to be made. All transcriptions will be anonomised and any identifiable 
factors removed. In any publications the branch name will also be removed and 
the session referred to as a number, e.g. focus group (or interview 1) one. Any 
audio­tapes and their transcripts will be kept in a locked cupboard in a secure 
room at the University of Bath for 10 years when they will be destroyed as 
appropriately. 
3.	 I am happy to supply a summary of the information obtained from the focus 
group to participants on their request and to enable me to do this I have asked 
for their addresses. The addresses will be stored separately to the transcripts. 
Again once this information has been sent to those requesting it, the addresses 
will be destroyed appropriately. 
4.	 It may be possible that a member of the focus group could become upset when 
recounting personal information about how these medicines have affected their 
lives and the life of the person for whom they care. I have worked with the 
elderly for some 16 years and feel that I should be able to deal with these 
instances in a sensitive manner. However, if possible it would be beneficial if 
there were a local branch representative who would be available during the 
session if the participant wanted to leave the focus group. 
I would be happy to fund refreshments (coffee, tea and biscuits for example) perhaps 
at the start of the event to enable people to relax prior to the session. I would also be 
happy to talk at a branch meeting if felt appropriate to discuss the outcomes of the 
wider study. 
I would be very happy to talk this through with you either face­to­face or on the 
telephone. My contact details follow at the end of this letter. Thank you for your time 
in reading this letter and I hope that it is something that you feel you would be able to 
support. 
Looking forward to hearing from you. 
Best wishes 
Denise Taylor 
Senior Teaching Fellow 
Telephone: 01225­383677 (work) 
Telephone: 07787717126 (mobile) 
Email: prsdat@ bath.ac.uk 
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Appendix A3­7: Advertising Flyer

Interview Advertising Flyer for Carers 
Draft 4: 25th July 2005. 
We, at the University of Bath would like a chance 
to interview you about your experience of caring 
for someone who takes or has taken medicines for 
dementia. 
An interview? What is that? 
It’s a one­to­one chat about your experiences of the effects of medicines for 
dementia on the person that you care for. 
How long will it take? About half an hour 
Where will it take place? 
Either here or in the comfort of your own home 
For further information please ask (contact name) from your local branch for an 
information leaflet. 
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Appendix A4­1: Categorisation of Carer Themes Phase One 
After IPA of the carer transcripts there were 131 themes generated. It then 
became a process of inductive and time consuming analysis of these. The process 
is described in 4.1. 
In the first analysis the themes seemed to settle into 8 superordinate themes; 
these were: 
1. Dealing with Uncertainty 
2. Seeking and Receiving Information 
3. Carer Expertise 
4. Living with a Degenerative Illness 
5. Dilemma in Decision­making 
6. Consultation Etiquettes 
7. Problems with diagnosis 
8. Trials and Tribulations of Medication 
Photocopies of the penned working of these superordinate themes in terms of 
critical analysis can be found next (pages Axx to Axx). These illustrate an initial 
attempt to understand how each of the themes interacted together as a whole 
explanation of the carer experience. 
On page A4xx a scan of one of the original pieces of working paper from the wall 
(Interaction with Healthcare Professionals) illustrates the eventual listing of three 
sub­ordinate themes. These were: Seeking information and help; Consultation 
etiquettes and Diagnostic issues. Further copies of the workings and organisation 
of these sub­sub themes are shown in pages Axx to Axx. 
This type of analytical process continued for each of the super­ordinate themes 
listed above until the (at that time) final super­ordinate themes presented in 4.1.1 
(and below) were settled. 
1. Carer expertise 
2. On Being a carer 
3. Living with a Degenerative Illness 
4. Interaction with Healthcare Professionals 
5. Trials and Tribulations of Medication. 
At this point I had to present to my colleague Dr Jane Sutton, the large pieces of 
paper with the sticky notes attached and explain my rationale for coding and 
analysis. 
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Appendix A4­2: Explanation of Superordinate Themes 
Superordinate Theme: On Being A Carer 
Becoming a carer resulted in a whole new persona and the perception that a life 
outside of caring was lost to them. This theme encompasses the associated role 
changes as well as the darker side of caring when the burden became 
overwhelming. 
Superordinate Theme: Interaction With Healthcare Professionals 
Many carer participants perceived that a major barrier or aid to their ability to care 
for a person with dementia was dependent on the successful interaction with a 
healthcare professional. However the perception for some was there was some 
unwritten test they needed to pass to receive the information, support or treatment 
they needed. Therefore many interactions’ with healthcare professionals were 
fraught with less than successful outcomes. 
Superordinate Theme: Living With A Degenerative Illness 
The term degenerative illness has been used in place of dementia or Alzheimer’s 
disease as the findings highlighted a chronicity of care and suffering associated 
with a continued and in many case unchecked progression in symptoms. Learning 
to live with this as a carer or a person with dementia was often dependent on the 
successful access to pharmacological treatment. 
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Appendix A5­1: Case Study Protocol

Case Study Protocol 
Living with Medicines for Dementia

– Patient and Carer Perspectives 
Denise Ann Taylor,

Department of Pharmacy and Pharmacology

University of Bath
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1. Introduction to the study 
Living with Medicines for Dementia- Patient and Carer Perspectives. 
The research proposes to explain whether the effect of a particular medicine for 
dementia on the day-to-day lives of people who take that medicine and those that care 
for them. is different if a different medicines is . The possible effects and perceived 
and/or experienced outcomes will be explored over time. The case study approach is to 
explain and explore whether a different medicine for dementia is associated with 
different outcomes. 
This study will compare patient outcomes with those perceived by carers; the prescriber 
of the medication and if appropriate a healthcare professional also supporting dementia 
care. Findings will also be compared with objective psychometric testing results recorded 
in the patients shared record. 
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1.1. The Study Research Team 
The Chief Investigators 
Miss Denise Taylor 
Senior Teaching Fellow,

Programme Lead for Pharmacist Prescribing

Department of Pharmacy and Pharmacology at the University of Bath.

PhD Supervisor 
Professor Marjorie Weiss 
Department of Pharmacy and Pharmacology 
University of Bath 
1.2. The Sponsors of the Study 
This study was funded by A GALEN award managed by the Pharmacy Practice Research 
Trust (PPRT) at the Royal Pharmaceutical Society of Great Britain (see later). The GALEN 
award is a research bursary awarded annually by the PPRT to support the development of 
research capacity in pharmacy practice research. It is made as a result of an annual 
bequest from Rowland Henry Williams for monetary support for research up to £10,000 
The Pharmacy Practice Research Trust 
The Pharmacy Practice Research Trust (the PPRT) was established in July 1999, by the 
Royal Pharmaceutical Society of Great Britain, as an independent research charity, with a 
broad objective to promote and develop the field of pharmacy practice research. “We 
aim to support and promote the professional practice and performance of pharmacists 
and the delivery of safe, patient focused services by the pharmacy workforce. We are 
committed to disseminating the results from research to ensure that the knowledge is 
used to inform evidence-based changes to policy, practice and services.” 
For more information please visit the website: www.pprt.org.uk 
2. Introduction to case study methodology and the purpose of the case study protocol 
The development of an appropriate case study protocol facilitates consistency in data 
collection between case study sites and is instrumental in maintaining the focus of the 
case study research to ensure reliability and ultimately quality of the findings. (Yin, 2003). 
This case study protocol includes: 
o An Introduction to the Study and the Purpose of the Study 
o Data Collection Procedures 
o Case Study Questions 
o Outline of Case Study Report 
2.1. An Overview of the Case Study 
Case study methodology was chosen as a research strategy for this project as it enables 
the researcher to make a thorough investigation of what actually happens in a given 
situation, and chronicles events that happen over time. Case study methodology allows 
the validation of quantitative data through the addition of qualitative information to 
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acheive triangulation of results in order to construct an overall robust picture of service 
provision (Yin, 2003). 
This study will use in-depth comparative case study methodology as a means of 
exploring a situation in which an intervention being evaluated has no clear single set of 
outcomes (Yin, 2003). In this research the situation is the day-to-day lives of people 
taking a medication for dementia and those that care for them. The intervention is the 
initiation of a medicine for dementia. The outcomes are multi-factorial, as these 
medicines are known to affect a range of domains including: the physical, mental, social 
and behavioural health of the person taking these agents and those of their carer. These 
domains can also affect quality of life and the wider social environment such as 
interaction with family and friends. 
It was proposed that here would be 8 case studies to investigate if there were differences 
between the cholinesterase inhibitors (donepezil, rivastigmine and galantamine); and the 
NMDA-receptor antagonist (memantine). Two other cases were chosen; the first to 
explore issues about how not being appropriate and/or refusing a medicine for dementia 
affected day-to-day life experiences; the second to explore the effect of the medication 
classes in combination. 
These are detailed in full, below: 
1. one where the medicine for dementia is donepezil; 
2. one where the medicine for dementia is rivastigmine; 
3. one where the medicine for dementia is galantamine; 
4. one where the medicine for dementia is memantine; 
5. one where an medicine for dementia has been withdrawn due either to adverse 
effects or lack of efficacy or has been swapped to another agent; 
6. one where there is co-prescribing of medicines for dementia; 
7. one where the person refused treatment, and 
8. one where the person was ineligible for treatment (e.g. because it was for a 
condition where these agents are not licensed such as vascular dementia). 
These case studies were chosen due to the issues in clinical practice when patients were 
first initiated on a medicine for dementia and to explore the dilemmas of when issues 
became complicated by things such as adverse effects of the reduction of efficacy after a 
period of time. Further information can be found in the study protocol. 
2.2 Data Collection Procedures 
2.2.1Access to Proposed Case Studies 
Potential patients were to be identified by clinic staff at a variety of locations to try to 
maximise the opportunities of recruitment. An aim was to attempt to recruit the person 
who might be eligible to take a medicine for dementia, before they actually started so 
expectations hopes and fears of the medicine could be explored and then compared with 
actual events and effects of the medicines over time. The researcher would not have 
access to the patients so recruitment was dependent on local clinicians identifying 
patients; giving them information about the study and then providing the actual patient 
information pack. (NB: originally there were only two recruitment sites; but when after 3 
months there had been no successful recruitment, two more were added (with LREC 
approval). Shortly after this one of the first two sites withdrew due to changes in their 
organisational policy so the lead clinicians agreed to help recruit from two further 
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Healthcare Setting 
1 
Research charity with a specialist interest in dementia 
2 Research memory clinic attached to care of the elderly wards in a 
large city 
3 Memory clinic as part of older people services at a community 
general hospital 
4 Memory clinic provided as part of a Community Mental Health 
Trust 
5 Memory clinic provided as part of a Community Mental Health 
Trust 
6 Memory clinic provided as part of a Community Mental Health 
Trust 
memory clinics. Each site had at least one research gatekeeper; these have been deleted 
for confidentiality purposes. 
2.2.2 Data to be Collected 
Patient and carers would be interviewed using a semi-structured interview technique to 
explore perceptions, experiences and viewpoints. They would be interviewed up to 4 
times over a 12month period. (NB: initially participants were to be followed up for a 
period of 6-months, however external events resulted in an increase to 12-months. 
Interviews were originally proposed prior to the start of the medication; 3 to 4 weeks 
after the start of the medication (to explore the incidence and severity and effects of 
possible adverse effects of the medication prescriber; again at 3 months to explore any 
titration issues and then at 6-months to establish if there were changes once an effective 
dose level was reached. Again the protocol needed to change as the procedures within 
each of the clinics change din response to concerns about the delays in access to 
treatment. Originally the clinics had seen patients at time 1 for physical and psychological 
investigation and they were also referred for other tests such as MRI or CT scans that 
were not available on site. Prior to time 2 the lead psychologist and the appropriate 
psychiatrist would discuss the possible diagnoses and the patient invited to attend at time 
2. At this visit the patient would receive their diagnosis and be able to ask for further 
relevant information before being invited back for a third visit where the medication 
would be explained and initiated. 
It had been planned that at time 2 the patient would be introduced to the study and 
invited to take part prior to straying the medication; however both original clinics 
reduced the process to two visits to reduce the time to initiation of therapy. This was 
because the literature supported findings that suggested delays in treatment represent 
lost function that may not be retrievable. Patients were then recruited at time 2 visit and 
the ability to explore perceptions and expectations of medicines prior to starting was lost. 
Prescribers and healthcare professionals were to be interviewed once during the life of 
the case study and with informed consent of all concerned an observation of a 
consultation between the prescriber and the patient (with/without carer would take 
place). 
Objective data from patient shared records would be accessed to see if documented 
findings supported claims by patients and their carers of the effects of the medicines for 
dementia. 
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Field Procedures 
This section explains procedures to be undertaken by the researcher when visiting case 
study sites. Following these procedures are important to ensure researcher and 
participant safety, as well as rigorous data collection. 
Lone working 
Lone work presents a greater potential for harm and may require more stringent 
precautions to comply with the law. Ideally researcher should work in pairs, but if this is 
not possible the following procedures must be followed. 
o	 The participant may wish for another person (that they know) to be 
present. The participant and researcher before hand must agree this. 
o	 The researcher must carry a dedicated mobile phone (which should be fully 
charged) that remains turned on during the visit so that they remain in 
constant contact with the research supervisor. 
o	 The researcher must ensure that the research supervisor has the address 
that they will be visiting. 
o	 The researcher must inform the research supervisor as they arrive at this 
address and as they leave this address. 
o	 If the researcher does not get in contact with the research supervisor 
after a specified time (1 ½ hours) the research supervisor must try to 
get in contact with them on the mobile phone or the phone number for 
the address supplied. 
2.3 Case Study Questions 
The research generally asks how and why questions about the effects of medicines for 
dementia on the day-to-day lives of those people who take them and those people who 
care for them. The second phase was a longitudinal study designed to explore the 
effects of medicines on the daily lives of people with early dementia and their carers 
over time. The objectives of this part of the study were to: 
1.	 explore lay and healthcare professional perceptions of the outcomes of medicines 
for dementia. 
2.	 explore whether there was consensus on perceived efficacy over time. 
3.	 explore perceptions on how medicines for dementia should be used in early 
dementia. 
4.	 to highlight the potential role of the pharmacist in supporting medication use in 
people with early dementia and their carers. 
5.	 to identify possible areas of educational need for healthcare professionals. 
It was proposed that findings from this study would provide qualitative and quantitative 
evidence of perceived effects of medicines for dementia in a naturalistic setting. It might 
also establish insight into the perceived effect on carer’s ability to cope. The results could 
also provide information to aid in the education and training of HCPs involved in the 
prescribing process. 
Questions to be addressed by the case studies 
(1) Do the medicines produce the same perceived effects? 
(2) How are these medicines perceived to effect the day-to-day lives of those 
that take them and those that care for them? 
(3) Are these findings supported by healthcare professionals and prescribers? 
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(4) How do the objective measures used at routine monitoring clinics compare 
with those observed in the field? 
These will also be guided by the content of the relevant interview topic guide. 
2.4 Guide for the Case Study Report 
Audience: 
RPSGB, Basis of doctoral thesis. 
Format 
An overview and description of the case studies recruited to as an appendix to an in-
depth cross-case analysis of the findings. Interview data will be analysed using Nvivo as a 
support tool and using interpretative phenomenological analysis as the analytical 
methodology. 
Appendix 
Annotated Bibliography (itemized list of all documents used for documentary review) 
3 References 
Yin, R. K. (2003). Case study research: design and methods. (3rd Ed ed.) Thousand Oaks 
(CA): Sage Publications, Inc. 
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Appendix A5­2: Topic Guide for Phase Two 
(Only patient versions will be presented) 
Patient Interview Topic Guide, Version3 13th April 2006. 
Living with Medicines for Memory Problems: Patient 
and Carer Perspectives 
PATIENT VIEWS ON MEDICINES FOR MEMORY PROBLEMS 
TOPIC GUIDE 
We are interested in finding out your views and beliefs about the medicines that are 
used to help treat memory problems. We would like to find out how you think these 
medicines affect your day­to­day life. We are also interested in finding out how 
effective you think they are and what changes they may make to every day activities. 
All information from the interviews will be treated in the strictest confidence – so we 
will not use your name or refer to any people you might mention directly by their 
name. The tapes from this session will be assigned a number and that is how we will 
refer to you and the other members of the group, when we present this information to 
other people. 
8. Background/Personal Information 
After a brief introduction at the start of the interview by the researcher, participants 
will be asked to think about the following as an ice­breaker: “What do you think 
about these medicines? Are they good? Do they work? Did you have any problems 
with these?” Responses will be explored and then this will lead into the major 
content of the interview. 
•	 Tell us the name of any medicine for memory problems you are familiar 
with 
9.	 Medicine Taking 
•	 What expectations do you have about these medicines being able to 
treat your condition? 
•	 What are you expecting to see? 
•	 Could you identify 3 or 4 key things you would like them to achieve 
(e.g. help you remember where you place keys or glasses; help you to 
be able to concentrate on reading or television or music etc) 
• Is there anything else you are hoping they may help with? 
10. The prescribing process 
•	 Were you given sufficient information about the medicine prior to 
starting 
•	 Were you told about the effectiveness of the medicine? 
•	 How are you managing to take the medicine every day? 
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•	 Are you involved with the monitoring of the medicine? For example for 
adverse effects; effectiveness of treatment etc 
•	 Did you discuss an end or withdrawal date issues prior to the medicine 
being started? 
11. The effect of these medicines on day­to­day life 
•	 Tell us about how these medicines affect your day­to­day life in the 
following areas:

­ Adverse effects

­ Compliance issues

­ Dosing or titration problems

­ Ordering and supply issues

­ General effects on day­to­day life

12. How effective are these medicines? 
•	 Tell us about the effects these medicines have on the ability for you to 
lead a life as per your usual routine. For example what are the: 
­ Positive effects 
­ Negative effects 
­ important improvements to you? 
­ important effects for the person who cares for you? 
13. Any other issues? 
•	 Is there anything else you would like to tell us about which is important 
to you and/or the person you care for with respect to these medicines? 
THANK YOU FOR YOUR HELP 
If you would like to receive a summary of your case group interviews, please complete 
the reply slip below and return it in the stamped addressed envelope provided. The 
researcher will send you the summary details once they have been compiled. 
Thank you for your time 
I would like to receive a summary of the findings of my case study group about 
the living with the medicines for memory problems. 
Name: 
Address: 
Thank you for your help! 
Please return to: 
Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath 
Claverton Down 
Bath BA2 7AY 
Telephone: 01225 383677 
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_________________ ______________ ______________________ 
_________________ ______________ ______________________ 
_________________ ______________ ______________________ 
Appendix A5­3: Consent for Observation of Consultation 
(Only patient versions will be presented) 
(Patient Consent Form, Version 4 21st April 2006) 
Living with Medicines for a Memory Problem: Patient and Carer 
Perspectives 
Lead Investigator: Miss Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath, BATH BA2 7AY 
Telephone: 01225 383677 (work) 
Telephone: 07981790025 (mobile) 
Email: d.a.taylor@bath.ac.uk 
Observation of Consultation 
.................................................................................... ......................................... 
Please initial the box 
5.	 I confirm that I have read and understood

the information sheet dated 14th March 2006

for the above study

6.	 I understand that my participation is voluntary

and that I am free to withdraw at any time

7.	 I am happy to have the consultation

observed

8.	 I agree to take part in the above study 
Name of participant Date	 Signature 
Name of witness to Date Signature 
Consent process 
Name of researcher Date Signature 
1 for participant; 1 for researcher 
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Appendix A5­4: Consultation Observation Tool 
Feedback Form on Pharmacist­Patient Communication 
(1) Explores patient’s ideas, concerns and expectations. Identifies the reasons 
for the consultation and explores how the problem affects the patient’s life. 
Facilitates patient’s responses through verbal prompts. Probes wider social issues 
impacting upon health. 
(2) Develops Rapport – Building the Relationship. Accepts legitimacy of 
patient’s views. Expresses empathy and concern. Picks up on patient’s verbal 
cues. Does not interrupt patient. Shares thinking with patient to encourage patient 
involvement. 
(3) Explaining Skills. Gives information in manageable chunks. Checks patient 
understanding. Elicits patient’s view of information that’s been given. Asks patient 
if they want any other information. Avoids jargon. 
(4) Shared Decision Making and Closing the Consultation. Involves patient by 
making suggestions rather than directives. Encourages patient to contribute their 
ideas, suggestions, preferences. Offers choices. Negotiates mutually acceptable 
plan. 
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Appendix A5­5: Study Information Sheet Phase Two 
(only the patient version will be presented) 
Patient Information Sheet, Version 7 14th March 2006. 
Living with Medicines for Memory Problems: 
Patient and Carer Perspectives 
Lead Investigator: Miss Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath, BATH BA2 7AY 
Telephone: 01225 383677 (work) 
Telephone: 07891790025 (mobile) 
Email: d.a.taylor@bath.ac.uk 
Information for Patients 
Dear Sir or Madam, 
We are asking people to take part in a research study who may need to take a 
medicine for a memory problem. The study is designed to help us find out what people 
may think about taking these medicines and how people may think they can help in 
day to day life. The research uses interviews to help us to do this. We would also like 
to interview your carer, your doctor and (if you have one) your clinic nurse. We would 
like to interview each of you one at a time. We will not share any information that you 
tell us with anyone else. 
You are being asked to take part in a research study. Please take time to read this 
information carefully. If you would like more information or if there is anything that is 
not clear, then please contact Denise Taylor. (Contact details above). 
Thank you for reading this. 
1. What is the purpose of this study? 
The purpose of this study is to find out what people who take medicines for memory 
problems think about them and whether you think these medicines work and how they 
may affect your day­to­day life. We would like to find out if what you think about 
these medicines will change over time. To do this, we would like to visit you at home 
and interview you and your carer for a maximum of 3 visits over a 6­month period. 
2. Why have I been chosen? 
You have been chosen because you have recently attended a clinic about the memory 
problems you have been experiencing. You are being asked to take part in the study 
to tell us about your experiences of taking medicines. We are planning to talk to up to 
7 groups of patients and carers. 
At this stage we do not know what your diagnosis will be. If following the diagnosis, 
you do not meet the inclusion criteria of our study there will be no need for you to 
continue to take part. The researcher will contact you and let you know that there will 
be no need for any further interviews. 
3. Do I have to take part? 
No. It is up to you to decide whether or not you want to do this research. If you do 
take part you can keep this information sheet and you will be asked to sign a consent 
form. If you decide to take part you are still change your mind later, without giving a 
reason. If you decide not to take part, any care or treatment you receive will not be 
affected. 
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4. What will happen during the study? 
If you agree to take part in the study, you will be contacted by the lady doing the 
research, who will explain things to you in further detail. She will arrange a suitable 
time and place for the first interview to occur. This could be in your own home or at 
the memory clinic. You will also be asked to sign a consent form. During each 
interview the researcher will follow a list of questions, which cover the issues in the 
research. We expect the interview to last between 20 and 30 minutes each time. 
The interviews will be recorded and you will be asked your consent for this to happen. 
When the tape is being written up, you will not be able to be identified in any way 
from the recording. 
5. What are the possible disadvantages and risks of taking part? 
Taking part in the study is very unlikely to put you at any risk. In the unlikely event 
that the interview brings up difficult issues for you, the researcher will deal with these 
sensitively. You may ask to stop the interview at any time. 
6. What are the possible advantages of taking part? 
We do not expect there to be any advantages to you in taking part. However the 
information you give us will help us to understand how these medicines can affect the 
day­to­day lives of people who take these medicines. This information will also help us 
to understand how your opinions of these medicines may change over time. These 
findings may help us to educate people involved in the prescribing of these medicines. 
7. What if something goes wrong? 
In the unlikely event that you are harmed by taking part in this study, there are no 
special compensation arrangements. However, if you wish to complain or have any 
concerns about any aspect of the way you have been approached or treated during 
the course of this study, you can contact the Lead Researcher; Miss Denise Taylor, 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY. 
Telephone: 01225­383677, or her supervisor Dr Marjorie Weiss at the same address 
on telephone 01225­386787. 
8. Will my taking part in the study be kept confidential? 
No information coming from any of the interviews or the consultation will have your 
name on it and will not be shared with anyone else who is not part of the study. The 
interviews will be typed up by a secretary who will not know who you are. Once the 
study is completed the interview tape will be kept in a secure place for 10 years and 
then destroyed. You can see the written report of your participation at any time. 
9. What will happen to the results of the research study? 
We may have some of what you say printed in a journal or magazine. If this happens 
your name and details will always be removed, so that nobody will know whose words 
they are. If you are interested to know more about the results, you should contact the 
Lead Researcher for further information. 
10.Who is organising and funding this research? 
The study is being organised as part of a doctoral thesis (PhD) by Miss Denise Taylor 
(the lady researcher). The study is supported by a grant from the Royal 
Pharmaceutical Society of Great Britain. 
11.Who has reviewed this study? 
This study has been reviewed by the Swindon Ethics Committee, and also has been 
internally reviewed by Dr Jenny Scott at the University of Bath and also peer reviewed 
by the Royal Pharmaceutical Society of Great Britain. 
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12.Who do I contact for further information? 
If you have any other questions, please contact Miss Denise Taylor at 
d.a.taylor@bath.ac.uk, Department of Pharmacy and Pharmacology, University of 
Bath, Bath, BA2 7AY. Telephone 01225­383677 (office) or 07891790025 
13.What do I do now? 
If you would like to take part, you can telephone the lead researcher on the number 
below. Or complete the reply slip below and return it in the stamped addressed 
envelope provided. The researcher will contact you over the next few days to discuss 
the research with you. 
Thank you for your time 
I would be interested in helping with this research study about living with medicines 
for memory problems. 
Name: 
Address: 
Telephone: (please indicate when the best time to contact you is) 
Thank you for your help! 
Please return to: 
Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath 
Claverton Down 
Bath BA2 7AY 
Telephone: 01225 383677 
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Appendix A5­5: Joint Recruitment letter 
Patient Invitation Letter version 1 8th August 2006 
To be on Clinic Headed paper 
Name of potential participant 
Address of potential participant 
Date 
Dear [Name of Potential Participant] 
We are writing to ask your help with a research project exploring people’s views on 
the medicines they use for memory problems. The aim of this study is to find out how 
you think these medicines work and how they help in your everyday life. The study is 
being led by a pharmacist called Denise Taylor, who works at the University of Bath, 
as part of her doctorate studies. 
The reason why this study is being done is because some people who take these 
medicines describe benefits that are not seen by staff at the memory clinic, so the 
study would like to find out more about these issues. The study also wants to ask the 
people who care for you the same questions. So we would like to ask whether you 
would be interested in helping with this study to talk about the medicines you are 
taking for memory problems and whether your main carer would also be interested in 
taking part. 
The study involves being interviewed on up to 3 occasions over a 6­month period. 
Each interview will last about 20 to 30 minutes and Denise will ask your views on how 
well you think the medicine has worked. Denise would prefer to talk to you separately 
from your carer, although they or a friend can be present during the interview if you 
wish. 
The interview will be quite informal. The interview can either be held here at the clinic 
or Denise can visit you in your own home if that would be more convenient. 
The interviews will be tape recorded, if you are happy for this to happen. Denise will 
produce a report but you will not be able to be identified in anyway from the written 
record. All identifying names and markers will be removed. You can ask for a copy of 
your interview if you would like one. The tape will be kept in a secure place so no one 
else has access to it and then it will be destroyed after 10 years. 
If you would like to take part in this study [please return the attached form directly to 
Denise in the FREEPOST envelope or you can contact her directly by telephone] you 
can read the enclosed information sheets or you can contact Denise directly by 
telephone (her number is at the end of this letter). Thank you very much for your time 
in reading this letter. Please feel free to contact us for further information. 
Enclosed are the following documents: 
1.	 The Patient Information Sheet: please read this carefully as it explains in 
further details what the research is about and what your involvement will be. 
The section at the end is what you return to Denise if you are interested in 
helping with this study. 
2.	 The Patient Topic Guide: this outlines the sort of things you will be asked to 
give your views on in the interview. 
3.	 The Patient Consent Form: this is the form you will need to sign on the day of 
the interview. It needs to be signed because it is a record that you have read 
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and understood the information and consented to take part in the study. It also 
states that we would like to record the interview session and we need your 
permission to do this. It is very important that you do not feel pressured into 
participating in the study and we need to be sure that you have understood the 
information and have had sufficient time to make up your own mind whether 
you would like to be interviewed. For this reason we ask another person 
(perhaps your main carer) to witness this. 
4. A stamped addressed return envelope 
Yours sincerely Yours sincerely 
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_________________ ______________ ______________________ 
_________________ ______________ ______________________ 
_________________ ______________ ______________________ 
Appendix A5­5: Consent Form for Interviews 
(Only the patient version will be presented) 
Patient Interview Consent Form; Version 3 14th March 2006. 
Living with Medicines for Memory Problems: 
Patient and Carer Perspectives 
Lead Investigator: Miss Denise Taylor 
Department of Pharmacy & Pharmacology 
University of Bath, BATH BA2 7AY 
Telephone: 01225 383677 (work) 
Telephone: 07981790025 (mobile) 
Email: d.a.taylor@bath.ac.uk 
Interviews 
..................................................................................... .....................................................

Please initial the box 
1.	 I confirm that I have read and understood

the information sheet dated 4th November 2005

for the above study

2.	 I understand that my participation is voluntary

and that I am free to withdraw at any time

3.	 I am happy to have the interviews

audio­tape recorded

4.	 I understand that relevant sections of my medical notes and

Data collected during the study may be looked at by the

Researcher. I give my permission for the researcher to have

access to my records.

5.	 I agree to take part in the above study 
Name of participant Date	 Signature 
Name of witness to Date Signature 
Consent process 
Name of researcher Date	 Signature 
1 for participant; 1 for researcher 
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Appendix A5­8: Shared Cared Record Data Collection Form 
Data Collection Form: Shared Care Record 
Name: 
D.O.B: 
Date of Recruitment: 
Date of Interview 1: 
Date of Interview 2: 
Date of Interview 3: 
Date of Interview 4: 
Date of Observed Consultation: 
Date Clinician Results & Comments 
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Appendix A5­11: LREC Approval of Changes to the 
Information Leaflet 
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Appendix A5­17: Case Study Report 
Single Case Study Results and Discussion 
(This has been taken from the final report to the Pharmacy Practice Research 
Trust on completion of the Galen Award, which supported this phase of the study). 
. 
Case Study 1: Mr and Mrs Black 
In total five interviews comprised this case study with three involving Mr George 
and Mrs Mildred Black, one with John the psychologist involved with the 
psychological assessment and one with the consultant in charge of the diagnosis 
and decision to prescribe, Dr North. Although it had been planned to observe the 
follow­up consultation in August 2007 this had not been possible due to 
unforeseen circumstances. 
In total there were 69 themes from the interviews with Mr & Mrs Black, but these 
settled into three superordinate themes; Living with a Memory Problem, 
Relationship Dynamics and Interacting with Healthcare Professionals. The main 
theme was living with a memory problem and the resultant effect and affects this 
had on day to day life and relationships and how this had been tempered in some 
way by his interaction with healthcare professionals. 
“my memory has always been very good, I have trained my memory, I 
mean my memory was like, well my brain was like a computer. I would log 
it file it, put it in a folder and then I could access it anytime I wanted.” 
George 
Mr Black spoke of his increasing frustration with his memory loss for short term 
events. He found this particularly frustrating as he had prided himself as having a 
great memory and had in fact taken over the role of being the knowledge font in 
the relationship. 
“that is when it really gets frustrating when things, when I am told about 
things and I hope to me, it has never happened I have never said it, never 
done it, no one has done it for me or given it to me or said it to me you 
know I thought black was black and white was white and now I am not sure, 
now I am not sure at all.” George 
“I like him to be very good with his memory and I don’t like him being 
stressed over it I don’t mind having to help and doing my bit that don’t 
bother me. I just sometimes do worry about him when he really do forget 
something and I and thinking how can he forgotten something so important 
that bit worries me you know.” Mildred 
Mildred described him as having a “brilliant, brilliant memory” which was not like 
hers where she typically could not remember peoples’ names. This lack of short 
term memory was described by George as being as if “it had never happened or 
never been said” and had resulted in many arguments with his wife which had 
culminated with her threatening to leave because of his aggressive response. 
These aggressive interactions also occurred with other family members and it 
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wasn’t until one of his sons “pulled me up on it” that he realised he had become “a 
nasty person.” 
“It has caused us major problems you know we have had arguments, it gets 
her stressed you know… I told her to be bloody blunt about it, excuse my 
expression……I tell my boys if I am out of order tell me because sometimes 
I do get out of order because frustration again that is what it is. I am not 
normally a nasty person you know I don’t normally bite the boys head off 
but I have been and the boys have told me one of my sons he took me 
aside and said ‘that was out of order Dad.’” 
George, Interview One 
At this point he had gone back to his GP and after a period of about six months 
wait received an outpatient appointment to be assessed at the local memory clinic. 
Just the process of admitting that there may be something wrong and then being 
assessed resulted in George and Mildred accepting that there was actually 
something wrong with his memory and they both had to come to some agreement 
on how this would be managed. George had had a heart bypass nearly two years 
previously and he had been told that some people experience some short term 
memory loss. However, for him it seemed to be getting worse and it also 
challenged his own self identity as the ‘memory bank’ of the relationship. 
“My memory has always been very good, I have trained my memory, I 
mean my memory was like, well my brain was like a computer. I would log 
it file it, put it in a folder and then I could access it anytime I wanted.” 
George, Interview One 
His psychological assessment showed that he had mild cognitive impairment and 
not a degenerative illness such as dementia, however up to 20% of people with 
MCI can go on to develop a dementia and for this reason he was to be followed up 
for a period of about 12 months by the memory clinic. He did not believe he was 
“going senile” and took comfort from this diagnosis that nothing was really wrong 
he just had a mild memory problem that may improve with time. This acceptance 
had a great effect on their relationship as described by Mildred below. 
“If I have got to be really, really truthful this past month or so has been 
really, really good quality of life I don’t feel stressed I don’t feel on the edge 
that he is going to blow. I feel that I can get through a day and look forward 
to the next day and not get through a day and think ‘oh God what is 
tomorrow going to be like?’” Mildred Interview One 
Dr North expressed that he found it difficult that there was currently no treatment 
options available for people like George as he knew there was little supportive 
evidence for prescribing cholinesterase inhibitors for people like George. James 
thought it was a pity that they no longer had the resources to do the 10­week 
memory training educational interventions that they used to hold for people with 
MCI or early dementia. This was because they helped people develop the skills 
and resources to cope with a failing memory and also promote the use of memory 
exercises to improve cognitive functioning. George had purchased an educational 
video for training your memory which he found very helpful and he had also 
started to use techniques such as word association with a visual prompt in order to 
help him to remember names. 
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Change Over Time 
George and Mildred remained in the study for ten months and over this time period 
his relationship with his wife improved. In joint interviews there was a decrease in 
the friction and frustration between them on subsequent visits and at the final 
interview they both seemed very happy with each other. 
George had been practising memory training activities and he felt that his memory 
was starting to improve again and that more importantly it wasn’t getting worse. 
George’s original MMSE was 26 out of 30 using ‘serial sevens’ and 28 out of 30 
using ‘world.’ In the MMSE there is an option where people are asked to subtract 
seven from 100 and repeat serially to as far as they can go without making a 
mistake. h other choice is to spell ‘world’ backwards. This latter option is to 
account for people who always had poor mathematical skills. 26 out of 30 is a 
‘mild’ cognitive impairment whereas 27 and above are classified as ‘normal.’ This 
disparity demonstrates how a persons’ prior knowledge or ability can affect the 
score achieved and perhaps bear no relation to heir functional ability in day to day 
activities. At two years follow­up George scored 29out of 30 on his MMSE. 
Point of 
Reflexivity 
There had been a planned observation of a follow­up 
consultation with Mr Black and his potential prescriber Dr X in 
August 2007. However prior to this appointment I was involved 
in a serious road traffic accident and I was on extended sick 
leave at the time. By the time that the project resumed the 
original prescriber had left the clinic and it was not possible to 
arrange another observation. 
Case Study Two: Mr and Mrs Smith 
There were three recorded interviews in total for this case study with two from Mr 
Harry and Mrs Joan Smith and one with Dr South the prescriber. There was also 
an observed consultation with Mr and Mrs Smith, their son­in­law and Dr South. 
There were 31 themes arising from the transcribed data from these interviews and 
the following superordinate themes arose: Living with Dementia and Medicines for 
Dementia. For this couple it was becoming an increasing “struggle” living with 
dementia on a day to day basis and this they thought was exacerbated by the fact 
that Harry had been unable to tolerate Medicines for Dementia. 
“I would say that the Aricept was one tablet that did sort of bring him out of 
himself more, you know because he is back in his shell and doesn’t say 
very much but that one did make Aricept it was wonderful tablet.” 
Joan, Interview One 
Although the local community hospital provided support for Harry in terms of 
helping him to wash and dress morning and night, they managed mostly on their 
own and with the help of two daughters who lived locally. They were both in their 
eighties and thought that this was a part and parcel of the ageing process. Harry 
expressed “we’re both no good” and Joan responded that you “Can’t expect much 
else for 85 can you really?” 
They also spoke of their admiration and gratitude for the support and help that 
they had received from the NHS and local carer groups. 
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“They are very pleasant all their carers are lovely to him really nice. I’d be 
lost without them I would be I can’t cope every day, push around pull 
around you know.” Joan Interview Two 
They spoke of their disappointment of Harry not being able to tolerate the 
medicines for mild dementia and this was especially sad because for the three 
months he had tried to tolerate the diarrhoea associated with donepezil they had 
noticed some improvements with his memory and social interaction which 
disappeared on withdrawal. Harry had been prescribed a second cholinesterase 
inhibitor but the symptoms of diarrhoea and nausea appeared on the first dose 
and only two doses in total were taken. 
Dr South did not believe in prescribing for side effects of medication as she 
thought that this was not good practice, especially in the older person. 
“I personally feel you don’t want to keep on adding in, unless it’s like a life 
saving drug that they’re on you know obviously people who have a knee 
operations then they have to take anti emetics for it but not that, although 
you do get improvements in cognition.” Dr South 
However this also meant that there were no further pharmacological options for 
Harry at this time as memantine was only licensed for moderate dementia. At the 
observed consultation Mr Smith had deteriorate further according to the results of 
the various cognitive assessments that he had undertaken. This meant that he 
was now in the moderate stage of the illness and could be prescribed memantine 
if he and his wife thought this was the best way forward. 
Change over Time 
Harry remained in the study for 10 months and he became more conversant with 
the researcher over time, but this was probably due more to increasing familiarity 
than any other reason. He had tried two cholinesterase inhibitors without being 
able to tolerate the side effects and both were anxious to try something else if 
possible because they recognised the beneficial response of the medication once 
it had been stopped. The course of his MMSE scores is depicted in Table Three 
next. 
Table Three: Clinic results for Mr Harry Smith 
Date MMSE Score 
(out of 30) 
Comments 
12.04.06 17 Referred to memory clinic by GP. Short term memory 
problems­poor recall; gets muddled with names; difficulty 
with practical tasks. Full assessment done. Diagnosed 
probable Alzheimer’s disease, started donepezil 
26.07.06 20 MMSE improved, memory not, diarrhoea a problem 
donepezil stopped 
21.10.06 17 
04.11.06 14 
28.11.06 20 Confused and not recognising he is at home; start 
galantamine 
30.11.06 Galantamine stopped after two doses because of diarrhoea 
20.03.07 18.5 
08.05.07 12 Increasing memory problems, lack of motivation and poor 
initiation and conversation. Memantine started 
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The results demonstrate the fluctuations in cognitive functioning that may be seen 
on a day to day basis. A three point increase was seen in response to donepezil 
but the side effect of three months of continual diarrhoea was seen to outweigh its 
benefit. It also shows deterioration over time in the general overall cognitive 
functioning for Harry. This was also reflected in his physical mobility. 
Observed Consultation Mr and Mrs Smith 
This consultation took place on the 11th April 2007 in a small community hospital 
memory clinic. Mr and Mrs Smith and Dr South all gave informed written consent 
for the consultation to be observed. 
At the start of the consultation the prescriber came out into the waiting area and 
greeted Mr and Mrs Smith and was introduced to their son­in­law. Mr Smith then 
went though to another room on is own with a psychologist who performed the 
neuropsychiatric assessments. While this was taking place Dr South met with Mrs 
Smith and their son­in­law and discussed the current status of Mr Smith in terms of 
cognitive functioning and activities of daily living. The set up of the room was quite 
informal, with Dr South sat to the side of a desk and Mrs Smith opposite her and 
her son­in­law across from her all facing each other. The researcher sat out of 
their visual range behind the carer and her son­in­law. 
Dr South opened the consultation by asking how her husband was and she 
responded that his walking was much worse and his legs were very painful and 
that he now needed to use a wheelchair to get around in the house. The prescriber 
then asked how he had been apart from his physical health. Mrs Smith explained 
that “today’s not quite so good, he has his days” and went on to give an example 
of how good his long term memory was when he helped the driver from the 
Alzheimer’s society find his way back to the town centre. However she went on to 
say that “when he was taking Aricept he was much better. That was a really good 
drug that was.” At this point the son­in­law interrupted with his reading about a 
new medication that might help Mr Smith and there was a discussion period where 
Dr South put the research into context for them with other results from clinical 
studies. She then went on to explain that there was one option that she could try 
with Mr Smith but that it was only licensed for moderate to severe disease and she 
was unsure if this was Mr Smith but that she “could probably get away with it” in 
terms of prescribing. The prescriber then explored his daily activities and noted he 
still enjoyed reading his paper and football and motor racing n the television but 
did tend to get bored. 
When asked what Mrs Smith found the most difficult in caring for him she replied 
“If I want him to do anything he needs to be told what to do and to do it he needs a 
lot of prompting and encouragement.” Dr South then said she would see how Mr 
Smith did on his memory tests but thought that memantine could be an option for 
him as it may help “with him taking more initiative.” She then explained briefly 
about the low risk of side effects and how there was a need to titrate the dose 
carefully up to the full dose. The process was quite complicated and Dr South got 
confused in explaining the titration regimen. 
At this point Mr Smith joined the consultation and he had not performed very well 
on the memory tests scoring 13/20 on the MMSE (moderate dementia). She 
welcomed him to the consultation and asked him how he had been getting on with 
things to which he replied “It’s one of those sort of things you got to remember 
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things.” When she asked how he was in himself he replied that there was “no 
sense in being miserable” and that he felt that “some people made it worse for 
themselves than is necessary.” At this point she asked Mr Smith if he would be 
prepared to try another tablet to help his dementia that it “was pretty well tolerated 
and might help.” He responded “Yep, I’m game for anything” and that he didn’t 
“mind taking a few more.” 
Dr South then explained the dosing schedule again and advised them that she 
would give them a six week prescription and that they should see an improvement 
by week four and that she would see them again in clinic in four months time. She 
emphasised that they must let her know if there were side effects and that she 
would like to know how they got on with them. She then asked if there was 
“anything else you want to ask me at the moment?” and finally produced a written 
instruction for the medication dosing schedule at their request. She then bade 
them goodbye and escorted them to the waiting room. 
Throughout the consultation the prescriber held a relaxed posture, using open 
body language and encouraging empathy and rapport by nodding her head and 
making verbal acknowledgements (mmm, yes) of any responses. Dr South 
opened the consultation well to establish rapport; asked appropriate questions to 
determine what the underlying wants of the participants were, involved Mr and Mrs 
Smith in the decision making process and then summed up the consultation and 
provided a written reminder. 
After the consultation Dr South shared her thoughts on how it had gone; being 
very annoyed with herself for confusing the carer about the dosing schedule. She 
also confided that it was almost good that Mr Smith had had a bad day because 
he then produced a score which supported her clinical decision to prescribe 
memantine and this could be used as justification on cost grounds if challenged at 
a later time. 
Case Study Three: Mr and Mrs Jones 
There were four recorded interviews in total; three with Mr Robert and Mrs Judy 
Jones and one with his prescriber Dr West. There was no home support involved. 
There was also one observed consultation with Mr and Mrs Jones and Dr West. 
Mr and Mrs Jones were also the only participants who agreed to keep a diary 
between interview one and interview two recording their thoughts on response to 
treatment. 
There were 66 themes arising from the interviews with Robert and Judy and these 
settled into four superordinate themes: Living with Dementia. Relationship 
Dynamics; Interacting with Healthcare Professionals and Medicines for Dementia. 
The distress of living with dementia had resulted in changes within their 
relationship which were becoming increasingly intolerable for Mrs Jones. 
Interaction with Healthcare Professionals resulted in Mr Jones being prescribed a 
medicine for dementia which had helped to ease the friction within their 
relationship and his relationship with his grandchildren. 
“ It affects every part of your life because we go, I go to to the little ones, 
they come over here and he’ll be quiet and not join in with the little 
grandson and I’d say “well why?” and he’d say “I don’t know why” and then 
he said “let’s go out for a meal” and I said “what’s the point of going out for 
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a meal if you’re going to sit there and not speak all through the meal.” 
Judy, Interview One 
Mr Jones had become increasingly quiet and withdrawn over the previous 12 to 
18months and forgetful about recent events and conversation. This had resulted in 
a serious blow to their relationship with both parties becoming increasingly 
frustrated with the situation and an increase in severity and frequency of 
arguments. Over the time of the study this became less of a problem as Mr Jones 
became able to increasingly participate in conversations; family events and the 
environment around him on the prescribing of rivastigmine. He described the 
medication as “I would say I think the presence they’ve given me have brought me 
back into the world really.” 
The following excerpt from interview two illustrates this positive response on 
improved socialisation very well. 
Robert: “I married a good lady, my mentor, that’s all I live for really plus the 
family. Whilst I’ve been in this state er I’ll admit I haven’t felt right, don’t 
know why just something that happens and er you sit and you think, but you 
want to put it all in little boxes and I’m gratified that I’ve now got to this 
stage with the help of good lady.” 
Judy: “It had got to the stage where we weren’t going out because I mean it 
was too embarrassing to go and sort of sit he’d sit there and not speak.” 
Robert: “We’d go and have a meal in the pub and I’d just sit there and have 
a meal and I wouldn’t say a word.” 
Judy: “And got to the point saying shall we go home?” 
Robert: “So I get a nudge to say ‘eh are you talking’. Pardon you know and 
I’d think why is she saying that but reality eventually comes back to me and 
sort of says, get switched on.” (now after the medication) 
However this then resulted in dissatisfaction with interactions with healthcare 
professionals as the delay in being prescribed the effective medication was 
perceived as a loss of 12 months and damage to their relationship and Mr Jones’s 
cognitive health. 
“If he could have gone on these instead of the antidepressants straight 
away he would have, we just feel as though we’ve had 12 months taken 
away you know which could have been avoided with if these tablets had 
been prescribed sooner. I suppose they have to go, eliminate certain things 
but um I think they really make a difference.” 
Judy Interview One 
The medication was seen as the reason for the return of the former Mr Jones in 
terms of interest in daily activities and social interaction. His short term memory 
remained poor but they developed systems of supporting this in terms of increased 
use of calendars and prompt lists. A continuing area of concern for Judy was how 
to increase the mental stimulation of her husband in order to help preserve what 
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cognitive function he had. This conflicted with Robert who had always been a 
practical man keen on gardening and DIY activities around the house and resulted 
in frequent heated discussions on the types of activities that he should engage 
with. The following excerpt from Interview One was part of a heated discussion on 
this subject. 
Judy: “But you’re not stimulating your brain doing that. That’s what 
I think, ok you’ll read the paper but you won’t read a book”. 
Robert: “No I’ve never sat long enough to read a book” 
Judy: “But you could do now.” 
Robert: “Right, yes but invariably if I do that I’ll fall asleep.” 
This was solved somewhat by Mr Jones taking up bowls again at the local club 
and receiving social stimulation from this group. 
Diary Recordings 
These were written by Mrs Jones who made a list after the first interview about the 
symptoms she had noticed her husband displaying. The day before the second 
interview she made a list of things that had changed. These are displayed in the 
table below. 
Table Four: Diary Notes by Mrs Judy Jones 
Symptoms Noted after First Interview Improvement Since taking Exelon 
Lack of conversation Went to hotel with relatives over New Year 
and held conversations at table over meals 
Quietness 
Wanting to sit quietly Repaired water barrel pump which has been 
broken for over a year 
Not going to bowling club Has shown interest in starting to play bowls 
again next season 
Aggressiveness 
Stopped gardening Has mowed the lawn and done some 
gardening. Has raked the path 
Can’t have a discussion without arguing 
Doesn’t join in conversations with friends & 
family prefers to sit quietly 
Makes more effort talking with family 
No conversation on a car journey 
No interest in money/family/finances etc 
Doesn’t play with grandson (age 2) Now plays with two grandsons 
Bad memory of recent things 
Keeps raking up the past 
Visited Coventry cathedral and went 
shopping 
These were not tabulated or linked together as a before and after by Judy; but 
presenting in a tabular format demonstrates clearly the improvements in 
sociability; initiative and self motivation which were lacking prior to taking the 
medication. 
Change over Time 
Robert and Judy remained in the study for 13 months and over the course of this 
time there was great improvement in Mr Jones’s sociability; interaction with friends 
and family and motivation and initiative in task completion. They had had several 
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holidays and trips away with each other and had enjoyed these increasingly over 
time. Robert’s short term memory was still poor and they developed a system of 
prompts to support this but this was outweighed by he benefits to their relationship 
that the sociability and increased initiative brought. 
Te comparison of findings from the interviews and information from the medical 
notes can be found in the table below. 
Table Five: Clinic Results for Mr Robert Jones 
Date MMSE (out 
of 30) 
Comments in Record 
01.11.06 DEMTEC low 
score (7); 
Dementia diagnosed; loss in memory domain 
(concentration, short term memory & executive 
function). Off license use of cholinesterase 
inhibitor 
05.04.07 DEMTEC 9 Cognitive testing improved significantly, slowness 
in processing &short term memory. Motivation and 
socialisation improved 
15.09.07 26 Wife depressed about her increasing duties e.g. 
organising builders 
17.01.08 26 Deficits in orientation and recall. Wife prompts 
tasks by using lists. Suggest increase in dose to 
4.5mg twice daily 
Robert was originally assessed in the regional memory research centre and they 
prefer the use of DEMTEC and other tests. After the initiation of rivastigmine Mr 
Jones improved on his cognitive functioning and his later assessments with the 
MMSE indicate a ‘mild’ stage of the illness. Although a dose increase was 
suggested b the prescriber they declined as they thought everything was going the 
right way on the lower dose. It had not been explained that the higher dose can 
actually result in greater improvements in function. They were going to request an 
increase at the next consultation. 
Observed Consultation: Mr and Mrs Jones 
The consultation took place in a small room at the memory clinic of location three 
on the 5th April 2007. Dr West walked out to the general waiting area and greeted 
the couple before ascertaining once again whether they were still in agreement 
about the consultation being observed. All participants gave informed written 
consent. He then led Mr ad Mrs Jones down a long corridor to the consultation 
room, where he sat side onto a desk and the couple sat side by side in front of 
him. He was quite formal in his approach “How are you sir?” But there was an 
obvious rapport with Mr and Mrs Jones. He went through Mr Jones’s recent head 
injury from a fall and his latest medication and then asked Mr Jones “How do you 
feel in yourself?” Mr Jones explained that previously he had a ”lack of drive, 
motivation or get up and go” but that “I’ve overcome that…been mowing the lawn 
today.” On talking to Mrs Jones Dr West established that he was socialising better 
and that his memory was a day to day problem with Mr Jones explaining that he 
“felt better than others on some days” and that word finding was a problem. 
D West then did a SET and the TE4D COG test which aim to test short term 
memory, orientation, co­ordination and problem solving using lists of common 
objects and numbers. Although his response was not very good it was better than 
four months previously to which Mr Jones responded that it was “not as good as 
what I want it to be.” 
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The prescriber was very honest and direct at this point saying “my own feeling is 
that you’ve shown some response but it’s like you’re half way there.” He continued 
“the picture I’ve got of you in my mind is that you’re on auto pilot. You’re good but 
under the surface there’s holes. I feel there is room for improvement.” 
Following this was an explanation to Robert and Judy on how the damage by the 
stroke had affected his speech a little and his speed of processing information. 
This explanation seemed to encourage them both. 
He then asked them how the medication was going and what dose they were 
currently on. Mr Jones replied that he took 3mg once a day as directed on the 
label and that before that he had taken 1.5mg twice a day. This was described as 
a “cock up bluntly” by Dr South as he should be taking 3mg twice daily. There then 
followed an explanation of the new schedule and the issue of a new prescription 
so that Mr Jones took 3mg each morning and 1.5mg at night for two weeks before 
increasing to 3mg twice daily. He emphasised that he should stay on this until he 
saw them again in six weeks time when he would like to increase the dose again 
to 4.5mg twice daily. 
At this point the consultation was brought to a close and the couple were escorted 
out of the clinic to the main reception area. At all times Dr West was polite but also 
very honest with the couple about his thoughts. Although he directed most of the 
questions to Mr Jones he also sought Mrs Jones’s qualification of what was said. 
After the consultation the prescriber shared his feelings on the medication error 
and that the highest dose would be most appropriate if it could be tolerated by Mr 
Jones. He then went on to explain that he had used more searching tests than is 
usually required because he was prescribing rivastigmine off license for vascular 
dementia. He therefore felt that he had to justify Mr Jones staying on the 
medication by demonstrating objective improvement at each follow­up 
consultation. 
Case Study Four: Mr and Mrs White 
There were five recorded interviews in total; three with Mr David and Mrs Annabel 
White, one with his prescriber Dr West and one with Mary the community 
psychiatric nurse who visited every 3 months in order to monitor the effects of the 
medication. Mr White was on a combined prescription of rivastigmine as well as 
memantine. There was also an observed consultation with Mr and Mrs White and 
Dr West. 
In total there were 65 themes emerging from the data but these settled into three 
superordinate themes: Living with Dementia; Medicines for Dementia and 
Relationship Dynamics. Mr and Mrs White had been living with dementia since his 
diagnosis in 2003 and medicines for dementia had enabled them to continue to 
interact with society and also consolidate their relationships with each other. 
Prior to medication Mr White explained how things had been for him. 
“I felt very frustrated and as my wife says I used to be quite keen at do it 
yourself, after that I couldn’t have tackled a job at all I would just sit and 
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look at it and think’ well what on earth am I meant to be doing?’ Frustration 
more than anything really and as my wife said I got up and talked at the 
camera club for 25 year’s; I would be half way through a sentence and I 
would stop and think what on earth, I’d have no idea. I couldn’t go on.” 
David Interview One 
For Mr White there was an expressed dread of the prospect of nursing home care 
and he felt that the medication was the main reason that he hadn’t deteriorated to 
that particular stage of the illness. 
“Well it’s affected me very well it’s made me think in a way how lucky I am. 
I’ve got three friends one of them has developed a (mumbled) they all 
moved into a home recently they are all our age with the same problem and 
they won’t come out again. I think to myself how lucky I am that I am not in 
a home. How long it will last I don’t know but I hope it continues.” 
David Interview One 
Although David was at the mild to moderate stage of the illness and also suffered 
from continuing strokes, they received no extra home help and Annabel coped 
with her husband on her own. She strongly believed in the powers of motivation 
and being organised and David had a weekly schedule to ensure he also engaged 
with external activities such as his art club and his camera club. 
“When you are looking after somebody in this situation and you are not 
experienced in it you do what you think is the right thing and I talk over with 
Mary or when Doctor West comes and they haven’t yet told me ‘you know 
you shouldn’t be doing that or the other and so we keep going and with me 
rather driving is a too strong a word but motivating Peter I think is better and 
if I find that he’s going down a little bit and a bit lethargic then I try to give 
him something else to concentrate on. And I personally think the 
combination of the drugs and that and how I contend with things works” 
Annabel Interview One 
. 
They lived in a residential park and the organisers of the local newsletter relied on 
David to deliver any mailings and he was supported in this by other residents who 
called his wife if he stayed for a cup of tea or a rest. The medication was perceived 
as being a great help in his socialising activities and he was able to converse with 
other parties when they went out on social events. He also suffered from hearing 
difficulties and found this also affected his communication in a different way from 
the dementia. Their sons visited regularly and organised joint holidays to ensure 
that Annabel gets a break as well. 
David had been co­prescribed memantine when Dr West had decided he had 
“fallen of the plateau” induced but he cholinesterase inhibitor rivastigmine that he 
had been taking. They had noticed an increase in social withdrawal, memory 
problems, speech and lethargy. With the addition of the memantine all of these 
areas improved; in fact David appeared on local television and in local 
newspapers talking about how the medicines had improved his daily activities and 
quality of life. He was also able to continue to give small talks at his local camera 
club without forgetting what he was talking about. He was a very keen proponent 
of medicines for dementia and spoke about articles he had read in the newspapers 
at two of the interviews. In the second one he was trying to make sense of why the 
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government said there was not enough money to fund the medicines when they 
seemed to be wasting it else where. 
“What I find is so bad that and er you’re, bureaucracy gone mad really. I 
have two hearing aids and they supply all the batteries, now they’re 
expensive batteries and I only have to send off a pack of used ones and 
they’ll send me back a brand new pack. Why don’t they charge for it, they 
say they’ve got no money and yet they’re giving them away? …Ridiculous. 
They’re not organised with things like that and somebody said “it would cost 
too much to collect.” David, Interview Two 
However over the course of the study David experienced a further mini stroke and 
an admission to hospital with a severe infection, the later of which was in January 
2008 and he became increasingly tired and frail over this time. He also expressed 
a fear that “the Alzheimer’s was creeping in” which also left him with periods 
during the day when he felt fuzzy headed and unable to communicate or think 
properly. Both Dr West and Mary were very supportive of David and the progress 
he had made on the co­prescription of medicines for dementia but knew that the 
inevitable would have to be faced at some time and that David would fall off his 
plateau once more and there would be very little they could to in order to help him. 
And at this point the memantine would probably be withdrawn. Mary described her 
feelings when a decision was made o withdraw medication in people that she 
cared for. 
“You always feel sad if somebody is coming towards the end life of mobility 
and so forth because you know in her situation the history is all around the 
photographs are all around her, her family, it’s quite sad that you feel as if 
you can’t do anymore and so on.” Mary, CPN 
Over the Course of the Study 
David and Annabel remained in the study for 13months. David was a highly 
intelligent man who struggled with the longer term consequences of the illness. His 
wife was a devotee to motivation and timetabled activities which stimulated him 
mentally and physically. There seemed no doubt that this was an effective 
supporting structure. Just prior to interview two he had experienced a minor stroke 
and seemed a bit quieter than the first interview but he conversed about recent 
articles in the newspaper and where they had been with friends. Unfortunately just 
before the third interview he had a hospital admission for a serious infection and 
he was very much quieter at this interview and said how he felt that the 
“Alzheimer’s was increasing.” At this interview his wife was obviously worried and 
concerned and she used it as more of a session to speak to someone about her 
concerns. We eventually agreed that he may need an extended period of 
rehabilitation before he got back into his stride. 
Mary who came to assess is cognitive functioning regularly had helped Mr and Mrs 
White to agree a set of target symptoms that they hoped the medication would 
improve over time. These are outlined in the table below. 
Table Six: Monitoring Target Symptoms for Mr & Mrs White 
Target 
Symptoms 
06.12.06 19.12.06 19.02.07 04.09.07 05.10.07 
Confidence Some Improving No change decreased No change 
Visual After No Decreased Two Decreased 
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hallucinations infection events but 
not 
distressed 
Losing items Wife supervises 
Restless nights Wife says 
no, 
Mr H says 
sometimes 
Sleeps 
better 
More 
sleepy 
after TIA 
January 
Mr W yes 
Mrs W No 
No change 
Table Seven: Clinic Results for Mr David White

Date MMSE 
(out of 30) 
Comments 
10.04.03 Alzheimer’s disease diagnosed; rivastigmine 
started 
February 2005 29 Rivastigmine 6mg twice daily 
16.02.05 27 Memantine introduced 
16.12.06 28 
19.12.06 30 
19.02.07 27 
04.09.07 29 NB Consultant left at this point, no follow­up 
13.02.08 Nocturnal agitation clonazepam prescribed. 
Gradual decline in memory, word finding 
difficulties 
08.05.08 Gradual deterioration over last 2 months; slower 
and lower in mood. Admits to being depressed as 
can’t get on top of pain. Sleeps well, good appetite 
In the above table, the MMSE scores indicate a mild stage of dementia, however 
functionally and cognitively David thought the dementia was increasing. Again the 
MMSE seemed not to reflect the true nature of the individuals cognitive 
functioning. 
Observed Consultation: Mr and Mrs White 
This consultation took place at location three and on the same day (5th April 2007) 
and with the same prescribers described in case study three above. Again Dr 
West went to the waiting area to greet the couple and again confirmed that they 
agreed to my presence in the consultation and showed them into the room with the 
same layout as described above. Dr West spoke slowly and clearly as Mr White 
had a hearing problem and wore two hearing aids. Mr White had recently been 
visited by Mary who completed his quarterly cognitive assessments and he scored 
very well attaining 27/30 on the MMSE. (Indicative of a very mild stage). Mr White 
and his wife were dressed smartly; with Mr W wearing a shirt, tie and jacket. 
The opening narrative was “I’ve had a nice report from the CPN about your 
assessment in February, how are you sir?” At this point Mr White was more 
concerned about the increasing pain in his legs more than anything else and this 
was responded to by the prescriber explaining that he just needed to take the 
“pain killers” regularly as he had only been taking them when he needed them. 
At this point the consultation seemingly became much less structured than the 
previous one with Dr West asking Mr White what he had been doing recently and 
what activities he had completed. Mr White began talking about their fish pond 
which he had been cleaning and also looking after the fish and there was some 
discussion about this. The prescriber explained afterwards that by asking about 
activities and how they have been done a clinician can get a better impression of 
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how they are functioning at a higher level as they bring things into the 
conversation, respond to questions and formulate sentences. It also demonstrated 
that his speech had clearly improved (this had been a major effect of the disease 
for Mr White). 
Mr White then went on to explain how they had been cleaning all the brasses in 
the front room while listening to a trilogy of CDs and he found that he could 
remember all the words but he had recently experienced “loss of memory in 
blocks” and he found this difficult to understand. An explanation of the differences 
in how short term and long term memories were laid down followed. The difference 
being that in short term memory if there was a lack of full attention or 
concentration then the information may never enter the memory pathway, just 
going straight in and straight out again whereas in long term memory there is often 
repetition (for example you sing along to a song and this reinforces the content) or 
an emotional content which enables it to be recalled more clearly. 
Dr West then went on to ask Mrs White how things were and she replied that they 
were “coping well with things during the day” and that he was “socialising very 
much more at ease.” Dr West then completed activities of daily living assessment 
first asking Mr White what he could do and then confirming this with his wife. Mr 
White no longer read very much because he fell asleep; and he didn’t write much 
because the writing just peters out at the end of a sentence. 
Dr South then asked him if he was still “seeing things that were not there” and he 
replied that he did but they “were brief and rare.” He sometimes saw a cat or “the 
girl from the Wizard of Oz.” As they were not causing him or his wife any distress 
and they were infrequent, no other intervention was thought to be necessary. 
The consultation was drawn to a close by Dr West asking Mr White how he 
thought he was doing. Mr White replied “pretty well. If my legs were better I’d feel 
a 100% better I’m sure.” Dr West then said that he thought Mr White was “doing 
brilliantly; technically in the mild stages.” He then seemed to qualify this statement 
by adding “I’m not saying everything is good and perfect; I think it’s brilliant. All 
down to you.” This last statement also seemed to acknowledge the role of the 
activities schedule that Mrs White used to keep her husband active and mentally 
stimulated. The interview closed with farewells and the couple being escorted to 
the waiting room. 
After the interview Dr West emphasised how well Mr White was doing because of 
the co­prescribing of memantine with rivastigmine and still felt clinically that both 
were warranted. Once there was no sign of benefit then the memantine would be 
withdrawn. 
Case Study Five: Mr and Mrs Green 
This case study composed of Mr Chris and Mrs Vicky Green, and his prescriber Dr 
East. Originally there had been a community psychiatric nurse assigned to their 
case (who also consented to take part in the study) but after her first visit the 
Green’s decided they did not need anyone coming to their home. The data set 
included four interviews; three with Mr and Mrs Green and one with Dr East. 
There were 61 themes arising from the data and these fell into four superordinate 
themes: Living with Dementia; Relationship Dynamics; Medicines for Dementia 
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and Interacting with Healthcare Professionals. Chris had been being assessed for 
memory problems for some time and had received a diagnosis of mild cognitive 
impairment. However he then suffered a major cerebral haemorrhage which 
worsened his cognitive functioning such that his score on the MMSE was 
congruent with a diagnosis of Alzheimer’s disease. 
“First of all which would be about a year ago or more, two years ago when I 
started having to say things twice. I got terribly annoyed about that ‘I just 
told you that’. Then of course I understood so that I can’t really say how far 
back whether it was 18 months or 2 years. So to me it’s not just memory 
really”. Vicky, Interview One 
There was a long history of interacting with healthcare professionals whilst living 
with dementia before a medicine for dementia was prescribed. This had led to 
some conflict within their relationship of which they were both very guarded. Chris 
said he worried about his wife because she had no children and would be on her 
own when he went and she worried that her husband confabulated and this would 
not be recognised. She refused however to be interviewed on her own as she saw 
this as a betrayal of her husband. Dr East commented that “the couple shared a 
special relationship and one gets the impression that one would be lost without the 
other.” 
The Green’s lived in a rural area and relied on Vicky’s ability to drive them 
anywhere in terms of household related tasks and social outings. Chris felt angry 
that his license had been taken from him and this settled only slightly when on 
assessment at a DVLA centre he was taken outside in preparation for a driving 
assessment and he could not read a car number plate at the appropriate distance. 
He suffered from macular degeneration and was already functionally blind in one 
eye and the other deteriorated over the course of the study. Chris seemed quite 
insecure at times and generally always confirmed what he was saying with his 
wife. When asked how he felt before the medication began he said “sometimes or 
another I just don’t know where I am and that does annoy me intensely. That’s 
right isn’t it?” (to wife) 
Both Mr and Mrs Green found it difficult to say exactly how the medication helped 
at the start of treatment because Mrs Green’s abilities fluctuated so much from day 
to day and in response to stimulus. 
Mrs Green: “I’ve been trying to see if I can make any constructive points on 
that score but I can’t honestly. If I had more knowledge myself I might find 
subtle differences but in everyday life, I mean recently when (Mrs Greens’ 
brother) came for Christmas you were marvellous weren’t you? Laughing 
and remembering things and chatting about things” 
Mr Green: “Yes, this is the stupidity of it all.” 
Mrs Green: “It depends on the stimulus he’s given.” 
Excerpt Interview One 
Vicky found it very difficult to find activities to engage her husband who preferred 
to live in the past telling stories about the days he was in the Navy and later as a 
leading dam building engineer, or on his cricket or golf playing career. She felt that 
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what he needed was the stimulation of male company as this seemed to enable 
him to engage more with his external environment. During the summer month this 
was augmented by people from the local golf club including him in their weekly 
activities. Chris explained “I’m quite pleased about it. I can get round quite happily 
and it’s important.” (Interview two). The long winter months seemed a problem to 
find other activities to do together other than dominos and listening to old records. 
“The last what couple of months you’ve been brilliant you’ve been far 
(laughs) more able to say what you want to say. You’re going to play golf 
tomorrow he’s got a new golf trolley so you’re going to use it for the first 
time”. Vicky Interview Two 
They experienced an increasing social isolation as previous friends stopped calling 
once the diagnosis had been made. This was exacerbated by a conflict between 
Mr Green’s children from his first marriage (now in their late fifties) who had not 
forgiven their father for remarrying 12 years after his first wife died. They refused 
to come to the house in case they had to have contact with Vicky and even 
refused to meet at a neutral place where she would not be present. He spent 
many hours ruminating on this conflict and worrying about the future of his children 
and his second wife. 
“I have a problem is that my children which are all very good but they don’t 
have anything to do with Sue…. Well it makes me sad because they are 
very good children and we looked after, I looked after almost most of all of 
them when they were young. It is a funny place, funny place but what can 
you do, I try to keep going” 
Chris Interview Three 
The medication was seen as enabling Chris to “get on with things” more effectively 
and his wife thought that they were working but couldn’t really say how. He said he 
was more engaged with her and tasks about the house even though his memory 
hadn’t seemed to change very much. 
“There down in the garden I have been doing all those things down there, 
building up those things there. Keeping myself going all the time, but there 
we are, she works very hard, she does look after me Felicity, we have a 
good laugh at times.” Chris Interview Three 
Over the Course of the Study 
Chris and Vicky remained in the study for 13 months and over this time there was 
an improvement in their relationship with less anxiety and irritation displayed by 
Vicky in interviews two and three. Chris was increasingly able to participate in 
tasks and activities such as golf and gardening but his deteriorating eyesight 
hindered his enjoyment of television and reading. 
Table Eight: Clinic results for Mr Chris Green 
Date MMSE Comment 
(out of 30) 
06.06.06 18 Diagnosed with Alzheimer’s disease (early stage). 
Short term memory problems, muddled with dates; 
function greater than MMSE 
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01.09.06 Started galantamine XL 8mg once daily, to increase 
to 16mg once daily after two weeks 
30.11.06 Recruited to study 
11.11.06 Letter sent to prescriber saying that she couldn’t talk 
in front of her husband as it would be unkind. 
Previously he was nervous anxious and highly 
strung; covering his memory problems by bluff and 
exaggeration 
03.05.07 Memory stable since last appointment, better since 
on medication, better activities of daily living 
August 
2007 
Prescriber left and no follow­up 
06.06.08 20 MMSE unremarkable, repetitive speech and obvious 
cognitive impairment 
Again the results demonstrate that functionally Mr P operates at a higher level 
than his MMSE score might predict, and how the los of a prescriber can mean 
reduced patient follow­up. 
Observed Consultation: Mr and Mrs Green 
This interview occurred in location three a described previously but on the 3rd May 
2007 and was led by Dr East. Dr East was the Senior House Officer for the 
memory clinic and it was gong to be the first time that he met Mr and Mrs Green. 
Dr East went to the waiting room and introduced himself to the couple and then 
confirmed with them again whether they were happy for the consultation to be 
observed. Informed consent was given by all attending. 
Once in the consultation room (with the same layout as above) he introduced 
himself again and then apologised that he had an accent that was “a bit fast” and 
that he would try to slow down and speak more clearly but they should ask if they 
needed anything repeating. He sat in a chair facing the couple and was very 
relaxed with open body language. Mr Green was in a suit, shirt and tie and said 
that he “always felt it was appropriate to dress in tie and suit” for appointments. Mr 
Green seemed to be more engaged and ready to converse whereas Mrs Green 
seemed to me much quieter than on previous meetings. 
Dr East asked Mr Green what his main problem was and he replied “I lose my 
memory very quickly; I don’t know whether I’m coming or going” but went on to say 
“I feel extremely well; playing a lot of golf.” Dr East explored this further 
establishing that Mr Green also found it difficult to express himself and that he got 
frustrated and sometimes a bit down by this. He then asked them both if they had 
noticed any difference since starting the medication. Mrs Green replied that “he’s 
been remarkably well with it, and able” but that “he does need someone there as 
back­up.” Mr Green then talked about his golf and cricket again and this was 
explored further by Dr East who asked him about recent televised games in order 
to further test recall. 
The conversation then turned to his macular degeneration and loss of vision in one 
eye and poor vision in the other and the anger which followed the loss of his 
driving license. Dr East explained about insurance policies and then went on to 
say “to be honest you have someone [nodding to Vicky] to take you around 
wherever you want” which was not received very well by Mrs Green. 
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In time Dr East said to Mr Green “Can I ask you a few silly questions” who 
responded “by all means.” Then Dr Green completed the SET test but mid­way 
through Mr Green became increasingly anxious and Dr East stopped the test and 
said that if you are “anxious it makes your memory impaired” so he needed to try 
and relax in future. 
He then asked if the couple “had any concerns on your side that had not been 
addressed.” Mrs Green wondered if there was a group for men that her husband 
could join for some added stimulus, but this was an unknown fact and it was 
agreed that it would be answered outside of the consultation. He then asked if they 
needed any help at home noting they had refused home visits from the CPN. Mrs 
Green responded “at the moment we don’t actually need any; might come a time 
when there is” and that she would ask then. She then went on to explain “but we’ll 
need to know a person to get confidence in them” with her demeanour (very tight 
and quiet) suggesting that strangers were not welcome in their home. Dr East 
suggested that he or someone would ask them each time they came for follow­up 
just to make sure everything was alright still. This was agreeable to them both. 
Dr East told them that “I will continue the same as I think it’s appropriate” and that 
he would make an appointment for them to be seen again in six months time. He 
reminded them of how to order a repeat prescription ad then closed the 
consultation and made his goodbyes. 
Case Study Six: Mr and Mrs Johnson 
This case study comprised of Mr John and Mrs Janet Johnson and his prescriber 
Dr West. There was no other healthcare professional involved as John had 
dismissed them as being “a waste of time.” There were only two interviews 
associated with this case; one with Mr and Mrs Johnson and one with Dr West. 
This was because John had been recruited to explore why people refuse 
medication when it has been offered, but once the interview had been arranged 
his wife had persuaded her husband that he should take a medicine for dementia 
and he had started on galantamine. 
There were 59 themes arising from the data and these settled into: Living with 
Dementia; Relationship Dynamics: Medicines for Dementia and Interacting with 
Healthcare Professionals. Mr Johnson had been being assessed for cognitive 
impairment since 2000 when problems with his memory had first been noted by 
his family so again there was a long history of interacting with healthcare 
professionals. Living with a dementia had put strain on their and family 
relationships and his son had eventually persuaded Mrs Johnson to take a more 
active role in the prescribing of a medicine for dementia. 
At first John’s memory problems were considered to be mild cognitive impairment 
and the chances of this developing into a dementia had been discussed with him. 
John had no intention of taking any medication that couldn’t be proved would 
benefit him and had previously objected to the prescribing of a medication. He had 
researched the area into memory problems and had found a possible relationship 
to memory loss and mercury dental fillings. He consequently had all his dental 
fillings replaced with non­mercury amalgates with no great results. 
“The strong beliefs would have been I do want to take them if they are 
doing me good, I think it was just as plain as that for me on any subject, if it 
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is doing me good I am all for it and that’s it really I cant elaborate on that 
because I mean it and if it weren’t doing me good I would be saying to him 
quickly here this stuff isn’t any good at all to me I am getting bloody worse!” 
John, Interview One 
John also became quite low and depressed and agreed to take an antidepressant 
which helped a great deal. He still however refused to accept that he had a 
memory problem as Mrs Johnson explains. 
“John sometimes used to say his memory wasn’t what it used to be, but he 
also thought it was better than what it was at the same time. Where he 
used to if he couldn’t remember something and he was getting a bit 
crotchety because he couldn’t remember he said’ my memory is not what it 
used to be’, then in a different context he would say ‘for my age my memory 
is very good isn’t it?’ I don’t think he realised how it really was.” 
Janet Interview One 
Janet admitted that she had not taken an active role because she was struggling 
with the implications of the future if a dementia was diagnosed. She was also 
struggling to keep on top of household activities and look after John on an 
increasingly closer basis. Her son, niece and sister came to help her cope with 
increased caring activities two to three days a week. Consequently she let her son 
deal with taking her husband to be assessed at the memory clinic for some years. 
It wasn’t until her son expressed his concerns to her that she decided that she 
would attend the next appointment with her husband. 
Janet: “I don’t know why I didn’t like going in but somehow I, and I thought 
back, perhaps I didn’t want to accept (pause)” 
Interviewer: “What it means?” 
Janet: “I think that must have been why I didn’t, I went up to the hospital but 
(their son) always went in with him and I didn’t. But in December I thought 
right and I more or less begged for them and then Dr West said I am almost 
sure I will be able to get them for you. I know it’s not easy for him to get is 
it?” 
At this appointment she was told that he had probable Alzheimer’s disease and 
she expressed that this then in some way made it easier for her to accept the 
behaviours of her husband as something outside of his control. 
John had previously been a man “who lived for his work” and had only recently 
retired (some 5 years past real retirement age) and found it increasingly difficult to 
occupy his time, getting bored easily and becoming very anxious when his wife left 
him on his own at home while she continued in her social and household activities. 
He said that he had always been a person with “go go go go” and he found it 
difficult to calm his mind and had difficulty in sleeping. For this reason his GP had 
prescribed olanzapine which they both thought helped to calm him and also 
helped him to sleep and when Dr West had experimented with taking him off this 
medicine because of the risk of stroke they found other alternatives ineffective and 
requested to go back on a small dose. 
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They found the assessments required to be prescribed a medication very difficult 
to understand the concept of and this is illustrated in the excerpt below. 
Janet: “When he first went up to Dr West and he had to do some drawings 
and things well he, what did you say to the lady there? He thought it was 
absolutely ridiculous what they asked him to do and he more or less told 
them as well, ‘what the hell have I got to do that for?’ 
John: “Well yes I think that would be me because some of these things, to 
be a free hand I am no good drawing what’s good drawing from bad ones 
and I never once, I never had the patience to be able to do good free hand 
drawings I would always get a wiggly line come somewhere and that 
…Don’t use them any more anyhow do they it is all, all electronic.” 
Many of his close friends had died over the past few years “from heart attacks or 
cancer” and he found it increasingly difficult to know where to go to meet people. 
He said that it was exacerbated because he was very “straight” and this may not 
be acceptable to some and that he liked people with “a bit of punch.” He had been 
offered a place at the local health authority’s men’s group but was struggling to 
accept it because he dreaded large groups and what he might think about the 
people there. 
“I am not, you know I would willingly go unless it is too far away and I might be 
no good at it at all because my patience can, can umm you know cause me to 
say ‘oh God what am I doing here?’ sort of thing.” 
John, Interview One 
Over the Course of the Study 
After the first interview it was decided not to follow this gentleman up as he had 
already started medication, so in terms of the actual study he was signed up for 
about one month in total. His MMSE scores are depicted in the table below. 
Table Nine: Clinic Results for Mr John Johnson 
Date MMSE 
(out of 30) 
Comment 
12.04.00 24 
08.06.06 Mild cognitive impairment diagnosed 
14.12.06 Alzheimer’s disease with vascular component 
diagnosed 
08.03.07 25 Bristol activities of daily living improved by two points 
and MMSE by one point. Wife more relaxed and 
willing to smile 
19.06.07 Anxiety and tension decreasing, high level of memory, 
both smiling 
14.06.08 23 Declining memory, irritability and low mood (when left 
on own); socialises and has return of good humour. 
Olanzapine 2.5mg for sleeping, citalopram for mood. 
MMSE loss in orientation and recall 
Case Study Seven: Mr and Mrs Smith 
On the 11th April 2007 at a follow­up consultation with their prescriber, Harry 
agreed to try memantine for his dementia. The couple had previously expressed a 
wish to try another medicine to see if that might help them cope. Because they 
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knew me they were happy to continue with the study but as new case where Mr 
Smith became a person with dementia taking memantine. A follow­up interview 
was arranged for the 19th June 2007 as by then they would have been able to 
titrate the mediation up to its most effective dose. With memantine the dose starts 
at one at night for one or two weeks increasing to two twice daily as a maximum. 
Because Harry had showed great sensitivity to cholinesterase inhibitors in terms of 
side effects it was decided to increase by one dose every fortnight to reduce the 
risk of adverse effects with memantine. 
I was on my way to the interview when I was involved in a road traffic collision 
which resulted in an extended period of sick leave. Unfortunately by the time I was 
capable of returning to work­related activities Mr Smith had passed away and his 
wife no longer wished to take part in the study. 
Information from his medical records indicated that he was “much brighter and 
responsive” and had agreed to attend a local Day Hospital in order to give his wife 
respite time once a week. He also started to respond better to the carers who 
helped him get washed and dressed each morning and those who came to get him 
ready for bed. Unfortunately Mr Smith developed a heart rhythm problem and 
became increasingly unwell. He was admitted to a District General Hospital where 
his physical health was stabilised and he was transferred to a rehabilitation unit in 
preparation for discharge. The afternoon of his multidisciplinary team meeting to 
plan discharge he became acutely unwell again and passed away. May he rest in 
peace. 
Over the Course of the Study 
This table demonstrates the general deterioration over time and how this is also 
reflected in physical activities and mobility. 
Table Eleven: Clinic Results for Mr Harry Smith 
Date MMSE Score 
(out of 30) 
Comments 
08.05.07 12 Increasing memory problems, lack of motivation and 
poor initiation and conversation. Memantine started 
18.05.09 Started Day Hospital for stimulation and respite for wife 
22.05.07 Mr H well, no further mobility issues at present 
05.06.07 Happy with care at present 
13.07.07 Increasing pain in legs and difficulty with mobilising and 
transferring (e.g. from bed to chair) 
23.07.07 Mobility and transfer assessment and training 
completed, 
31.07.07 Transferred improved, now has electric wheelchair which 
he copes with well. 
21.08.07 New problem, Mr H refusing to respond to requests 
06.09.07 Admitted DGH with cardiac problems 
03.10.07 Medically fit for discharge 
15.10.07 Suddenly unwell, RIP 
No further memory assessments completed 
The Prescribers 
In total there were four prescribers with Dr West being common to three case 
studies. Because of the generality of the discussion within the interviews about 
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their thoughts and perceptions of the medicines for dementia and how they are 
prescribed, the transcript data were analysed together. There were a total of 85 
themes arising from the data and these settled into three superordinate themes: 
Decision Making in Prescribing; Medicines for Dementia and the Therapeutic 
Relationship. Prescribers’ perceived their therapeutic relationship with their 
patients and their carers as being very important and one that should be protected. 
It was via this relationship they learned about what it was like for people to live 
with dementia and after making a decision to prescribe a medicine for dementia 
they then witnessed the value of this in their patients and their carers on follow­up. 
“ I’d say it’s the rule of thirds, a third of people improve the third people 
stabilise and a third of people don’t um benefit, the improvement can go 
from really dramatic to mild, but mild can be just the one straw that breaks 
the camels back, the remaining one straw is the camels back, sometimes a 
mild improved in function can still be the difference between staying at 
home and being in care” Dr West 
Obviously all prescribers wanted to be able to offer an effective pharmacological 
treatment for their condition an d they experienced this as being hampered by the 
NICE guidance issued in 200631 which stated that cholinesterase inhibitors should 
no longer be offered to people with mild Alzheimer’s disease (when the 200127 
guidance stated they were effective in this area) and that memantine was not to be 
prescribed for people with moderate disease. The fact that both agents have a 
license for those indications and research and clinical experience booth 
demonstrate efficacy in those areas resulted in clinicians feeling sad about the 
future of their patient’s care. 
“It’s going to be hard if we do have to follow the NICE guidelines but um 
we’ll see what happens. Um because you know it is nice that there is 
something to offer and basically you know if we’re not allowed to use 
memantine then there is nothing to offer the more severe people um and to 
be only able to treat people once they reach a certain level of dysfunction 
seems very wrong as a clinician…The treatments are licensed for 
Alzheimer’s you think once you’ve made the diagnosis you should be able 
to use them but, there you go.” Dr South 
Prescribers made decisions routinely about prescribing a particular medication for 
an individual patient and these became almost second nature as they shared their 
own practice skills in this area. The decision on which agent to prescribe was part 
of a prescribing choice pathway for all of the prescribers who used clinical 
experience and the known side effects of the medications and concomitant illness 
of their patient when selecting a first line cholinesterase inhibitor. 
“As for my knowledge is concerned of the three probably donepezil or even 
galantamine are sort of the first choice I would think about these two 
medications before starting. Again the recent researches on rivastigmine in 
dementia its good in Lewy body type of dementia or even Parkinson’s so 
sort of prescribe that for that category but overall if a person comes with no 
other problems just sort of cognitive impairment then probably I would be 
prescribing donepezil which has a better side effect profile than any 
others.” Dr East 
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They generally thought the medication was of great benefit in up to 60% of those 
in which it was prescribed; however they were unable to predict which people it 
would help most. The response rate was described as the rule of thirds; that is a 
third improved dramatically a third responded and a third seemed to show no 
response. However if the medication was withdrawn in non­responders carers and 
people with dementia often experienced a deterioration in their condition which 
necessitated a reinstatement of the medication. 
“On the whole if the functionality is reasonably maintained and they are still 
at home with carer support then I would be reluctant to do it if it can be 
avoided because the trouble is that I have seen this before. Some of the 
carers feel that they may not be working and they tell them and think lets try 
and stop it and with the patient being lower in their mental state you say try 
and stop it and you can see a dramatic difference in the people and you 
reinstate it back on, back on in time just as long as you do it fairly soon you 
know.” Dr North 
Dr West was the prescriber with the most years experience in prescribing for 
dementia and he felt that by the three­month follow­up he could see indicators that 
demonstrate a good response. He was also emphatic that people prescribed these 
medicines needed to be up to the maximum therapeutic dose that could be 
tolerated to gain best effect. He said that if people were monitored whilst they were 
still in their titration phase (galantamine and rivastigmine) then any response seen 
was probably a placebo response because they were not yet at a therapeutic 
dose. (When agents have a longer half life and they are being titrated up slowly in 
order to reduce the chance of side effects then it takes longer for the full potential 
of the medication to be demonstrated). He explained that a response to treatment 
was often seen at this stage but he termed this as being a placebo response i.e. 
the fact they were now on active treatment; something was being done and that 
they had been able to absorb and accept the diagnosis to a greater extent. He 
contrasted this with donepezil which rapidly reaches therapeutic effect and that the 
response seen at 3­months follow­up was a true reflection of response. 
“I think there’s a danger in that first follow up consultation, there may well 
be a degree of placebo effect within that something’s getting cracking in the 
pot and is therapeutic and the original trials show this the placebo group 
improved as well at 6 months that’s when the placebo and treatment group 
really separated I do think there is a degree, the hardest bit is balancing it 
expectations and not giving too much hope.” Dr West. 
This was one of many examples of how difficult prescribers found it to actually 
assess the efficacy of the treatment. The assessment of response was performed 
by “a battery of tests” in order to obtain an objective account of improvement; 
however what was often needed was the subjective experience from the person 
with dementia and/or their carer. Although NICE recommends the MMSE as the 
preferred test prescribers experienced it as a tool which only told half the story and 
did not account for improvements in socialisation skills, activities of daily living and 
engagement in their environment in terms of being able to see things that needed 
to be done and contribute more to their personal relationships. 
“Um same with memory it might have been a hard day when they are doing 
the mini mental or the ADAS­cog and it probably is not the same results 
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testing at that point in time and I tend to go by what the carers and the 
patients feel important as well so that gives me a part of this.” 
Dr North 
The therapeutic relationship was one that was developed over time between both 
parties and was valued by the people with dementia and their carers as a place 
where they could ask questions and receive information that was relevant to them. 
Prescribers talked about the usual information they would discuss with the patient 
prior to making any prescribing decisions and this included talking about 
concomitant illness, the possible response to medication and duration of that 
response. However Dr West shared how this was often difficult to judge on what 
was actually heard in that people generally did not remember all the facts they 
were told in a consultation and a few days later tended to have developed their 
own précis of the interview. 
“The problem is the difference of what comes out of my mouth and what the 
patient and carer hear and can take a day later. The reality you are only 
going to take three points from a consultation and so you may well take the 
three best ones, so I do my best but sometimes it’s hard to judge the 
difference between mine and the judgement of patients and carers.” 
Dr West 
Interestingly the age of the person with dementia and their carer seemed to 
influence their attitude and/or acceptance of the illness and the outcomes of 
treatment. Older people were described as being more realistic about the possible 
effects of treatment and less likely to demonstrate a placebo response in the early 
stages. This attitude also affected the services provided with younger patients 
being experienced as more demanding in their requests. 
“The hardest bit is balancing it expectations and not giving too much hope 
where some people will expect the drugs to cure it; interestingly older old 
people are more happy with anything that helps, younger old people are 
expecting more of the magical hit…In my expectations older old are just 
happy you know their expectations are much lower, younger old are more 
assertive..” Dr West 
Occasionally there were conflicts within the therapeutic relationship and prescriber 
Dr South thought that these generally related more to the siblings of their patients 
who could not come to terms with a diagnosis. She went on to explain that 
considering there was potentially a huge impact on receiving a diagnosis of 
depression, on the whole people received and seemed to accept this very well. 
She perceived that people seemed to relax after a year or so on treatment 
because things stabilised and nothing was progressing as fast as they thought it 
might have done. 
“You know people are lovely on the whole and you can talk about things 
and come to an agreed decision about things; its not usually an issue. I’m 
amazed how well people take you know being given a diagnosis you expect 
people to have catastrophic reactions much more often than they do but I 
suppose they’ve been having problems for a long time usually, it’s not 
something that happens one week and they come and see you the next. 
So they’ve probably had a bit of an inkling”. Dr South 
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Prescribers felt they were making decisions all the time, some which came 
naturally without any thought and then others which challenged them on deeper 
personal and ethical levels. Prescribers shared how they felt when they diagnosed 
somebody as having mild cognitive impairment when there was nothing within the 
guidelines or in the evidence base to offer these people as an effective treatment. 
The conversion rate from MCI to dementia is about 20% so for many of these 
people it became a “watch and wait” follow­up so that if necessary they could offer 
appropriate treatment when they deteriorated further. 
Dr West described a difficult decision he made when one of his patients was 
admitted to a nursing home when her carer could no longer cope. She had been 
on medication for dementia on admission and this was kept on, however she had 
insight into her situation and became very distressed in the care home, not liking 
the way she was being cared and not being able to understand her husbands 
unavailability. It was decided in collaboration with the care staff and the community 
psychiatric nurse involved that the medication would be withdrawn in order to 
reduce her distress levels by reducing her insight. 
. 
“I would not automatically stop because somebody had gone into care we 
have to look at the needs of that person in that care environment. If 
somebody is in a grotty home aware of their environment it might be a good 
place to stop where somebody is in a residential home and liking it and we 
are trying to place them in residential rather than going to EMI nursing still 
carrying on the medication.” Dr West 
Other Healthcare Professionals 
There were two community psychiatric nurses (CPNs) recruited to the study 
originally but one withdrew when the person she was supposed to be monitoring 
decided they no longer wished anyone to come to their home. At the end of the 
study there was one CPN Mary and one psychologist James interviewed in their 
workplace. 
There were a total of 41 themes arising from the data and these settled into two 
superordinate themes of: Medicines for Dementia, and Procedural Issues. James 
and Mary were part of a team delivering supporting care to an individual and 
generally did not have autonomy. All decisions and findings were to be discussed 
with either their manager or the relevant prescriber. This meant that narratives 
consisted of Procedural Issues which they followed in order to deliver their service 
which was either to provide the neuropsychiatric or the response assessment 
details to the relevant clinician in order for a medicine for dementia to be 
prescribed. 
James’s remit was to perform all the neuropsychiatric assessments for the initial 
diagnosis to be made and these would be repeated on an annual basis if the 
diagnosis was mild cognitive impairment. He generally only spoke to people with a 
memory problem or dementia and their carers as part of doing his assessments 
and was not involved in any prescribing decisions. 
“I would give the results to my manager who would then score up the 
memory assessments and interpret it and then she would allocate the 
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diagnosis into that and that goes to a consultant to look at and that forms 
part of the assessment.” 
James (psychologist) 
Mary followed­up people who had been stabilised on a medicine for dementia in 
their own home at three or six monthly intervals dependent on their perceived 
need. In this respect she had a better idea of how medicines for dementia affected 
people’s day to day lives as she witnessed their functional and cognitive ability in 
their own homes. 
“Well the people I see who are already stabilised on them at home and I 
dare say there are some people who may have done well but the majority 
and all of those I see they are effective as I said before they have helped 
people who they’ve enabled people to stay in their own homes for much 
longer periods than they would have done at all.” 
Mar CPN 
The assessment was a complex process for both, notably more scale driven for 
James whereas Mary described how there also needed to be some subjective 
measure and that you had to “use your eyes” in order to actually see what else 
was going on. She described how the following issues could be picked up in this 
manner and that in order to maintain stability of the caring process they all needed 
to be addressed: an underlying infection; relationship issues; the need for extra 
support for the carer or a possible dose increase for the person taking the 
medicine. 
There was some discussion on the assessment scales available both at a 
diagnostic level and at a monitoring level. The MMSE has been designated as the 
preferred tool by NICE but both outlined difficulties they had with it. Mary 
described how it only gave part of the picture and that she usually used it in 
combination with one or two other tests (e.g. SET or HALF SET). James thought 
that it was not a sensitive tool in those people of previous high intellect as they 
often scored highly (i.e. supposedly demonstrating no cognitive impairment) but 
had gross functional ability. 
“I guess they’re as objective as we can be mostly because it’s an 
acknowledged and evidenced tool/trait if you like, so it can be quite useful 
but sometimes we see people who have deteriorated and clearly they’ve 
deteriorated because there are other ways of seeing I mean you use your 
eyes and yes you’re right it is subjective but you use your eyes you look 
around you and you look at the state of the patient, their dress, their 
demeanour you can check and the state of the home they’re living in if you 
like or just generally how they’re responding to you and all of those things 
are part of it as well. So yeah I guess some of it subjective.” 
Mary CPN 
The importance of a reliable informant (i.e. the carer) was referred to by both as 
being a necessary part of the assessment procedure to ensure that a greater 
depth of understanding was ascertained and also the level of carer distress or 
carer burden. To help support this process there were often target symptoms 
agreed by both the person with dementia and their carer which they hoped the 
medication would improve. This also gave a greater means of assessing the 
334 
efficacy in terms of the individuals concerned. A target symptom could be 
something like not misplacing or losing objects such as car keys or glasses or 
repetition of questions to the carer. 
Mary experienced the medicines as “without exception” producing some form of 
response in people who took them. Both described improvements in mood, 
behaviour, speech, sociability, quality of life and maintaining independence and 
Mary perceived that they helped to maintain facets of personality. 
“I mean yes it does improve their quality of life I mean I think the hope 
sometimes as well improves their self esteem that they’re able to do little 
things more.” Mary CPN 
Mary also described occasions where she had found it difficult in being included in 
the decision to stop a medication when there was no other option available and 
knowing that there would be a sudden decline in functioning. Her practice involved 
an element of clinical supervision which meant that she had the facility to offload 
her experiences in order to carry on working. 
“I have the option to opt in we do do clinical supervision so as part of my 
clinical supervision is that I do talk about it. I mean after a long time, in 
nursing I feel as no one is forever you know that and it can be as 
comfortable as it can be and that’s fine.” Mary CPN 
Recruitment Issues 
As discussed in the interim report the start of the study was delayed due to a 
series of correspondence with the Local Research Ethics Committee LREC), 
which finally approve the study. However by this time the process of prescribing 
for newly diagnosed people with dementia had changed on both originally 
proposed study sites. (Instead of people being assessed physically and 
psychologically on visit one and then a diagnosis being decided prior to their next 
visit in three weeks time where prescribing also occurred; the assessment, 
diagnostic and prescribing were all to take place on the initial assessment visit. 
This was because the delay of three weeks in prescribing these medicines was felt 
to be deleterious to the person cognitive function). 
This meant that a further substantial amendment had to be made to the LREC and 
also the changing of all patient and carer information leaflets and consent forms. 
These received approval from LREC and then one of the study sites dropped out 
due to increased workload and staffing pressures. At this stage a further four 
potential study sites were approached for their agreement to be a recruitment site 
for the study. These sites agreed and this meant a further substantial amendment 
being made to LREC for their approval which was granted. As well as the addition 
of the four new recruitment sites, approval was also sought for two changes to the 
recruitment process as this was not going very well. Approval was given for: 
1.	 the lead researcher to be on site at new patient clinic days and for the 
healthcare professional leading the consultation to briefly explain to them 
about the study and ask if they would like to speak to the person who could 
talk to them immediately after the consultation, and/or 
2.	 For the study site consultant to invite people to take part in the study by a 
joint letter from them and the lead researcher. 
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Appendix A6­1: Coding Taxonomy for Phase Two 
Superordinate Theme: Living With A Memory Problem Or Dementia 
Personal Changes 
Ageing and Concomitant Illness

An elusive memory

Fluctuations and progression

Comparative Changes 
Behaviours

Activities

Relationship Dynamics 
Perspectives of day­to­day living 
Communicating with a memory problem 
Effects on Others 
Acceptance and Living Together 
Superordinate Theme: Interacting With Healthcare Professionals 
The Therapeutic Relationship 
Consultation Etiquette 
Therapeutic Decision­making 
Diagnostic Processes

Prescribing Decisions

Predicting Response

Assessment, follow­up & support 
Testing for response

Assessing the response

Follow­up and Support

Superordinate Theme: Medicines For Dementia 
Prescribing Hindrances 
Access to Acetylcholinesterase Inhibitors 
Prescribing and Co­prescribing of Memantine 
Responding to a Medicine for Dementia 
Response Rate and Duration 
Beneficial Response 
Sociability and Returning to Old self 
Perceived Quality of Life 
Medication Issues 
Experiencing Side Effects 
Getting the prescription and the medication 
Mislabelling 
Compliance and Titration Problems 
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Appendix A6­2: Description of Superordinate Themes 
Superordinate Theme: Living With A Memory Problem Or Dementia 
This theme describes how a memory problem or early stages of a dementia 
impairs memory and effects personal behaviours and activities which in turn 
impact on relationships. The spousal relationship required renegotiation with an 
adaptation and acceptance of new roles and lifestyles. 
Superordinate Theme: Interacting With Healthcare Professionals 
Both carers and participants with dementia or a memory problem had therapeutic 
relationships which required interacting with healthcare professionals. In this 
phase of the study there seemed to be a more acceptable consultation etiquette 
which participants found supportive. 
Superordinate Theme: Medicines For Dementia 
Medicines for dementia were perceived to improve relationships y aiding the 
participant with dementia to engage more fully in their life word and with other 
people. The result was improved social skills and relationships. There was also a 
negative charge for the medicines in terms of pharmaceutical issues related to 
supply and correct labelling. 
337 
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From Chapter 1­3 
1.	 Masters by Research. Continued Inpatient Medication Counselling by a Pharmacist: does it 
improve outcome post discharge. 2000. University of Bristol, Faculty of Medicine. 
th 
2.	 Taylor D.A. ‘Chapter 19: Dementia’ Drugs in Use 4 Edition Ed Linda J. Dodds (In Press) 
Pharmaceutical Press 2008 
3.	 Taylor D.A. Section 8: Dementia in Presentation and Management of common mental 
disorders: an open learning course for pharmacists. Continuing Pharmacy Practice 
Education (CPPE), Manchester University 2005. 
rd 
4.	 Taylor D.A. ‘Chapter 19: Dementia’ Drugs in Use 3 Edition Ed Linda J. Dodds ISBN 0 
85369 541 5 Pharmaceutical Press 2004 
5.	 Taylor D.A. Module 6 “The Dementias and Related Disorders” Postgraduate certificate in 
Psychiatric Pharmacy by Distance Learning. Aston University School of Life and Health 
Sciences. November 1999 (Updated August 2000­2009) 
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From Chapter 8 
Dissemination of Findings from Phase One and Two 
I have been able to present the findings of Phase One at a number of conferences; these were: 
•	 An oral presentation at the Health Services Research in Pharmacy Practice in April 2006, 
•	 A poster presentation at the annual British Association of Psychopharmacology in July 
2006, 
•	 An oral presentation at the British Pharmaceutical Conference (BPC) in September 2006, 
and 
•	 An oral presentation at the United Kingdom Psychiatric Pharmacy (UKPPG) Conference in 
October 2006 where it also won the UKPPG Travel Award (£1500). 
•	 A poster presentation at the European Society for Clinical Pharmacy Conference in 
Edinburgh May 2007. 
After the BPC I was approached by the Editor of the Pharmacy Magazine to write an article on how 
to complete a Medication Usage Review for PWD. (Ref) A summary of the findings has also been 
sent to the branch lead of each of the Alzheimer’s Society branches that took place and those 
participants who expressed a wish to receive it. 
I was also approached by BBC Points West and BBC Radio Bristol to comment on various aspects 
of dementia as outlined below: 
•	 BBC One Points West Television interview Medicines for dementia 6.30pm and 10.30pm 
2nd April 2007 
nd 
•	 Radio Bristol Live Interview Medicines for dementia 7am 2 April 2007 
th 
•	 BBC One Points West Television Interview The effect of antipsychotics on older people 7
June 2007 
•	 Radio Bristol Live Interview Antipsychotics in care Homes 7am Friday 8th June 2007 
I have had some of the findings of Phase Two accepted for oral presentations at two conferences 
so far; these were: 
•	 The National Health Services Research conference at Birmingham in June 2009, and the 
•	 Annual British Pharmaceutical Conference in September of 2009. 
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